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“Poor quality of life and high psychological distress are prevalent outcomes in individuals experiencing 
chronic spontaneous urticaria. Not only do cognitive representations of chronic spontaneous urticaria 
predict quality of life and psychological distress significantly better than socio-demographic and clinical 
factors, it does so independent of coping procedures and is amenable to change via intervention”.  
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Abstract 
 
Chronic Spontaneous Urticaria (CU) is a pruritic skin disorder that affects 0.8% of the 
population. As its aetiology is not fully understood the aim is to control symptoms through 
medicines to improve quality of life (QoL). Demographic and clinical factors have been 
inconsistent and poorly predict QoL but one modifiable factor that has gained credence is ones 
illness representations. The Common-Sense Model (Leventhal, Meyer and Nerenz, 1980) 
postulates that these guide coping procedures that impact outcomes. The aim of the thesis was 
to examine whether CU representations (mediated by coping) predicted QoL and whether both 
representations and QoL in CU were amenable to change via intervention.  
 
Preliminary studies undertaken validated CSM measures in CU and confirmed key 
reference values for CU-related QoL and its measurement. CU was seen as uncontrollable, 
emotionally arousing, chronic, cyclical, caused by stress and immunity with serious 
consequences and has a moderate impact on QoL (n=78). The necessity to take CU medicines 
equalled concerns about side effects. Cognitive representations were the strongest predictors of 
QoL explaining 35.0-60.6% of the variance independent of coping. Qualitative analyses 
presented CU as unsightly, uncontrollable and difficult to comprehend and self-regulate. 
Fifthteen participants undertook psych-education and action plans to change CU 
representations. Multivariate analyses found a strong within-group main effect on QoL outcomes 
(p<.001) and for aspects of outcome over time (all p<.001). Correlation based change analysis 
further inferred that targeting CU cognitions resulted in changing QoL outcomes over time. In 
summary the thesis supported that: poor QoL is prevalent in individuals experiencing CU. Not 
only do CU representations predict QoL outcomes, they are amenable to change via intervention 
as are QoL outcomes. Such findings have implications for CU-related QoL research and how 
health psychology-dermatology collaborations maybe instrumental to improving outcome 
through psycho-education interventions in routine care to facilitate better CU self-management.   
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Preface 
 
Chronic Spontaneous Urticaria (CU) is the experience of itchy hives (pruritus) and skin swellings 
(angioedema) that persist after six weeks duration but typically last for years (Zuberbier, Grattan Maurer, 
2009). CU has no cause and although bio-medical research has broadened our understanding of it, its 
current theories only partially explain it and cannot predict what interventions will improve outcomes, 
hence it is the urticaria that researchers, clinicians and patients describe as an “enigma” (Maurer, Grattan, 
Zuberbier, 2009).  
 
In the absence of a cure patients must partake in daily self-regulatory behaviours to control 
symptoms by taking CU medicines and avoiding triggering factors, however CU medicines often result in 
sub-optimal treatment outcomes and eliciting factors are rarely identified. Consequently, it is not 
surprising that CU has detrimental effects on quality of life. How patients with CU plan for the future based 
on its unpredictability is often a concern, as experts themselves have no solid understanding of prognosis 
(Maurer, Weller, Bindslev-Jensen, Gimenez-Arnau, Bousquet, Canonica, et al. 2011) and it is common 
for health professionals to view these patients as ‘difficult to satisfy and hard to guide’ (Weller, Viehmann, 
Brautigam, Krause, Siebenhaar, Zuberbier and Maurer, 2012). It is argued that biomedical research has 
been a one-dimensional approach to studying a complex condition limiting opportunities to establish other 
factors that may explain some of the variance in CU outcome.  
  
One such model that has gained credence is the Common-Sense Model or CSM (Leventhal, 
Mayer and Nerenz, 1980) that suggests chronically ill individuals construct lay perceptions of their illness 
to make sense of it. These together with emotional responses inform coping behaviours that impact 
outcomes. If perceptions significantly predict CU-related QoL and act as mechanisms for change, it may 
prove useful for experts communicating with these patients to challenge misperceptions and develop 
action plans that lead to better management. 
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Chapter 1 
An Introduction to Chronic Spontaneous Urticaria 
 
1.0: Chapter Scope and Aims 
The aim of this chapter is to provide an introduction to chronic spontaneous urticaria (CU) by 
presenting an overview of its characteristics, pathogenesis, prevalence, and disease management. The 
thesis’ outcomes quality of life and psychological distress are also introduced prior to exploring the 
Common-Sense Model as a useful framework for exploring predictors of both outcomes in Chapter 2.  
 
1.1: Definition and Clinical Presentation 
 
1.1.1: Definition and Characteristics 
CU is defined as the spontaneous daily (or almost daily) presentation of pruritic cutaneous wheals 
(itchy hives) and/ or angioedema (swellings) for at least six weeks duration of no identifiable cause 
(Zuberbier et al. 2009a). Central to CU onset is the sudden presentation of a cutaneous wheal. As 
illustrated in Figure 1.1 below these are characteristically pale and pink in colour (Zuberbier et al. 2009a) 
and are usually accompanied by an inflammation of the surrounding skin. It is the pruritic (or itchy) nature 
of the wheals that is problematic and those who experience them describe the itch as stinging, tickling 
and burning with sensations of heat and actual sweating (Yosipovitch, Ansari, Goon, Chan, and Goh,  
 
Figure 1.1: Urticarial Wheals and Angioedema on the Left Hand* 
 
                 Left to right: Maurer and Grabbe, (2008); international CU Society (www.iicus.com) and *Maurer and Grabbe, 2008 
 
2002). Pruritic wheals are fleeting and cyclical in nature and can last for 1 to 24 hours but there can be 
considerable overlap between cycles (Zuberbier et al, 2009a). Where wheals represent a superficial 
swelling of the upper skin layer, angioedema (Figure 1.1) embodies the appearance of a much deeper 
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swelling of the inner dermal and subcutaneous tissues, the experience of pain and a longer life cycle of 
up to 72 hours (Kaplan and Greaves, 2009; Zuberbier et al. 2009a). Angioedema symptoms are often 
reported on the facial areas (e.g. cheeks, lips and eyelids), tongue and feet (Kaplan and Greaves, 2009) 
and if severe this can result in anaphylaxis (Kaplan, 2004).  
 
Urticarial wheals can occur anywhere on the skin but Maurer, Ortonne and Zuberbier, (2009a) 
found that the arms and legs were the most reported areas effected representing 56% of the sample but 
women reported significantly more symptoms on the legs, hands, face and scalp (p < 0.05). In line with 
Yosipovitch et al. (2002) Maurer et al. (2009) further found that 34% of patients reported that symptoms 
worsened in the evening and 55% reported them to worsen at night resulting in sleep disturbance (Maurer 
et al. 2009a; Zuberbier, Asero, Bindslev-Jenson, Walter Canonica, Church et al. 2009b). Further it is not 
unusual for patients to report headaches, stiff joints or gastrointestinal symptoms often explained by the 
inflammatory effects of histamine release (Maurer and Grabbe, 2008).  
 
1.1.2: Classification and Diagnosis 
The classification of CU usually comes after a complex process where urticaria subtypes of 
known aetiologies has been eliminated (Zuberbier et al. 2009). To add to the complexity of diagnosis a 
single patient may have multiple co-morbid physical or other urticarias (see Table 1.1 below).  
 
Table 1.1: Co-morbid Urticaria Subtypes in CU* 
Urticaria Type Urticaria Subtype Eliciting Factor 
 
Physical urticaria 
 
Cold 
Delayed pressure  
Heat contact, solar 
Urticaria factitia/ dermographic 
Vibratory urticaria / angioedema 
 
Cold objects, air, fluids, wind 
2-12 hours of vertical pressure, tight clothing 
Localized heat 
UV and/ or visible light  
Vibratory forces 
 
Other 
 
Aquagenic  
Cholinergic 
Contact 
Exercise induced anaphylaxis/ urticaria  
 
Water 
Increase in core temperature  
Urticariogenic substance 
Physical exercise 
   *adapted from Zuberbier et al. 2009a 
 
As a general rule European guidelines on urticaria (Zuberbier et al. 2009a) recommend that  
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they be classified by disease duration (acute or chronic), the frequency of symptoms and known causative 
factors. When symptoms persist for more than 6 weeks urticaria is deemed as chronic.  
 
Researchers further classify CU into two subsets: chronic idiopathic urticaria (CIU) and chronic 
autoimmune urticaria (CAU), the latter reflecting research relating CU to autoimmune mechanisms 
(Bagnasco, Minciullo, Schiava et al. 2011; Kaplan and Greaves, 2009; Kurt, Aktas, Aksuet et al. 2011)CU 
is further determined by disease-activity using the gold standard urticaria-activity score (or UAS; Mylnek, 
Zalewska-Janowska Martus, Staubach, Zuberbier and Maurer 2008) but diagnosis is complicated CU 
can be both an illness and a symptomatic manifestation of another illness (Brodell and Beck, 2008). 
Consequently CU has numerous differential diagnoses including urticarial vasculitis, (Zuberbier et al. 
2009a). The CU diagnosis itself is made after an evaluation of the patient's history, physical examinations 
and laboratory tests to rule out systematic diseases (Table 1.2).  
 
Table 1.2: Urticaria Diagnostic Checklist* 
1.   Onset of disease 
2.   Frequency and duration of wheals 
3.   Diurnal variation 
4.   Occurrence in relation to weekends, holidays, foreign travel 
5.   Shape, size, distribution of wheals 
6.   Angioedema 
7.   Associated subjective symptoms of lesion (e.g. itch, pain) 
8.   Family and personal history regarding urticaria  
9.   Previous or current allergies, infections, internal diseases, or other possible causes 
10. Psychosomatic and psychiatric diseases 
11. Surgical implantations and events during surgery 
12. Gastric/ intestinal problems (stool, flatulence) 
13. Induction by physical agents or exercise 
14. Drugs (e.g. NSAIDs, injections, immunizations, hormones, laxatives, alternative remedies) 
15. Observed correlation to food 
16. Menstrual cycle 
17. Smoking habits 
18. Type of work 
19. Hobbies 
20. Stress 
21. Quality of life related to urticaria and emotional impact 
22. Previous therapy and response to therapy 
*Adapted from Zuberbier et al. (2009a) 
 
Patients may undergo a pseudo-allergen diet to see if these are implicated and physical urticaria 
is determined using challenge testing (e.g. placing ice cubes onto the skin; Zuberbier et al. 2009a). Tests 
used in CU diagnosis are defined below (BMJ, 2011 or Saini, 2011, unless stated).  
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■Full blood count: Identifies the presence of infectious diseases and presence of other illnesses.  
■Erythrocyte sedimentation rate: A non-specific test that provides evidence for the presence of urticarial 
vasculitis and other auto inflammatory syndromes.  
■C-reactive protein (CRP): A non-specific test that provides evidence for the presence of urticarial 
vasculitis and other auto-inflammatory syndromes.  
■Thyroid-stimulating hormone/ Anti-thyroid antibodies: Helps with CU aetiology as CU has been 
associated with antithyroid antibodies and autoimmune thyroid disease 
■Autologous serum skin test (ASST): A non-specific test to detect circulating auto-antibodies that trigger 
wheal-flare reactions (Sabroe, Grattan, Francis, Kobza Black and Greaves, 1999). 
■Basophil histamine release assay: A non-specific screening test that detects histamine-releasing 
autoantibodies from white blood cells (Grattan and Humpreys, 2007). 
■Skin prick: Allergy (Kaplan, 2004; Kulthanan, Jiamton, Rutnin, Ni-on, Insawang and Pinkaew, 2008).  
Kozel Bossuyt, Mekkes and Bos (2003) in their urticaria systematic review found that over 20 laboratory 
tests can be requested for a single patient but CU guidelines recommend against such testing (Zuberbier 
et al. 2009a, 2014). 
 
1.2: Pathological Process and Aetiology 
 
1.2.1: Patho-Physiological Process 
Even though little is known about CU aetiology the actual process is much better (if not 
completely) understood. There are many cells involved in CU but the major ones implicated are mast 
cells and white blood cells called basophils (Vonakis and Saini, 2005). Mast cells can be found in the skin 
and are normal involved in processes such as defending organ cells from external pathogens (Metz, 
Siebenhaar and Maurer, 2008). For this mast cells create chemicals known as mediators, the main one 
central to CU being histamine (Zuberbier, Grattan and, Maurer, 2009). As illustrated in Figure 1.2 (p5) 
mast cells become activated and begin to degranulate releasing histamine and other mediators by a 
known (e.g. IgE) or unknown triggering factor. Mediators allow the leakage of other mediators and cell 
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components (e.g. proteins, water, electrolytes) through the walls of the blood vessels that lay underneath 
the skin by increasing the permeability of the skins capillaries via vasodilatation (the relaxing of the 
muscles of blood vessels as depicted on the bottom right half of Figure 1.2. 
 
Figure 1.2: CU Physiological Process 
 
 
These capillaries eventually become too congested resulting in skin inflammation, swelling on 
the skin surface (wheals) and in the deeper compartments of internal organs (angioedema; Schocket, 
2006). The sensation of itch occurs when pro-inflammatory mediators (e.g. histamine) activate neuro-
physiological pathways in the brain (Paus, Schemiz, Biro and Steinhoff, 2006). This can result in 
individuals becoming involved in an itch-scratch cycle where the scratching itself provides short-term 
relief but then triggers further histamine release in response to skin damage that results in more itch. 
 
1.2.2: Patho-Physiological Mechanisms  
A definitive cause of CU is not yet established and none currently predict CU course or inform 
treatment (Saini, 2011). Current theories fall into allergic-immunological, non-allergic immunological and 
non-immunological categories (Grattan and Humpreys, 2007) and are reviewed below:   
 
Allergic Immunological Mechanisms 
The evidence that CU is caused by an allergic reaction to foods is poor (Kulthanan et al. 2008;  
Kaplan and Greaves, 2009). In susceptible individuals, the first time the allergen enters the body it is  
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seen as a pathogen. This signal stimulates the immune system to develop allergy-specific antibodies 
called immunoglobin-E (IgE) that is created to respond to foreign substances. If the substances 
subsequently enter the body and bloodstream again they may combine to food allergen-specific IgE 
antibodies attached to mast cells activating histamine release (see Figure 1.4). 
 
Figure 1.4: Mast Cell with Functional Auto-Antibodies involved in CU* 
 
 *From Ortonne (2003) 
 
2. Non-Allergic Immunological Mechanisms   
Non-allergic immunological mechanisms differ in that agents other than IgE activate mast and 
basophils cells. These are reviewed below. 
 
a) CU is an autoimmune disease  
This research suggests that up to 45% of CU cases maybe implicated by autoimmune 
mechanisms. Ones immune system attacks its own thyroid gland and damage is caused by the formation 
of thyroid reactive T-Cells that penetrate the thyroid causing symptoms (Kaplan and Greaves, 2009; 
Sabroe and Grattan, 2006). This subset of CU is called chronic autoimmune urticaria (CAU). This theory 
stems from research suggesting that thyroid autoantibodies are more common in CU patients 
(approximately 30%) than the general population (5-10%; e.g. Bagnasco, Miniciullo, Saraceno, Gangemi 
and Benvenga, 2011; Sagdic, Sener, Bulucu, Karadurmus, Yamanelet et al. 2011). However, the severity 
of CU does not often relate to thyroid functioning and CU patients in studies usually have normal 
functioning thyroids (Kaplan and Greaves, 2009).  
  
b) Histamine releasing factors from the patient’s own serum or blood plasma 
This research suggests that there is a substance in the patient’s own sera that causes the  
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degranulation process and stems from positive ASST results to their own serum. In up to 50% of cases 
these substances usually identified as human immunoglobulins (or IgG) molecules have demonstrated 
that they are capable of starting the degranulation process in cells (Grattan, Hamon, Cowan, Kikuchi and 
Kaplan, 2002; Sabroe and Greaves, 2006; Saini, 2009). The shortcomings of this research again lie in 
the ASST and its non-specific results in patients with or without CU and health subjects (Konstantinou, 
Asero, Maurer, Sabroe, Schmid-Grendelmeier and Grattan, 2009).  
 
C) Abnormal cell functioning of mast cells and basophils 
These studies suggest a malfunctioning of mast cells and basophils in patients with CU where 
basophils with similar levels of cell histamine appear to be hypo-response to the anti-IgE auto-antibody 
and the escape of basophils to the skin during the degranulation process presents with lower basophil 
levels in CU patients than controls and correlates with disease severity (Greaves, Plummer, McLaughlan, 
Stanworth, 1974; Luquin, Kaplan, Ferrer, 2005; Caproni, Giomi, Volpi, Melani, Schincagliaet al. 2005; 
Grattan, Dawn, Gibbs and Francis, 2003). Studies have found that histamine release could be reduced 
via activating the IgE receptor but not other receptors in some CU patients (Cohen and Rosenstreich, 
1986). Vonakis (2007) labelled these CU patients as ‘responder’ and ‘non-responders’ of IgE 
autoantibodies. However, the distribution of responders and non-responders do not correspond to those 
labelled as autoimmune or idiopathic (Kaplan and Greaves, 2009).  
 
3. Non-Immunological Mechanisms 
Research has linked CU to many non-immunological mechanisms but the main ones involve 
infectious agents, pseudo-allergens and drug reactions.  
 
The strongest evidence for infectious agents comes from the bacterium helicobacter pylori (Wedi, 
Raap, Wieczorek and Kapp, 2010; Magan, Mishal, Schlesinger and Scharf, 2007; Di Camli, Gasbarrini, 
Nucera, Franceschi, Ojetti et al. 1998) that weaken the stomach wall allowing digestive juices to pass 
through. Wedi et al. (2010) reviewed helicobacter pylori in CU across 22 studies between 1994 and 2008 
 8 
 
and found that when the bacterium is eradicated from infected patients, symptoms are significantly 
reduced or go into remission, however more research is necessary in determine its role in CU 
pathogenesis (Shakouri, Compalati, Lang and Khan, 2010).  
 
CU has also been linked to pseudo-allergenic substances that mimic true allergic reactions. 
including food additives, foods rich in histamine, sulphites and nitrates (Mageral, Pisarevskaja, Scheufele, 
Zuberbier and Maurer, 2010; Bunselmeyer, Laubach, Schiller Stanke, Luger and Brehler, 2009; Henz 
and Zuberbier, 1998; Haustein, 1996) however non-steroidal anti-inflammatory drugs (NSAIDS) including 
ibuprofen and aspirin can induce pseudo-allergenic reactions (Mastalerz, Setkowicz and Szczeklik, 
2005).  
 
1.2.3: Personality and Psychological Mechanisms  
There is a growing research literature on the role of personality and psychological factors as a 
cause of CU and this has primarily focused on CU personality traits and stressful life events. 
 
Psychological Stress 
The effect of psychological stress in the onset and maintenance pruritus in skin disorders has 
been postulated (Milard, 2005; Gupta and Gupta; 2004; Picardi and Abeni, 2001). Exactly how 
psychological stress as a non-immunological mechanism is related to CU process is not completely 
understood however research strongly suggests a role for stressful life events. Fava, Perini, 
Santonastaso and Fornasa (1980) found that patients with CU (n= 20) reported experiencing stressful 
life events prior to disease onset and Berino, Voltolini, Fiaschi, Pellegrini, Bignardi, et al. (2006) assessed 
30 patients with CU via semi structured interviews and confirmed that most had experienced a stressor 
within six months of disease onset. Stressors included bereavement, job stress, family problems and 
accidents. Malhotra and Mehta (2008) found that 16% of 16 patients had experienced a stressful life 
event within the year preceding CU onset and replicated the themes reported by Berrino et al. (2006). 
Using cluster analysis, Yang, Sun, Wa and Wang (2005) found that 6 months prior to onset patients with 
CU (n= 75) had higher weightings for stressful life events, somatic symptoms, severe insomnia, less 
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family support and negative coping than tineapedis patient controls (n= 133). Further in a study by Chung, 
Symons, Gillian and Kaminski (2010a), of 100 patients with CU 34% met the diagnostic criteria for post-
traumatic stress disorder and were 1.89 times more likely to have this than allergy controls independent 
of disease severity. This study supports the argument that CU is a form of post-traumatic stress disorder 
(PTSD) that requires further investigation (Gupta and Gupta, 2012; Hunkin and Chung, 2012). Such 
studies contribute to understanding CU process but limitations lay in the retrospective way stress has 
been measured and in determining the direction of the relationship.  
 
Personality  
Personality theories propose that pre-dispositional factors within individuals makes them more 
susceptible to developing illnesses (Baiardini, Abba, Ballauri, Vuillermoz and Braido, 2011; Willemsen, 
Roseeuw and Vanderlinden, 2008). CU itself has a history of being related to personality traits (Shipman, 
Shoemaker, Levine and Mally, 1959); Buffet, 2003) including alexithymia (i.e. difficulties self-regulating 
emotions) placing CU within a stress-diathesis model. However studies in this area like stressful life 
events have been retrospective so cause and effect has not been established. Pasaoglu, Bavbek, Tugcu, 
Abodoglu and Misirligil (2006) assessed personality traits and psychological status in 59 patients with CU 
and concluded that these individuals were more depressive, hysteric, touchy and suspicious with 
hypochondriac tendencies compared to health controls. They also appeared more in conflict with their 
social environment and needed perfectionism, external control, and love and approval from others. 
Barbosa, Freitas and Barbosa (2011a) similarly reported that those with CU experienced problems 
dealing with emotional arousal. Further 56.9% reached the diagnostic criteria for alexithymia that 
correlated strongly with an insecure attachment style, psychopathological symptoms and defence 
mechanisms that turn against the self, independent of clinical variables. Other studies have also reported 
similar findings in CU (Maniaci, Epifanio, Marino and Amoroso; 2006; Conrad, Geiser, Haidi, Hutmacher, 
Liedtke and Wermter, 2008; Ugus, Engin and Yilman, 2008; Staubach, Dechene, Metz, Magerl,  
Siebenhaar, et al. 2011).  
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Personality and stressful life event have also been implicated in the on-going maintenance of 
skin disorders. How such variables upon impact the thesis’ outcomes CU-related quality of life (QoL) and 
psychological distress will be discussed further in Chapter 2. Other factors have also been implicated in 
the origin/ maintenance of chronic skin disorders and these have included appearance schemas, illness 
representations, illness-related feelings/ distress, coping behaviours and socio-cultural factors 
(Thompson, 2005). As these individual socio-cognitive variables are yet to be comprehensively explored 
in CU and act as components of the Common Sense Model (the theoretical framework that will be used 
to explore new predictors of CU-related QoL) they will also be reviewed in Chapter 2  
 
1.3: Prevalence 
 
1.3.1: General Prevalence 
Determining how prevalent CU is in the United Kingdom (UK) general population and beyond is 
difficult to establish as no studies have been undertaken (Maurer, Weller, Bindslev -Jensen, Gimenez-
Arnau, Bousquet, Canonica et al. 2011; Maurer et al. 2010). Consequently data predicting who will be at 
risk of developing CU in the future is limited especially as a cause is unknown. The only study to report 
the prevalence of CU under current guidelines is that by Zuberbier, Balke, Worm, Edenharter and Maurer 
(2010) in 4093 German individuals. Zuberbier et al. (2010) found a CU lifetime prevalence of 1.8% (95% 
CI 1.4- 2.3%) and 12 month pre-assessment period prevalence of 0.8% (95% CI 0.6 - 1.1%). In studies 
of individuals with CU who also have physical urticaria between 33-67% experienced wheals and 
angioedema, 29-65% wheals only and 1-13% angioedema only (Maurer et al. 2010).  
 
1.3.2: Gender, Age and Other Socio-Demographic Factors 
It is unanimous from study data that women outnumber men by a ratio of at least two to one, 
irrespective of geographical location or time. (Maurer et al, 2011). Why this is so has not been formally 
studied. In contrast CU is prevalent at all ages but there is a consensus across studies that a substantial 
proportion of patients tend to be between twenty to fifty years old (Silvares et al. 2007; Kulthanan et al. 
2007; Ferrer, 2005; Kozel et al. 2001; Sibbald, Cheema, Lozinski and Tario, 1991)  
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CU studies are inconsistent in what socio-demographic variables they report beyond age and 
gender, however CU appears irrespective of occupational, financial, educational or marital status, 
geographical location or ethnicity (Ferrer et al, 2009; Zuberbier et al. 2010; Gaig et al. 2004; Bakke et al. 
1990) but exceptions exist. Herrmann-Kunz et al. (1999) and Silvares et al. (2007) reported a higher 
prevalence in urban city areas as well as those with high economic status and White ethnicity. 
 
1.4: Treatment and Disease Management 
1.4.1: Treatment 
Treating CU is complex as patients present with idiopathic aetiologies and many also have 
concurrent physical urticaria hence treatments are diverse. However, CU management guidelines are 
the same for all patients (Zuberbier et al. (2009b). The first strategy is to avoid the cause or eliciting 
mechanism but this is usually avoiding the acerbating factors as to the causes (Zuberbier et al. 2009b). 
Approaches include avoiding drug induced hypersensitivities and physical stimuli (tight clothing), 
eradicating infectious agents, treating inflammatory processes and reducing autoantibodies (Zuberbier et 
al., 2009b). Further, for some patients identifying pseudo-allergens can help reduce symptoms. The 
primary treatment for CU is H1 antihistamines and it is not unusual for clinicians to prescribe doses of up 
to 4 times the licensed recommendations (Maurer et al. 2011). H1 antihistamines are preferred over H2 
varieties that can cause sedation, impaired psychomotor functioning and reactions with alcohol and drugs 
(Zuberbier et al. 2009b). In up to 50% of patients H1 antihistamines are unresponsive (Mauer et al. 2010) 
and other drug treatments including immunological therapy and phototherapy are used (Bingham, 2008; 
Engin, Ozdemir, Balevi and Mevlitoglu, 2008).  
 
1.4.2: Self-Management and Treatment Adherence  
CU is managed on an outpatient basis and this requires patients to partake in health behaviours 
to control symptoms. Despite being provided with treatment advice during dermatological consultations 
Maurer, Ortonne and Zuberbier (2009a, b) in their European survey of 321 patients with CU found that 
although 78% were taking CU medicines only 33% took them preventatively, hence most waited until 
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symptoms began before starting treatment. Additionally 50% reactively used anti-itch lotions, a quarter 
did not avoid triggers to an outbreak and a third did not take medicines. Further, of the 83% of patients 
with CU under physicians care only 44% reported discussing symptoms that were not responding to 
treatment. There are health psychology theories that attempt to explain such behaviours and one 
explanation is that these individuals hold perceptions of their CU that effect how they cope and behave 
(Leventhal and Cameroon, 2003). For example twenty-five percent of patients in the Maurer et al. (2009a, 
b) survey believed CU to be a sign of personal weakness and a large proportion perceived that its 
emotional aspects were not addressed by health professionals and felt insufficiently educated about it. 
Illness perceptions indeed are said to develop from exposure to socio-cultural influences (e.g. doctors) 
and personal illness experiences. Illness perceptions and coping as components of the CSM (the model 
applied in this thesis) will be reviewed in detail in Chapter 2.  
 
1.5: Health Outcomes 
 
1.5.1: Physical Course and Prognosis 
Little is known about CU’s natural course and of the studies reporting data most have used 
selected study samples and findings have varied considerably. Twenty to 47% of patients reported going 
into remission after 1 year of onset (Kulthanan, et al. 2007; Toubi, Hessal, Avshovich, Bamberger, Sabo, 
Nusem and Panasoff, 2004; Kozel, Mekkes, Bossnyt and Bos, 2001; Julin, 1981) however this might be 
dependent on the healthcare service level. For example Van der Valk, Moret and Kiemeney 2002) 
evaluated 372 patients from a tertiary clinic from 1968 to 1990 and found a 29% remission rate but this 
was after five years of disease onset. Those experiencing CU for five to eight years have been reported 
to be between 11-15% (Gaig et al. 2004; Toubi, et al. 2004; Julin, 1981) and for ten years as high as 51% 
(Van der Valk et al. (2002).     
 
Few studies have reported data predicting the course of CU but Maurer et al. (2010) found 
consistent patterns across studies. Those diagnosed with more severe CU experienced more 
angioedema; a positive reaction to their own skin serum and concurrent physical urticaria appeared to 
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have the worst prognosis. Data across studies suggested that two years from diagnosis 64-70% of those 
with moderate-severe CU still experienced symptoms compared to those with mild CU who were 
symptom free (43-48%). Further 30% of moderate-severe patients continued to experience symptoms 
after 5 years. After one year 43-48% of those with wheals still had symptoms whereas this was much 
greater in those with wheals plus angioedema (64-70%) or angioedema only (80%) and this was also 
true for those with CU and physical urticaria.  
 
1.5.2: Socio-Economic Impact 
Even though the healthcare costs of CU have not been evaluated in the UK, the diagnostic 
process of the condition as well as the fact that patients need to take oral medication daily to control 
symptoms and attend specialist clinics (in addition to GP visits) suggests an socio-economic impact. Even 
though health services differ between countries, one often-cited European study provides some insight 
into what needs to be costed. Kapp and Demarteau (2006) explored costs (e.g. medications, medical 
procedures, hospitalisation, workdays lost) in 294 French patients for one month and reported total 
incurred annual costs of €2128.00 per patient (£1834.78). 
 
1.5.3: Quality of Life  
CU is now known to significantly impact quality of life and prior to the first documented study by 
O’Donnell and colleagues in the late 1990’s (O’Donnell et al, 1997), CU was described as a relatively 
‘benign’ non-life threatening condition with little impact on patient’s psychosocial functioning and QoL 
compared to other conditions (Grob Revuz, Ortonne, Auquier and Lorette, 2005; Grob and Guaudy-
Marqueste, 2006; Yosipovitch and Greaves, 2008). Using the Nottingham Health Profile (Hunt and 
McKenna, 1985) O’Donnell et al. (1997) published the reports of 147 patients with CU and discovered 
that almost half reported poor energy levels (47%) aand a third sleep problems (32.4%). Further 29% 
had experienced emotional reactions and 13.3% negative social interactions due to having CU. Mobility 
(7.1%) was also impeded for some. Further analysis (see Table 1.3, p14) revealed problems in at least 
38-56% of activities related to areas of daily life. As expected O’Donnell et al (1997) found itching 
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Table 1.3: Aspects of Daily Life Affected by CU- NHP* 
*Adapted from O’Donnell et al. (1997) 
 
swelling and pain as the most bothersome as well as affects on home management, personal care, social 
interaction, emotions and work (Table 1.4 below). Individuals were more affected if they also experienced 
angioedema and physical uticaria. In a second key study Poon, Seed, Greaves, Seed, Greaves and 
Kobza-Black (1999) used the Dermatology Life Quality Index (DLQI) confirmed that those with CU and 
co-morbid physical urticaria reported more impairments but these were also comparable to severe atopic 
dermatitis outpatients and worse than patients with psoriasis, acne and vitiligo.  
 
Table 1.4: Aspects of Daily Life Affected by CU- Study-Specific Questionnaire* 
Domains Item examples Affected (%) 
 
Home Management 
 
Housework, cooking, gardening, temperature regulation 
 
49-71              
 
Personal care 
 
 
 
Choice of clothes/ footwear 
Avoid changing rooms 
Washing temperature 
Diet restrictions to improve CU 
 
71  
57  
58  
54                                       
 
Recreation & Social 
interaction 
 
Restricted exercise, social life curtailed 
Cancelled social events, 
Sexual relationships 
 
                   ---- 
73  
73  
 
Mobility 
 
 
 
Take shorter distances  (always/ sometimes) 
Unable to run  (always/ sometimes) 
Avoid prolonged standing   (always/ sometimes) 
 
12/ 43  
10/ 35   
18/ 42      
 
Emotional factors 
 
Self image (e.g. less attractive, self-conscious, embarrassed) 
Anxiety – Condition would worsen/ Unpredictability of CU 
- Believe CU caused serious condition 
- Afraid of choking/ breathlessness 
 
46 
               42 
25 
20    
 
Sleep/ Rest 
 
Disruption 
Interference 
Daytime relaxation 
 
38  
54  
41-50   
 
Work 
 
1+ days lost (mean 6.4, range 1-31) 
Performance deterioration 
 
56  
74  
*Adapted from O’Donnell et al. (1997) 
 
 
Interests/ hobbies                                               56.0 
Social life                                                            51.0 
Sex life                                                               47.3 
Work                                                                   40.0 
Looking after the home                                      40.0 
Holidays                                                             48.0 
Home relationships                                            38.5 
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Further Baiardini, Giardini, Pasquali, Dignetti, Guerra et al. (2003) used the SF-36 and confirmed that 
individuals with CU experienced worse QoL than those with respiratory allergy and healthy adults. Berrino 
et al. (2006) using the NHP and DLQI confirmed previous studies that these patients had higher levels of 
psychiatric co-morbidity than the general population and had suffered from at least one major and 
significant stressor six months prior to disease onset. These key studies also collectively provided support 
that QoL is still impaired when socio-demographic and clinical variables are controlled for.  
 
Chronic Urticaria Related Quality of Life Measurement 
An observation of the key papers published on CU-related QoL above highlight that studies have 
used different QoL instruments to examine this relationship including measures of generic health status 
(i.e. SF-36, NHP) and disability (DLQI; Finlay and Khan, 1994) that miss important disease-specific 
information. Consequently although the impact of CU on outcomes is evident, comparison across studies 
is difficult in terms of indicating the intensity of this impact and which areas are most affected as 
instruments present with diverse items and domains. Baiardini and colleagues (2005) developed the 
Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) however consensus guidelines for assessing 
patient reported outcomes (PROs) and QoL in urticaria (Baiardini et al. 2011) highlighted the lack of 
reviews on the CU and QoL literature to gain an overall picture of the nature of this phenomenon and 
prognostic factors. A pilot search of the literature (using Medline, EMBASE and PsychINFO) by the 
current author (DB) confirmed that no systematic reviews existed. In light of this it was decided to 
undertake a systematic review of QoL in CU as a preliminary study to create consensus reference values 
on QoL in CU for comparative purposes in the thesis’ proceeding studies. 
 
1.5.4: Anxiety and Depression  
Anxiety and depression are two of the most implicated co-morbidities in CU (Berrino et al. 2006; 
Staubach et al. 2011) there is strong evidence to support that individuals with CU who report poorer QoL 
also tend to report significantly higher psychological distress (Staubach et al. 2006a; Engin et al. 2007; 
Ozkan et al. 2007; Uguz et al. 2008; Barbosa et al. 2011b), the reason psychological distress has been 
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chosen as a secondary outcome. To review the literature an electronic database search of Pubmed using 
the terms chronic urticaria, anxiety, depression, psych* and co-morbidity was undertaken. The findings 
provided strong evidence suggesting that individuals with CU experience high levels of anxiety and 
depression implicated not only in CU outcome but also its aetiology and maintenance (Buffet, 2003) 
suggesting a bi-directional relationship. For example Fava, Perini, Santonastaso and Fornasa (1980) 
found that those with CU had not only experienced a stressful life event immediately before disease onset 
but also experienced significantly more anxiety and depression than fungal infected controls. Gupta, 
Gupta, Schork and Ellis (1994) further found that clinical depression can modulate perceptions of pruritus 
(i.e. itch perception) in CU, but also considered that the depression could also be secondary to the pruritus 
itself. To support this further Berrino et al. (2006) interviewed 30 individuals with CU of which nearly two-
thirds had experienced a stressful life event six months prior to CU onset associated with depression and 
anxiety and Chung, Symons, Gillianand Kaminski (2010a) in a CU sample of 100 patients found that 
these individuals where 1.8 times more likely to have a post-traumatic stress disorder (PTSD) than those 
with allergy and this PTSD significantly related to psychiatric co-morbidity.  
 
The prevalence of anxiety and depression in CU is difficult to determine as studies have 
consisted of heterogeneous samples (e.g. Os-Mendendorp, Eland de Kok, Grypdonck, Bruijnzeel-
Koomen et al. 2006; Coskun et al. 2005). Referring to the database search of CU co-morbidity it was 
revealed that studies consisted largely of females in their mid-thirties to forties (see Table 1.5, p17 below) 
and despite the limited number of studies reflects the typical socio-demographic representation of this 
patient population described in section 1.3. Prevalence rates of anxiety and depression varied 
considerably from 12% to 76.1% for the former and 17% to 43.3% for the latter. The discrepancies 
between studies may be explained by the range of screening and diagnostic instruments used and 
sample characteristics, although in most instances around a quarter to a third score above the cut-off 
point for at least mild disorder. What was consistent were that individuals with CU suffered significantly
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Table 1.5: Socio-demographic Characteristics and Prevalence of Anxiety and Depression in CU 
 
 
First Author 
 
 
N 
 
 
Gender 
Female 
 
Age 
Years 
 
                        Instruments 
Diagnostic                      Screening 
 
Anxiety 
Prevalence (%) 
 
Depression                                          
Prevalence (%)               
 
Badoux & Levy 1994◊ 
Barbosa (2011) 
Berrino (2006) 
Bzoza (2011) 
Chung (2010) 
Conrad (2008) 
Engin (2007) 
Hashiro & Kuma (1994) 
Ozkan (2007) 
Staubach (2011) 
Uguz (2008)* 
 
74          
55 
30 
54 
100 
55 
73 
30 
84 
100 
30 
 
------- 
78.0% 
83.3% 
63.0% 
82.0% 
87.0% 
58.9% 
NR 
84.0% 
69.0% 
68.2 
 
--------------- 
45.3 ± 16.1 
44.0 (21-40) 
33.0 median (19-46) 
46.5 ± 14.10 
49.6% 18.5 
27.0 ±10.8 
39.1 ± 15.7 
36.83 ± 10.26 
43.80 ± NR 
36.84 ± 12.90 
 
NR 
DSM Interview 
DSM Interview 
NR 
NR 
DSM Interview 
NR 
NR 
SCID-1 
MINI-DIPS 
SCID-1 
 
BSI*    
HADS** 
BDI*** 
STAI▲/ BDI 
GHO-28▼ 
SCL-90R●                                                                 
BAI/ BDI 
MAS○/ SDS◄ 
NR 
HADS/ SCL-90R 
NR 
 
----------- 
76.10% 
25.00% 
NR 
NR 
NR 
NR 
40.00% 
12.00% 
30.00% 
13.50% 
 
-------------- 
NR                              
25.00%                       
24.00%                            
NR 
NR 
NR                                                                             
43.30%                       
40.00%                             
17.00% 
43.30% 
 
NR: Not reported 
◊Some data missing as information taken from abstract, as paper could not be retrieved 
*Brief Symptom Inventions, **Hospital Anxiety & Depression Scale, ***Beck Depression Inventory, ▲Spielberg State-Trait Anxiety Inventory, ▼General Health Questionnaire-28,  
●Symptom Checklist 90-Revised, ○Manifest anxiety scale, ◄Self-rating Depression Scale 
*All scores for Axis 1 diagnosis only
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higher anxiety and depression than health controls (Barbosa et al. 20011b; Bzoza et al. 2011; Engin et 
al. 2008; Uguz et al. 2008; Conrad et al. 2008; Hashiro and Kuma, 1994; Badoux and Levy, 1994; 
Sheenan-Dare et al.1990) and patients with allergy (Chung et al. 2010b).  
 
Predictors and Prognosis 
Individuals with CU appear to experience anxiety and depression irrespective of gender, age, 
marital or occupational status (Barbosa et al. 2011b; Uguz et al. 2008; Berrino et al. 2006), however one 
study found that women were more affected than men (Badoux and Levy, 1994) and Barbosa et al. 
(2011b) found significant differences for educational status where Uguz et al. (2008a) did not. Individuals 
with CU also appear to experience both co-morbidities regardless of clinical variables (Barbosa et al. 
2011b; Uguz et al. 2008a; Ozkan, Oflaz, Kocaman, Ozseker, Gelincik and Buyukozturk, 2007; Chung et 
al. 2010b). Studies have further found that anxious and depressed individuals with CU are more likely to 
score near cut-off points for other psychiatric co-morbidities than those with CU alone (Staubach et al. 
2011; Barbosa et al. 2011a; Chung et al. 2010b; Maniaci et al. 2006). In this thesis psychological distress 
will also be explored within the CSM to determine cognitive representations as predictors excluding 
participants with co-morbidities that my act as co-variates.  
 
1.6: Conclusions 
Bio-medical approaches to CU do not completely explain CU process nor inform what 
interventions improve outcomes. Because CU is a multi-faceted illness, the thesis proposes that 
understanding CU more bio-psychosocially through socio-cognitive models may further help to 
understand it more and inform new interventions adjunct to medical care. CU places great demands on 
those who experience it. Consequently, it is not surprising that CU has effects on quality of life outcomes. 
There is now strong evidence to support that individual’s across illnesses hold cognitive representations 
of their illness that (through coping behaviours) predict illness outcomes including QoL and distress, 
hence these predictors my help explain some of the variance in CU outcome yet explained. Perceptions, 
coping and outcome within the Common Sense Model is reviewed in Chapter 2 
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Chapter 2 
The Common Sense Model: Self-Regulatory Process and Intervention 
“It's been 3 years since I have been diagnosed with CIU [chronic idiopathic urticaria]. My allergist ran numerous tests to find a cause but it 
was useless. However I think stress triggers it because I noticed that when I am highly stressed it will appear...this is not a fact though. CIU 
is so unpredictable. You could be free of it one day and the next day, you wake up with a swollen lip, eye or nose. I really hate when that 
happens. It saddens me because there are times that I'm so swollen and itchy that I can't go to work or even go out. .My allergist prescribed 
Allegra but I think my body has grown accustomed to it so I started taking Zyrtec...it works well .I really wish there was a real cure for CIU!”  
Woman with CIU, Patient Experience UK forum (www.patient.experience.co.uk) 
 
2.0: Chapter Scope  
It has been proposed that an individual’s response and adaptation to chronic illness is best 
explained as a self-regulatory process (Di Ridder and Di Witt, 2006; Cameron and Leventhal, 2003). The 
Common Sense Model (or CSM) focuses on explaining how one comes to represent beliefs about their 
illness. In chronic spontaneous urticaria (CU) this is important as illness perceptions have been found to 
guide coping actions and predict outcomes (Hagger and Orbell, 2003). This chapter reviews the CSM, 
the literature supporting its’ components (cognitive representations) as predictors of quality of life and 
psychological distress and studies of the CSM in dermatological conditions and interventions. The 
chapter ends with the thesis research questions. 
 
2.1: Self-Regulation of Health and Illness  
 
2.1.1: Self-Regulation  
It has been suggested that any system able to problem solve has the ability to self-regulate 
(Powers, 1973). Self-regulation is said to be a human being’s inherent ability and motivation to set 
meaningful goals and achieve them through directed behaviours that remove barriers to those goals 
(Scheier and Carver, 2003). The concept of self-regulation itself in psychology is a considerable leap in 
the understanding of human behaviour as prior to Bandura’s Social Cognitive Theory and the concept of 
self-efficacy (Bundura, 1977) cognitive processes and behaviours where theorised as independent of the 
motivational and external socio-cultural influences that may impact them (DeRidder and De Wit, 2006). 
There are differing approaches to understanding self-regulation (e.g. Baumeister, Bratslavsky, Muraven 
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and Tice, 1998; Prochaska and DiClemente, 1984) however they do share the communality of placing 
the individual as an active component of behaviour, focusing on purposeful goals and making efforts to 
reach them through volitional processes (see Dr Ridder and De Wit, 2006 for a review). One such 
approach is underpinned in Cybernetic Control Theory (Miller, Galanter and Pribram, 1960). In this 
simplistic conceptual model self-regulation is governed through a TOTE (i.e. Test, Operate, Test, Exit). 
Firstly the problem-solving system needs to test its existing position (the input stimuli) against an 
appropriate reference value before it can then operate a sequence of events to reduce the discrepancy 
between the two. It then undergoes another Test to determine if the desired outcome is fulfilled. If solved 
the system will Exit, if not it will feedback to operate and try again until this is achieved. It is this simple 
mechanism that lays the foundation of generic self-regulation theories such as that by Scheier and Carver 
(2003) but motivation and self-efficacy can be impacted by external influences and it is these factors that 
bring the socio-cognitive element to such models when applied to human behaviour. 
 
 
The CSM was extensively developed by Leventhal and colleagues (Leventhal, Meyer and 
Nerenz, 1980; Leventhal, Nerenz and Steele, 1984; Leventhal, Diefenbach and Leventhal, 1992) is a 
step further from Scheier and Carver’s model in that it contains both the framework (that explicitly shows 
what is being regulated) and the specific contents presenting how this self-regulation is achieved. A core 
feature of the CSM is the assumption that the goal of self-regulating illness is not only one of dealing with 
and resolving the physical self (i.e. those concrete perceptual experiences of bodily sensations and 
symptoms of illness) but also the subjective self: the emotional responses to illness threat (Leventhal, 
Brisette and Leventhal, 2003). The strategies adopted to regulate the self are said to be dependent on 
how the illness was originally interpreted and the resources available to achieve better health influenced 
by ones socio-cultural environment. Socio-cognitive models of health behaviour such as the Theory of 
Planned Behaviour (TPB; Ajzen, 1991) and Health Belief Model (HBM; Rosenstock, 1974) contain basic 
elements of self-regulatory processes but tend to emphasise intentions towards changing specific acts 
which is not the same as the higher order nature of goal setting, as one does not always carry out ones 
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intentions, and further one may act against them (de Ridder and De Wit, 2006). Similarly the concept of 
perceived control is not the same as goal striving through volitional processes as individuals do not 
always undertake behaviours they believe are within their control. Equally socio-cognitive models focused 
on attitudes towards change (Theory of Reasoned Action or TRA, Ajzen and Fishbein, 1980) do not fully 
explain the impact of social relationships on self-management. Even though a positive evaluation of an 
action by others may create a norm promoting it, it says nothing about the role the social environment 
plays in acquiring the skill of that action, how effective the observation of important others were or how 
both can shape the representation of health threat and self-management (Cameron and Leventhal, 2003). 
The CSM differs from these models in that intentions/ attitudes towards health threats are not only 
concrete (e.g. experiencing symptoms, emotions), but abstract cognitive (discussed later). 
 
2.1.2: The Parallel Response Model 
The CSM itself is a more content driven version of the Parallel Response Model (Leventhal, 
1970) presented graphically in Figure 2.1 below.  
 
Figure 2.1: The Parallel Response Model 
 
 
 
 
 
The parallel response model emerged as a successor to the Fear-Drive model by Doller and 
Miller (1950) who used it to theorise the impact of fear communication on health behaviours. Applied to 
health, fear was assumed to be a motivational state, hence procedures undertaken to reduce the fear 
could be reinforced and learnt. Leventhal and colleagues carried out a series of experiments to test these 
assumptions. In summary it was hypothesised that a high fear message (e.g. smoking kills) teamed with 
an action plan (attend clinic) would be more effective in eliciting adherent health behaviours (stop 
smoking) than low fear messages teamed with an action plan. It was found that high fear messages were 
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more effective in changing attitudes to change but this effect only lasted for one to two days. More 
detrimental was that the impact of the high fear message was not significantly better than the low fear 
message in eliciting actual health behaviours, however as the action plan alone was a poor predictor of 
taking up behaviours, it was evident that the fear itself was still a necessary factor in eliciting attitudes 
and behaviour (e.g. one will not attend a vaccination appointment if there is no fear of contamination). 
They proposed a parallel response model hypothesising that in the face of an illness threat one holds not 
only a cognitive representation of the fear that requires coping procedures for fear control (emotional 
responses) but also a cognitive representation of the illness that also requires coping strategies for 
danger control, These processes occur in parallel and serve as the interpretation of the illness threat (the 
input) against where one wants to be: healthy and emotionally regulated (the reference value). It is the 
interpretation of these processes that guide the operation of coping procedures (i.e. do something or 
nothing) that are appraised to determine if congruency has occurred (test) and if not act as the feedback 
mechanism to try something else until the outcome is satisfactory. 
 
2.2: The Common-Sense Model of Illness Perceptions (CSM) 
 
2.2.1: The Symmetry Rule  
As highlighted in Section 2.1.2 motivation to change behaviours in the face of an illness threat 
was not due to fear communication but by some component of it being interpreted by representations of 
fear and perceived danger driving a motivation to adopt coping procedures. Experiments allowed for 
conclusions to be drawn suggesting that motivation was driven for danger and fear control (i.e. cognitive 
and emotional representations) based upon the individuals concrete subjective sensations and 
experiences of symptoms (or procedures), their interpretation of them and at the same time by referring 
to higher order cognitive schemas of how these sensations and experiences are interpreted. Johnson 
and Leventhal (1974) demonstrated this bi-level phenomenon in patients undergoing an endoscopy 
(procedure involving a tube being inserted down the oesophagus). They found that if the patient 
interpreted the procedure as a threat they were more likely to become anxious and gag during the 
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procedure, however if they were primed beforehand that the procedure was non-threatening (i.e. 
changing the cognitive schema of the concrete sensations) and given instructions for coping, the fear 
was reduced or diminished resulting in less gagging (as the concrete sensation was deemed normal or 
less threatening). Research by Meyer, Leventhal and Gutman (1985) further demonstrated that this bi-
level phenomenon was not only limited to emotional fear but was evidently also true for illnesses identity. 
In patients with hypertension they found that 90% held concrete perceived experiences of their condition 
(e.g. face flushing), which from their cognitive schema indicated what that, meant (e.g. blood pressure 
going up). In contrast, 80% of this sample also reported that people could not actually tell when their 
blood pressure was going up (knowledge in cognitive schema) and this was represented by a concrete 
experience (I have no symptoms). Meyer et al. (1985) termed this incessant need to connect bi-level 
concrete (bottom-up) and abstract (top-down) processes (i.e. linking symptoms to labels and with this 
label identify symptoms) as the symmetry rule.  
 
In a further key study Easterling and Leventhal (1989) determined how the symmetry rule 
affected the parallel representation of fear (or emotion). They found that regardless of whether women 
had cancer in the past or never at all, those who had experienced non-cancer symptoms were more likely 
to worry about getting future cancer if they perceived that this was more of a reality for them. In line with 
this, those who reported no symptoms, although believing that cancer would occur in future reported no 
fear. In contrast women who experienced symptoms but perceived them to be unrelated to cancer also 
worried less. Cameron and Leventhal (2003) equate these processes as similar to Schachter and 
Singer’s (1962) theory of cognitive labelling (a bottom-up physiological arousal and its top-down 
interpretation creating emotional responses). 
 
2.2.2: Symptom Perception and Social Messages 
Leventhal’s CSM proposes that individuals deal in parallel with the emotional and illness 
perceptions of an illness threat, however it also hypothesises how these representations initially develop 
through one’s personal experiences of illness. Much of the initial research on symptom perceptions was 
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undertaken by Pennebaker and colleagues (Pennebaker and Skelton, 1981; Pennebaker, 1982; 
Pennebaker, 1983) who demonstrated in a series of studies how one perceives symptoms is influenced 
to some degree by how much one focuses on internal states and how this is interpreted from their 
cognitive schema. In one study participants were led to believe that an ultrasonic sound would either lead 
to an increase in skin temperature or a decrease while a third group were told nothing about what the 
outcome should be. They found that those who were primed cognitively to expect a temperature rise 
reported more increases in their temperature change and their finger getting warmer as emitted through 
a thermostat. The opposite was reported for those expecting a temperature drop. The pertinent part of 
this study was that the ultrasound was faked and the temperature remained constant across all 
participants. It was concluded that schemas could influence reports of somatic body sensations in a 
concrete or abstract way. The reporting of the sensations confirmed what was expected from the 
ultrasound signal, however focusing more intensively on internal body sensations was found not to equate 
to the accuracy of the sensation. In the CSM, it is these symptom perceptions that are subject to individual 
differences in interpretation that form representations of danger and fear. 
 
Not all cognitive representations develop though symptom perceptions as how one interprets 
present or future symptoms might be influenced by one’s socio-cultural environment. It is not unusual for 
individuals to form their knowledge of illness, what to expect from it and how to interpret it from others 
such as family, friends and work colleagues (Scambler, 1981). This information seeking has been termed 
as one’s lay referral system (Freidson, 1970) where decisions of whether to visit the pharmacy or seek 
professional help maybe influenced by a significant other who has experienced similar symptoms. Also 
a formal diagnosis might be provided by a GP and research has suggested that how this is presented 
can affect how the individual interprets the illness as a problem (Ogden, Branson, Bryett, Campbell, 
Febles, Ferguson et al. 2003). In their study Ogden et al. 2003 found that individuals felt that they were 
being taken more seriously and were more trusting of the doctor’s ability when presented with the 
illnesses medical term as to the lay. Further Taylor and Ogden (2005) found that the description of an 
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illness as heart failure as to fluid on the lungs due the heart not pumping enough lead to perceptions of 
more devastating consequences and higher psychological distress. Individuals are also surrounded by 
media messages of illness threats and culture and religion can further affect how symptoms are 
interpreted (Zoller and Worrell, 2006; Liddell, Barrett and Bydawell, 2005). Zoller and Worrell (2006) 
looked at how audiences interpreted depictions of multiple sclerosis from the television drama West Wing 
using qualitative methodologies and found that individuals made self-comparisons with the depictions 
which consequently had both physical and social consequences in terms of the accuracy and meaning 
of the perceived messages. Liddell et al. (2005) reviewed the literature on sub-Saharans illness 
representations of acquired immune deficiency syndrome (AIDS) and found that although biomedical and 
traditional depictions of its cause complemented each other, beliefs about its prevention conflicted as 
biomedical approaches challenged the integrity of cultural values and denied people in the culture the 
opportunity to shift blame outside of the self and their own behaviour. 
 
2.2.3: Support for Components of Cognitive Representations 
Even though symptom perceptions and social messages are said to influence the development 
of cognitive representations, it is the content specific components of these representations that have 
been the dominant focus of CSM research. In section 3.2.1 the symmetry rule was first introduced 
describing how individuals experience symptoms, search for abstract information and find a schema (or 
label) for that experience that in it is based on concrete evidence undertaken by searching for body 
sensations (Meyer et al. 1985). The development of the CSM in the late seventies was dominated by 
symptom (or illness) identity as a core domain, however later studies using semi-structured interviews, 
open-ended questionnaires and factor analytical techniques (Lau, Bernard and Hartman, 1989; Bishop 
and Converse, 1986, Lau and Hartman, 1983; Baumann, 2003) consistently found that regardless of the 
illness, illness perceptions (components of a cognitive representation) tended to cluster around the 
following five core dimensions (also depicted in the CSM diagram in Figure 2.2, p26). 
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o Identity: Original core domain involving applying labels to symptoms and symptoms to labels 
(e.g. ‘I am itching so I have hives’ or ‘I am about to break out in hives, I will itch) 
o Cause: Beliefs about what caused the illness (e.g. psychological stress caused my hives);   
o Timeline: Perceptions of illness duration (acute/ chronic) and reoccurrence (cyclical nature). 
o Consequences: The perceived severity and bio-psychosocial impact of the illness 
o Curability/ controllability: Beliefs about whether the illness can be cured or controlled.  
 
Figure 2.2: The Common-Sense Model  
 
o  
o  
o  
o  
  
The development of the illness perception questionnaire (IPQ; Weinman, Petrie, Moss-Morris and Horne, 
1996) provided a standardised way of measuring illness perceptions across differing illnesses, allowing 
for a more detailed study of the components and how they relate to other CSM components. The use of 
the IPQ lead to further developments as factor analysis of participant IPQ data provided evidence to 
suggest that individuals may construct perceptions of illness timeline, duration and reoccurrence 
separately (Moss-Morris, Weinman, Petrie, Horne, Cameron and Buick, 2002). Further the items 
representing the cure/ control domain were found to load onto two factors named personal control beliefs 
and treatment control (Moss-Morris et al. 2002). These lead to the development of the Revised Illness 
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Hagger and Orbell (2003) to undertake a meta-analytic review consisting of a diverse range of chronic 
illnesses over 45 studies that provided further strong support for the five dimensions. A major finding was 
that individual illness perceptions significantly inter-correlated in similar and very predictable patterns. In 
summary positive relationships were found between the identity, timeline and consequences subscales 
and negative relationships were found between these three subscales and the curability/control 
subscales. Hagger and Orbell (2003) have argued that individual factor analyses are not necessary as 
data from generic and disease-specific versions of the IPQ and IPQ-R have produced similar findings. 
Factor analyses in cervical cancer (Hagger and Orbell, 2005), myocardial infarction (Brink, Alsen and 
Cliffordson, 2011) and diabetes (Abubakari, Jones, Lauder, Kirk, Devendra and Anderson, 2011) have 
largely supported this viewpoint however Wittkowski, Richards, Williams and Main (2008) failed to 
replicate the IPQ-R factor structure in atopic dermatitis. 
 
2.2.4: Coping  
Even though much of the research on the CSM has focused on cognitive representations they 
are said to guide coping procedures. In line with self-regulation theory, coping procedures are the action 
plans to achieving goals for fear and danger control. Its position in the model as a mediator separates 
coping in the CSM to that of generic coping models (Lazarus and Folkman, 1984; Scheier and Carver 
and Weintraub, 1989) as cognitive representations act as antecedents influencing how to cope. This 
cognition-coping link is known as the IF-THEN rule (Anderson, 1983; Brownlee et al. 2000). 
 
The IF-THEN rule 
The IF refers to the cognitive representation that help to define outcome expectancies and the  
THEN is the coping action (e.g. IF my symptoms get worse THEN I must visit my GP). As the relationship 
between both is bi-directional, the appraisal of the coping action may also change the cognitive 
representation. Coping actions are related to causal attributions in that perceiving a stomach ache to be 
caused by food may result in taking over the counter medications; however perceiving it to be caused by 
a stomach tumour may result in a GP visit, but goals must be relevant in terms of disease management, 
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hence outcome expectancies also result from perceptions of consequences, timeline and dose-
responsive curability/ controllability beliefs. For example a relevant goal for a headache is to take 
painkillers, however individuals have their own timeline for when this procedure will work (e.g. twenty 
minutes). Further curability/ control expectations will be dependent on the strength of the dosage taken. 
In summary IF-THEN rules have been linked to heuristics that govern them including the symmetry rule 
described extensively earlier, the stress-illness rule (i.e. attributing symptoms to acute stress; Cameron, 
Leventhal and Leventhal, 1995) and the age-illness rule (attributing symptoms to aging; Leventhal et al. 
2003; both associated with the avoidance/ delay of seeking help) and the duration rule (i.e. perceiving 
long illness timelines with worse disease severity; Mora, Robitaille, Leventhal, Swigar and Leventhal, 
2002) and the prevalence rule (perceiving rare illness as more severe; Kahneman and Tversky, 1973).  
 
Risk Perceptions 
A second aspect of the IF-THEN rule is considering the risks and benefits of the coping 
procedure. For example if one believes that a medicine is addictive despite its effectiveness, this will 
impact on whether the coping action will be implemented. Risk perceptions (or collectively a risk 
representation) have been studied in terms of likelihood and severity estimates that are postulated to be 
underpinned by the individual perceptual components of illness representations that are driving emotions 
and behaviours (Cameron, 2003). The illness perceptions of identity, cause and timeline are associated 
with the generation of likelihood estimates of whether one will become ill whereas consequences and 
controllability are said to act as severity estimates and like the perceptions eliciting them, do so as 
concrete-perceptual (bottom-up) and abstract-conceptual (top-down) processes. Firstly the risk that one 
is in disease progression may emerge from identifying concrete symptoms as a risk indicator (e.g. I’m 
showing signs of more hives) and linked to a clear abstract label for the risk (e.g. acceptance of diagnosis 
from doctor). Likewise risk can be estimated by cause concretely (e.g. visions of parent being ill) and 
abstractly (e.g. the illness is genetic) and timeline in terms of abstract perceptions of when particular 
illnesses occur (e.g. diabetes in mid 40’s) and concrete evidence (e.g. ‘I’m in my forties so at risk’). In 
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terms of severity, individuals may have concrete images of how worsening symptoms will impact on social 
life with abstract knowledge of this possibility from others and controllability in terms of severity appraisals 
(e.g. the risk of not utilising strategies for control). Risk representations have been shown to act 
independently of emotional representations that influence how information is processed in that worry has 
been demonstrated to predict behaviour where risk judgement has not. For example Cameron and 
Diefenbach (2001) found that worrying about breast cancer (as to perceived risk) predicted an interest in 
genetic testing. Interestingly in another study Cameron, Booth and Schlatter (2003) found evidence 
suggesting that worry and risk can have opposing influences. They studied worry about re-occurring 
breast cancer and found that perceived risk was not highly related to worry, in fact the risk perception 
reduced women’s reported alcohol intake whereas worry increased it, despite high levels of motivation to 
adopt new behaviours to reduce risk. 
 
Despite studies like the ones described above (including those on cognitive representations), 
few studies have been published examining how coping procedures and IF-THEN rules are held in one’s 
cognitive schema, however a recent study by Henderson, Orbell and Hagger (2009) found that the 
effective use of a coping strategy in the past is assimilated into ones episodic and working memory, 
hence this representation elicits the goal strategy and not personality traits of coping and actions that are 
less amenable to change. To demonstrate this Henderson et al. (2009) primed participants who had 
either used lozenges or not as a coping strategy (with a control group) for illness words related to the 
common cold. Measured by response time, individuals who were primed or were past users of the coping 
procedure did show more attention bias for both the common cold and its remedy. More traditionally 
relationships between illness perceptions and coping tend to find that a strong identity, chronic timeline 
and serious consequences positively relate to emotional expression and avoidance/ denial coping 
behaviours (Hagger and Orbell, 2003) and cure/ control perceptions in contrast to greater use of cognitive 
appraisal/ problem focused coping and seeking social support.  
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Measuring Coping as a Mediator between Illness Perceptions and Outcomes 
The section so far has focused on coping behaviours and the antecedent influence of cognitive 
representations (i.e. the IF-Then rules) however the purpose of such coping procedures in the CSM is to 
attain goals to better outcomes (see Figure 2.2, p26). Indeed, a considerable proportion of research to 
date has found illness perceptions to bear significant relationships to a range of health and illness 
outcomes. For example, Illness perceptions have been found to be significant predictors of treatment 
adherence (Telles-Correia, Barbosa, Mega and Monteir, 2012; Whitmarsh, Koutantji and Sidell, 2003; 
Jessop and Rutter, 2003) and help seeking behaviours (Hurt, Burns, Brown and Barrowclough, 2012; 
Pryce, Metcalfe, Hall and Claire, 2012; Lawson, Lyne, Bundy and Harvey, 2007) as well as physical 
disability in gout (Dalbeth, Petrie, House, Chong, Leung, Chequdi et al. 2011) and survival rates in 
haemodialysis patients (Chilcot, Wellsted and Farrington, 2011). The most pertinent findings have been 
summed in Hagger and Orbell’s (2003) meta-analytic review of 23 conditions across 45 studies.  
 
In their meta-analysis Hagger and Orbell (2003) found that a high illness identity, perceptions of 
serious consequences and a chronic timeline significantly related to lower scores on adaptive outcomes 
(e.g. QoL, health status) and higher scores on maladaptive ones (e.g. psychological distress. Further 
illness perceptions have been found to be significant predictors of QoL and psychological distress, which 
as the respective primary and secondary outcomes of the current thesis will be reviewed, in further detail 
later in the chapter. Much of this research has been cross-sectional in nature but more recently published 
longitudinal studies do support this effect across illnesses (Griva, Davenport, Harrison and Newman, 
2012; Chaboyer, Lee, Wallis, Gillespie, Jones, 2010; Kaptein, Bijsterbosch and Scharloo, 2010; Fischer, 
Scharloo, Abbink, vanHul, van Ranst and Rudolphus, 2010), however the relationship between 
representations and outcome is said to be mediated by coping (see Figure 2.2) Even though studies have 
regressed coping behaviours on outcome finding it a significant contributor in certain aspects with illness 
perceptions (Lawson et al. 2007; Whitmarsh et al. 2003) very few studies have tested for mediation in 
the CSM (Hagger and Orbell, 2003) and of those that have findings have been mixed. Where some have 
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established some mediation (e.g. Evans & Norman, 2009; Rutter and Rutter, 2002), others have failed 
(e.g. Hurt, Burns, Brown and Barrowclough, 2012; Scharloo, Kaptein, Weinman, Hazes and Willems, 
1998; Scharloo, Baatenburg de Jong, Langeveld, van Velzen-Verkaik and Doorn-op den Akker, 2005; 
Bergman and Rooijmans, 1998; Heijmans, 1998; Kaptein, Helder, Scharloo, Van Kempen, Einman, Van 
Houwelingen andRoos, 2006; Kemp, Morley and Anderson, 1999; Moss-Morris, Petrie and Weinman, 
1996). Studies using the CSM to explore predictors of QoL and psychological distress outcomes are 
reviewed in section 2.3 (p36). 
 
Even though they did not test for mediation in their meta-analytic review Hagger and Orbell 
(2003) argued that studies might have failed to establish mediation is because they have used generic 
measures of coping. However, as there are studies showing a meditational role for coping using such 
measures (e.g. Lawson et al. 2007; Rutter and Rutter, 2002; Whitmarsh et al. 2003) this view is 
questionable. As the role of coping in the CSM is conflicting, it will be tested as a mediator in the thesis. 
 
2.2.5: The Extended CSM: Treatment Perceptions 
 
Treatment perceptions 
This chapter so far has reviewed the CSM as a way of operationalising illness perceptions 
however studies in the late 1980’s to 1990’s (e.g. Conrad, 1985; Fallsberg, 1991; Britten, 1994; Morgan 
and Watkins, 1988) led Horne (1997) to propose that individuals also have representations of their 
treatment. For example Britten (1994) explored beliefs about medicines in 30 patients via semi-structured 
interview and found themes related to perceptions of the properties of medicines, preferences of taking/ 
not taking medications and usage. They concluded that patients take medicines but also worry about side 
effects. Further Conrad (1985) undertook 80 interviews regarding patient’s medication management and 
concluded that what doctors perceived as non-adherence was often the patient’s attempt to regulate 
illness through remaining independent, de-stigmatised and developing their own practice, themes 
replicated later by Shoemaker and Ramalho de Oliveira (2008).  
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The theorisation of treatment perceptions originally stemmed from trying to understand why 
patients did not adhere to prescribed medicines as the earlier literature tended to focus on their ability to 
take medicines (e.g. misunderstanding instructions, forgetting) but ignored the role of motivation (Horne, 
1997, 2003). Although it is an important outcome the aim of the thesis was to keep the study of cognitive 
representations of illness and treatment to adding something novel to the relationship between CU and 
its impact on quality of life (QoL) and psychological distress. Further treatment perceptions is being 
studied here in relation to how it relates to illness perceptions as part of the overall model fit of an 
extended common-sense model of both quality of life and psychological distress as CU outcomes. 
Relationships between illness and treatment perceptions are reviewed in further detail later. 
 
Evidence for Treatment Perceptions and Measurement 
Horne and Weinman (1999) conducted further research on 1200 individuals with a diverse range 
of conditions including cardiovascular disease and renal impairment and found that the need to take 
similar medicines differed among individuals with the same illness. For example while some believed that 
their health depended on medicines, others believed that medicines would protect them from getting 
worse or from being constantly ill, however a fifth of patients were unsure about the necessity of their 
medicines. Overall they found that patient’s perceptions of their prescribed medicines or treatments could 
be themed into one of the following two dimensions: 
o Specific necessity: Perceptions of the necessity of taking medicines/ treatments as prescribed  
o Specific concerns: Concerns about the negative side effects of medicines or treatments. 
 
Horne (1997) noted that necessity and efficacy beliefs were not the same as a patient might see a 
treatment as effective in controlling symptoms but feel that they do not need it. Studies regarding patients 
concerns about their medicines suggested that concrete experiences of negative side effects and the 
daily intrusiveness of medication routines teamed with fears about long-term usage (e.g. addiction, harm 
to body) appeared to be consistent across illnesses and cultures (Horne et al, 1999; Horne and Weinman, 
1999). Concern beliefs may also be influenced by their perceptions of personal sensitivity to the side-
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effects of ‘harmful’ treatments and the overuse by doctors (Horne, Faasse and Cooper, Diefenbach, 
Leventhal, Leventhal et al. 2013). Early findings led to the development of the Beliefs about Medicines 
Questionnaire (BMQ; Horne, Weinman and Hankins, 1999) which provided a more systematic way of 
assessing treatment perceptions which also reflected further themes regarding general concerns about 
the harmful effects of medicines (general harm) and their overuse by doctors (general overuse). Since 
it’s development subsequent studies have been able to replicate the necessity and concerns factor 
structure and general harm and overuse dimensions (e.g. Mahler et al. 2012, De las Cuevas, Rivero-
Santana, Perestelo-Perez, Gonzalez-Lorenzo, Perez-Ramos and Sanz, 2011; Iihara, Suzuki, Kurosaki, 
Morita and Hori, 2010; Francis, Wileman, Bekker, Barton, Ramsay and REFLUX Trial Group, 2009) 
supporting the hypothesis that individuals hold cognitive representations of treatment. As the thesis is 
only concerned about views regarding disease-specific treatment, the remainder of this section will be 
limited to the necessity-concerns framework. 
 
Mechanisms of Treatment Perceptions 
Even though necessity and concern beliefs are two distinct concepts the necessity-concerns 
framework (Horne, 2003) proposes that individuals have to balance the benefits of taking prescribed 
medications or treatments against the costs (i.e. a cost-benefit analysis). For example a medication may 
relieve symptoms short-term but cause harmful side effects long-term. The literature on necessity-
concern beliefs suggest that patients tend to believe more in the necessity of their medicines (range 64-
90%) and hold fewer concerns (32.0%- 47.7%; e.g. Nicklas, Dunbar and Wild, 2009; Neame and 
Hammond, 2005; Horne, Sumner, Jubraj, Weinman and Frost, 2001, Horne and Weinman, 1999) and 
with few exceptions (i.e. disease severity) this appears to be unrelated to socio-demographic and clinical 
variables. Findings also suggested that necessity beliefs positively correlated to treatment uptake and 
the reverse was evident for concerns (e.g. Horne and Weinman, 1999; Nicklas, Dunbar and Wild, 2009; 
Neame and Hammond, 2005). The balance between these beliefs is technically known as the necessity-
concerns differential and Horne (2003) drew parallels of this to concepts described in the Health Belief 
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Model (Rosenstock, 1974) and Transtheoretical Model (Prochaska and Diclemente, 1984) respectively 
but within the CSM necessity-concern beliefs are influenced by parallel emotional representations of 
treatment and also cognitive and emotional representations of illness. 
 
Relationships between Illness and Treatment Perceptions 
Horne (2003) hypothesised that a decision to take medicines stem from one’s illness perceptions 
as well as one’s treatment beliefs. Like the original CSM individuals hold parallel perceptions of treatment 
and an emotional representation of the treatment that are all interacting with representations of illness 
threat and the emotional responses to the illness. In order to decide whether to take medicines the ill 
individual must create common-sense coherence between the representation of both illness and 
treatment before establishing whether the illness is severe enough to warrant the treatment options 
available. In terms of symptom identity, the experience of symptoms may elicit a medication usage coping 
response also reinforced by a necessity belief in taking them, however symptoms can also be perceived 
as a negative side effect of medicines or treatments reinforcing concerns about taking further doses and 
creating emotional responses. In terms of timeline, perceiving an illness as cyclical when it is chronic due 
to an absence of symptoms may result in not taking medications on a regular basis (Horne and Weinman, 
1999). Likewise perceiving illness to have serious consequences may reinforce medication necessity 
beliefs (Nicklas et al, 2010) and as found by Figueiras, Marcelino, Claudino, Cortes, Maroco and 
Weinman (2010) perceptions of serious consequences, a chronic timeline and a high illness identity can 
reinforce concerns in spite of reinforcing necessity beliefs. Further medication necessity beliefs may be 
reinforced by beliefs that the condition can be cured or controlled (Horne and Weinman, 2002; Figueiras 
et al. 2010) but this has been found to be true for the efficacy of the treatment and not the personal control 
beliefs of overcoming illness (Horne and Weinman, 2002). Causal attributions have been found to be 
poorly correlated to necessity beliefs (Horne, 2003).  
 
In some circumstances the distinction between cognitive representations of illness and treatment 
beliefs become blurred, as individuals may actually perceive their prescribed treatments as the health  
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threat in a similar way one would hold an emotional representation of an illness threat. This may further 
impact on necessity-concern beliefs as well as perceived consequences and timeline and pose a threat 
to one’s self-identity (Horne, 2003). Under these circumstances it has been proposed that individuals 
may hold an illness cognitive component that represents their perceptions about different types of 
treatments as they do for illness. For example one may have an ideal representation of symptoms, what 
they represent and the type of treatment they warrant. These idealisations or prototypical beliefs of the 
illness (e.g. cause, timeline, consequences) and treatment must be coherent with the types of treatment 
being offered by health professionals to be persuasive enough for uptake (Horne, 2003). For example 
Figueiras et al. (2010) found that hypertensive patients with negative illness and treatment perceptions 
significantly preferred branded medications over those with positive perceptions who were more likely to 
choose generic versions. As stated earlier adherence is not an outcome of the thesis but such a study is 
an example of exploring relationships between illness and treatment perceptions and their impact on an 
area that is related to (but not) adherence.  
 
Empirical Support for the Extended CSM 
As stated earlier much of the research into treatment perceptions as part of exploring the 
extended CSM has been predominantly routed in the treatment adherence literature (with a notable 
absence of exploring a role for coping behaviour). For example Horne and Weinman (2002) explored the 
role of illness and treatment perceptions in explaining non-adherence to preventer medication in one-
hundred patients experiencing asthma using the IPQ-R and BMQ and Medical Adherence Report 
Schedule (MARS) and found that non-adherence was significantly related to less necessity and more 
concern beliefs and perceptions of serious illness consequences. Further analyses also supported the 
hypothesis that illness and treatment perceptions were better predictors of adherence than socio-
demographic and clinical factors, which explained little of the variance in outcome. In a second example 
Nicklas et al. (2010) studied adherence to treatment in chronic pain and found that patients holding 
perceptions of serious consequences and high emotional responses had more specific concerns about 
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medication and were less adherent, however serious illness consequences were also associated with 
stronger beliefs about the necessity of medicines and greater adherence. With a few exceptions (i.e. 
Byrne, Walsh and Murphy (2005) finding that illness and treatment perceptions only predicted 2% and 
7% of adherence respectively in coronary heart disease), similar findings have been replicated in other 
chronic illnesses (e.g. Ross, Walker and MacLeod, 2004; Bishop, Yardley, Lewith and 2008; Aflakseir, 
2012). The importance of these findings is that they mirror illness perception in that specific-concerns 
about treatment as a cognitive representation can be said to be associated with maladaptive outcomes 
(non-adherence) and necessity beliefs with adaptive ones (adherence) as would be expected. The next 
sections become more specific and consider CSM research in relation to the thesis outcomes and studies 
that provide preliminary evidence for the existence of cognitive representations in CU. 
 
2.3: Cognitive Representations, Quality of Life and Psychological Distress 
 
2.3.1: Illness Perceptions and Quality of Life 
As reviewed in Chapter 1, quality of life (QoL) is a critical outcome of chronic illnesses, particularly 
as QoL measurement is said to provide a more comprehensive assessment of overall functioning from 
the patient’s own perspective. This importance is further reflected in the CSM research literature where 
the aim has been to test CSM components as possible predictors of QoL independent of socio-
demographic and clinical variables. The review in this section is based on non-systematic searches from 
PubMed-Medline, Embase and psycINFO electronic databases.  
 
Cognitive Representations, Coping and Quality of Life 
The research exploring relationships between CSM components and QoL (see Table 2.1, p38) 
provide strong evidence that illness representations are significantly related to poorer QoL (e.g. Rutter 
and Rutter, 2002; Spain, Turbrid, Kilpatrick, Adams and Holmesi, 2007; Llewellyn, McGurk and Weinman, 
2007a,b; Timmers, Thong and Dekker, 2008; Dorrian, Dempster and Adair, 2009; Stafford, Burk and 
Jackson, 2009; Chaboyer, Lee, Wallis, Gillespie and Jones, 2010; Sawicki, Sellers and Robinson, 2011; 
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Tiemensma, Kaptein, Pereira, Smit, Romijn and Biermasz, 2011a,b; Le Grande, Elliott and Worchester, 
2012; Telles-Correia et al. 2012), however in line with the research literature the role of copng as a 
mediator has been inconsistent. For example in one cross-sectional study of 209 individuals with irritable 
bowel syndrome, Rutter and Rutter (2002) found that perceptions of serious consequences (p <.001) and 
poorer curability control (p<.01) strongly related to poorer QoL. Further, path analyses supported both a 
direct predictive relationship between consequences and QoL and a partial mediating role for generic 
COPE strategy of acceptance; however in contrast Dorrian, Dempster and Adair (2009) found that in a 
CSM of inflammatory bowel disease illness perceptions explained a considerable 21% of the variance in 
QoL as compared to coping (as measured by the COPE) which only explained 2%, concluding coping to 
be an insignifican mediator between coping and outcome.    
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Table 2.1: Studies of Cognitive Representations, Quality of Life and Psychological Distress 
 
First Author 
 
Design 
 
Cognition 
 
Coping 
 
QoL Measure 
 
Psychological distress 
 
Mediation  
 
Chaboyer 2010 
Chilcot (2011) 
Dempster (2011) 
Dorian (2009) 
Evans & Norman (2009) 
Fu (2011) 
Griva (2010) 
Griva (2009) 
Hemele (2007) 
Kaptein (2006) 
Knibb & Horton. (2008) 
Llewellyn (2007a) 
Llewellyn (2007b) 
McCabe & Barnason (2012) 
Rutter & Rutter. (2002) 
Sawicki (2011) 
Scarloo (2005) 
Scarloo (1998) 
Spain (2007) 
Stafford (2009) 
Telles-Correia (2012) 
Tiemensma (2011) 
Tiemensma (2012) 
Timmers (2008) 
 
Longitudinal 
Cross-section 
Cross-section 
Cross-section 
Longitudinal 
Cross-section 
Cross-section 
Cross-section 
Cross-section 
Cross-section 
Cross-Section 
Longitudinal 
Cross-section 
Cross-section 
Cross-section 
Cross-section 
Cross-section 
Cross-section 
Cross-Section 
Longitudinal 
Cross-section 
Cross-section 
Cross-section 
Cross-section 
 
IPQ-R 
IPQ-R 
IPQ-R 
IPQ-R 
IPQ-R 
IPQ-R 
IPQ 
IPQ 
IPQ-R 
IPQ 
IPQ-R 
IPQ-R, BMQ 
IPQ-R, BMQ 
IPQ-R 
IPQ 
IPQ-R 
IPQ-R 
IPQ 
IPQ-R 
IPQ-R 
IPQ-R 
IPQ-R 
IPQ-R 
IPQ-R 
 
 
NA 
NA 
Cancer Coping 
Questionnaire 
COPE 
MCMQ 
NA 
NA 
NA 
NA 
COPE 
COPE 
Brief COPE 
Brief COPE 
COPE 
COPE 
NA 
NA 
Utrecht Coping List 
NA 
NA 
NA 
NA 
NA 
 
 
SF-36 
NA 
NA 
IBDQ-British FLP 
N/A 
NA 
NA 
SF-36 
NA 
SIP 
GHQ, 
SF-12, QlQ-C30 
EORTC QLQ-C30, SF-12, PGI 
NA 
Global question 
CFQ-R 
EORTC QLQ-C30 
SF-20 
SF-36 
SF-36 
N/A 
PSC, EuroQoL, ACroQoL 
PSC, EuroQoL5D, CushingQoL 
SF-36 
 
NA 
BDI II 
HADS 
HADS 
HADS 
HADS 
BDI 
NA 
POMS 
N/A 
PSS 
LOT-R, SCIP 
HADS 
SCL, PMS 
HADS 
NA 
NA 
NA 
HADS 
HADS 
HADS 
NA 
NA 
NA 
 
Untested  
Not tested 
No  
No                 
Partial 
Untested 
Untested 
Untested 
Untested   
No 
Partial    
Untested  
Yes 
Untested 
Complete & Partial 
Untested 
Untested 
Untested 
Untested   
Untested 
Untested 
Untested 
Untested   
Untested 
IPQ: Illness Perception Questionnaire, IPQ-R: Illness Perception Questionnaire Revised, BIPQ: BriefIllness Perception Questionnaire, BMQ : Beliefs about Medicines Questionnaire,    
PMS: Profile of Mood States, IBDQ: Inflammatory Bowel Disease Questionnaire, FLPFunctional Limits Profile, SF-36 Short-Form 36 Item Health Survey, POMS: Profile of Mood States 
EORTC QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire MCMQ: Medical Coping Modes Questionnaire 
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One of the arguments in the CSM literature is that generic coping measures maybe an 
explanation for the lack of mediation shown between representations and outcome (see Table 2.1, p38), 
however as these two examples demonstrate in similar illnesses this is not always the case, however 
another explanation maybe in the choice of QoL instrument used in studies which has varied from the 
generic to disease-specific which can result in different findings. For example in a cross-sectional study 
of baseline data in patients with head and neck cancer Llewellyn, McGurk and Weinman, 2007a) found 
that illness identity (with age and depression) and emotional representations (with depression and the 
COPE strategies alcohol and drugs) explained 35% and 54% respectively of the variance in physical QoL 
and mental QoL as measured by the generic SF-12, but not the Patient Generated Index (PGI) individual 
QoL instrument. Another issue to be mindful of in CSM studies are that most are cross-sectional which 
not only has consequences in not knowing the direction of relationships but how representations affect 
outcomes overtime. Llewellyn, McGurk and Weinman (2007b) demonstrated this in a prospective study 
where baseline representations were unable to predict QoL (measured both generically and specifically) 
at 1 and 6-8 month follow-up.   
 
Of significance in Table 2.1 is the numbers of studies exploring CSM predictors of QoL omitting 
the role of coping, arguably in light of the mixed empirical support for coping as a mediating factor. These 
studies vary but all have found direct relationships between cognitive representations and QoL outcome 
in the direction indicated by Hagger and Orbell (2003). For example Timmers, Kessel, Avshovich, 
Bamberger, Sabo, Nusem and Panasoff (2007) in their study of 133 dialysis patients found that even 
though socio-demographic variables explained between 9-23% of the variance in most components of 
the SF-36, illness perceptions explained between 17-51% of this variance. In a second example Spain 
et al. (2007) in their study of 580 patients with multiple sclerosis found illness perceptions (with fatigue, 
pain, anxiety and depression) explained 22% variance in SF-36 physical QoL and 56% in SF-36 mental 
QoL outcomes. In longitudinal examples Stafford, Berk and Jackson (2009) examined relationships 
between perceptions and QoL in 193 individuals with coronary artery disease at baseline, 3 and 9 months 
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follow-up. They found that although age was a better predictor, at time 1 and 2 (i.e. T1 and T2) positive 
illness perceptions contributed to 16% (low beliefs in negative consequences, low illness identity) and 
11% (lesser chronicity beliefs, greater belief in treatment control) of the variance in better self-reported 
physical QoL but not changes at 9 month follow-up. Further behind neuroticism and smoking at T1 and 
T2 illness perceptions explained a modest 4% (low identity, high personal control, p < .01) and 6.0% (low 
identity, p< .01) respectively in positive mental QoL and 4% at 9 months (p <.02). Similarly but with greater 
contributions of illness perceptions as predictors of outcome Chaboyer et al (2010) examined predictors 
of QoL at baseline, 3 and 6 months in 114 individuals with injury. With patient characteristics failing to 
predict outcome, 6 month physical QoL was predicted by 3 month physical QoL and the identity and 
timeline perception (75·1%). Six-month mental QoL was predicted by the same perceptions plus 
emotional representations and 3 month mental QoL (72·4%). It is difficult to draw conclusions from such 
few studies but there appears to be preliminary evidence to suggest that baseline cognitive 
representations may be initially predictive of QoL but should be interpreted with caution when used to 
predict QoL over time and further the QoL instrument used needs consideration.  
 
2.3.2: Illness Perceptions and Psychological Distress 
As reviewed in-depth in Chapter 1 psychological distress as anxiety and depression is a common 
co-morbid part of the chronic illness experience, and strong evidence supports that negative illness 
representations are strong and significant predictors of both co-morbidities on poorer QoL (Dempster, 
McCorry, Brennan, Donnelly, Murray and Johnson, 2012; Telles-Correia, Barbosa, Mega, Monteiro, 
2012; McCabe and Barnason 2012; Chilcot, Wellsted and Farrington, 2011; Dorian, Dempster and Adair 
2009; Fu, Bunmdy and Sadiq 2011; Griva, Davenport, Harrison and Newman 2010; Stafford et al. 2009; 
Knibb and Horton, 2008; Liewellyn et al. 2007a, b; Hermele, Olivo, Namerow and Oz, 2007; Rutter and 
Rutter, 2002), however the role of coping as a mediator has been inconsistent. 
 
In a first example Rutter and Rutter (2002) found that illness perceptions and coping behaviour 
explained 41% of the variance in anxiety where serious consequences directly predicted anxiety but also  
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partially mediated by the COPE’s behavioural disengagement scale. Behavioural disengagement also 
completely mediated the relationship between weak control perceptions and depression and further 
consequences were directly (and partially mediated) through behavioural disengagement and restraint 
coping on depression. In a second example Knibb and Horton (2008) in their study of 156 allergy suffers 
found that illness perceptions (i.e. a strong illness identity and emotional representations) and 
maladaptive coping (e.g. venting emotions) explained 6- 26% and 12- 25% of the variance respectively 
on higher levels of psychological distress. Further strong personal control perceptions and adaptive 
coping strategies (e.g. positive reinterpretation and growth) predicted less distress and coping did partially 
(but not completely) mediate the above-mentioned perceptions, hence they also directly predicted 
distress. In contrast Dempster et al. (2012) also using the HADS but a disease-specific coping instrument 
found that perceptions explained 22% and 23% of the variance in oesophageal cancer related anxiety 
and depression respectively as to 12% and 7% respectively for coping. As coping did not significantly 
contribute in final models it was deemed an insignificant mediator. Dorian et al. (2009) similarly found 
weak relationships for cognitions and coping and no mediation in irritable bowel disease and McCabe 
and Barnason (2011) concluded in their study of 207 patients with atrial fibrillation that illness perceptions 
were more important than coping in predicting outcome mirroring studies that have focused on direct 
relationships, (Chilcot, Wellsted and Farrington, 2011; Fu, Bunmdy and Sadiq, 2011; Griva et al. 2010; 
Hemele, Olivo, Namerow and Oz, 2007).   
 
In longitudinal examples of cognitive representations on psychological distress over time the 
findings have also been inconsistent. For example as for QoL Llewellyn et al. (2007b) found that even 
though high chronicity perceptions (28.0%) and self-blame (21.0%), low satisfaction with information and 
high acceptance at baseline predicted depression at 6-8 months (67%; but not anxiety) no mediation was 
found, Stafford et al. (2009) found that perceptions of serious consequences of coronary artery disease 
significantly predicted higher levels of depression at 3 and 9 months. It appears that like QoL baseline 
cognitive representations may be initially predictive of QoL but may not always be indicate of 
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representations overtime. Even though some effects maybe disease-specific it appears that further 
research is warranted to determine why this is the case. It also suggests that interventions based on the 
CSM may need to measure representations over time and not rely on baseline reports.  
 
2.4: Cognitive Representations and Coping in Dermatological Disorders 
 
2.4.1: Cognitive Representations in Dermatological Disorders 
This chapter so far has departed from the previous chapter on CU to review a new theoretical 
framework in which to explain some of the variance in significant CU outcomes and possibly intervene to 
change them. As highlighted in the preface the CSM is particularly suitable for studying CU as unlike 
many illnesses studied in medicine and health psychology, skin disorders are visible to the naked eye. 
More specifically individuals with skin disorder have to cope with cultural and social factors associated 
with skins appearance (e.g. stereotypes, stigmatisation) as well as specific disease and treatment factors 
(e.g. severity, treatment type), personality characteristics/ core beliefs about the disorder (e.g. 
alexithymia, attachment style, beliefs about condition) that impact adjustment and whether on-going 
support/ acceptance is available verses social rejection (Thompson, 2005). What is evident from chapter 
1 (p11) is that individuals with CU share some of those traits, states and beliefs that have been implicated 
in the origin/ maintenance of skin disorder (e.g. alexithymia, perceived unmet treatment needs, core 
beliefs about CU and feelings of distress from CU.  For this reason the model can account for the social-
cultural influences that maybe pertinent as to how one might perceive their skin disorder while accounting 
for symptom perceptions and realities which are often poorly understood by patients with CU and experts 
alike (Maurer et al. 2009) and hence setting up the development of schematic illness stimuli that CSM 
predicts will inform cognitive representations. The findings of cognitive representation studies of pruritic 
dermatological disorders (Cartwright, Endean and Porter, 2009; Fortune et al. 2002, 2004; Fortune et al. 
1998; Schaloo et al. 2000; Wittkoski, Richards, Griffiths and Main, 2007) has reflected CSM study findings 
reviewed earlier including iIllness perceptions being better predictors of outcome over coping and patient 
characteristics (28-50%, 2-13.0% and 3.50- 5.0% respectively; e.g. Cartwright et al. 2009; Fortune et al. 
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2002). These findings support that illness representations in skin disorder is similar to non-dermatological 
conditions and suggests that individuals with CU who share similar symptoms and effects may also hold 
them in this way. 
 
Such a proposition may suggest that if this is so exploring cognitive representations of CU in a 
PhD thesis is redundant as one could learn from what has already been done and consistently found in 
previous research, however as described in further detail in chapter 1 CU is different to many pruritic skin 
disorders due to its highly fluctuating and unpredictable presentation (Weller, Church, Kalogeromitros et 
al. 2011; Zuberbier et al. 2009a) and further medications for any particular patient can change often to fit 
its existing presentation Zuberbier et al. 2009a). How patients with CU plan for the present and future 
based on its unpredictability is often a concern, as experts themselves have no solid epidemiological 
understanding of prognosis (Maurer, Weller, Bindslev-Jensen, Gimenez-Arnau, Bousquet, Canonica, et 
al. 2011). Such complexities have lead dermatologists to notoriously name CU as a complete enigma 
compared to other skin disorders (Zuberbier, Grattan and Maurer, 2009) and it is common for health 
professionals to view patients with CU as ‘difficult to satisfy and hard to guide’ (Weller, Viehmann, 
Brautigam, Krause, Siebenhaar, Zuberbier and Maurer, 2012). Such perspectives of interacting with 
those experiencing CU may impact upon the patients perceptions of how their condition is viewed (social 
messages) and misdiagnoses may impact on the patient’s symptom perception in terms of what they 
think they are experiencing that together may inform the development of their cognitive representation of 
illness. Overall in testing the common-sense model perceptions of identity, cause, timeline and 
cure/control may differ depending on how CU is presenting at any particular moment in time per patient 
and may show more within group variance amongst patients compared to those with psoriasis and atopic 
dermatitis. If cognitive representations are significantly related to CU outcome as the CSM predicts it may 
prove useful for experts communicating with and treating these patients in regards to asking questions 
about perceptions in consultations leading to interventions that challenge misperceptions, filling in gaps 
in knowledge and creating action plans that lead to better patient self-regulation and management. 
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2.4.2: Evidence for Illness Perceptions and Coping in CU         
Indeed cognitive representations in CU and its relationship to outcome has yet to be formally 
studied, however there is anecdotal evidence in the literature that suggests that individuals with CU do 
hold such perceptions. In the following examples the representation that the study reflects is italicised in 
brackets. O’Donnell et al. (1997) in their study of 146 patients found that most associated CU with itching, 
swelling, pain, fatigue and sleep problems (identity) and 46.0% and 42.0% respectively reported that they 
were worried that their CU would worsen over time (timeline-acute/ chronic) and were concerned about 
its unpredictable nature (cyclical timeline). O’Donnell et al. (1997) also found that 25.0% were afraid that 
their CU was caused by a more serious disease (cause). In other study examples Berrino et al. (2006) 
and Ozkan et al. (2007) reported that 30% and 81% of their participants respectively believed that their 
CU was caused by psychological factors. Further Ozkan et al. (2007) found that 78.0% of 84 participants 
reported their CU to have consequences regarding a disturbed body image, attitude towards others, 
attractiveness, feeling different, self-conscious and embarrassed. Additionally 71.0% of these patients 
believed that they were insufficiently informed about CU and this poor understanding of CU (illness 
coherence) reflected Maurer et al. (2009b) survey where 989 individuals with CU reported waiting until 
symptoms began before taking medications. One commonality across studies is the high emotional 
distress that CU elicits and the insufficient emotional support from doctors (Maurer et al. 2009b). Further 
Maurer et al. (2009b) found that even though 40-60.0% of patients were reluctant to take CU medicines 
(concerns), 45.0% of those did take them (necessity). These studies further support in CU additional 
factors implicated in the origin/ maintenance of skin disorders (Thompson, 2005) reviewed earlier 
including holding appearance schemas & self-discrepancies (Ozkan et al. 2007) and beliefs about one’s 
condition. 
  
Little is also known regarding coping behaviour in CU as this is a new line of empirical enquiry 
but an internet based study-specific questionnaire survey of 321 randomly selected participants with CU 
by Maurer et al (2009) reported that 25.0% believed that CU was a sign of personal weakness suggesting 
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possibly an inability to cope. Further Yang et al. (2005) found that the use of positive coping strategies in 
CU was associated with a decreased frequency of CU severity and served as a preventative factor, 
however a more recent study by Chung et al. (2010b) using the Ways of Coping Checklist provided a 
more in-depth picture of coping behaviour in CU. They found that individuals with CU used both problem 
and emotion-focused coping. The most common strategy was seeking social support to find more 
information (75%) and to discuss feelings (69%). In terms of the escape-avoidance and distancing coping 
strategies most wished CU to go away (81%), turned to eating, drinking and/ or smoking (53%), wished 
for a miracle (46%), tried not think about it (73%) or tried not to take it too seriously (71%). Self-control 
strategies involved keeping feelings to oneself (64%) and not letting others know how bad the condition 
was (62%) and for planful problem solving these involved concentrating on procedures for self-
management (68%) and coming up with solution to CU (66%). How these reported beliefs about illness 
and emotional responses relate to each other and how they may affect CU-related QoL and psychological 
distress is currently unknown, as this has not been systematically explored. With patient characteristics 
explaining little variance in outcomes, this thesis hypothesises that the CSM may provide a more 
systematic way of establishing such relationships. Establishing such relationships has implications for 
developing and implementing CSM related interventions designed to change perceptions of CU and result 
in behaviour change.   
 
2.5: Changing Illness Perceptions: Self-Regulation Interventions  
 
2.5.1: Designing and Implementing Behaviour Change Interventions 
Good interventions are said to be best built upon empirically supported theoretical frameworks 
(Medical Research Council, 2002, 2010), as theoretically informed interventions allow for important model 
determinants to be systematically mapped onto model mediators and outcomes to establish possible 
mechanisms of behaviour change (Mitchie and Abraham, 2004; Michie, Johnson, Francis, Hardeman 
and Eccles, 2008). Despite the CSM literature fulfilling this criterion especially with its’ empirically 
supported specific contents of its well-defined determinants (see section 2.2.3) and instruments to 
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measure them few researchers and applied psychologists have applied CSM findings to interventions 
(McAndrew, Musumeci-Szabo, Mora, Vileikyte, Burns, Halm et al. 2008). 
 
Translating CSM Findings to Interventions 
The discrepancy in timeline between published studies testing relationships between CSM 
components and outcome (1990’s, Hagger and Orbell, 2003) and undertaking applied CSM interventions 
(early 2000’s; Petrie, Cameron, Ellis, Buick, Weinman et al. 2002) might be explained by researchers and 
practitioners experiencing difficulties in translating findings from the model to practical interventions 
(McAndrew, Musumeci-Szabo, Mora, Vileikyte, Burns, Halm Leventhal and Leventhal, 2008). Prior to the 
2000’s there were few formal published guidelines on how to develop, implement, evaluate and report 
interventions such as those found in behavioural medicine and health psychology which usually consist 
of multiple cognitive and behavioural components (Craig, Dieppe, Macintyre, Michie, Nazareth and 
Petticrew, 2012). Original MRC guidelines by Campbell et al. (2000) state that the following five 
processes of increasing evidence should govern a well-developed intervention: 
o Theory: Be underpinned by a relevant theory to explore intervention hypotheses  
o Modelling: Have model components identified that may act as underlying mechanisms to 
influencing outcomes. 
o Exploratory trial: Have undergone a pilot study testing the impact of changing the identified 
process variable components on outcome that is replicable from a developed protocol. 
o Definitive RCT: A full intervention has been undertaken with the appropriate statistical power 
o Long-term implementation: Ability to be replicated over time by others has been determined. 
Despite these guidelines attempts to replicate studies were often hindered, as researchers of published 
studies were inconsistent in what aspects of interventions they were reporting. To avert this, the  
CONSORT statement (Consolidation Standards of Reporting Trials; Moher, Schultz, Altman, CONSORT 
Group, 2001; Altman, Moher and Schulz, 2012) was introduced as guidelines for writing up and reporting 
research to be used in conjunction with MRC guidelines. This statement was first introduced in the mid-
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1990’s by Altman et al. (2012) but this was aimed at medical researchers. In light of this Davidson, 
Goldstein, Kaplan, Kaufmann, Knatterund, Orleans, et al. (2003) published additional guidelines for 
researchers of behavioural interventions which consisted of reporting the following elements: contents 
and elements; the characteristics of those delivering intervention and its recipients; the setting; mode of 
delivery (e.g. one-to-one, group); intensity (e.g. contact time); duration (sessions over a period) and 
adherence to delivery protocols.  
 
Davidson et al. (2003) was a step further to guiding researchers to improving the quality of 
behavioural interventions but Mitchie and colleagues (Craig et al. 2012) observed that although many of 
these published studies reported such characteristics the contents and elements part were often poorly 
developed. They found that interventions often consisted of an array of behaviour change techniques 
(BCTs) but it was difficult to know how or why they were chosen or what mechanisms of the determinant 
they were targeting to improve outcome. Further many studies claiming to use a theoretical framework 
were more “theoretically inspired” then informed meaning that model determinants were not empirically 
tested to establish if they were initially related to the outcome in the given target population (Mitchie et al. 
2004, 2008). Critically even when interventions were well designed and implemented researchers often 
used different terminology to name the same BCTs across studies and what a particular BCT actually 
consisted of was often omitted meaning that others trying to replicate them possibly missed conducting 
important procedures that are critical to the study being evaluated as efficacious. This lack of 
standardisation meant that systematic reviews, which attempted to systematically summarise BCTs, used 
their own classification systems and therefore differences occurred between reviews. Altogether it was 
difficult to decipher which singular or combinations of BCTs were more efficacious at changing particular 
behavioural determinants. 
 
Mitchie et al. (2008) attempted to resolve these issues by conducting a major study that used 
BCT findings of these reviews and other identified sources (e.g. textbooks, intervention manuals) to 
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create an expert consensus list of standardised definitions and descriptions of BCTs and map them onto 
the determinant components of theories of human behaviour and behaviour change. Twenty-six BCT’s 
were identified independently by two psychologists using a 5 page coding system to judge the presence 
or absence of a technique in intervention descriptions and manuals and applied to the 3 reviews where 
the agreement rate was 93.0% between judges (0.79 kappa per technique). Definitions and descriptions 
were used to identify techniques being used in the healthy eating and physical activity intervention 
research literature by two psychologists to test the reliability of the reliability with a % agreement rate. 
The individual 26 BCTs identified reflected different theoretical frameworks including the TPB, TRA and 
SCT. Cognitive determinants and mediators of the CSM are not directly mapped to particular techniques 
by Abraham and Mitchie (2008) but they did map BCTs for Carver and Schiere’s self-regulation theory 
(Carver and Scihere, 1998) which as mentioned earlier is a generic and content free version of the illness 
specific common-sense model (Leventhal, Meyer, Nerenz, 2003), hence BCTs for the former would be 
relevant to the later. The BCTs related to self-regulation theories included (1) prompting specific goal 
setting and (2) reviews of behavioural goals, (3) providing self-monitoring of behaviours and (4) providing 
feedback on behaviour and are defined in Table 2.2 below. 
 
Table 2.2: Self-Regulation Behaviour Change Techniques  
Behaviour change technique Definition 
 
Prompt specific goal setting 
 
 
Involves detailed planning of what the person will do, including a definition of 
behaviour, specifying frequency, intensity or duration and specification of at least 
one context, that is where, when, how or with whom.     
 
Prompt review of behavioural goals 
 
Review and/ or reconsideration of previously set goals or intentions   
 
Provide self-monitoring of behaviour  
 
The person is asked to keep a record of specified behaviour(s) (e.g. in a diary)  
 
Provide feedback on performance 
 
 
Providing data about recorded behaviour or evaluation performance in relation to 
a set standard of others performance (i.e. receiving feedback on behaviour). 
*Adapted from Abraham and Mitchie (2008) 
 
2.5.2: Designing and Implementing CSM Interventions  
Behaviour change techniques (BCTs) recommended by Abraham and Mitchie (2008) fit well into 
the nature of self-regulation theory in that the individual is seen as part of an active problem solving  
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system attempting to regulate the self by applying meaningful goals and achieving them through directed 
behaviours that remove barriers to those goals (Scheier and Carver, 2003), however undertaking such 
BCT’s as described in Table 2.2 only addresses the behavioural aspect of the CSM (i.e. bottom-up 
processes which use concrete/ behavioural strategies). According to CSM intervention development 
guidelines this approach serves well for illnesses such as diabetes where the focus maybe on behaviour 
to create an overall understanding of diabetes as a condition that needs consistent self-regulation with 
the use of objective instruments (e.g. blood sugar monitors), however as described in Section 3.1, the 
specific contents of CSMs determinants (i.e. identity, cause, timeline, consequences, control and 
emotions responses) which are said to guide coping actions/ behaviours are well defined so targeting the 
mechanisms of patient’s cognitive processes might also be fundamental in other illnesses. Unlike 
conventional educational approaches this top-down approach uses abstract/ cognitive strategies (i.e. the 
patient’s own implicit representational model of their illness) as a basis for filling in gaps in knowledge 
and challenging misconceptions providing them with a conceptual framework for the illness so that they 
can recognise that it is still chronic even when asymptomatic, hence the new conceptual framework 
provides the patient with an implicit model to appropriately interpret bottom-up information generated by 
behaviours (McAndrew et al. 2008). In line with the model incorrect perceptions are tackled at the abstract 
and experimental level of the representation (i.e. combining abstract-conceptual information of the illness 
along the dimensions of the representation) with imagery of the disease through pictures/ diagrams to 
address incorrect visual perceptions of the illness (i.e. as the processing of the patient’s representation 
of illness is also concrete-perceptual with the CSM). 
 
McAndrew et al. (2008) explains that it is the CSM’s self-regulatory feedback loop that acts as a 
dynamic mechanism between cognitions, behaviours and outcome (Figure 2.2, p26) that allows the  
CSM to be used in either in a top-down or bottom-up way approach when designing interventions (i.e. 
from the bottom-up (using concrete/ behavioural strategies) or from the top-down (using abstract/ 
cognitive strategies). McAndrew et al. (2008) clarified that using both approaches is not mutually 
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exclusive and whether to focus on representations or coping actions (or both), will be dependent on the 
nature of the illness and the patient. For example focusing on coping actions may be of benefit to 
conditions that are highly symptomatic where individuals are constantly reacting to concrete perceptual 
experiences of symptoms. In contrast a focus on representations maybe beneficial to those perceiving 
that they are asymptomatic because they cannot ‘feel’ their illness. deRidder, Theunissen and Dulmen 
(2007) found that when practitioners focused on perceptions patients asked more questions about the 
illness as compared to coping action plans which generated more questions regarding psychosocial 
functioning. As behaviour change does not occur in isolation and happens between patients, significant 
others and health professionals, McAndrew et al. 2008) further stipulated that when embarking on 
interventions based on the CSM the roles different health professionals will take in managing the chronic 
illness need to be considered. This is important as it needs to be decided who will be responsible for 
seeing new warning signs when the patient is no longer engaging in good disease self-management 
because they are no longer experiencing symptoms and so stop participating in self-regulation. They 
suggest that a discrepancy between the patient’s and professional’s perceived level of illness severity 
risk and actions to be taken (IF-Then rules) need to monitor which will be critical to continued self-
management. Importantly intervening would be undertaken from the top-down and bottom-up in a person-
centred manner while respecting general guidelines for evidenced based interventions (reviewed earlier).    
 
2.5.3: Empirical Support for CSM Interventions  
In the emerging area of CSM interventions to increase patients self-regulation and management 
there is a growing research evidence base to support that cognitive representations of illness are 
amenable to change and lead to a range of preferable health outcomes (Petrie, Cameron, Ellis, Buick 
and Weinman et al. 2002; Fortune, Richards, Griffiths and Main, 2004; Karamanidou, Weinman, and 
Horne, 2008; Ward, Donovan, Gunnarsdottir, Serlin, Shapiro and Hughes, 2008; Broadbent, Ellis, 
Thomas, Gamble and Petrie, 2009). As recommended by McAndrew et al. (2008) studies have generally 
made use of the dynamic self-regulatory features of the model incorporating both top-down and bottom-
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up processes with abstract and concrete strategies to improve the patient’s understanding of the illness, 
linking alternative adaptive coping actions to expected outcomes with goal setting and action plan 
strategies and patient appraisals of coping actions on outcomes. In line with Davidson’s guidelines CSM 
interventions have consisted of psycho-education techniques to change the patient’s implicit illness 
model along the five dimensions of the CSM and have been delivered by psychologists, nurses or a 
combination of these professionals to a range of patient groups. Most have taken place in either 
secondary outpatient hospital clinics or university departments where the interest is in behavioural 
medicine. Further most have been brief consisting of up to three sessions of 30-60 minutes on a one-to-
one basis where a generic protocol has been followed but tailored to the patient’s individual needs.  
 
In an early example Petrie et al. (2002) examined the effect of an RCT intervention to change 
perceptions of myocardial infarction (MI) in 65 in-patients. Those in the intervention group undertook 
sessions consisting of didactic teaching of MI patho-physiology and had their own implicit illness model 
and self-management behaviours examined in order to change misconceptions and create action plans. 
They found that intervention participants had a better understanding of MI and modified their perceptions 
of consequences, timeline and controllability, the latter two being maintained at 3-month follow-up. 
Further, more intervention patients returned to work than controls at 3-month follow-up. Broadbent et al. 
(2009) in their replication involving 103 patients were able to mirror Petrie et al. (2002) findings at 3 and 
6 months follow-up. In a third example Karamanidou et al (2008) conducted a pilot study psycho-
educational intervention to improve haemodialysis patients’ understanding of phosphate-binding 
medication found that those in the intervention group reported better knowledge and showed better 
outcome efficacy at follow-up. In a different approach Fortune et al. (2004) examined the efficacy of a 6-
week patient-preference group intervention to change illness perceptions, coping and outcome in 40 
patients with psoriasis, with assessments at pre/ post intervention and 6 month follow-up. Sessions of 
2.5 hours duration consisted of didactic teaching of psoriasis physiology and treatment, stress- reduction 
techniques, cognitive appraisals of maladaptive beliefs about psoriasis and homework based upon 
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individualized model-centered goals. Compared to controls they reported a reduction in illness identity 
scores, serious consequences and attributions, less emotional causes, however perceptions of timeline, 
curability/ control and cause remained similar to the control group as did coping strategies post-
intervention and at follow-up possibly reflecting the realities of the condition and the lack of coping 
activities within the study protocol. An exception is one RCT where no change in perceptions was found 
(Lavery, O’Neil, Parker, Elborn and Bradley, 2011) however challenging perceptions was not a primary 
focus of this study. What has remained relatively untested in CSM interventions are tools for emotional 
regulation even though some have incorporated relaxation and other stress reduction strategies, an 
omission observed Cameron and Jago (2008) who proposed strategies including a writing self-regulation 
technique for expressing emotions in women experiencing cancer. 
  
2.5.4: Developing CSM Interventions in CU 
How a CU intervention based on the CSM might be developed, implemented and evaluated 
according to the guidelines reviewed in this section would draw upon reports of previous studies but 
would also be dependent on three other factors. The first relate to the model fit of CU data to the 
theoretical framework in question. It would need to be established initially how individuals with CU hold 
representations of their illness and if they hold them schematically in similar relationships to other chronic 
illnesses. It would also need to be established if cognitive representations of CU are directly related to 
the primary outcomes in question (i.e. quality of life and psychological distress) or whether exploratory 
intervention that mainly focuses on changing perceptions (top-down processing) or action plans (bottom-
up processing) but still includes both. The second relate to how services which interact with individuals 
with CU operate, for example dermatology services presently consist of dermatologists, nurses, 
immunologists and allergists with no health psychology input meaning whether to promote the benefit of 
psychologists to CU services or training medical professionals to raise issues regarding illness 
perceptions and undertaking action plans needs to be considered. The third lies in the coping procedures 
mediate this relationship as this would have implications for designing an nature of CU itself as a chronic 
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condition that requires consistent self-regulation and self-management and its complex presentation and 
pathophysiology which was considered extensively in Section 1.2 and 1.4 (p4 and 11).  
 
2.6: Research Questions 
 
Preliminary  
1. What is the impact of CU on overall and bio-psychosocial aspects of quality of life? (Study 1) 
2. What is the best measure for assessing CU-related quality of life? (Study 2) 
3. Is the Revised Illness Perception Questionnaire and Beliefs about Medicines Questionnaire a 
valid and reliable instrument’s for measuring cognitive representations of CU? (Study 3) 
Main 
1. What are the cognitive representations of individuals with diagnosed CU? (Studies 4 and 5) 
2. Do individuals with CU hold cognitive representations of their illness in similar patterns to those 
experiencing other chronic physical illnesses? (Studies 4) 
3. As predicted by the Common-Sense Model are cognitive representations of CU significantly 
related to CU-related outcomes? (Study 4) 
4. Is the relationship between CU-related cognitive representations and outcome mediated by 
coping strategies as predicted by the CSM? (Study 4) 
5. Are CU-related cognitive representations of CU amenable to change via intervention (Study 6) 
6. Can an intervention to change cognitive representations of CU influence outcome? (Study 6) 
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Chapter 3 
Quality of Life in Chronic Urticaria: a Systematic Review (Study 1) 
 
3.0: Rationale for Study 
As identified in Chapter 1 the CU-related QoL research literature had grown immensely since 
1997 and a collation of this literature had yet to be undertaken. The aim of this study was to undertake a 
systematic review of quality of life in CU. This was important to create consensus reference points for 
comparative purposes in the thesis’ proceeding studies, determine the impact of socio-demographic and 
clinical predictors on CU-related QoL compared to CSM predictor variables and what QoL instrument 
were most valid and reliable. 
 
3.1: Introduction  
 
3.1.1: Quality of Life in Chronic Urticaria 
Despite breakthroughs in CU drug treatment up to fifty-percent of patients report symptom 
management needs that remain unmet by pharmaceutical interventions (Maurer et al. 2010), hence a 
new primary aim is to improve QoL (Zuberbier et al. 2009b). Assessing QoL in CU is important as it allows 
for a more complete assessment of illness outcome when conventional measures do not consider 
psychosocial factors and therefore facilitates more targeted treatment decision making (Van Craneburgh, 
Prinsen, Sprangers et al. 2012). It also allows CU to be compared to other illnesses on the same criteria 
when competing for healthcare funding (Finlay, 2005).   
 
    Existing reviews on CU-related QoL (Baiardini et al. 2011; Grob and Gaudy-Marqueste, 2006; 
Weldon, 2006) highlight the scope of the problem but are limited in that they provide conclusions based 
upon a very limited selection of studies (Baiardini et al. 2011; Maurer et al. 2010). They also do not 
provide a consensus on the nature of QoL in CU to act as reference points in CU research. This first 
study of the thesis systematically reviewed the CU-related QoL literature using CRD and Cochrane 
guidelines (CRD, 2009; Cochrane, 2011). Its objectives are stated below:    
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3.1.2: Review Question and Objectives 
 
Review Question: What impact does CU have on quality of life?   
Review Objectives: To identify and overview the (I) overall impact of CU on quality of life (II) physical, 
psychological and social aspects of CU-related QoL (III) relationships between patient characteristics and 
CU-related QoL and (IV) research comparing QoL in CU to reference samples. The final aim was to (IV) 
critically appraise the methodological quality CU-related quality of life studies. 
 
3.2: Method  
 
3.2.1: Identification of Studies 
Search Process and Strategies  
Before undertaking the review a scoping exercise was undertaken to confirm that a review had 
not been disseminated. A search of the Database of Abstracts of Reviews and Effects (DARE); Cochrane 
Library; Current Controlled Trials and PubMed systematic review database confirmed this. To identify 
studies assessing QoL in CU a search of published sources relevant to psychology, health, medicine and 
urticaria were undertaken between January 1997 (year of first study) and 5th October 2012. Searches 
were limited to studies in English language. The sources searched were as follows:   
 
Electronic databases and citation indexes: Combined MEDLINE, EMBASE, CINAHL and PsyINFO 
search (Ovid online), Pascal BIOMED, E-Star (British Library); Combined Science Citation Index and 
Social Science Citation Index (Web of Science) and the Cochrane Library.  
 
By dividing the systematic review question by population and outcome a pilot search of CU and 
QoL keyword terms was undertaken. What terms to use was decided by exploring Medline’s subject 
indexing database (MeSH) to find standardised terms. Secondly core edited textbooks in urticaria (i.e. 
Kaplan and Greaves, 2009; Zuberbier et al. 2009) were searched. Thirdly leading expert Consultant 
Dermatologists in urticaria at St John’s Institute of Dermatology, St Thomas Hospital London were 
consulted to establish if further synonyms existed. The final terms can be found in Table 3.1 (p55). As 
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the primary aim of the review was to describe quality of life and QoL in relation to patient characteristics, 
it was predicted that studies would be of either a cross-sectional or cohort (retrospective or prospective) 
design. These studies are more subjected to bias but are good for assessing disease burden and can be 
useful for informing decisions regarding patient care, allocation of health resources and preliminary 
hypothesis testing, however the pilot search also indicated an increasing number of RCT’s using QoL 
measures which are a good source of baseline data and large sample sizes.  
 
Table 3.1: Identified Keyword Synonyms for CU and Quality of Life 
Keyword                Synonyms 
Urticaria                 spontaneous; ordinary; idiopathic autoimmune; recurrent; resistant; persistent 
Quality of Life        quality of life; health-related quality of life; subjective health status; health status 
 
  
A high sensitivity-low precision search was used to identify relevant papers. This approach 
sacrifices specificity but maximises obtaining all papers. Conventional search filters were avoided as they 
were highly specified for MEDLINE randomised control trials (the review was not evaluating 
effectiveness). The search strategy used for the OVID search (titles and abstracts) was as follows: 
Urticaria AND (spontaneous OR ordinary OR idiopathic OR autoimmune OR recurrent OR resistant OR 
persistent) AND (quality of life OR health status) Limiters: ENGLISH LANGUAGE AND 1997-2012 
 
3.2.2: Study Selection Criteria 
Studies were included if: participants had a primary chronic spontaneous urticaria (CU), 
idiopathic (CIU) or autoimmune (CAU); were available in English language and used multi-dimensional 
QoL instruments. Studies were excluded if they assessed: primarily acute or physical urticaria or used 
child QoL instruments. CU was defined using CU classification guidelines (Zuberbier et al. 2009a). Once 
potential papers were selected the full-text versions (and their references) were retrieved for further 
investigation. If the main assessor was uncertain as to what papers should be included, this was 
discussed to a consensus with a second assessor (authors academic supervisor). If the information 
necessary to make a decision was insufficient from the paper, its corresponding author was contacted by 
email for further information and given two weeks to reply. Studies were excluded if requests for 
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information were not provided. If it appeared that authors had duplicated data across studies, the 
corresponding author was contacted to confirm this. This data was treated as one the selection process 
is illustrated in Figure 3.1 below. 
 
Figure 3.1: Flowchart of the Selection Process of CU-Related Quality of Life Studies 
 
 
The search generated 2741 hits from 8 sources. From the abstracts 64 papers including 6 
reviews were retrieved (Weller et al. 2011; Baiardini et al. 2011; Grob and Gaudy-Marqueste, 2006; 
Welden, 2006; Basra, Fenech, Gatt, et al. 2008; Kini and Delong, 2012). After applying the selection 
criteria full-texts papers were excluded because they: acknowledged CU and QoL but were not exploring 
it; no further information could be retrieved; no patients with CU were in the dermatological sample, 
urticaria patients ofv different types were grouped as one homogenous group. The references of full-texts 
only retrieved studies already identified. Eleven studies were rejected leaving 53 included papers. 
Rejected papers can be found in Appendix 1 (pA2).  
 
3.2.3: Data Extraction 
Data was extracted from each included study based on general citation information, study  
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characteristics and participant characteristics as recommended by the Centre of Reviews and 
Dissemination guidelines (CRD, 2009) plus data required to answer the studies own specific objectives. 
Data extracted to answer the review objectives included those concerning QoL assessment and analysis: 
baseline overall QoL, baseline aspects of QoL, relationships between patient characteristics and QoL 
and comparative data from reference samples. One standardised data extraction sheet was developed 
to extract data. The extracted elements are stated briely below and are explained in more detail in 
Appendix 1 with a copy of the data extraction sheet (pA3-4). 
Data Extraction 
Part 1: General, study and participant characteristics 
(a) General information:  (b) Study characteristics (c) Participant characteristics:  
Part 2: Quality of Life outcome data and results  
(a) QoL assessment/ analysis (b) Baseline overall QoL 
Part 3: Relationship between patient characteristics and quality of life 
(a) Clinical variables (b) Socio-demographic variables (c) Other factors identified 
Part 4: reference samples  
a) Other skin disorders (b) chronic diseases and c) healthy populations 
 
3.2.4: Quality Assessment  
During the data extraction process studies were concurrently assessed for methodological 
quality. To do this a compound checklist without a scoring system was used as scoring systems have 
been heavily criticised for being unreliable and not accounting for bias (CRD, 2009; Cochrane, 2011). As 
the aim was to collate data across studies describing the impact of CU on quality of life it was decided to 
abandon the conventional hierarchy of evidence used to evaluate studies as this usually applies to the 
effectiveness of health interventions and does not account for which study designs are best for answering 
certain types of questions. However, despite studies undergoing a quality assessment none were 
excluded as the pilot search indicated that there would be a high degree of clinical and methodological 
heterogeneity across studies in respect to design, objectives, severity and QoL instruments used. This 
indicated that meta-analysis was unlikely but highlighted the need for an appraisal of research 
methodology in CU-related QoL research in addition to the qualitative synthesis.  
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To assess quality an existing standardised checklist by Mols, Vingerhoets, Cobergh and Poll-
Franse (2005) to assess the methodological quality of studies reporting QoL in breast cancer survivors 
was modified to assess QoL studies in CU. The checklist draws upon theoretical and methodological 
considerations of prognostic cohort studies but was adapted by Mols et al (2005) to incorporate cross-
section studies and studies comparing groups. Importantly the checklist was also modified to address 
studies specifically assessing QoL; hence it assesses common methodological issues that occur in these 
studies that threaten internal validity (e.g. baseline treatment status, prognostic factors), external validity 
(description of study samples and selection criteria) and precision (sufficient sample size to detect 
differences or determinants). These qualities made it very suitable for assessing heterogeneous studies. 
In line with guidelines (CRD, 2009) the terms met, partially unmet or unmet due to lack of reporting were 
used. Its items are described briefly below and in more detail in Appendix 1 (pA3).  
Quality Assessment 
1. Socio-demographic and clinical variables data are described 
2. Inclusion and/or exclusion criteria are formulated 
3. Process of data collection is described 
4. CU treatment described at baseline 
5. The results are compared between two groups or more 
6. Participation and response rates for groups 
7. Patient characteristics of responders/ non-responders presented 
8. Valid QoL questionnaire was used 
9. Results described for both QoL and physical, psychological and social functioning 
10. Mean, standard deviations or percentages are reported for important outcomes 
11. Attempt made to find determinants with the highest prognostic value 
12. Patient signed an informed consent form 
13. Power analysis  
14. Quality of reporting 
 
3.3: Results 
 
3.3.1: General Study and Participant Characteristics 
The 53 included studies summarised in Table 3.2 (p60) spanned the full study search period 
starting from O’Donnell et al (1997) and the English language restrictions applied were reflected in the 
mainly European (31) and North American/ Canadian (9) studies. In light of this restriction studies 
included those from Asia (India, Japan), one each from Iran and Australia and three included a cross-
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continental sample including European, African, Austrialian, Asian and Middle Eastern patient samples 
(Potter et al. 2008; Yun et al. 2011; Zuberbier et al. 2010). A substantial proportion of studies were cross-
sectional (28.30%, n= 15) but near equal numbers were longitudinal studies that consisted of RCT studies 
(30.19%, n= 16) and pilot/ cohort based trials. The main objectives of cross-sectional studies were to 
describe the impact of CU on quality of life whereas trials aimed to evaluate the efficacy or safety of drug 
treatments. No RCT’s evaluated psychological interventions. A proportionate number of studies 
developed and/ or validated QoL questionnaires (16.98%, n = 9). Studies predominantly took place in 
secondary services (hospital or university dermatology/ allergy departments) but 16.98% (n = 9) occurred 
in tertiary settings including a private clinic (Godse, 2006). No studies existed in primary care however 
one used a community Internet survey (Maurer et al.  2009).  
 
The majority of studies (47.17%, n = 25) described patients as chronic idiopathic urticaria (CIU) 
but similar numbers used chronic urticaria (37.74%, n =20) to either mean the same thing or describe 
samples including those with CU physical urticaria. Two studies (n = 3.77%) used chronic autoimmune 
urticaria and more recent studies used the newly recognised chronic spontaneous urticaria (3 studies; 
Kocaturk et al. 2011a, b; Magerl, 2010). One study used urticaria resistant (Okubo et al. 2011). Further 
most studies made use of comparison/ reference groups including other urticaria, dermatological 
disorders, healthy adults and reference samples from the general population.   
 
Baseline Participant Characteristics 
Sample sizes across studies ranged from 12 (Kaplan et al. 2008) to 1356 (Grob et al. 2005) and 
females almost always-outnumbered males (exception Godse et al. 2006; Yadav et al. 2008). The age 
of participants ranged from 16 (Tondury et al. 2011) to 83 years old (Mylnek et al. 2008) with means 
ranging from 27 (Buyukozturk et al. 2012; Engin et al. 2008) to 53 years (Baiardini et al. 2005). Disease-
severity were assessed in 32 studies and ranged from mild to severe, but instruments varied in their 
contents and scoring and this lack of standardisation caused difficulties in collating data across studies 
and in knowing what mild to severe actually meant when comparing across studies.  
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Table 3.2: Summary of Included Studies  
General Study characteristics Participant Characteristics Quality of Life 
 
First Author/ 
Country/ 
 
SD: Study Design   
AO: Study Aim/ Objective  
 
S: Service/ D:CU Descriptor 
C: Comparison  
 
S: Sample Size (All)/  G:Gender/  
A: Age in years (CU only) 
 
M: Measure  MS: Mean  
I:Importance/  O: Other 
 
Study and QoL Conclusions 
 
1. Akashi  
 2011 
Japan 
 
SD:  Clinical study 
AO: Explore relationships to 
        helicobacter & test  efficacy   
        of antibacterial treatment  
 
S: Secondary/ University  
     Dermatology Department  
D: CU 
C: Prurigo chronic multiformis 
 
S: 99    (CU 82, PCM 17) 
 
G: CU:   M 21  F: 61    
A: CU:  45.3 ± 14.9  
 
M:    Skindex-16 
MS:  N/A* 
I:      Primary 
O:    Disease-severity 
 
Only emotional related QoL was 
significantly better at statistical 
level as to symptoms & 
functioning  
 
2. Augustin    
2000 
Germany 
 
SD:  Questionnaire validation 
AO:  To develop a QoL 
measure   
for chronic skin disorder 
 
S: Tertiary/ Specialist clinic  
D: CU  
C: Psoriasis (P),  
Atopic Dermatitis (AD)  
 
S: 747  (P:  401, AD: 254,  CU: 47)  
 
G: M: 34%,    F: 66 
A: 41.7 ± 13.0 (18-66)   
 
M:    FLQA-d, DLQI 
MS:  NR   
I:      Primary 
O:    Other QoL 
 
QoL poorer in AD. FLQA-d is a 
valid & easy to use measure to 
evaluate QoL in skin disease 
 
3.  Baiardini      
2005 
Italy 
 
SD:  Questionnaire validation 
AB:  To develop a disease-   
         specific QoL questionnaire   
         for CU   
 
S: Setting not identified 
D: CU  
C: No 
 
 
S: Develop (D): 76, Validate (V): 125       
 
G: D: M: 29,  F: 47,    V: M: 46  F: 79 
A: D: 48.9 ± 7.82       V: 53.69 ± 
11.7 
 
M:    CU-Q2oL, SF-36  
MS:  NR 
I:      Primary 
O:     No 
 
CU-Q2oL is adequate to 
measure subjective well-being, 
global evaluation of CU impact 
& effectiveness of treatment. 
 
4. Baiardini      
2003 
Italy 
 
SD: Cross-Sectional  
AO: To evaluate QoL by  
        subjective health status & 
        satisfaction. 
 
S: Allergy Unit 
D: CU 
C: Respiratory Allergy (RA) 
     Healthy subjects 
 
S: CU 21, RA: 27,  Controls: 608  
 
G: M: 5  F: 16   
A: 46.3 ± 12.4 
 
M:   SF-36 
MS: PCS 65.64, Mod 
        MCS 59.39 Mod 
I:      Primary 
O:    Satisfaction Profile 
 
Health status scores sig. lower 
in CU than RA for most 
aspects&  all domains to 
controls. CU sig. impacts on 
QoL. 
 
5. Baker 
2008 
USA 
 
SD: Clinical study 
AO: To evaluate CIU severity,  
Basophilhistamine release,  
use, of oral corticosteroids,  
work absence & QoL   
 
S: University Allergy  
Dermatology  
D: CIU Basopenic, B, 
 CIU B non-responders, NR 
CIU B responders,  
 
S: 50 (B: 8,  NR: 15,  R:19) 
 
G:M: 24%,   F: 74% Total sample 
A:  44 ± 16 
 
M:    Skindex-29 
MS:  NR 
I:      Secondary 
O:     Disease severity 
 
QoL similar in all CIU subsets.   
BR subtype had longer disease 
duration, more emergency 
department use & sig. more itch. 
 
6. 
2011a, b)*  
UK 
 
 
SD: Cross-sectional 
AO: To study anxiety in CIU & 
        compare to health controls       
 
 
S: Secondary/ University  
    Dermatology Department 
D: CIU 
C: Healthy controls (HC) 
 
S: 86 (CIU: 55, HC: 31  
 
G: CIU: M: 21.8%, F:78.2, 
A: CIU: 45.25 ± 16.1 
 
M:   SF-36  
MS: Not reported 
I :    Secondary 
O:   Hospital & Anxiety   
       Scale    
 
Higher anxiety in CIU verses 
control. Relationship between 
anxiety, personality, attachment 
style, alexithymia & QoL 
dimensions  
*Studies used the same dataset 
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Table 3.2 continued 
 
General Study characteristics Participant Characteristics Quality of Life 
 
First Author/ 
Country/ 
 
SD: Study Design   
AO: Study Aim/ Objective  
 
S: Service/  D:CU 
Descriptor  C:Comparison  
 
S: Sample Size (All)/  
G:Gender/  
A: Age in years (CU only) 
 
M: Measure  MS: Mean  
 I: Importance   O: Other 
 
Study and QoL Conclusion 
 
7. Berrino  
(2006) 
Italy 
 
SD:  Cross-sectional 
AO:  To evaluate depression, 
         QoL, life events, motivation  
         for psychological therapy 
 
S: Setting not stated 
D: CU 
C: No 
 
S: 30  
 
G: M: 5,   F: 25   
A: 44  Range 21-40 
 
M:    DLQI, NHP 
MS:  Moderate 
I:      Primary 
O:     BDI 
 
Most CU patients experienced a 
stressor event 6mths prior to 
onset/ Depression in CU higher 
than general population. 
 
8. Brzoza  
(2011) 
Poland 
 
 
SD: Questionnaire Development 
AO: To develop and validate a  
       Polish version of the CUQ-oL 
       & present initial results in a 
       Polish sample. 
 
S: University Allergy & 
     Immunology Department 
D: CU 
C: None 
 
S:126 
 
G: M: 37 (29.4%),   F:  89 
(70.6%) 
A: 45.4 ± 14.1 
 
M:   CU-Q2oL, DLQI, 
       Skindex29 
MS: DLQI 9.02±6.96 mild    
       Skindex 29 mild/mod 
I:      Primary 
O:    AS 
 
Itching/ embarrassment most 
impaired & eating/ limits least.  
CU impairs QoL. Polish version 
is reliable, valid, responsive &  
easy to use in research & 
practice 
 
9.Bunselmeyer  
(2009) 
Germany 
 
SD: Pilot, pre-post test 
AO:To test a food challenge  
       procedure  through a 
       pseudo-allergen-free diet  
 
S: Dermatology Department    
     Inpatients & Outpatients  
D: CU 
C: None 
 
S:153 
 
G: M: 52 (33%),    F: 101 (67%) 
A: M: 43 (13-68),  F: 39.5 (10-76) 
 
M:   CU-Q2oL 
MS: 55.19 Mod 
I:    Primary 
O:  Symptom disturbance  
 
17% had remission, 51% partial 
remission & 32% no remission 
but all reported <impairment, 
urticaria symptoms & better QoL.  
 
10.Buyukozturk   
(2012) 
Turkey (Istanbul)  
 
SD: Uncontrolled trial 
AO: To test the omalizumab in  
        resistant CU on activity and   
        QoL over time   
 
S: Secondary/  
    Allergy Department  
D: CSU  
C: None 
 
S: 14 12 CSU, 2 Idiopathic        
                           angioedema 
G: F: 10 M: 4      total sample 
A: 43.07 (27-57) 
 
M:   CU-Q2oL  
MS: 57.5 ± 13.8 Mod 
I:     Primary 
O:  Disease-severity-UAS 
 
Omalizumab improved QoL and 
reduced urticaria activity from 
baseline to 6months. 
 
11. Dastghelb  
(2011) 
Iran 
 
SD: Pilot study 
AO: To test the effectiveness of  
        Masalazine as therapeutic  
        option for CIU 
 
S: Secondary/ University   
     Dermatology Outpatient  
D: CIU       
C: None 
 
S: 33 
 
G: M: 12 (36.4%)   F:  21 (63.6%) 
A: 32.8 ± 9.4 
 
M:   DLQI 
MS: 9.5 ± 4.2 Mild 
I:     Primary 
O:   Disease severity 
 
Mesalazine sig. decreased DLQI 
scores in 66% of participants & 
symptoms scores in at least half 
 
12. Dias (2011) 
Italy 
 
SD: Questionnaire validation 
AO: To cross-culturally adapt & 
        validate a Brazilian- 
        Portuguese CU-Q2oL 
 
S: University  Hospital 
     Dermatology 
D: Chronic Urticaria 
C: Physical urticaria only 
 
S: 112 (27 physical urticaria only) 
 
G: M: 96 (86%), F: 16 (14%) 
A: 46 ± 14.28 
 
M:   CU-QoL, DLQI 
MS: CU-QoL: 36±22 Mod     
       DLQI:6.25±6.53 Mild 
I:     Primary  
O:    Severity 
 
Brazilian-Portuguese version is 
acceptable to patients, valid & 
reliable to evaluate treatment 
outcomes & clinical research 
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Table 3.2 Continued 
1: General 2: Study Characteristics 3: Participant Characteristics 4: Quality of Life 
 
First Author/ 
Country/ 
 
Study Design (SD) 
Study Aim/ Objective (AO) 
 
S: Service/ D: CU 
Descriptor C: Comparison 
 
S: Sample Size (All)/  G:Gender/  
A: Age in years (CU only) 
 
M: Measure     MS: Mean  
 I: Importance/  O: Other 
 
Study and QoL Conclusion 
 
13. Engin (2008) 
Turkey 
 
SD:  Cross-sectional 
AO: To determine levels of   
        anxiety, depression & QoL 
 
 
S: Urticaria Clinic 
D: CIU 
C: Healthy controls 
 
S: 107 (CIU  73, Control 34) 
 
G: CIU: M: 30, F: 43,  C: M: 14 F: 20 
A: CIU: 2 7 ± 10.8,      C: 36.1 ± 10.3     
 
M:   WHO QoL-BREF 
MS: No mean score 
I:     Primary 
O:   BDI* & BAI** 
 
QoL reduced. Patients with 
CIU suffer depression & 
anxiety that sig. decreased 
QoL. 
 
14.  Gimenez-
Arnau (2007) Italy 
Argentina,Europe 
Romania, Poland 
 
SD: RCT 
AO: Assess efficacy & safety of 
        rupadine 10 & 20mg on  
        symptoms, treatment, QoL 
 
S: Dermatology  Centres 
D: CIU 
C: CIU placebo 
 
S: 98 
G: M: P: 42, 10mg: 30,     20mg: 26 
 
F   P: 69.0,  10mg: 77.0,   20mg: 79.0  
A: P: 35.8,   10mg: 40.2,   20mg: 37.6 
 
M:   DLQI 
MS: Not reported 
I:     Secondary 
O:   Disease severity 
 
As reflected in DLQI scores, 
10mg Rupadine improves 
QoL at baseline, 2, 4 & 6 
 
15.Godse (2006) 
India 
 
 
SD:  Cross-sectional 
AO: To evaluate QoL in  
        patients with CU in India 
 
S: Private skin clinic 
D: CU 
C: No 
 
S: 50 
 
G: M: 33 (66%), F: 17 
A: Mean 43, Range 18-80 
 
M:   DLQI 
MS: 7.16 Mild 
I:     Primary 
O:    None 
 
CU had mild impact on QoL 
in > 75% of patients. Patients 
with DPU & positive ASST 
reported sig. worse QoL. 
 
16.Grob (2009) 
France 
 
 
SD: RCT 
AO: To seeif Desloratadine 
        Daily 5mg is better than     
        PRN to improve QoL 
 
S: 35 Dermatology Centres  
D: CIU 
C: CIU placebo 
 
S: 129 ITT (Daily: 46  PRN: 60) 
 
G: M: 38,  F: 68   Total sample 
A:  43.0 ± 13.6   Total sample 
 
M:   DLQI, V-Dermato 
MS: 6.1±4.5 & 5.1±4.5 Mild 
I:     Primary 
O:   Rescue drugs, PRN 
 
Ccontinuous 5mg daily 
desloratadine better than 
desloratadine as PRN over 
time in preserving QoL  
 
17. Grob (2005) 
France 
 
 
SD:  Cross-sectional 
AO: To determine which QoL  
        aspects are mainly  
        impaired. To compare  
        across skin diseases 
 
S: Dermatology clinic 
D: CU   
C: Atopic Dermatitis (AD) 
     Psoriasis (PS) 
 
 
S: 1356 (CU 466, PS 464, AD 426) 
 
G: CU: M 130,  F 237,  
A: CU 37 ± 11 
 
M:   V-Dermato 
MS: No global score 
I:      Primary 
O:    Patient pruritus  
        rating of legions on VAS  
 
QoL impaired in all conditions 
but are qualitatively different 
across conditions. Impact of 
CU has been underestimated  
 
18. Grob (2008) 
France 
 
 
 
SD:  RCT 
AO: To evaluate the effects      
        of desloratadine 5mg & 
        placebo on QoL scores  
        To assess tolerability 
 
S: 40 Dermatology centres 
D: CIU 
C: CIU placebo (P) 
 
S: 137  (CIU 65   P: (P)  72) 
 
G: CIU: M: 24  F: 41,   P: M: 29  F: 43 
A: CIU:  41.2 ± 15.4    P: 41.5 ± 15.2    
 
M:   DLQI (Dl)  V-Dermato (V) 
MS: Dl D: 9.7±5.9, P 8.8±5.2 
       V:D:35.2 ± 18.8  
       P: 35 ± 20.2  Mild-mod 
I:     Primary 
O:   Sleep, daily activities 
 
Desloratadine 5mg sig. 
Related to improvements 
from baseline to day 42 in 
both QoL measures. Drug 
reduces QoL score & is a 
useful outcome measure. 
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Table 3.2 Continued 
1: General  2: Study Characteristics  3: Participant Characteristics 4: Quality of Life 
 
First Author/ 
Country 
 
SD: Study Design   
AO: Study Aim/ Objective 
 
S: Service/ D: CU 
Descriptor C: Comparison 
 
S: Sample Size (All)/  G:Gender/  
A: Age in years (CU only) 
 
M: Measure     MS: Mean  
 I: Importance/  O: Other 
 
Overall QoL Impact 
Study and QoL outcome 
 
19. Jariwala 
(2009) 
 USA 
 
SD: Questionnaire Validation 
AO: To develop a CU specific  
        Questionnaire: Urticaria  
        Severity Score (USS) 
 
S:  Out-patient Clinic 
D:  CU 
C:  None 
 
S:  80 
 
G:  M: 21   F : 59  
A:  42.8±16.2 
 
M:   DLQI 
MS: Mild 
I:     Primary 
O:   Urticaria severity 
 
The USS is valid & reliable 
for  monitoring urticaria 
severity and maybe more 
applicable than the DLQI   
 
20. Kaplan  
(2008) 
USA 
 
SD: Clinical Study 
AO: To investigate the  
        efficacy of omalizumab  
        in patients with CAU  
 
S: University  Dermatology 
D: CAU 
C: CAU placebo 
 
S:  12  
 
G:  M: 4    F: 8  
A: 32-62 (range) 
 
M:    DLQI 
MS: 14, Mod 
I:      Secondary 
O:    Sleep & daily activities 
 
Omalizymab is effective in 
CAUr as indicated by DLQI 
 
21. Kapp & 
Picher (2006) 
Switzerland/  
Germany 
 
SD:  RCT 
AO: To assess efficacy of  
        Levocetrizine 5mg, QoL  
        & productivity in CIU 
 
S: Dermatology centres 
D: CIU 
C: CIU placebo 
 
 
S: 124   (CIU: 81  Placebo (P) 85) 
 
G: M:  CIU 23   P 25, F:  CIU 58  P 60 
A: CIU: 44.3,   Placebo: 39.7 
 
M:   DLQI 
MS: CIU: 11,  P: 12 Mod 
I:     Secondary 
O:    Pruritus severity & features 
 
Drug reduced disease 
severity & improved QoL & 
productivity in patients  
from baseline to 4 weeks 
 
22. Kocaturk     
(2011a,b) 
Istanbul,  
Turkey 
 
SD: RCT 
AO: To assess the efficacy of  
       autologous whole blood  
       serum (AMB) autologous    
       serum (AS) injections 
 
S: Dermatology department 
     research hospital 
D: Spontaneous  CU 
C: Placebo control 
 
S: 88 
 
G:ASST+: M: 24 (40.7%), F: 35 (59.3) 
    ASST-: M: 35 (59.3%), F: 23 (79.3)  
A: +: 39.36 ±11.95 &  -: 39.07± 14.13 
 
M:   DLQI 
MS: A+ 11.10 ± 5.89 Mod 
        A- 10.07 ± 5.83 Mod 
I:      Primary 
O:    See disease-severity 
 
Even though not sig. better 
than placebo therapy 
resulted in a marked 
decrease in scores of 
disease activity & DLQI. 
 
23. Lachapelle   
(2006) 
Belgium 
 
SD:  RCT  
AO: To assess the effect of  
        5mg desloradine once  
        Daily 
 
S: 24 Dermatology centres 
D: CIU 
C: None 
 
S: 121 
 
G: M: 40%  F: 60% 
A:  41.1 ± 15.7 
 
M:    DLQI 
MS: 13.4 ± 5.2 Mod 
I:      Primary 
O:    Sleep & daily activities 
 
QoL improved at day 7 and 
42. QOL scores correlate 
with pruritus hive size. 
Desloradine improves QOL 
as measured by the  DLQI 
 
24. Lennox & 
Leahy (2004) 
USA 
 
SD: Questionnaire   
       development 
AO: To test the validity of     
       DLQI in two CIU samples       
       treated with fexofenadine 
 
S: Not identified 
D: CIU 
C: No 
 
 
S: 857 (418 and 439) 
 
Gender and age not stated in paper 
 
M:   DLQI 
MS: 9.66- 9.83 Mild 
I:     Primary 
O:   Disease severity 
 
One dimensional structure 
& lack of random error in 
CU. Distinguished between 
levels of impairment & is 
valid &reliable. 
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Table 3.2 Continued 
1: General  2: Study Characteristics 3: Participant Characteristics 4: Quality of Life 
 
First Author/ 
Country 
 
SD: Study Design   
AO: Study Aim/ Objective 
 
 
S: Service/ D: CU 
Descriptor C: Comparison 
 
S: Sample Size (All)/  G:Gender/  
A: Age in years (CU only) 
 
M: Measure     MS: Mean  
 I: Importance/  O: Other 
 
Overall QoL Impact 
Study and QoL outcome 
 
25. Liu (2012) 
China 
 
SD: Questionnaire validation 
AO: To study QoL in Chinese  
        patients with CU & DLQI      
        psychometric properties 
 
S: Cross-sectional 
    Questionnaire Validation 
D: CU 
C: None 
 
S: 131 
 
G: F: 83, M: 48       
A: 32.94 ± 0.70 
 
M:   DLQI 
MS: 9.93 ± 0.46 Mod 
I:     Primary 
O:   None 
 
DLQI had two latent factors 
& a Cronbach alpha of .85. 
CU has a moderate impact 
on life quality. 
 
26. Magerl   
(2010) 
Germany 
 
SD: Prospective trial 
AO: To assess the effects of  
       a  pseudo allergen-free  
       diet on disease severity & 
       QoL 
 
S: Tertiary/Specialist   
Urticaria Clinic  
D: Spontaneous CU   
C: None 
 
S:  140  
 
G:  Females sig outnumber males   
A:  18- 70+ range 
 
M:   DLQI 
MS: NR 
I:     Secondary 
O:   None 
 
20 subjects strongly 
responded to diet & 19 
partially responded. 9 
subjects made reductions in 
medication. Diet is 
beneficial in 1/ 3 patients 
 
27. Mathias    
(2010) 
USA 
 
 
SD: Validation 
AO: To qualitatively identify   
       outcomes important to  
       patients, to assess content 
       validity of a patient diary  
       based on UAS 
 
S: University Dermatology  
D: CIU 
C: None 
 
S: 31 (baseline, stage 1) 
 
G: F: 26 (84%), M: 5 (16%) 
A: 46.0 ± 16.1 
 
M:   DLQI 
MS: Not reported 
I:     Primary 
O:   Sleep, activity, symptoms,     
       Management 
 
The urticaria patient diary is 
an easy to administer & 
comprehensive assessment 
tool of CIU symptoms. 
 
28. Maurer    
(2009) 
France/  
Germany 
 
SD: Cross-sectional 
AO: To investigate QoL,  
        treatment usage & doctor- 
        patient relationship 
 
S: Internet Survey 
D: CU 
C: None 
 
 
S: 321 (Germany 169, France 150) 
 
G:  M: 134 (41.9%) F 186 (58.1%) 
A:  Total: SD 37 
 
M:   Skindex-29 
MS: No global score 
I:     Primary 
O:   Treatment use, doctor-  
       patient relationship 
 
CU has substantial impact 
on QoL. Physicians who 
discuss emotional impact 
increase trust & satisfaction 
in their patients.    
 
29. Mylnek      
(2009) 
Germany  
 
D:   Questionnaire development 
AO: To develop a German  
        version of CU-Q2oL 
 
S: University Dermatology   
D: CU 
C: No 
 
S: 157 
 
G: Twice as many females as 
     males 
A: Range 31–75 yrs 
 
 
M:   CU-Q2oL, Skindex-29, DLQI         
MS: DLQI 6.8 Mild 
I:     Primary 
O:   See severity 
 
Six scales identified. Is a 
reliable measure to assess 
burden of CU on QoL in 
research. 
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First Author/ 
Country 
 
SD: Study Design   
AO: Study Aim/ Objective 
 
 
S: Service/ D: CU 
Descriptor C: Comparison 
 
S: Sample Size (All)/  G:Gender/  
A: Age in years (CU only) 
 
M: Measure     MS: Mean  
 I: Importance/  O: Other 
 
Overall QoL Impact 
Study and QoL outcome 
 
30. Mlynek   
(2008) 
Germany 
 
 
SD:  Cross-section 
AO:  To determine correlations  
         between the UAS & QOL  
 
S: Dermatology & Allergy  
Clinic 
D: CU 
C: None 
 
S:  111 
 
G:  M: 32  F: 79 
A:  43.7 ± 15.4 (range 18-83) 
 
M:   DLQI 
MS: 7.97 ± 5.8  Mild 
I:     Primary 
O:   See severity 
 
UAS positivity correlates 
with QoL & monitors 
disease-activity using 
mean values over 4 days. 
 
31. O’Donnell      
(1997) 
England 
 
SD: Cross-section 
AO: To assess QoL for the  first  
time in CU 
 
 
S: Tertiary Urticaria Clinic  
D: CU, CU+  Delayed  
Pressure Urticaria (DPU) 
C: Urticarias, heart disease 
 
S:  142  (69 CU, 73 CU with DPU) 
 
G:  M: 45,  F: 97 
A:  39.7  (range 14-71) 
 
M:   NHP, Study-specific  
MS: No composite 
I:     Primary 
O:    None 
 
Many aspects of QoL sig. 
impaired & comparable to 
heart disease. Worse in 
patients with CU& DPU  
 
32. Okubo  
(2011) 
Japan 
 
SD: RCT 
AO:Test double dose cetirizine   
       hydrochloride 10 & 20mg & 
       Olopatadine10mg on QoL 
 
S: University dermatology  
D: Urticaria resistant 
C: CU treatment groups 
 
S: 51 
 
G: M: 16, F: 35 
A: 39 ± 18.1 (range 17-81) 
 
M:    Skindex-16 
MS:  42 Mod 
I:      Primary 
O:    Disease severity 
 
Doubling dose cetirizine > 
efficacious. Emotions 
most effected over 
symptoms & functioning 
 
33. Ozkan 
(2007) 
Istanbal,  
Turkey 
 
 
SD:  Cross-sectional 
AO: To determine prevalence 
        of psychiatric co-morbidity 
        in CIU. To compare QoL in  
        CIU to  controls 
 
S: University Allergy       
     Department 
D: CIU 
C: Healthy Controls (C) 
 
 
S: 159 (CIU: 84, C: 75) 
 
G: M: 13,    F: 15 
A: CIU: 36.83 ± 10.26   
 
M:    SF-36 (0-100) 
MS: PCS: CIU: 58.25,C:75.5 
        MCS: CIU:56.85, C:73.43 Mod   
I:      Primary     
O:    None 
 
Psychiatric co-morbidity 
high in CIU and is 
detrimental to QoL 
 
34. Poon     
(1999) 
England 
 
SD:  Cross-sectional     
AO: To determine the extent of  
        disability in different  
        urticarial conditions 
 
S: Tertiary Urticaria  Clinic 
D: CIU 
C: Delayed Pressure  
Urticaria DPU), Others 
 
S: 170 (CIU 47  CIU+ swelling (A) 26) 
 
G: M: 44%        F: 56% 
A: 37.6 ± 10.3 
 
M:   DLQI  
MS: CIU 25%±24, CIU+A 43%±23* 
I:     Primary 
O:   None 
 
DPU& cholinergic 
urticaria have worse QoL 
than CIU & comparable to 
other skin disorders.   
 
35. Potter    
(2008)    
Europe  
Romania 
South Africa  
 
SD: RCT 
AO: To compare efficacy of  
        levocetirizine 5mg & 
        desloratadine 5mg daily on  
        symptoms activity & QoL 
 
S: Dermatology Centres 
D: CIU 
C: None 
 
 
S:  886 (Lev  438, Des  448) 
 
G: M: 296 (33.4%)     F: 590 (66.6%) 
A: 43.10 ± 15.08 overall 
 
M:    DLQI 
MS: 11.58±6.31 &    12.16±6.68 
I:      Secondary 
O:    Treatment satisfaction 
 
Levocetirizine 5mg sig. 
more effective than 
desloratadine 5mg over 4 
weeks. Both improve QoL  
*Percentage scoring 10 or above 
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First Author/ 
Country 
 
SD: Study Design   
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S: Service/ D: CU 
Descriptor C: Comparison 
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A: Age in years (CU only) 
 
M: Measure     MS: Mean  
 I: Importance/  O: Other 
 
Overall QoL Impact 
Study and QoL outcome 
 
36. Reeves    
(2004) 
Australia 
 
SD: RCT 
AO: To evaluate the efficacy of   
        Hydroxychloroquine 
         immunodulation therapy 
 
S: Tertiary/ Immunology & 
     Allergy  
D: CAU 
C: CAUplacebo 
 
S:18,  9 placebo (P), 9 Hydrox  (H) 
 
G: Stated as 5:1 ratio 
A: 38.2 
 
M:   SF-12,   
MS: SF-12 P 19.1 P  24.1 Severe 
I:      Primary 
O:    Disease severity 
 
Improved SF-12 scores with 
hydroxychloroquine, but 
poor reporting of measure 
in study. 
 
37.Seidenar    
(2006) 
Italy 
 
SD:  Non-randomised trial 
AO:  To measure effects of  
         Descloratadine(DL) 5mg  
         once daily on QoL 
 
S: 28 Investigation sites  
D: CIU 
C: CIU moderate & severe   
 
 
S: 255 
 
G M: 87 (34.1%)  F: 168 (65.9) 
A: 43.5 (42 median), range 18-79   
 
M:   DLQI 
MS: 9.4 ± 5.4 mild 
I:     Primary 
O:   CU severity, sleep, activities 
 
Descloratadine 5mg 
improved QoL irrespective 
of moderate or severe 
levels of CIU. 
 
38. Shikar   
(2005) 
USA/  
Canada 
 
SD: Questionnaire validation 
AO: To estimate the minimal   
        important difference (MID)   
        of the DLQI in CIU  
 
S: Dermatology clinic sites 
D: CIU  
C: None 
 
S: 944 (476 and 468) 
 
G: NR 
A: NR 
 
M:   DLQI 
MS: 9.64± 6.19 & 9.32± 5.61 Mild 
I:     Primary 
O:   None 
 
MID of 2.24-3.10 
recommended for 
interpreting DLQI scores in 
CIU 
 
39. Silvares   
(2011) 
Brazil 
 
SD: Cross-sectional survey 
AO: To evaluate the impact of    
       QoL on CU out-patients     
       using the DLQI 
 
S: University Out-patient  
     Clinic     
D: CU 
C: Other Dermatoses  
 
S: 100 
 
G: F: 86%,  M: 14% 
A: 41.8 
 
M:DLQI 
MS: 13.5 Mod 
I: Primary 
O: None 
 
CU seriously compromises 
QoL of patients evaluated. 
 
40. Spector  
(2007) 
USA 
 
SD: RCT  
AO: To examine  fexofenadine  
        HCL 180mg on QoL,  
        Work productivity& activity  
 
S: Dermatology Centres  
D: CIU 
C: CIU control 
 
S: 254 (CIU 163, Control 91) 
 
G: NR 
A: NR 
 
M:    DLQI 
MS: 11 ± 16.3 Mod 
I:      Secondary 
O:     WPAI* 
 
Fexofenadine improves 
HRQoL, work productivity & 
activity score.  
 
41.Staevska  
(2010)  
Germany 
 
SD:  RCT 
AO: To provide evidence for    
        dosage up to 4-fold  H2–  
        antihistamines in CU 
 
S: Specialist Urticaria Clinic 
D: CU 
C: CIU treatment groups 
 
 
S: 80 (40 Lev, 40 Des) 
 
G: Overall    M: 27  F: 53 
A:  36.5  (35 median ) 19-67 range 
 
M:   CU-Q2oL 
MS: Not reported 
I:     Secondary 
O:    Disease severity 
 
Increasing lev.& des. 4-fold 
improves CU symptoms in 
¾ of patients. Improves 
QoL 
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42. Staubach  
(2006a) 
Germany 
 
SD:  Cross-sectional 
AO: To determine aspects of  
        QoL affected by CU.  
        factors that impact QoL  
 
S: University Hospital 
D: CU 
C: Healthy Controls (C) 
 
S:  196 (CU 100,  C: 96) 
 
G:  M: 33,     F: 67,  
A:  CU 42.3 ± 1.2,    C: 42.8 ±1.4 
 
M:    Skindex-29 
MS:  70 severe 
I:      Primary 
O:    HADS & SOMS* 
 
QoL in CU markedly impaired 
to control, more for emotional & 
social function. Psychiatric 
diagnoses further impaired QoL 
 
43. Staubach   
(2006b) 
Germany 
 
 
SD: RCT 
AO: To test benefit of AWB 
       (Autologous whole blood)  
       injections  
 
 
S: University Dermatology 
D: CU  
C: CU placebo 
 
S: 56 (ASST+  35, ASST- 21) 
 
G: M:  ASST+: 9  ASST- : 6 
     F: ASST+ : 26, ASST-: 5  
A:  ASST+42.1±2.9,  ASST- 45.5 ± 4.0 
 
M:   DLQI 
MS: 8.5 ± 1.0 & 9.3± 1.6 Mild   
I:     Primary  
O:   Rescue medication 
 
ASST+ CU patients showed 
significantly reductions in 
disease severity, anti-histamine 
usage & QoL improvements 
with 8 weeks of AWB.   
 
44. 
Thompson       
(2000) 
USA 
 
 
SD: RCT 
AO: To investigate effect of  
       60mg twice daily fexo-  
       fenadine HCL on QoL    
       QoL, work/ classroom  
       Productivity & regular  
       activity 
 
S: 70 Dermatology Centres 
D: CIU 
C: CIU placebo  (p) 
 
S:Study 1: 160  (60mg 87, P:  76)  
G: M: 60mg: 24  P: 22,  F: 60mg: 63 P:51 
A: 60mg:  40 ± 11   P: 38 ± 13 
 
S: Study 2: 167 (60mg: 82  P:  85) 
G: M: 60: 14   P: 20,   F:  60mg: 61  P: 65 
A: 60mg= 38 ± 13  P = 40 ± 13 
 
M:   DLQI 
MS: S1: P: 11.0: F: 10.0  Mod 
       S2: P: 12.1  F: 10.6  Mod 
       Mild-moderate 
I :    Primary 
O:   Disease severity, WPAI** 
        
 
DLQI scores sig. improved in 
the treatment group as to 
control for all variables. 
Fexofenadine 60mg improved 
HRQOL and other variables in 
moderate-severe CIU 
 
45. Tondury   
(2011) 
Switzerland 
 
SD: Cohort 
AO: To investigate effect of  
        psychological factors on   
        the  course of CU 
 
S: Tertiary/ University  
Dermatology  
D:   CU  
C:   None 
 
S: 95 
 
G: Female 55 (58%) 
A: 39.3±13.6 (range 16-79 yrs 
 
M:   DLQI, Skindex-29(S-29) 
MS:DLQI 10.2± 6.2 Mod 
      S-29: 38.1± 21.6 Mod  
I:    Primary    
O:  PRISM*** 
 
PRISM showed high burden of 
suffering. Considerable 
impaired QoL reported but did 
not relate to PRISM over time.   
 
46. Uguz   
(2008) 
Turkey 
 
 
SD: Cross-sectional 
AO: To compare CIU  
       patients with & without  
       Axis 1 or Axis 2 (A! & 2)  
       psychiatric disorder & 
       healthy controls on QoL 
 
S: University Hospital  
D: CIU Outpatients 
C: Health Controls (HC) 
 
S: CIU 200, HC: 25 
 
F: Axis 1 only: 17   35.00 ± 13.57 
    Axis 2 only: 16   33.04 ± 10.62 
    Axis 1&2:    19   37.32 ± 13.49  
    CIU only:       6   34.72 ± 1.75  
    HC:             17   35.48 ±  9.24 
 
M:   WHO-QOL BREF 
MS: No global score 
I:     Primary 
O:   No 
 
 
Axis I & II psychiatric disorders 
seem considerable factors of 
QoL. Similar QoL between CIU 
patients with no Axis diagnosis 
& HC but CIU patients overall 
have sig. poorer QoL than HC 
*Hospital Anxiety & Depression Scale and Screening for Somatoform Disorders     ** Work Productivity and Activity Instrument   ***Pictorial Representation of Illness and Self Measure instruent 
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47. Valero 
  (2008) 
Spain 
 
SD: Questionnaire validation 
AO: To validate the Spanish   
        CU-Q2oL & to assess its  
 
S: Dermatology centres  
D: CU 
C: CU severity groups 
 
S:  695 (68% Spontaneous) 
 
G:  Female: 62.1 %  
A:  42 ± 15 
 
M:   CU-Q2oL & Skindex-29  
MS: CU-Q2oL 22.2 ± 15.6 Mild 
I:     Primary 
O:   No 
 
Correlated well with skindex-
29, good reliability, valid & 
sensitive to change. Suitable 
for clinical & research settings 
 
48. Vena et al 
(2006) 
Italy 
 
 
SD:  RCT  
AO: To assess the efficacy & 
        safety of oralcyclosposin   
        A  (CSA) in CIU 
 
S: Outpatient Clinic  
D: CIU 
C: CIU placebo (P)/  
     Treatment group 
     16 & 8 weeks(W)  
 
 
S: 99 (16W: 31,   8W: 33,    P: 35) 
 
G: M:  16 W: 14,      8W: 16,       P: 12  
     F:   16 W: 17      8 W: 17,       P: 23 
 
A: 16w: 44.0 ± 9.8,  8w: 37.1 ± 11.3          
     P: 41.7 ± 11.5 
 
M:    DLQI 
MS: 16W: 7.9 ± 5.6, Mild 
         8W: 7.9 ± 4.6 Mild 
         P: 7.8 ± 5.7 all  Mild 
I:       Secondary 
O:     Disease severity 
 
Cyclosporine with cetrizine 
useful in the treatment of CIU.  
Less symptoms & a 
significant improvement in 
DLQI score.  
 
 
49.Yadav et 
al (2008) 
India 
 
SD:  Pre-post test 
AO: To assess the  
        prevalence of H.Pylori  
        (HP) infection & effect of  
        its eradicationin CIU  
 
S: Allergy Clinic 
D: CIU 
C: Controls (C) 
 
S: 136  CU 68,    C: 68 
 
G: M: CU: 37, C: NR,  F: CU: 31    C: NR  
 
A: CU:33.54 ± NR  (14-63),  C: NR 
 
M :   CU-Q2oL 
MS: CU- HP: 70.92 ±12.59  
CU: HP: 65.57 ±11.57 Severe 
I:     Primary 
O:   Rescue treatment  
 
70% had HP related gastritis. 
81% responded to eradication 
therapy. Patient response to 
treatment sig. as indicated  
on CU-Q2oL  
 
50. Yun et al 
(2011) 
Australian,  
Sri Lanka 
 
 
SD: Cross-section 
AO:To assess QoL in Sri  
       Lankans& Australians  
       (Aus)  
 
S: Immunology Clinic/   
    University 
D: CIU 
C: Cultural groups 
 
S: 125   Aus 43 (34.4%)    Sri 82 (65.5%) 
 
G: F: 83 (60.4%)   M: 42 (33.6) 
 
A:  ≤ 40 61 (48.8%), ≥ 40 64 (51.2%)  
 
M:   CU-Q2oL 
MS: Not reported 
I:     Primary 
O:   None 
 
Differences between Sri 
Lankan’s & Australians in 
respect to mood, sleep, daily 
activities and food choice. 
 
51. Zuberbier 
et al (2010) 
Europe 
Romania, 
Argentina 
 
SD:  RCT 
AO: To compare the  efficacy  
        & safety of bilastine (B)  
        20mg vs levocetirizine 5  
        mg (L) & placebo (P)      
        CIU 
 
 
S: Dermatology Centres  
D: CIU 
C: CIU Placebo/   
Treatment Groups 
 
S: 525 in moderate to severe CU 
 
G: B: M 63, F 109,   L: M: 54, F:109    
 P: M: 40, F: 141    
 
A: B: 41.7 ± 13.8,     L: 39.8 ± 13.5        
P:  39.4 ± 13.9 
 
M:    DLQI 
MS: 13.38 ± 5.96 Mod 
I:      Secondary 
O:    Disease-severity 
 
 
Bilastine 20 mg is a novel, 
effective & safe treatment for 
the management of CIU. Also 
improves QoL scores as 
indicated on DLQI 
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3.3.2: Quality of Life Questionnaires 
Quality of life was measured with 8 different questionnaires of which four were generic; three 
dermatology-specific and one disease-specific. Generic questionnaires included the SF-12 and SF-36 
1992 used in five studies, the NHP used in two studies and the WHO QoL-Bref used in two studies.  
Dermatology-specific questionnaires included the Skindex (16 and 29) used in ten studies, the DLQI used 
in 28 studies (> 50% studies), the FLQA-d used in one study and the V-Dermato used in 3 studies. The 
disease-specific instrument was the CU-Q2oL. Assessing QoL was a primary measure in 42 of the 53 
studies of which 11 used two or more questionnaires. Overall questionnaires differed considerably in 
terms of items, domains, scoring and theoretical underpinning. Only four were directly subjected to 
psychometric assessment in CU: the DLQI (Lennox and Leahy, 2004; Shikar et al, 2005) and CU-Q2oL 
(Baiardini et al, 2005; Broza et al, 2011; Mylnek et al, 2009; Valero et al, 2008), SF-12 (Reeves et al, 
2004) and FLQA-d (Augustin et al, 2000). 
 
3.3.3: Overall Quality of Life 
The differences in the construction, subscale weightings and scoring of questionnaires meant 
that an overall QoL score was only available from instruments that produced composite scores. Thirty-
one studies presented a composite mean QoL score (or one that could be calculated) however the overall 
impact of CU on QoL was dependent on the questionnaire used. A substantial 22 studies (41.51%) used 
the dermatology-specific DLQI where overall scores ranged from 5.10 ± 4.50 (Grob et al. 2009) to 14.00 
(Kaplan et al. 2008), however an observation of Table 3.2 suggested that the substantial majority of 
studies ranged scores of around 9.50. With scores ranging from 0 (no impact) to 30 (worst impact) this 
represented a mild impact on QoL. Grob et al. (2008) replicated this mild impact using the V-Dermato 
where mean scores suggested a mild (borderline moderate) impact on a 0-100 scale. Conversely, four 
studies reporting Skindex-29 data reported scores off 29.0, 38.10, 42.0 and 70.0 (Brzoza et al. 2011; 
Tondury et al. 2011; Okubo et al. 2011 and Staubach et al. 2006a respectively). With scores ranging from 
0 (better QoL) to 100 (worse QoL) this suggested a more moderate (to borderline severe) impact on QoL. 
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Overall scores from the SF-36 (presented as a physical and mental summary score where 0-49 means 
worse health and 51-100 better health) ranged from 58.25/ 56.85 (Ozkan et al. 2007) to 65.64/ 59.39 
(Baiardini et al. 2003). With mean scores ranging around the scale mid-point this also suggested a 
moderate impact. Four studies presenting overall CU-Q2oL scores (Valero et al. 2008 Bunselmeyer et al. 
2009; Buyuloz et al. 2012; Yadav et al. 2008) reported scores of 22.20, 55.19, 57.50 and 70.92 
respectively. With scores ranging from 0- 49 (better QoL) to 51-100 (worse QoL) this represented an 
overall moderate impact (average 51.45). 
  
3.3.4: Aspects of Quality of Life 
The full spectrum of aspects of quality of life affected by CU is presented in Tables 3.3 (p71). 
They are represented by component/ domain names as defined in the questionnaires from which they 
were derived. These components were further grouped into physical, psychological and social functioning 
independently by two researchers (DB and JK) before a consensus was made on what should go into 
each category. No distinctions were made as to how frequently individual aspects appeared in the text 
as this was more of a reflection of how often each QoL instrument had been used across studies as to 
their importance (e.g. pruritus and swelling are core impairments in CU but do not feature in studies pre-
2005 as no CU specific instruments had existed whereas the less specific symptoms variable was an 
available option on instruments such as the DLQI and Skindex-29). It was considered that CU-Q2oL 
variables would have more weighting but this instrument is still largely untested and comes in various 
factor-analysed formats. At this stage the goal was to reveal the full spectrum of QoL aspects reported 
across studies regardless of frequency or degree of affect. To help researchers to look at certain aspects 
in more detail the QoL instruments that feature each item is also representated in Table 3.3 (p71) as well 
as the studies they feature in.  
 
Physical Functioning 
Reported problems regarding physical functioning were themed into one of three areas:
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Table 3.3: Content Analysis of Bio-Psychosocial Aspects of Quality of Life in CU 
Aspect Component (Instrument) Studies featured  n % Studies 
 
Physical 
Physical Health (C)  13,46   2 03.92 
Physical Function/ Mobility (A,B) 4,6,33,36,7,31   6 11.96 
Role Limitation-Physical (A) 4,6,33,36   4 07.84 
Physical Pain/ Complaints (A,B,F,G) 2,4,6,16,17,18,33,36,7,31      10 19.60 
Vitality (A) 4,6,33,36   4 7.84 
Sleep (B,H) 3,7,8,9,10,12,29,31,41,47 10 19.60 
Energy (B) 7,31   2 03.92 
Pruritus (H) 3,8,9,10,12,29,41,47   8 15.69 
Swelling (H) 3,8,9,10,12,29,41,47   8 15.69 
Impact on Life Activities (H,D,F,B,G) 2,3,7,8,9,10,11,12,14,15,16,17,18,19,20,21,22,23,24,25,26,27,29,30,31,34,35,37,38,39,40,41,43,44,45,47,48,49,51 39 76.47 
Symptoms (D,E) 1,5,7,11,12,14,15,16,18,19,20,21,22,23,24,25,26,27,28,29,30,32,34,35,37,38,39,40,42,43,44,45,48,49,51          35 68.63 
Treatment (D,F,G) 2,7,11,12,14,15,16,17,18,19,20,21,22,23,24,25,26,27,29,30,34,35,37,38,39,40,43,44,45,48,49,51 32 62.75 
Psychological (generic)(C) 13,46   2 03.92 
 
Psychological. 
 
Emotional functioning (A,B,F,E)  2,1,4,5,6,7,28,31,32,33,36,42,45 13 25.49 
Mental Health/ Mood (A,G) 4,6,16,17,18,33,36   7 13.73 
Looks/ Self-image (H,G) 3,8,9,10,12, 16,17,18,29,41,47 11 21.57 
Feelings (D) Satisfaction (F) 2   1 01.96 
Social Relationships (C) 13,46   2 03.92 
 
 
Social 
 
 
Social function/ Life/ Isolation (A,F,B,E,G) 4,6,16,17,18,33,36,7,31   9 17.65 
Limits (H) 3,8,9,10,12,29,41,47   8 15.69 
Personal relationships (D) 7,11,12,14,15,16,18,19,20,21,22,23,24,25,26,27,29,30,34,35,37,38,39,40,43,44,45,48,49,51 30 58.82 
Leisure activities (D,G) 7,11,12,14,15,16,17,18,19,20,21,22,23,24,25,26,27,29,30,34,35,37,38,39,40,43,44,45,48,49,51 31 60.87 
Work or school (D) 7,11,12,14,15,16,18,19,20,21,22,23,24,25,26,27,29,30,34,35,37,38,39,40,43,44,45,48,49,51 30 58.82 
Other Environment (C) 13,46   2 03.92 
 
A: SF-36, 12: 4: Baiardini, 2003; 6: Barbosa, 2011a,b; 33:Ozkan, 2007; 36: Reeves, 2004     
B: NHP: 7: Berrino, 2006; 31:O’Donnell, 1997       
C: WHOQoL Bref: 13: Engin, 2008; 46: Uguz, 2008           
D: DLQI - 7:Berrino, 2006; 11:Dastghelb; 12:Dias, 2011; 14:Gimenez-Arnau, 2007; 15:Godse, 2006; 16:Grob, 2009;18:Grob, 2008; 19:Jariwala, 2009; 20:Kaplan, 2008; 21:Kapp & Picher,2006;   22:Kocaturk, 2011a,b; 23:Lachapelle, 2006;    
     24: Lennox & Leahy, 2004; 25:Liu, 2012, 26:Mageri, 2010; 27:Mathias, 2010; 29:Mylnek, 2009;30:Mylnek, 2008; 34:Poon, 1999; 35:Potter, 2008; 37:Seidenari, 2006; 38:Shikar, 2005; 39:Silvares, 2011; 40:Spector, 2007; 43:Stuabach,  
     2006b; 44: Thompson, 2000; 45: Tondury; 48:Vena, 2006; 49: Yadav, 2008; 51: Zuberbier, 2010    
E: Skindex - 1:Akashi, 2011; 5:Baker, 2008; 28:Maurer, 2009; 32:Okubo; 42:Stubach, 2006a; 45:Tondury    
F: FLQA; 2: Augustin 2000    
G: V-Dermato: 16: Grob, 2009; 17: Grob, 2005; 18: Grob, 2008    
H: CUQ2oL - 3: Baiardini, 2005; 8: Brozoza, 2011, 9:Bunselmeyer, 2009; 10:Buyukozturk, 2012; 12:Dias, 2011; 29:Mylnek, 2009; 41:Staevska, 2010; 47:Valero, 2008; 50:Yun 2011
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Physical Symptoms 
CU and its symptoms were reported to impair quality of life generally (68.63% of studies, n= 35) but more 
specifically the most experienced symptoms were pruritus (15.69%, n= 8), swelling (15.69%, n= 8), 
physical pain/ complaints and sleep (both 19.60%, n= 10). Other symptoms included experiencing low 
vitality, energy and problems related to sleep and rest (see Table 3.3, p71). 
 
Physical functioning/ limitations 
Participants with CU across studies reported discomfort related to mobility (11.96%, n= 6), especially 
those with concurrent physical urticarial (O’Donnell et al. 1997). Undertaking daily life activities were also 
affected (76.47%, n= 39) and were covered as a domain in 5 of the 8 QoL instruments. Impaired physical 
functioning further impacted in the ability to undertake ones roles (07.84%, n= 6). 
 
Treatment  
The final aspect related to CU treatments and their negative impact on physical functioning which was 
reported in 62.78% of studies (n= 32) and represented by 3 questionnaires. 
 
Psychological Functioning 
Problems regarding psychological functioning were themed into three identified areas of concern:  
 
Mental Health 
Aspects related to overall psychological health but included reports of experiencing poorer than average 
mental health and mood (13.73%, n= 7) and negative feelings in general (01.96%, n= 1). 
 
Emotional Responses 
Participants across studies reported that CU negatively affected their emotional functioning which 
featured in a quarter of studies (25.49%, n= 13) and four QoL questionnaires. 
 
Self-Perception/ Feelings 
A fifth of studies (21.57%, n= 11) reported that CU negatively affected looks and self-image (using the 
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V-Dermato and CU-Q2oL). One study reported that CU affected satisfaction with life (01.96%) 
 
Social functioning 
Problems regarding social functioning were themed into four identified areas 
 
Personal relationships 
Participants in over half of studies (58.82%, n= 30) reported that CU interfered personal relationships.  
 
Social Interaction  
CU affected social functioning leading to social isolation (17.65%, n= 9), which was covered, by 5 QoL 
instruments and limitations in social function (15.69%, n= 8), which was covered by the CU-Q2oL. 
 
Leisure Activities 
Participants across 60.87% of studies (n= 31) reported difficulties in participating in leisure activities 
because of CU and this aspect was covered by the DLQI and V-Dermato. 
 
Work and Study 
Participants with CU reported in over 50% of studies that the condition affected their undertaking of work 
or study activities (58.82%, n= 30) and these aspects were covered by the DLQI. 
 
One aspect that it was agreed did not fit into the areas of physical, psychological and social functioning 
was the generic QoL aspect of environmental functioning which is separated from these three aspects in 
the WHO-QoL Brief instrument used in 2 studies (Engin et al. 2008; Ozkan et al. 2008).  
 
Area of Quality of Life most Affected 
Findings regarding areas of QoL most affected was collated from 21 studies and are presented 
in Table 3.4 a-h (p74). Due to the variety of different questionnaires of differing levels of specificity and 
contents used across studies, aspects reported were compared by the common questioonaire used in 
studies. Where possible scores across studies using the same instrument were collated to give an 
average score but should be taken as crude analyses as patient characteristic were not controlled for.  
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SF-36 data was available from two studies (Baiardini et al. 2003; Ozkan et al. 2007). With scores 
of 0-50 indicating poorer than average functioning and 51-100 better functioning the combined findings 
presented in Table 3.4a suggested that physical functioning, social functioning and role physical (roles 
requiring good mobility) were the most impaired with bodily pain being the least affected aspect. Scores 
for mental and emotional aspects lied between these aspects. It was noted that scores for physical 
functioning varied greatly between the featured studies.  
 
Table 3.4: Comparison of Bio-Psycho-Social Aspects Affecting CU 
3.4a: SF-36 
   
Baiardini, 2003 
 
Ozkan, 2007 
 
Barbosa 2011 
 
Average Score 
Physical Functioning 
Social Functioning 
Role Physical 
Vitality 
Role Emotion 
General Health 
Mental Health 
Bodily Pain 
05.95 ± 22.73 
64.28 ± 24.77 
58.33 ± 38.99 
53.33 ± 20.88 
60.32 ± 38.90 
59.14 ± 16.82 
59.62 ± 19.79 
59.14 ± 30.19 
63.00 ± 22.40 
67.10 ± 24.40 
55.40 ± 37.60 
53.60 ± 20.00 
51.00 ± 43.60 
53.50 ± 17.80 
55.70 ± 18.50 
61.10 ± 24.50 
Scores NR 
 
 
 
 
 
 
 
34.48 ± 22.57 
44.53 ± 24.59       
46.50 ± 38.30                                
53.47 ± 20.44 
55.66 ± 41.25 
56.32 ± 34.62        
57.66 ± 19.15  
60.12 ± 27.35 
* Key: 0-50:  Poorer than average   51-100 Better than average 
 
As shown in Table 3.4b data for the NHP was available from two studies (O’Donnell et al. 1997; 
Berrino et al. 2006) however only complete data was available from O’Donnell et al. (1997) where energy 
levels were the most reported as impaired followed by sleep and emotional functioning. Poorer energy 
and emotional functioning were also highlighted as significant areas by Berrino and colleagues.  
 
Table 3.4b: NHP   
NHP Berrino, 2006 O’Donnell, 1997 
Energy 
Sleep 
Emotion 
Pain 
Social 
Mobility 
28.02% ± 18.46* 
NR 
33.30% ± 21.5 
NR 
NR 
NR 
47.00** 
32.40 
29.00         
15.80 
13.30  
07.10 
Key: % of sample reporting as to % impairment, ** 0-100:  Higher scores = worse outcome,  
 
Data for the WHOQoL Brief was available from two studies (Engin et al. 2007; Ugus et al.  
2008). With higher scores indicating poorer outcome, individual and combined study scores suggested  
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that environmental aspects of outcome were the least affected with psychological and physical aspects   
being the most and similarly impaired. 
 
Table 3.4c: WHOQoL Brief 
 Engin  2007 Ugus, 2008*** Average Mean Score 
Psychological 
Physical 
Social 
Environmental 
65.22 ± 18.53 
66.54 ± 18.73 
62.00 ± 21.56 
62.73 ± 13.96 
74.64 ± 12.50 
71.76 ± 14.99 
75.76 ± 19.66 
68.92 ± 13.20 
69.93 ± 15.52 
69.15 ± 16.86 
68.88 ± 20.61 
65.83 ± 13.58 
Key: 0-100:  Higher score = poorer outcome 
 
As shown in Table 3.4d, data on the Skindex instruments could be extracted from 7 of the 
included studies. With scores ranging between 0-100 and higher scores indicating worse outcome, 
symptoms was ranked as the aspect most impairing QoL in 4 studies (Brzoza et al. 2011; Maurer et al. 
2009; Mylnek et al. 2009; Tondury et al. 2011). Emotions was ranked second in these studies (except 
Mylnek et al, 2009) but ranked highest in two further studies emotions (Akashi et al. 2011; Okubo et al. 
2007). Functioning was least affected overall.  
 
Table 3.4d: Skindex-29, 16 
Skindex-29, 16 
Akashi, 2011* 
Brzoza, 2011** 
Maurer, 2009** 
Mylnek, 2009** 
Okubo, 2007* 
Staubach, 2006b* 
Tondury, 2011* 
Symptoms 
25.00 
34.70 
68.00 
40.00 
42.00 
18.00 
37.52 ±18.64 
Emotions 
46.00 
26.30 
53.00 
22.00 
58.00 
24.00 
36.52 ± 21.67 
Functioning 
18.00   
23.90  
50.00  
38.00  
18.00   
25.00   
23.46 ± 21.45  
Key: 0-100:  higher scores =  worse outcome  *mean score,  **median score 
 
Data for aspects of QoL for the DLQI is presented in Table 3.4e (p76). Data was presented in 
different ways and was absent in two studies (Berrino et al. 2006; Liu et al. 2012). Symptoms and feelings 
were reported as severe compared to other aspects in one study (Berrino et al. 2006) and above the 
scale mid-point in 2 studies (Liu et al. 2012; Shikar et al. 2005) where higher scores equal worse outcome. 
Symptom and feeling scores were reported by over 50% of the sample in Poon et al. (1999) but work and 
study was more reported in this study.  
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Table 3.4e: DLQI 
 Berrino 2006* Liu, 2012* Poon 1999** Shikar 2005* 
Symptoms & Feelings 
Daily activities 
Leisure 
Work & School 
Personal Relationships 
Treatment 
NR Severe 
NR moderate 
NR moderate 
NR moderate 
NR moderate 
NR moderate 
3.04 ± 0.10 
NR 
1.26 ± 0.10 
NR 
NR 
NR 
56.00    ± 25  50.64% 
42.00    ± 31.00 
44.00% ± 35.00 
71.00    ± 36.00 
31.00% ± 32.00  
15.00    ± 29.00 
3.49 ± 1.49/ 3.48 ± 1.39 
1.92 ± 1.69/ 1.84 ± 1.60 
1.46 ± 1.64/ 1.38 ± 1.56 
1.21 ± 1.01/ 1.15 ± 1.04 
1.04 ± 1.53/ 0.96 ± 1.39 
2.00 ± 0.79/ 0.51 ± 0.76 
*Scale 1-5: higher scores = worse outcome,        ** % of sample experiencing    
  
Data from the FLQA-d was found in one study (Augustin et al. 2000. With higher scores indicating 
worse outcome on a scale of 1 to 5 (see Table 3.4f), the findings indicated that everyday living and 
satisfaction levels were the most affected followed by emotional status. Social life appeared to be the 
least affected with physical complaints and treatment reports falling at the scale mid-point.  
 
Table 3.4f: FLQD-d                               
FLQA-d 
Augustin, 2000 
EL 
3.11 ± 0.98 
SA 
3.10 ± 0.85 
ES 
2.91 ± 0.55 
PC 
2.50 ± 0.60 
TM 
2.46 ± 0.92 
SL      
2.38 ± 1.06              
PC: Physical complaints        TM: Treatment              ES: Emotional status              SL: Social life                SA: Satisfaction            EL: Everyday life 
*1-5 Higher scores = worse outcome 
 
As shown in Table 3.4g, data from the V-Dermato was available from one study. With higher 
scores indicating worse outcome findings from this instrument indicated that physical discomfort and 
mood state were the most impaired. Treatment aspects were the least impaired. 
 
Table 3.4g: V-Dermato                                                      
                     PD                    MS                    LA                     DL                     SF                    SP                      TR       
 
Grob, 2005   61.40 ± 23.70   50.30 ± 25.00   36.70 ± 28.10   36.20 ± 20.40   27.50 ± 22.90   23.80 ± 21.80   17.00 ± 20.70   
PD: Physical discomfort,     MS: Mood state,      TR: Treatment induced restrictions,     SP: Self-perception,    SF: Social functioning,     LA: Leisure activities       
DL: Daily living activities, 0-112 Higher score = worse outcome 
 
Data for the CU-Q2oL was available from 5 studies as presented in Table 3.4h. Establishing 
which areas were more affected was not clear as the included studies included different factor analysed 
versions of the instrument, however 4 of 5 studies found that pruritus was the most detrimental aspect of 
CU-related quality of life with mean and median scores falling around the 0-100 scale mid-point (except 
Dias et al. 2011) representing a moderate impact. The second ranking aspect indicated was sleep 
problems (Kocaturk et al. 2011; Mylnek et al. 2009; Valero et al. 2008) were score fell just below the 
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scale mid-point but also indicated a moderate impact. 
 
Table 3.4h: CU-Q2oL 
Author 
   
 
Brzoza, 2011* 
 
Dias, 2011**                                      Kocaturk, 2011*** 
 
Valero, 2008** 
 
Mylnek, 2009*  
 
Itch            62.00* 
Swell/Ms    40.00* 
Sleep         30.00* 
Embarass  58.00* 
Function    34.00* 
Eat/ limits  26.00* 
 
Sleep/mental status/eating 39.90       Pruritus         50.00/ 57.30 
Pruritus/Life activities          34.40      Swelling       12.50/ 21.60 
Swelling/limits/looks            34.80      Sleep            45.00/ 44.10 
     Looks           20.00/ 24.30  
     Life activities 25.00/ 28.50 
     Limits            33.30/ 32.10 
 
46.10 ± 23.60 
10.80 ± 19.50 
24.40 ± 21.00 
17.80 ± 17.20 
21.00 ± 18.20 
20.80 ± 18.70 
 
Itch/Emba     50.00**                
Sleep            44.00**               
Swell/Eat      31.00**                     
MS                31.00**                                       
Limits/Looks 31.00**                               
Function       29.00**                    
*0-50: Better than average, 51-100 Poorer than average  *Median score,     **Mean score,      ***Mean & median score,       Yun 2011 NR 
 
3.3.5: Patient Characteristics and Quality of Life 
  
Relationships between Socio-Demographic Characteristics and Quality of Life 
Fifthteen studies explored relationships between socio-demographics and QoL (see Table 3.5, 
p78) but the use of different QoL questionnaires made comparisons complicated. Fourteen studies 
exploring age and QoL indicated that age did not statistically relate to or predict QoL however exceptions 
were found. Ozkan et al. (2008) found that higher age positively correlated with impaired social function 
and mental health of the SF-36. Further Mylnek et al. (2009) who used the CU2-QoL found that age 
predicted daily functioning, sleep, itching/ embarrassment and swelling/eating domains where older 
patients were more severely affected by problems with sleep and swelling/ eating and younger patients 
with itching/ embarrassment and daily functioning. Of the twelve studies comparing relationships to 
gender it was found that this relationship was also generally insignificant however there tended to be a 
consensus that women were more affected than men in domains related to symptoms and appearance. 
Maurer et al. (2009) found that women were strongly and significantly more affected on the Skindex-29 
symptom scale than men and Mylnek et al. (2009) found that women were more impaired on the 
itch/embarrassment and looks/limits domains of the CU2QoL. In line with this, Ozkan et al. (2007) found 
worse physical functioning and bodily pain in females in addition to poorer vitality and role-emotion of the 
SF-36. Although not significant, Poon et al. (1999) found that men were more affected in the areas of 
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work/ study (49.0% of sample) and leisure activities (32.0%) of the DLQI than women (i.e. 32.0% and 
22.0% respectively). Education (Ozkan et al. 2007, Maurer et al. 2009), marital (Ozkan et al. 2007) and 
economic status (Ozkan et al. 2007) were found to be unrelated to QoL 
 
Table 3.5: Relationships between Socio-Demographic Characteristics and Quality of Life 
 
Study 
 
Age 
 
Gender 
 
Other 
 
SF-36 
   
 
Ozkan, 2007* 
 
Social Function: P= .01; r= .274 
Mental Healrh:   P= .02; r= .245 
 
Women > affected 
Physical Functioning P =.02    
Bodily Pain                P =.03    
Vitality                       P =.02         
Role Emotional         P =.03 
 
Education, marital 
economic status  
all Insignificant 
 
WHO-QoL    
 
Engin, 20 
 
Physical r = -0.16 
Psychological r = -0.01 
Social relationships r = 0.11 
Environmental r = -0.05 
All insignificant at .05 
 
Not reported (NR) 
 
NR 
Skindex-29, 16    
 
Maurer, 2009  
 
 
Okubo, 2011 
 
Age insignificant  
 
 
Functioning 0.42 (r = 0.42, 
p0.01) 
 
Gender sig. predictor of symptoms: 
Women > affected (p< 0.001) 
 
NR 
 
Educational & 
employment insig. 
 
NR 
 
Staubach 2006a 
 
QoL impaired independent of 
age 
 
QoL impaired independent of gender 
 
 
DLQI    
 
Godse 2006 
 
Liu, 2012 
 
 
Poon, 1999 
 
Age unrelated 
 
Age unrelated 
 
 
Mean score not affected by age 
 
NR 
 
women > affected 
Daily activity p=.02  Work/ school 
p=.03 
 
Mean score not affected by gender 
 
NR 
 
NR 
NR 
 
NR 
 
Silvares, 2011 
 
 
 
 
Gender predicted greater impact on  
Clothing p < .05 (women > affected) 
Work & study  p < .05 (men > affected) 
 
NR 
CU-Q2oL    
 
Broza, 2011 
 
Dias, 2011 
 
Kocaturk, 2011 
 
 
Mylnek, 2009 
 
 
Age unrelated 
 
Age not predictor 
 
Age predicted Pruritus p <.05 
 
 
Predicted functioning, sleep, 
itching/ embarrassment and 
swelling/eating, all p<.01 
 
Gender unrelated 
 
Gender not predictor 
 
Gender predicted sleep problems (p < 
.05) with women more affected. 
 
Women predicted as more affected by 
itching/ embarrassment (p= 0.001) and 
looks limits (p= 0.048).  
 
NR 
 
NR 
 
NR 
 
 
NR 
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Relationships between Clinical Variables and Quality of Life 
As shown in Table 3.6 below, twelve studies assessed disease-severity/ activity and QoL but 
assessment varied considerably. Some used versions of the Urticaria Activity Score (UAS) which 
measures the number/ size of wheals and intensity of itch over a period of time, but others consisted of 
systems including further symptoms and reactions, visual analogue scales and different combinations of 
patient and physician subjective and/ or objective ratings, however consistent patterns were found. 
Severity/ activity of CU were statistically unrelated to generic health status and QoL (SF-36 and WHOQoL 
studies) but significantly related to all aspects of dermatology and disease-specific QoL (Skindex, DLQI 
and CU-Q2oL studies). Nine studies explored relationships between disease-duration and QoL. Disease-
duration generally did not significantly correlate with QoL outcome but correlated with more treatment 
induced restrictions in one study (Grob et al. 2005) and worse physical functioning in another (Ozkan et 
al. 2007). Other clinical factors reported to worsen QoL overall included treatment satisfaction (Okubo et 
al. 2011), having CU plus helicobacter pylori (a gut bacterium; Yadav et al. 2008), gaining a positive 
ASST (an allergic reaction to one’s skin serum; Godse, 2006) and experiencing concurrent angioedema 
(Silvares et al. 2011). In regards to particular aspects, urticaria type predicted more pruritus and impaired 
life activities (Dias et al. 2011) and experiencing concurrent physical urticarias (esp. delayed pressure) 
significantly related to more pain (O’Donnell et al. 1997).  
 
Table: 3.6 Relationships between Clinical Characteristics and Quality of Life 
Study Disease severity/ activity Disease duration Other 
SF-36    
 
Ozkan, 2007 
 
Insignificant across domains 
 
PF (P= .009; r = .286) 
 
NR 
WHO-QoL    
 
Engin, 20 
 
All insignificant (p > .05), UAS 
 
All insignificant (p > .05) 
 
NR 
  Physical health 
Psychological health 
Social relationships 
Environmental health 
r= 0.14 
r =0.07 
r= 0.03 
r= 0.06 
Physical  health 
Psychol. health 
Social relations 
Environ. health 
r=  21 
r= -.05 
r= .11 
r=.12 
NHP    
 
O’Donnell, 
1997 
 
NR 
 
NR 
 
Controlling for age & gender CU 
with delayed pressure urticaria > 
impaired for NHP pain p =.002 
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Table 3.6 continued 
 
Study 
 
 
Disease severity/ activity 
 
Disease duration 
 
Other 
Skindex    
 
Okubo, 2011 
 
Itching (All  P = 0.01)   
Global Skindex-16     r = 0.40 
Symptoms                 r = 0.52  
Emotions                   r = 0.34 
Functioning               r = 0.42 
 
 
NR 
 
Satisfaction with treatment insignificant 
 
 
Staubach, 
2006a 
 
QoL impaired independent of 
angioedema or CU cause 
 
QoL impaired 
independent of duration 
 
QoL impaired independent of disease 
cause  
DLQI    
 
Dias, 2011 
 
Disease severity predicted  
Overall QoL  p <.001 
Pruritus/ life activities p <.001 
Swelling/ looks/ limits p =.012 
 
 
QoL no predicted by 
duration  
 
Urticaria types predicted 
Pruritus/ life activities    p =.04 
 
 
Godse 2006 
 
NR  
 
NR 
 
ASST+ CU (21/30) more affected than –
ASST- (9/30)  
 
Kocaturk 
2011a 
 
NR 
 
NR 
 
ASST- autologous whole blood serum test, 
(AWB) CU more affected than ASST+ 
 
Mylnek, 2008 
 
Sig.  r2 = .31, p< .05 
 
NR 
 
NR 
 
Seindenari 
2006 
 
QoL worse in severe CIU  
 
 
NR 
 
NR 
 
Silvares, 
2011 
 
NR 
 
Symptoms and clothing 
 
Presence of angioedema significantly 
related to higher DLQI scores (p <.01) 
 
V-Dermato    
 
Grob, 2005 
 
Measured but controlled for 
not analysed on outcome 
 
 
Measured as age of first 
manisfestation but 
controlled for not 
analysed on outcome 
 
 
Measured but controlled for not analysed 
on outcome 
 
CU-Q20L    
 
Broza, 2011 
 
UAS-7 severity predict 
Itching                        p .001 
Swelling/ mental        p .03 
Functioning                p .02 
Sleep B .36,               p .03 
Eating/ limits              p .37 
Embarrassment         p .04 
 
Insignificant across 
subscales 
 
NR 
 
Buyulozturk, 
2012  
 
UAS-reduced & QoL 
improved after drug 
intervention: Overall QoL*    
Pruritus*       Swelling*Life 
activities*      Sleep*Limits***               
Looks**  *p <.001 ** p <.01  
p<.05*** 
 
 
NR 
 
NR 
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Table 3.6: Continued 
 
Study Disease severity/ activity Disease duration Other 
 
Kocaturk, 
2011b 
 
UAS-7 predicted overall 
QoL*  
Pruritus*         Swelling*** 
Life activities**      Sleep  
Limits*                   Looks*  
*p <.001 ** p <.01  p<.05***  
 
 
Duration not a significant 
predictor 
 
ASST results insignificant 
 
Mylnek, 2009  
 
UAS-7 severity predicted all 
subscales (p<.001) 
 
 
Insignificant across 
subscales 
 
NR 
 
Valero, 2008 
 
Greater severity of wheals/ 
pruritus, greater impaired 
QoL 
 
 
NR 
 
NR 
 
Yadav, 2008 
 
NR 
 
NR 
 
CU patients with helicobacter pylori 
infection more impaired 70.92 ± 12.59 
verses 65.57 ± 11.57* 
 
 
Yun, 2011  
 
 
NR 
 
CU > 1 year > affected 
by wheal, tiredness, 
irritability 
 
NR 
*0-49 better outcome, 50-100 poorer outcome  
 
Personality, Psychological Co-Morbidity and QoL 
Six studies explored personality and or psychological co-morbidity factors on quality of life. As 
shown in Table 3.7 (p82) two studies indicated that those with alexithymia and other psychiatric disorders 
were significantly more impaired on the mental health and vitality aspects of QoL compared to those with 
a CU diagnosis only (Barbosa et al. 2011; Ozkan et al. 2007). Two further studies found that those with 
concurrent personality disorders generally reported worse QoL across all aspects verses those with CU 
only (Ugus et al. 2008; Staubach et al. 2006a). In the three studies exploring anxiety and depression, 
higher levels of both co-morbidities significantly related to poorer QoL in all aspects in one study (Engin 
et al. 2007) and physical functioning, social functioning, mental health and general health in another 
(Barbosa et al. 2011). Staubach et al. (2006a) found no significant differences in this respect. One study 
(Tondury et al. 2011) found that patients with CU who were not open to new ways of seeing phenomena 
(described as being cognitively inflexible) reported significantly worse quality of life than those who were 
described as cognitively flexible.  
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Table 3.7: Relationships between Personality, Psychological Co-Morbidity and QoL 
 
 
Study 
 
 
Personality 
 
Anxiety and Depression 
 
Other 
SF-36    
 
Barbosa, 
2011a,b 
 
Sig. Diff between Alexithymia verses 
non-alexithymia CIU  
 
Mental Health (MH): z= 2.724; p<.0.00 
Vitality (VT):              z= 2.882; p<0.00  
 
 
Sig difference in QoL of CIU patients with 
moderate & severe anxiety and 
 
Physical Functioning (PF)  z= 2.585; p<.04   
Social Functioning              z= 2.064; p<.04   
Mental Health                     z= 2.918; p<.00  
General Health                   z= 2.267; p<.02 
 
NR 
 
Ozkan, 
2007 
 
CU+ Vs CU- psychiatric disorder 
 
PF:  70.3 ± 17.5/ 58.3 ± 24.0  p.01* 
VT:  61.3 ± 19.9/ 48.3 ± 18.4   p.00* 
MH: 60.0 ± 19.3/ 52.1 ± 17.3   p.03* 
 
 
N/A 
 
 
NR 
WHO-QoL    
 
Engin, 
2007 
 
NR 
 
Anxiety BAI/ Depression BDI, P<.01* 
Physical  health       r= -0.53/ -0.72* 
Psycho. health         r= -0.55/ -0.73* 
Social relationship   r= -0.43/ -0.67* 
Environ. health         r= -0.36/  0.55* 
 
 
NR 
 
Ugus, 
2008 
 
Difference between CU groups with/ 
without DSM disorder P <.0001 
Physical health         F= 10.61 
Psychol. Health        F=  09.09 
Social relationship    F= 10.44 
Environ. health         F=  05.54 
 
 
NR 
 
NR 
Skindex29    
 
Staubach, 
2006a 
 
CU+ psychiatric disorder sig. more 
impaired than CU without:  
Symptoms:     p <.05 
Emotions:       p <.005 
Functioning:   p <.01 
 
 
QoL similar in those with CU+ anxiety, 
depression, somatoform disorder 
 
NR 
DLQI    
 
Tondury, 
2011 
 
 
NR 
 
NR 
 
Cognitively 
inflexible  
patients have 
worse QoL  
 
*0-49 worse outcome, 50-100 better outcome 
 
3.3.6: Quality of Life against Reference Populations 
Eleven studies used reference populations to compare CU-related quality of life.  
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Other Dermatological Conditions 
As shown in Table 3.8a four studies compared CU with other dermatological conditions. Poon 
et. al. (1999) found that those with CU and concurrent delayed pressure urticaria reported impairments 
(not as severe but) comparable to severe atopic dermatitis (AD) and psoriasis outpatients but worse than 
acne and vitiligo patients. In contrast, Grob et al. (2005) and Augustin et al. (2000) found that AD patients 
generally reported a greater impact over CU and psoriasis patients. Further Akashi et al. (2011) reported 
worse QoL in those with prurigo chronic multiformis than those experiencing CU. 
  
Table 3.8a: Quality of Life in Chronic Urticaria verses other Dermatological Conditions 
 
Study 
 
 
Chronic Urticaria 
 
Dermatological Disorders 
Skindex-29*   
 
Akashi, 2011 
 
Chronic urticaria 
Symptoms:        26.00*  
Emotions:          46.00* 
Functioning:      15.00* 
 
Prurigo chronica multifotmis 
Symptoms:       30.00* 
Emotions:         58.00* 
Functioning:     18.00* 
 
DLQI**   
 
Poon, 1999 
 
CU                     25.00% ±  24.00% 
CU with DPU     43.00% ±  23.00% 
 
Atopic dermatitis     60.00%      Psoriasis 29.70%   
Acne                       24.30%      Vitiligo     16.10%  
FLQA-d***   
 
Augustin, 
2000 
 
Chronic Urticaria* 
Physical complaints:    2.40** 
Everyday life:               3.20 
Social life:                    2.30* 
Emotional status:         3.20 
Treatment:                   1.80*** 
Satisfaction:                 3.20* 
 
                                     AD*           Psoriasis*     
Physical complaints:     2.80          2.40*** 
Everyday life:                3.40          2.90*** 
Social life:                     2.60          2.20***   
Emotional status:          3.30          2.80*** 
Treatment:                    2.60          2.60 
Satisfaction:                  3.40          3.00*** 
AD sig. more affected than CU & psoriasis on most 
scales    (p .05*, p.01**, .001***) 
 
VDermato▲   
 
 
Grob, 2005 
 
Chronic Urticaria 
 
 
 
 
                      
Atopic Dermatitis 
 
 
Psoriasis 
 
 
ANOVA 
 
 Self-perception (SP):  
Daily living activities (DL): 
Mood state (MS): 
Social functioning (SF): 
Leisure activities (LA): 
Treatment  restrictions (TR) 
Physical discomfort (PD) 
 
23.80 ± 21.8 
36.20 ± 20.4 
50.30 ± 25.5 
27.50 ± 22.9 
36.70 ± 28.1 
17.00 ± 20.7      
61.40 ± 23.7 
SP: 
DL: 
MS: 
SF: 
LA: 
TR 
PD: 
 
34.20± 24.5 
35.50± 21.3 
50.10± 25.5 
34.10± 23.5 
46.70± 27.9 
32.50± 26.4 
69.80± 21.3 
 
37.40± 24.7 
19.30± 19.4 
49.30± 25.2 
31.30± 23.7 
47.20± 29.3 
38.60± 26.0 
44.40± 28.2 
 
< 0.001 
< 0.001  
< 0.01 
< 0.01  
< 0.001 
< 0.001  
< 0.001  
 
All higher score worse outcome   *Skindex-29: 0-100, **DLQI: 0-100%,***FLQA-d: 1-5,  ▲V-Dermato:0-112   
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Non-Dermatological Conditions 
Finally, two studies compared CU to non-dermatological disorders. As highlighted in Table 3.8b, 
data from the SF-36 indicated that (with exception to similar mental health and better vitality) CU has a 
more significant impact on most aspects of general health status over respiratory allergy (Baiardini et al. 
2003). Using the NHP, O’Donnell et al (1997) found similar levels of energy, sleep and emotions in CU 
and ischemic heart disease, but worse sleep, less pain and better mobility in CU.      
  
Table 3.8b: Quality of life in CU verses Non-Dermatological Conditions 
 
Study 
 
 
 
Chronic Urticaria 
 
Non-Dermatological 
SF-36*    
 
Baiardini, 2003 
 
Domain 
 
Physical functioning 
Bodily Pain 
Vitality 
Role emotional 
Role physical 
General health 
Social functioning 
Mental health 
 
 
Chronic urticaria 
 
85.95 ± 22.73 
59.14 ± 30.19 
53.33 ± 20.88 
60.32 ± 38.90 
58.33 ± 38.99 
59.14 ± 16.82 
64.28 ± 24.77 
59.62 ± 19.79 
 
Respiratory Allergy 
 
94.07 ± 08.55                        p 0.05 
91.11 ± 13.44                        p 0.00 
48.15 ± 16.53                        p 0.82 
79.01 ± 33.52                        p 0.04 
81.48 ± 28.24                        p 0.01 
72.18 ± 15.96                        p 0.00 
69.44 ± 20.89                        p 0.21 
65.33 ± 16.00                        p 0.13 
 
NHP**    
 
O’Donnell, 1997 
 
Domain 
 
Mobility 
Sleep 
Social 
Pain 
Energy 
Emotion 
 
Chronic urticaria (%) 
 
07.10 
32.00 
13.30 
15.80    
47.00   
29.00  
 
 
Ischemic heart disease (%) 
 
NR*** 
  
*SF-36: 0-49 poorer outcome, 51-100 better outcome, **NHP: 0-100 higher score worse outcome  ***Poor print on original document   
 
 
Healthy Controls and Reference Populations  
As presented Table 3.8c (p86) there was a consistent finding that individuals with CU reported 
significantly more impaired QoL than both healthy controls independent of patient characteristics. 
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Table 3.8c: Quality of life in CU Verses Healthy Controls/ Reference Samples 
 
 
Study 
 
 
Chronic Urticaria 
 
Health Controls/ Reference Samples  
SF-36*   
 
Baiardini, 
2003 
 
PF   85.95 ± 22.73RP  58.33 ± 38.99 
BP   59.14 ± 30.19GH  59.14 ± 16.82 
VT   53.33 ± 20.88SF   64.28 ± 24.77 
RE  60.32 ± 38.90MH   59.62 ± 19.79 
 
CU patients strongly & significantly more impaired on all 
subscales than 608 health adults from reference sample (p < 
0.0001) 
 
Barboas, 
2011ab  
 
NR 
 
 
 
QoL> impaired to age/ sex match healthy adults, all p< .000 
PF  t: -4.795,     SF  t  -5.213       RP  t  -7.681,     RE  t  -7.230                  
MH  t -6.310,     BP  t  -5.916       VT: t -5.363,       GH t  -8.501 
 
Ozkan, 2007 
 
 
 
 
PF:   63.00 ± 22.40    RP:  55.4 ± 37.6 
BP:   61.10 ± 24.50    GH: 53.5 ± 17.8 
VT:   53.60 ± 20.0      SF:  67.1 ± 24.4 
RE:  51.90 ± 43.6      MH:  55.7 ± 18.5 
 
QoL > impaired than age/ gender matched controls, all p< .01 
PF: 82.3 ± 17.9,   t -5.91             RP: 82.30 ± 30.6,  t -4.89 
BP: 72.5 ± 22.1,   t -3.01             GH: 65.70 ± 19.4,  t -4.03 
VT: 63.0 ± 21.2,   t -2.84             SF:  82.30 ± 19.4,  t -4.22 
RE: 80.8 ± 33.4,   t -4.79             MH: 67.60 ± 17.9,  t -4.04 
 
WHO-QoL**   
 
Engin, 2007 
 
 
PH: 66.54 ± 18.73    PS: 65.22 ±18.53 
SO: 62.00 ± 21.56    EN: 62.73 ±13.96 
 
CU patients more impaired to age/ sex match control  *P <.05 
PH: 77.74 ± 11.08  z -3.27*   PS:72.25 ± 12.64   z -2.13* 
SO: 69.42 ± 17.94  z -1.91    EN:62.65 ±   9.48   z -.37*** 
 
 
Ugus, 2008 
 
CU (group 4, no psychiatric disorder) 
PH: 71.76 ± 14.99    PS: 74.64 ±12.58 
SO: 75.76 ± 19.66    EN: 68.92 ±13.20 
 
CU more impaired to healthy controls, all sig p <.0001 
PH: 78.04 ± 11.19, F 10.61    PS: 75.48 ± 11.60, F   9.09 
SO: 74.40 ± 13.99, F 10.44    EN: 70.72 ± 11.23, F   5.45 
Skindex29***   
 
Staubach et 
al 2006a 
 
Overall:     75.00*  Symptoms:   18.00* 
Emotions: 25.00*   Functioning: 25.00* 
 
CU  > impaired than healthy age/ sex controls All p<.005    
Overall:              13.00*            Symptoms:        11.00* 
Emotions:          13.00*            Functioning:      13.00*    
 
*SF-36: 0-49 poorer outcome, 51-100 better outcome   PF: Physical functioning, BP: Bodily Pain, VT: Vitality, RE: Role emotional, RP: Role physical, GH: 
General health, SF: Social functioning, MH: Mental health PH:  
**WHO-QoL: 0-100 higher score poorer QoL   Physical health, PH: Psychological functioning, SO: Social functioning, EN: Environmenral 
***Skindex-29: 0-100 higher score poorer QoL 
 
3.3.7: Methodological Quality of Studies 
Most studies met the quality criteria (see Table 3.9, p87), however only eleven reported a power 
analysis and despite all reporting participation rates only seven reported recruitment response rates at 
baseline. The differences in characteristics between participation responders and non-responders were 
presented in only four studies. The reporting of participant treatments at baseline was excellent in RCT 
studies but poor in cross-sectional and questionnaire validation studies. Finally, although most studies 
used validated QoL questionnaires, only four had been formally validated in CU samples and these were 
the DLQI, CU-Q2oL, SF-12 and the FLQA-d instruments.             
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Table 3.9: Quality Assessment of Included Studies 
 
  
Socio-
demographic 
& clinical 
variables 
described 
 
Inclusion  
and/ or 
exclusion 
criteria 
formulated 
 
 
Data 
collection 
process 
described 
 
The type of 
CU is 
treatment is 
described for 
baseline 
 
 
Results 
compared 
between 
two or 
groups or 
more 
 
 
Participation 
& response 
rates for 
patient 
groups 
 
Characteristics of 
responders and 
non-responders or 
if there’s no 
selective response 
at baseline 
 
Standardized 
or valid QoL 
questionnaire 
used 
 
 
 
Results 
described for 
QoLand 
physical, 
psychological 
and social 
domain 
 
Mean, 
median, SD 
or % 
reported for 
important  
outcomes 
 
Attempt 
made to 
find a set of 
determinants 
with highest 
prognostic 
value  
 
Patient 
signed a 
informed 
consent 
 
 
 
A power 
analysis 
was 
carried 
out 
Akashi, 2011 ● ○ ● ○ ▪* ▪ ○ ● ● ● ● ●● ○ 
Augustin, 2000 ● ○ ● ● ● ▪ ○ ● ● ● ○ ○ ○ 
Baker, 2008 ● ● ● ▪ ● ▪ ○ ● ○ ○ ● ● ○ 
Barbosa, 2011a,b ● ● ● ● ● ● ○ ● ● ▪ ● ● ○ 
Baiardini, 2005 ● ● ● ○ ○ ▪ ○ ● ● ○ ● ○ ○ 
Baiardini, 2003 ● ○ ● ● ● ▪ ○ ● ● ● ○ ● ○ 
Berrino, 2006 ● ● ● ○ ○ ▪ ○ ● ● ● ▪- ** ● ○ 
Brzoza, ● ○ ● ○ ○ ▪ ○ ● ● ● ● ● ○ 
Bunselmeyer ● ● ● ● ○ ▪ ○ ● ○ ● ● ● ○ 
Buyulozturk, 2012 ● ○ ● ● ○ ● ○ ● ● ● ● ○ ○ 
Dastghelb, ● ● ● ● ○ ▪ ▪ ● ● ● ● ● ○ 
Dias, 2011 ●○ ▪ ● ▪ ● ▪ ▪ ● ● ● ● ● ● 
Engin, 2008 ● ● ● ● ● ▪ ○ ● ● ● ● ● ○ 
Gimenez-Arnau, 2007 ● ● ● ● ● ▪ ○ ● ● ○*** ● ● ● 
Godse, 2006 ● ● ● ○ ○ ▪ ○ ● ○ ● ● ▪ ○ 
Grob, 2009 ● ● ● ● ● ▪ ○ ● ● ● ● ● ○ 
Grob, 2008 ● ● ● ● ● ▪ ○ ● ● ● ● ●  
Grob , 2005 ● ● ● ○ ● ▪ ○ ● ● ● ● ○ ○ 
Jariwala, 2009 ● ● ● ● ○ ○ ○ ● ● ● ○ ● ○ 
Kapp & Picher, 2006 ● ● ● ● ○ ● ○ ● ○ ● ● ● ● 
Kaplan, 2008 ● ● ● ● ○ ○ ○ ● ○ ○*** ● ○ ○ 
Kim, 2008 ● ● ● ● ○ ▪ ○ ○ ● ● ● ● ○ 
Kocaturk, 2011a ● ● ● ● ● ▪ ○ ● ○ ● ● ●  
Kocaturk, 2011b ● ● ● ● ● ▪ ○ ● ● ● ● ● ○ 
Lachapelle 2006 ● ● ● ● ○ ▪ ○ ● ● ● ● ● ○ 
Lennox & Leahy 2004 ○# ○# ● ○# ○ ▪ ○ ● ● ● ● ● ○ 
Liu 2012 ● ● ● ▪ ● ▪ ○ ● ● ● ● ● ○ 
Met ●    Partially met ▪   Not reported ○  *Data available to compare but not formally compared,   **Qualitative accounts  ***Not QoL,  #Reported elsewhere     ●+ Multivariate  ●-Univariate 
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Table 3.8: Quality continued 
 
  
Socio-
demographic 
& clinical 
variables 
described 
 
Inclusion  
and/ or 
exclusion 
criteria 
formulated 
 
 
Data 
collection 
process 
described 
 
The type of 
CU 
treatment is 
described for 
baseline 
 
 
Results 
compared 
between 
two 
groups or 
more  
 
Participation 
& response 
rates for 
patient 
groups 
 
Characteristics of 
responders and 
non-responders or 
if there’s no 
selective response 
at baseline 
 
Standardized 
or valid QoL 
questionnaire 
used 
 
 
 
Results are 
described for 
QoL & physical 
psychological 
and  social 
domain 
 
Mean, 
median, SD 
or  
percentages 
are reported 
for  important  
outcomes 
 
Attempt  
made to 
find a set of 
determinants 
with highest 
prognostic 
value  
 
Patient  
signed an 
informed 
consent▲ 
 
 
 
A power 
analysis 
was 
carried 
out 
Magerl, 2010 ● ● ● ● ○ ▪ ○ ● ● ○ ● ● ○ 
Maithias, 2010  ● ● ● ● ○ ▪ ○ ● ○ ● ○ ● ● 
Maurer, 2009 ● ● ● ▪ ○ ▪ ● ● ● ● ● ○ ○ 
Mylnek, 2009 ● ○ ● ○ ● ▪ ○ ● ● ● ● ● ● 
Mylnek, 2008 ● ○ ● ○ ○ ▪ ○ ● ○ ○ ● ○ ○ 
O’Donnell, 1997 ● ● ● ▪ ● ▪ ○ ● ● ● ○ ● ○ 
Okubo, 2011 ● ○ ● ● ● ▪ ○ ● ● ● ● ● ○ 
Ozkan, 2007 ● ● ● ● ● ▪ ○ ● ● ● ● ● ○ 
Poon, 1999 ● ○ ● ○ ○ ▪ ○  ● ● ● ○ ● ○ 
Potter, 2008 ● ● ● ● ● ▪ ○ ● ○ ● ● ● ● 
Reeves, 2004  ● ● ● ● ○ ● ○ ● ○ ● ● ● ○ 
Seidenari, 2006 ● ● ● ● ● ▪ ○ ● ● ● ● ● ● 
Shikiar, 2005 ○* ● ● ○ ○ ▪ ○ ● ● ● ● ○ ○ 
Silvares, 2011 ● ○ ● ● ● ▪ ○ ● ● ● ● ● ● 
Spector, 2007 ○ ● ● ○ ● ● ○ ● ○ ● ● ● ○ 
Staubach, 2006a ● ● ● ○ ● ▪ ○ ● ● ▪ ●   ● ○ 
Staubach, 2006b ● ● ● ● ● ▪ ○ ● ○ ● ● ● ○ 
Staevska, 2010 ● ● ● ● ● ▪ ○ ● ○ ○ ● ● ● 
Thompson, 2000 ● ● ● ● ○ ● ○ ● ● ● ● ● ○ 
Tondury, 2011 ● ● ● ○ ● ▪ ● ● ● ● ●- ● ○ 
Uguz, 2008 ● ● ● ○ ○ ▪ ○ ● ● ● ●  ● ○ 
Valero, 2008  ● ○ ● ● ○ ▪ ○ ● ● ● ● ● ○ 
Vena, 2006 ● ● ● ▪ ● ● ● ● ● ● ● ○ ● 
Yadav, 2008 ● ● ● ○ ● ▪ ○ ● ○ ● ● ● ○ 
Yun, 2011 ● ● ● ○ ● ▪ ● ● ● ● ● ○ ○ 
Zuberbier, 2010 ● ● ● ● ● ▪ ▪ ● ● ● ● ● ● 
Met ●     Partially met ▪     Not reported ○   ▲met if ethical approval was stated    * reported in another paper Shikiar(Nelson, Reynolds, Mason, 2000 and Finn, Kaplan, Fretwell, Long, 1999);  Spector (Kaplan, Spector, Meeves et al, 2005)
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3.4: Discussion 
The objective of this study was to achieve a consensus view on the nature of quality of 
life in CU; however the heterogeneity between studies in respect to design, participant 
characteristics, QoL questionnaires used and severity measures applied complicated data 
synthesis. A more stringent inclusion criterion may have increased homogeneity but too few 
studies would have reduced external validity. Despite this consistent findings did emerge and 
are discussed in further detail below 
 
Chronic Spontaneous Urticaria has a mild-moderate impact on Quality of Life 
Although the results of the included studies could not be collated together comparisons 
across studies by a common QoL instrument predominantly provided mean (or median) scores 
which lied within a mild or moderate impact regardless of whether a generic, skin-specific or 
disease-specific questionnaire was used however this finding was not conclusive. On a closer 
observation of the data there appeared to be conflicting findings between scores that were 
presented from the SF-36, Skindex-29, CU-Q2oL and the DLQI. Where the SF-36, Skindex-29 
and CU-Q2oL scores overall indicated strong evidence to support that CU had a moderate overall 
impact on QoL, scores of the DLQI suggested a mild impact. These findings suggest that the 
impact of CU on QoL may not range from mild to moderate but be either mild or moderate and 
which value to accept may depend on the validity of the DLQI against other instruments. Although 
this is not a measurement review this finding suggests that the estimated reports of impact found 
by researchers may be dependent on their choice of QoL instrument. This finding of a difference 
between the DLQI and other instruments is an important one as the DLQI is the most dominant 
QoL instrument used in dermatological research and practice (Basra, Fenech, Gatt et al. 2008) 
and this was reflected in its use in over fifty-percent of the included studies in this systematic 
review. Based on this review study and the extensive use of the DLQI in clinical practice, it can 
be hypothesised that patient-reported QoL at this level might possibly be underestimated.  
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Policy and practice based decision making processes based on research using 
measures that underestimate the true impact of CU on QoL may have implications on CU patient 
care at both the individual and population level. At the individual level it may suggest that these 
patients’ subjective accounts of overall impairment are minimal and so little therapeutic input is 
required. Used in clinical trials it may underestimate the efficacy of therapeutic interventions due 
to a lack of the instruments responsiveness to change (the DLQI is extensively used in CU-based 
RCTs). Further CU-related QoL research based on measures that underestimate impact in the 
CU population might harm financial applications for CU-specific research, health and support 
resources where competition for such grants which may go to what are seen as more moderate 
to severe conditions. It could be argued that the DLQI is the true estimate of overall QoL impact 
in CU but a systematic review of QoL questionnaires in CU would need to be undertaken to help 
decide which instrument/s provide the most valid reports. Until then the evidence suggests that 
CU has at least a mild to moderate impact on overall quality of life.  
 
Whatever the degree of QoL impact these findings confirm that CU is not just a benign 
condition with no impact on patient functioning and minimal impact on QoL (Grob and Gaudy-
Masqueste, 2006) as originally found by O’Donnell et al. (1997) the review findings support the 
decision made in current CU expert management guidelines that in the future QoL assessment 
should be undertaken in both CU-related research and clinical practice (Zuberbier et al. 2009). 
CU does impact QoL regardless of the instrument used as demonstrated in the review by Weldon 
(2006) however the recommended QoL questionnaire suggested since this systematic review 
was first undertaken is the disease-specific CU-Q2oL as it would show the greatest sensitivity 
over other instruments (Baiardini et al. 2011). It is argued that such a decision may not be simple 
as it has been stated at various times in this thesis that although the CU-Q2oL maybe more 
internally valid the review further drew attention to different versions of the CU-Q2oL, validated 
in different ways (e.g. language translation, factor analysis) with different domains that do not 
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allow for between CU study comparison. More problematic guidelines do not consider that when 
used alone the CU-Q2oL does not allow for cross-disease comparison when competing for 
research grants or address wider generic issues so an analysis of generic instruments that 
complement the CU-Q2oL is suggested as a recommendation for future research.  
 
CU affects many aspects of bio-psychosocial functioning 
The second main finding of the review confirmed that impairment in those experiencing 
CU goes beyond problems concerning participating in daily activities and other aspects of 
physical functioning. At the study selection criteria stage of this systematic review many RCT 
papers were excluded because they only measured CU outcome in terms of such physical 
aspects. A data synthesis of the full spectrum of QoL aspects reported across studies revealed 
a variety of psychosocial impairments. Although CU symptom and treatment factors largely 
featured as expected, negative psychological aspects related to mental health, emotional 
responses, self-perception and feelings were also well represented across studies. Social 
aspects were the least affected however issues pursed related to personal relationships, social 
interaction, leisure activities and work and study.  
 
The most pertinent finding was that the impact on psychological functioning was often 
as similarly (or more impaired) than the physical aspects and in many studies physical functioning 
was the least impaired. Further, despite a collation of scores was not possible due to the diversity 
of instruments used across studies, a common pattern emerged that bio-psychosocial 
impairments largely concerned CU symptoms (e.g. pruritus), physical functioning/ everyday 
living, undertaking physical roles, energy levels, sleep, emotions/ feelings, satisfaction, mood 
state, work and study. Such predominantly affected areas are in line with those originally found 
in the key studies by O’Donnell et al. (1997), Poon et al. (1990) and Berrino et al. (2006) 
especially those regarding energy, sleep, emotions and work/study. The review is also in line 
with recent findings suggesting that health professionals do not consider the emotional aspects  
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of CU and this needs to be addressed (Maurer et al. 2009a. b).  
 
CU guidelines and taskforce papers acknowledge that CU has at least psychosocial 
outcomes (Zuberbier et al. 2009b; Maurer et al. 2011; Baiardini et al. 2011, Weller et al. 2011) 
but what is often highlighted is that there are currently no CU-based psychological interventions 
(a gap further confirmed in this systematic review study). These particular review findings may 
indicate which specific impaired outcomes may arise during doctor-patient consultations that 
need to be targeted but this has implications for whether dermatologists have the skill set (and 
the additional consultation time) to help patients cope with the psychosocial aspects of CU 
adjunct to medical care. CU medicines may help to somewhat alleviate CU symptoms and lead 
to better overall bio-psychosocial functioning but the prescription of CU medicines is not an exact 
science (Saini, 2011; Zuberbier et al. 2009b) and can have unsatisfactory efficacy on outcome 
in up to 50% of patients taking them (Maurer et al. 2011). Individuals with CU may already be 
experiencing psychosocial issues at the point of attending their first urticaria specialist 
appointment hence it may take more than prescriptions of medications to help re-integrate 
patients back to their social and working environment. In light of these points possible areas for 
future direction could be to either integrate psychologists into existing services or to liaise with 
existing psychology services to develop referral systems for patient requiring such services.  
 
With some conflicting evidence CU impacts quality of life independent of patient characteristics 
The third main finding concerned the role of patient characteristics on QoL The 
systematic review findings indicated that CU relatively impacted quality of life irrespective of 
disease-duration, marital, educational or occupational status and the majority of studies also 
indicated that CU impacted QoL independent of age, gender and disease-severity/ activity 
however such findings were again not completely conclusive.  
 
Age overall was not significantly related to overall QoL across studies using generic and  
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dermatology-specific questionnaires and in so the conflicting evidence laid within studies who 
administered the disease-specific CUQ2-oL. Within these papers age was reported as unrelated 
to QoL in two studies (Brzoza et al. 2011; Dias et al. 2011) but a predictor of specific aspects in 
three others (Kocaturk et al. 2011; Mylnek et al. 2009; Yun et al. 2011). The CU-specific affected 
aspects did not mirror each other in these studies and this might be explained by these studies 
using different factor analysed versions of this instrument. For example Mylnek et al. (2009) 
found that older patients were more severely affected by problems with sleep, swelling and eating 
than younger patients who were more affected by itching/ embarrassment and daily functioning. 
Kocaturk et al. (2011) nor Yun et al. (2011) reported this finding with the exception of itching in 
the former. With the exception of Yun et al. (2011) all five studies were CU-Q2oL questionnaire 
cultural adaptions and may explain cross-cultural differences in the way individuals experience 
aspects of QoL but only future studies using these adaptations can confirm this. Further research 
may also explain the high representation of patients in their mid-thirties to forties. There is a small 
but emerging research literature on skin disorder throughout the lifespan which includes the 
cumulative effects of stigmatization, physical and psychological comorbidities on life impairment 
(Warren, Kleyn and Gulliver, 2011) and how this plays a role in CU may be important in identifying 
factors that result in better outcomes. 
 
Gender like age bore an insignificant relationship to overall QoL outcome in most studies 
but where significant relationships were reported women were always significantly more affected 
than men (Kocoturk et al. 2011; Liu et al. 2012; Maurer et al. 2009; Mynek et al. 2009; Ozkan et 
al. 2007; Silvares et al. 2011; Yun et al. 2011), more specifically significant relationships were to 
symptoms (i.e. itch, pain and vitality), appearance (e.g. embarrassment, clothing), sleep 
problems and physical and emotions functioning. An important point to consider if these findings 
are pertinent is whether these aspects are a CU-specific gender issue or a more general gender-
specific issue entering into the CU domain. It is known that women with CU significantly 
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outnumber men by up to 4:1 as confirmed in this review but answers may lie in patients with 
chronic pruritus (CP) who experience the relentless itching that patients with CU experience. 
Stander, Stumpf, Osada, Wilp, Chatzigeorgakidis and Pfleiderer (2013) found that women had 
significantly more neuropathic and psychosomatic aspects underlying their CP than men which 
was worsened by emotional (p = .002) and psychosomatic factors (p < .05). However for pain a 
recent systematic review of 172 studies showed no clear differences between males and females 
for most types of pain (Racine, Tousignant-Laflamine, Kloda, Dion, Dupuis and Choiniere 
(2012a, b) suggesting a CU-specific gender factor. In terms of physical appearance the real world 
research literature suggests that women are more exposed to sociocultural norms to idealised 
appearance than men which is more ridged, homogenous and pervasive than for men (Buote, 
Wilson, Strahan, Strahan, Gazzola and Papps, 2011) hence in terms of the visible nature of CU 
this could be a possible implicating factor. Buote et al. (2011) in their literature review also 
highlighted that subsequently women experience significantly worse body dissatisfaction than 
men in general, hence the embarrassment of visible CU symptoms may add to this 
dissatisfaction. Further the literature suggests that women have more sleep problems than men 
(e.g. Nowakowski, Meers and Heimbach, 2013) so such problems might be amplified further by 
urticaria symptoms and explain CU-related gender differences. Of equal importance the 
evidence-based literature suggests that women use more emotional regulation strategies than 
men and ruminate more relating to significantly more psychopathology (Nolen-Hoeksema, 2012).  
 
Indeed the above suggestions of possible determinants or mediators are merely 
speculative but do lead to suggestions for further research if CU-related QoL is to be understood 
better. Considering patient characteristics overall, more longitudinal cohort studies and focused 
qualitative studies may help explain why women are more affected by these variables in CU. 
Further, although reporting was adequate overall relationships between patient characteristics 
and QoL were often unreported as were reasons for patient non-participation at recruitment. 
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Consequently conclusions were drawn from limited data and opportunities were missed to 
decipher whether females suffer more CU or if males are less likely to engage with studies. 
 
Disease-severity/ activity was the clinical factor that provided conflicting findings to QoL 
outcome but consistently significantly related to dermatology and CU-specific outcome but not 
to generic health-status and QoL. One interpretation of these findings is that CU disease severity/ 
activity affects the former but has not such effect on the later.  Such findings may suggest, 
however another interpretation is that generic instruments are not psychometrically sensitive 
enough to capture such relationships. As stated earlier determining which questionnaire best 
measures CU-related QoL combining it with a standardised disease severity-activity measure 
may help address inconsistent findings. Current guidelines recommend the urticaria activity 
score or (UAS) as the gold standard (Zuberbier et al. 2009a; concerns with the recommended 
CU-Q2oL were discussed earlier). Clinical factors that did impact overall QoL outcome such as 
presence of helicobacter pylori (Yadav et al. 2008), positive ASST’s (Godse, 2006), concurrent 
angioedema (Silvares et al. 2011) and specific ones including urticaria type predicting more 
pruritus and impaired life activities (Dias et al. 2011) and concurrent physical urticarias to more 
pain (O’Donnell et al. 1997) require further investigation. 
 
In regard to psychological and psychiatric factors the findings of the systematic review 
confirmed research reviewed in chapters 1 and 2 historically implicating pathological and 
personality determinants to CU and CU-related outcome (see section 1.2.2-3 and section 1.5.4: 
Anxiety and Depression). Examples included those experiencing CU with alexithymia and other 
personality and psychiatric disorders (clinical anxiety and depression) generally reporting worse 
QoL (Barbosa et al. 2011; Ozkan et al. 2007) and significant more than those with CU alone 
(Ugus et al. 2008; Stubach et al. 2006a). Other studies confirmed the strong relationship between 
both anxiety and depression as either determinants or outcome factors and QoL outcome 
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discussed in Chapter 2 as those studies were found by the review search strategy (e.g. Engin et 
al. 2007; Barbosa et al. 2011; Uguz et al. 2008). What was important about these findings was 
that most studies in the review did not measure such variables (especially anxiety and 
depression) which evidence suggests that they could be a confounding or mediating variable. 
Future studies may consider measuring and controlling for these variables to obtain a more 
accurate account of QoL in CU (or at least measure it as another outcome), but being mindful of 
whether these co-morbidity factors are being measured as determinants, outcomes (or bi-
directional) needs to be considered as to the limitations of using screening as to diagnostic 
approaches. Psychosocial aspect itself to date has predominantly been measured as end-points 
in pharmaceutical efficacy and personality-psychiatric studies at a consequence to studying 
psychosocial aspects as possible determinants of outcome, however the finding by Tondury et 
al. (2011) suggesting that those with CU who were more cognitively flexible (open to new ways 
of seeing phenomena) had significantly less impaired QoL suggests more explorations of 
cognitive and/ or behavioural strategies that my improve outcome. QoL worse in some aspects 
of CU compared to other conditions and worse than healthy controls  
 
One of the most important findings was the confirmation that individuals with CU 
experience impaired QoL similar to (and sometimes worse in some aspects) than those with 
other dermatological and non-dermatological conditions (e.g. O’Donnell et al. 1997; Baiardini et 
al. 2003). It was also unanimous that QoL impairment was also significantly worse than health 
controls. Such findings support that CU is not a condition to be under-estimated in terms of QoL 
impact and does deserve the research and clinical efforts being made to assess this important 
outcome in this debilitating condition, however more comparative research needs to be 
undertaken, especially in regard to using reference norms to the general population (e.g. Grob 
et al. 2005; Yosipovitch and Greaves 2008).    
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The most pertinent area not addressed is how QoL assessment will be integrated into 
clinical practice as recommended in guidelines and how the data will be utilised. Dermatology 
services currently adopt a bio-medical model and lack multi-disciplinary structure. Except for 
increasing consultation times in overstretched services CU practice risks mirroring CU research 
and limiting data to examining the effectiveness of dermatological treatments and not avenues 
for psychosocial referrals. Further much of the research has been undertaken outside of a 
primary care setting. This is a key concern as participants from secondary and tertiary services 
may present with relatively more severe disease and may not represent the CU population as a 
whole. In light of the methodological concerns of the included papers, which subsequently 
impacted the approach to data collation and analysis in this systematic, this study has 
nonetheless succeeded in systematically reviewing the current status of quality of life in CU and 
the quality of the research itself. In line with guidelines recommending compulsory CU-related 
QoL assessment in the absence of CU reference norms, this review will hopefully act as an 
accessible comprehensive summary of the literature in which both researchers and clinicians 
can make evidence-based decisions about patient care and resource funding. 
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Chapter 4 
Quality of Life Measurement in Chronic Spontaneous Urticaria: A Systematic Review (Study 2) 
 
4.0: Scope and Rationale for Study 
The use of QoL questionnaires to CU research reflects its strong bio-psychosocial impact 
(Baiardini et al. 2011). However a pilot search of the literature highlighted that the suitability of the 
instruments used to measure CU-related QoL had yet to be examined. The study reported in this chapter 
differs from the preceding one in that it focuses on examining the adequacy of QoL questionnaires used 
in CU research as to the findings reported from them. This would help to establish the instrument/s 
sensitive enough to show relationships between representations and QoL in proceeding studies.    
 
4.1: Introduction 
4.1.1: Quality of Life Measurement in CU Research  
QoL measurement in CU studies has increased since O’Donnell and colleagues first did this 
using the Nottingham Health Profile in 1997. However, it emerged in Study 1 that studies have consisted 
of different instruments making comparisons between them difficult and the term QoL has been used 
synonymously with similar but conceptually different terms such as health status. As the primary outcome 
measure of the thesis it was important to evaluate which instrument/s were the most reliable and valid to 
measure QoL especially in light of unresolved areas found in study 1 as to whether CU has a mild or 
moderate impact on QoL (which was dependent on the instrument used in studies). Existing CU reviews 
(e.g. Baiardini et al. 2011) only review from selected studies. Although there is currently no standardised 
consensus for evaluating QoL questionnaires in skin disorder there is a general agreement in the 
literature of what constitutes a good one (Augustina, Amonb, Bullinger, Gielerd et al. 2000; Basra et al. 
2008; Both et al. 2007; de Korte et al. 2002; Finlay, 2005; Halious, Beumont and Lunel, 2000; Van Beek 
et al. 2007). The current review created a framework based on these sources and guidelines for culturally 
adapting instruments (Eremenco, Cella and Arnold, 2005; Swaine-Verdier, Doward, Hagell et al. 2004).  
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4.1.2: Review Question and Objectives 
 
Review Question: In CU which questionnaires are most valid and reliable in measuring quality of life? 
Review Objectives: To (I) overview the variety of QoL questionnaires being used in CU research; (II) 
critically review the psychometric properties of these questionnaires and (III) evaluate which measure/s 
are the most adequate for CU-related QoL research. 
 
4.2: Method  
 
4.2.1: Identification of Studies 
The search strategy used was identical to Study 1 and can be found in section 3.2.1 (p54) of 
Chapter 4 however the aim here was only to include papers that were exploring the development and 
psychometric properties of QoL instruments in individuals with CU. If development and psychometric 
information was being collected from a revalidation paper (i.e. validating CU samples to an already 
existing questionnaire) the original development paper were still retrieved to obtain more information on 
development and construction. 
 
4.2.2: Study Selection Criteria 
Studies were included if they contained questionnaire development, psychometric and cultural 
adaptation data of multi-dimensional questionnaires and consisted of participants with a primary 
diagnosis of chronic urticaria and were in English. Culture-specific questionnaires were excluded, as 
primary physical urticarial samples. If the main assessor (DB) was uncertain about what papers to include 
this was discussed to a consensus with a second assessor (JK) who was a PhD researcher at the same 
academic institution. The selection process can be found in Figure 4.1 (p99). 
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Figure 4.1: Flowchart of Election Process of CU Papers using QoL Questionnaires 
 
 
4.2.3: Data Extraction 
The criterion for data extraction was based on the references reported in section 4.1.1 (p97) for 
what constitutes a valid and reliable QoL questionnaire in dermatology. Data was extracted on the areas 
listed below which are described further in Appendix 2 (pA5) with a copy of the see data extraction. 
Part 1: General Questionnaire Information 
Name; Type; Authors; Language; Original population  
Part 2: Questionnaire Construction: Description and Feasibility 
Development: (a) Measurement goals; (b) questionnaire item generation (c) Item reduction 
Description: Items/ domains; response scale; scoring; timeframe 
Feasibility: Patients understanding; completion time 
Validation Study: Total sample: structural validity and internal reliability  
Part 3: Psychometric Properties  
Reliability: Internal; Test-retest    Validity: Content; Construct; Convergent; Discriminant  
Responsiveness & Clinically Significant Change (CSC) 
Part 4: Cultural Validation: Translation 
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Records identified through 
database searching 
N = 2741 
Full text records screened 
N = 69 
[64 papers + 5 reviews] 
Studies with development/ 
validation data of QoL 
questionnaires from CU 
samples 
N = 12 
Studies without psychometric 
data seperated 
N = 57 
 
SF-12 and 36  
DLQI 
FLQA-d 
Skindex 29 
CU-Q2oL 
 
WHO-QoL Bref  
NHP 
 
 
 QoL questionnaires identified 
in cross-section, RCT, 
observation studies with no 
validation data in CU samples 
retrieved for review 
 
 Instrument 
excluded: 
V-dermato 
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4.3: Results 
 
4.3.1: Study Selection Process 
From the 53 studies included in the search strategy undertaken in Study 1, only twelve included 
development and psychometric data and/ or information on QoL instruments in CU. These were as 
follows: Augustin et al. 2000, Baiardini et al. 2005; Brzoza et al. 2011; Dias et al. 2011; Kocaturk. 2011a,b; 
Lennox and Leahy, 2004; Liu et al. 2012; Mylnek et al. 2008, 2009; Shikar et al. 2005; Spector et al. 2007 
and Valero et al. 2008). The French culture-specific questionnaire V-Dermato was excluded.  
 
4.3.2: General Review 
 
1. General Questionnaire Information  
From the 12 included studies, 8 instruments were accepted by the inclusion criteria and this 
consisted of 4 generic, 3 dermatology-specific and 1 disease-specific questionnaire/s. Generic measures 
included the short form health surveys SF-12 (Ware et al. 1996) and SF-36 (Ware and Sherbourne, 
1992), the NHP (Hunt et al. 1985) and the WHOQoL-BREF (WHOQoL Group, 1998b). Dermatology-
specific measures included the Skindex-29 (Chen et al. 1997), the DLQI (Finlay and Khan, 1994) and the 
FLQA-d (Augustin et al, 2000). The disease-specific instrument was the CU2QoL (Baiardini et al. 2005). 
The developmental origin of instruments was predominantly American and European with exception to 
the multi-centred WHOQoL-BREF but total languages available per instrument ranged from 6 for the CU-
Q2oL to 50 plus for both the SF-36 and DLQI respectively.  
 
2. Questionnaire Construction 
CU samples in original QoL instrument construction was restricted to the original Italian disease-
specific CU-Q2oL and its cultural validated versions; hence they did not feature in the original 
development of all generic instruments and were only included in the original development of the 
dermatology-specific FLQA-d. Generic and dermatology-specific instruments predominantly featured to 
help inform the construct validity of the CU-Q2oL (i.e. SF-36, Skindex-29, and DLQI) and only one were 
formally validated in individuals with CU for the first time (i.e. DLQI). No revalidation featured of generic 
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instruments in CU (i.e. SF-36, NHP, WHO-QoL Bref). The most common validation technique of an 
existing instrument was via exploratory factor analysis (EFA). Development and descriptions for generic 
and dermatology-specific instruments used in CU are presented in Table 4.1 (p102). 
  
Measurement Goals, Items, Generation and Reduction 
CU samples were involved in 2 papers related to the development of a new QoL instrument (i.e. 
the Italian CU-Q2oL and FLQA-d). Both papers reported the measurement goals, study purpose, and 
target populations. In both, item generation was undertaken in conjunction with patients and experts 
including dermatologists, allergists and psychologists. Even though CU samples were not involved in the 
original development of the other instruments, information on their construction was well documented. 
Generally item generation was undertaken by experts only for generic measures and with patients for 
dermatology-specific ones. Item reduction involved patient piloting and statistical analysis. 
 
Description, Feasibility and Validation Study 
Items for QoL questionnaires varied greatly ranging from 10 for the DLQI to 53 for the FLQA-d. 
As expected generic measures tended to focus on QoL aspects that were not necessarily related to 
health and specific measures allowed for more items that affected skin diseases in particular. Items were 
themed into domains that ranged from 3 for the Skindex-29 to 8 for the SF-36 but all instruments covered 
bio-psycho-social aspects of QoL to varying levels of focus. All measures were designed for self-report 
and participants were expected to respond on mainly continuous 3-5 point Likert scales but could be 
administered in other formats (e.g. 1-2-1 interview). The majority of instruments were constructed to 
produce a domain (e.g. Skindex-29, CU-Q2oL) or summary score (SF-26) but could also be transformed 
to allow for an overall score. The timeframe for measures ranged from 1 week for the DLQI and FLQA-d 
to 4 weeks for the Skindex-29 and completion times varied widely depending on the amount of items (2 
minutes for the DLQI and SF-12 to 10 minutes for the generic SF-36 and NHP). The number of patients 
with CU involved in validation ranged from 47 for the FLQA-d to 857 for the DLQI.  
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Table 4.1: QoL Questionnaires- General Information, Development, Description and Feasibility 
 
1. General Questionnaire Information 
 
2. Construction                              Description                                                                                         Feasibility                 Validation Study  
Name/ abbreviation/ Language/ 
Translations 
Development Items/ Domains Response Score/ 
Time 
Frame 
Patient 
Understanding/ 
Completion Time 
CU Sample 
size 
Generic Instruments        
 
World Health 
Organisation  
Quality of Life 
Questionnaire  
(WHO-QOL BREF)* 
 
WHOQOL Group 
(1998b) 
 
 
Original  
Multiple-  
18 countries 
 
Translations/ 
Yes 
 
Original sample 
 
 
 
Measurement Goal: To develop 
a reduced version of the 
WHOQOL-100, a QoL tool 
developed to be cross-culturally 
applicable.   
 
Purpose: Evaluation/ 
Discrimination  
 
Item Generation: Experts 
 
Item Reduction:  
Experts and patients 
 
Items: 26 
 
Domains: 4  
Physical Health, Psychological, 
Social Relationships, 
Environment  
 
1 facet on ‘overall QoL’ and 
‘general health’ 
 
 
 
Continuous 
Scale  
 
5 point Likert 
 
0-100 
Higher scores 
= poorer 
outcome 
 
By domain  
 
 
2 weeks 
 
 
 
 
Not reported 
 
 
 
CU in Sample: 
 
None  
 
Medical Outcomes  
Study 36-Item  
Short-Form Health  
Survey (SF-36)** 
 
Ware and Sherbourne 
(1992) 
 
 
 
Original  
USA 
 
Translations/ 
Yes 
 
Original sample 
 
 
 
 
 
 
Measurement Goal: To develop 
an health survey tool for clinical & 
epidemiological research 
 
Purpose: 
Evaluation/ Discrimination 
 
Item Generation: Experts 
 
Item Reduction: Experts 
 
 
 
Items: 36 
 
Domains: 8 
Physical Functioning, Role 
Limitations (Physical), Bodily 
Pain, General Health, Vitality, 
Social Functioning, Role 
Limitations (Emotional), Mental 
Health,   
 
Single item on ‘change in 
health’’ 
 
Continuous 3-
5 Likert scales 
for items 1-3 
& 6-11 
Dichotomous 
for items 4-5 
 
0-100 
transformed 
scale: Higher 
scores= better 
outome 
 
By domain 
 
2 summary 
scores 
 
Physical 
component  
(PCS) & 
Mental 
component 
(MCS) 
 
 
4 Weeks  
 
(Except 1 year for 
general health 
item) 
 
 
7-10 minutes 
 
 
CU in Sample: 
 
None 
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Table 4.1 Continued 
 
General Questionnaire Information 
 
Construction                                    Description                                                                                          Feasibility                Validation 
Name/ abbreviation/ 
 
Language/ 
Translations 
 
Development 
 
 
Items/ Domains Response Score/ 
Time 
Frame 
Patient 
Understanding/ 
Completion Time 
CU Sample 
size 
 
Medical Outcomes  
Study 12-Item  
Short-Form Health 
Survey (SF-12)*** 
 
Ware, Kosinski and 
Keller (1996) 
 
Original  
USA 
 
Other 
Yes 
 
 
Original sample: 
 
Purpose: 
Evaluation/ Discrimination 
 
Measurement Goal: To develop 
a reduced version of SF-36 for 
use in large scale epidemiological 
and clinical research  
 
Item generation: Experts 
 
Item reduction: Experts 
 
 
Items: 12 
 
Domains: 8 
 
2 items each from SF-36’s 
Physical Functioning, Role 
Limitations (Physical), Role 
Limitations (Emotional), Mental 
Health   
 
1 item each from SF-36’s 
Bodily Pain, General Health, 
Vitality, Social Functioning,  
 
Continuous on 
items 1-3 & 8-
12 
 
3-6 point 
Likert  
 
Dichotomous 
on Q. 4-7, No-
Yes 
0-100 scale 
transformed: 
Higher scores  
better outome 
 
Domain/ 
 
2 summary 
scores 
 
Physical 
component  
(PCS) & 
Mental 
component 
(MCS) 
 
4 Weeks  
 
2 minutes 
 
 
CU in Sample: 
 
None 
 
Nottingham Health  
Profile (NHP)**** 
 
Hunt, McEwen and 
McKenna (1985) 
 
 
 
Original  
UK 
 
Other 
Yes 
 
 
Original sample: 
 
Purpose: 
Evaluation/ Discrimination 
 
Measurement Goal: To develop 
an epidemiological population 
based survey tool to assess 
perceived health status    
 
Item generation: Patients 
 
Item reduction: Patients 
 
Items: Part 1: 38,  
            Part 2: 7 statements    
 
Domains: 6 (part 1) 
Sleep, Physical Mobility, 
Energy, Pain, Emotional 
Reactions, Social Isolation 
 
Part 2 statements: paid 
employment, domestic 
activities, social life, personal 
relationships, sex life, hobbies 
and interests, holidays   
 
Dichotomous 
 
Yes- No 
 
0-100% of 
sample 
response 
 
Higher % 
poorer % 
outcome 
 
 
 
Domain  
 
Not reported 
 
 
5-10 minutes 
 
 
CU in Sample: 
 
None 
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Table 4.1 continued 
 
General Questionnaire Information 
 
Construction                                           Description                                                                Feasibility       Validation Study 
Name/ abbreviation/ 
 
Language/ 
Translations 
 
Development 
 
 
Items/ Domains Response Score/ 
Time 
Frame 
Patient 
Understanding/ 
Completion Time 
CU Sample 
size 
Derma-Specific        
 
Frieburg Life Quality 
Assessment -
dermatology 
(FLQA-d)***** 
 
Augustin, Zschocke,   
Seidenglanz et al. 
(2000) 
 
 
Original  
German 
 
Other 
Not found 
 
 
 
 
 
 
 
 
 
Measurement Goal: To design a 
QOL tool that has both generic & 
disease-specific components for 
chronic skin disease allow 
comparison with acute & healthy 
populations also 
 
Purpose: Evaluation/ Discrimination 
 
Item generation:  
Patients and experts  
 
Item reduction 
Patients and experts  
 
Items: 53 (40 general, 10 
specific) 3 visual analogue 
scales (VAS) 
 
Domains: Physical Complaints, 
Everyday Life, Social Life, 
Emotional Status, Treatment, 
Satisfaction 
 
VAS: General health, Skin 
condition, QoL 
 
 
 
Continuous   
5 point Likert 
 
0-112 
Higher 
scores= 
poorer 
outcome 
 
 
 
Domain & 
Composite 
 
1 Week 
 
 
Not reported 
 
CU in Sample: 
 
Yes  45 of 747 
 
 
SKINDEX-29****** 
 
Chren, Lasek, Quinn 
et al. (1997) 
 
 
 
 
 
Original  
US 
 
Other 
Yes 
 
 
 
 
 
 
 
Measurement Goal: To improve the 
61-item Skindex, a tool developed to 
measure the patients perceived 
effects of skin disease on QOL 
 
Purpose: Evaluation/ Discrimination 
Item generation: Research literature, 
experts and patients  
 
Item reduction 
Patients and experts  
 
Items: 30 (29 assigned to 
scales, item 18 separate) 
 
Domains: 3 
Emotions, Functioning, 
Symptoms 
 
 
 
 
Continuous  
5 point Likert 
 
0-100 higher 
score= poorer 
outcome 
 
 
 
Domain  
(ideally) 
 
 
 
 
 
4 weeks 
 
 
5 minutes 
 
 
CU in Sample: 
 
 
None 
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Table 4.1 continued 
 
General Questionnaire Information 
 
Construction                                           Description                                                             Feasibility          Validation Study 
Name/ abbreviation/ 
 
Language/ 
Translations 
 
Development 
 
 
Items/ Domains Response Score/ Time 
Frame 
Patient 
Understanding/ 
Completion Time 
CU Sample 
size 
 
Dermatology Life 
Quality Index  
(DLQI) ******* 
 
Finlay and Khan 
(1994) 
 
 
 
Original  
UK 
 
Other 
Yes 
 
 
 
Measurement Goal: To develop a 
compact tool applicable to all skin 
disease for routine clinical practice  
 
Purpose: Evaluation/ discrimination 
 
Item generation:  
Patients 
 
Item reduction 
Patients and experts  
 
 
Items: 10 
 
Domains: Symptoms & 
feelings, daily activities, 
leisure, work/ school, 
personal relationships, 
treatment 
Continuous  
4 point Likert 
 
(8 questions 
have a ‘not 
relevant, 
option) 
 
0-30 (or % 
proportion of 
smaple) 
Higher score/ 
% = poorer 
outcome 
 
 
Composite  
 
(often 
summed by 
domain but 
evidence 
suggests 
instrument as 
one-
dimensional) 
 
1 week 
 
1-3 minutes 
 
CU in Sample: 
 
None 
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3. Psychometric Properties 
A summary of generic and dermatology-specific QoL instrument development and psychometric 
properties in CU samples can be found in Table 4.2 (p107). An observation of Table 4.2 clearly shows 
that no factor analytical techniques or psychometric testing was reported for generic instruments in CU 
but this was available for dermatology-specific instruments. These will be discussed in further detail in 
the more specific individualised review of the instruments in Section 4.3.3.  
 
Reliability 
All questionnaires validated in CU (FLQA-d, DLQI and CU-Q2oL) showed good internal 
consistency with Cronbach alphas above .7 in most instances and test-retest reliability were also good 
across instruments. Test-retest reliability correlations ranged from .68 (FLQA-d) to .91 (DLQI). 
 
Validity  
Even though the generic SF-36 and dermatology-specific Skindex-29 was not formally validated 
in CU populations they played a role in the convergent validation of the disease-specific CU- Q2oL 
demonstrating good levels for equivalent items and/ or domains. The DLQI also showed good convergent 
validation when correlated with the FLQA-d and most versions of the CU-Q2oL. In full validation studies 
patients with CU where generally involved in the content validation process and discriminant validity was 
always demonstrated to be of a mild to moderate magnitude where reported.    
 
Responsiveness and Clinical Significant Change       
All instruments validated in CU (FLQA-d, DLQI and CU-Q2oL) showed responsiveness in virtually 
all domains with significance levels ranging from p <0.05 in the Italian CU-Q2oL to p <0.0001 or more for 
the Brazilian-Portuguese and Turkish versions. Clinical significant change (or minimal important 
difference) information was only available for the DLQI (Shikar et al. 2004). 
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Table 4.2: Validation of Generic & Dermatology-Specific Instruments  
 
Instrument 
 
 Construction                                  Validation 
 
Psychometric Properties  
 
Abbreviation 
 
Item Reduction/      
Factor Analysis  
 
CU Sample 
 
Reliability 
 
Validity 
 
Responsiveness 
 
Clinical Sig. Change 
Generic       
 
WHO-QOL 
BREF 
 
NR 
 
None 
 
 
NR 
 
NR 
 
NR 
 
NR 
 
SF-36* 
 
NR 
 
None 
 
 
NR 
 
Good Convergent validity with 
equivalent CU2QoL items or domains 
in the validation of original Italian 
version of CU2QoL 
 
NR 
 
NR 
 
 SF-12** 
 
NR 
 
None 
 
NR 
 
NR 
 
NR 
 
NR 
 
NHP 
 
NR 
 
None 
 
NR 
 
NR 
 
NR 
 
NR 
Dermatology       
 
FLQA-d*** 
 
 
NA (see Table 5.1) 
 
45 from 747 
 
Internal reliability: 
All >0.8 (except 
treatment 0.69)   
 
Test-retest: 
Pearson r 0.68 to 0.91 
 
Content: 
Yes (patients/ experts) 
 
Convergent: 
Yes: Good to strong convergent 
validity with relevant DLQI domains 
 
Discriminant: 
Yes. Differed on 5/6 of scales with 
psoriasis & atopic dermatitis patients.  
All received the same treatment 
reflected in no change on 6th scale 
 
 
Good sensitivity to change. 
All scales <0.0001 
 
 
Not reported 
KEY: NR Not Reported, NA Not applicable, *SF-36:  Baiardini et al (2005), **SF-12: Reeves et al, 2004,***FLQA-d Augustin et al, 2000 
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Table 4.2 Continued 
 
Instrument 
 
 
 Construction                           Validation 
 
Psychometric Properties  
 
 
 
Item Reduction/      
Factor Analysis  
 
CU Sample 
 
Reliability 
 
Validity 
 
Responsiveness 
 
Clinical Sig. Change 
 
Skindex-29**** 
 
NR 
 
None 
 
None 
 
Good convergent validity with 
equivalent items & domains of the 
CU2QoL (German, Polish, Turkish & 
Spanish versions).    
 
 
NR 
 
NR 
 
DLQI***** 
 
 
 
Factor analysis showed a uni-
dimensional structure in one 
USA study supporting the use 
of a total score but a two-
factor structure in Chinese 
sample.  
 
 
 
 
163 to 857 
 
(944 for MID 
study) 
 
 
Internal reliability: 
Average overall score 
>0.8 in studies 
assessing this. 
Distribution analysis 
showed items were free 
from floor and ceiling 
effects) 
 
Test-retest: 
Spearman rank 
correlation between 
scores 0.99 (P<0.001) 
 
 
Content: Yes, using the item 
response model 
 
Convergent: Yes. Converges well 
with tested items and/ or domains of 
the FLQA-d, CUQ2oL (Brazilian-
Portuguese, German, Polish, Spanish 
and Turkish versions).  
 
Discriminant: Moderate 
discriminating power reported in 
differentiating patients with high or 
low QoL except item 1 (symptoms). 
 
Scores reported to be in line 
with other clinical changes in 
patients 
 
 
MID of between 2.24-
3.10 
 
Skindex-29****: Brozaet al, 2011, Kocaturk et al, 2011a, Valero et al, 2008, Mylnek et al,  2009,  
DLQI***** Augustin et al, 2000; Brzoza et al, 2011; Dias et al, 2011; Kocaturt et al, 2011a, Lennox & Leahy et al, 2004; Liu et al, 2012; Mylnek et al, 2009, 2008; Shikar et al, 2005; Spector et 
al, 2007 Valero et al, 2008
                                                                                                                                                                                                                                      
 
110 
 
4. Cross-Cultural Adaptations  
CU samples were used in the cultural adaptation of one instrument, the disease-specific CU-
Q2oL (see Table 4.3, p120). In these five studies (Brzoza et al. 2011; Dias et al. 2011; Kocaturk et al. 
2008; Mylnek et al. 2009; Valero et al. 2011) the full validation process was comprehensively described 
with the use of factor analysis to the use of standardised forward and back translation techniques to 
convert instruments from the original Italian version. Even though cultural adaptations did exist for other 
instruments in this review, the involvement of patients with CU was not identified. 
 
4.3.3: Instrument Review 1: Generic Instruments 
 
WHO Quality of Life Questionnaire- Brief (WHOQoL-BREF) 
The WHOQoL-BREF (WHOQoL Group, 1998b) is an abbreviated version of the WHOQoL-100 
and reflects the philosophy of its original, which was to create a cross-culturally applicable instrument 
developed to a consensus across 15 international WHO-QoL Group centres. By deciding on the facets 
most important in assessing QoL, 236 items were generated and piloted on 300 individuals with a range 
of health problems. The development of the WHOQoL-100 is presented elsewhere (WHOQoL Group, 
1994, 1998a) and the present review will focus on the WHOQoL-BREF. The WHOQoL-BREF was 
developed because the WHOQoL-100 was deemed too long for some larger epidemiological studies or 
studies using multiple measures. It correlates significantly well on all domains of the WHOQoL-100 and 
exhibits good psychometric properties in its original test populations.      
 
The 26-item WHOQoL-BREF retained the 4 domains of its original (physical, psychological, 
social and environmental). The reduced items selected within each domain represent at least 1 item that 
best explained the largest variance in the original WHO-QOL 100 domain, hence is representative of the 
original domain (this principle was also used in the single statements of overall QoL and general health 
perceptions). Patients self-report on a 5-point scale and a score of 4 to 20 can be given per domain. 
Domains are scored by multiplying the mean items by 4 and higher scores indicate better QoL.  
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The use of the WHOQoL-BREF is relatively new in skin research and from the findings of this 
review has not been psychometrically tested in CU samples in any aspect making evaluating its adequacy 
for CU research difficult to establish at this moment in time. The WHOQoL-BREF has been reviewed to 
be a promising instrument in skin disease research (Both et al, 2007) but its relatively limited use in CU 
research (reflected in 2 cross-section studies in Chapter 3) suggests that validation in CU populations is 
required to establish its benefits over other generic instruments and further usage in CU-related QoL 
studies is needed to reach a consensus on its performance.  
 
The Medical Outcomes Short-Form Health Surveys (SF- 36, SF-12) 
 
SF-36 
The SF-36 (Ware and Sherbourne, 1992) was created as an improvement to the previous SF-
20. The purpose of its development was not only to bridge a gap between the long, time consuming 
existing measures in general health surveys but also to improve the content and construct validity of the 
SF-20. The developers selected items from previously published questionnaires over the previous 20-40 
years resulting in a comprehensive psychometrically evaluated questionnaire designed to measure 
health in the Medical Outcomes Study (MOS) across disease samples. It is available in many languages 
and administration formats and correlates well with the SF-20.    
 
The 36-item SF-36 consists of 8 scales (see Table 4.1) determined by factor analysis that can 
be summed up into a mental component (MCS) or physical component (PCS) score. Participants report 
on a continuous scale (except for 2 dichotomous responses) and a score of 0-100 is given per domain. 
Higher domain or summary scores designate better health status. It requires 7-10 minutes to complete 
and patients report feelings over the past 4 weeks (except 1 year for general health item). The measure 
is recommended for use in epidemiological and clinical research in specific and general populations.  
 
The SF-36 is widely used in skin research (Both, 2007) but like the WHO-QoL-BREF appears to 
lack any formal validation testing in CU populations making an evaluation of its psychometric performance 
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limited. However the SF-36 was used in the convergent validation of the original version of the disease-
specific CU-Q2oL. Associations were found in the authors predicted directions where higher statistically 
significant correlations where found between conceptually similar domains. One example included 
patients reporting lesser symptoms and better QoL on the CU-Q2oL also reported better health status on 
the SF-36.  
 
The SF-36 is often recommended as the reference measure in both skin disease and general 
research and demonstrated above its sensitivity to detect differences in CU and other populations on its 
scales. It also has themes around positive health, lacking in some questionnaires. Even though this is 
the case a few concerns arose. As its developers point out the SF-36 does not account for factors such 
as sexual functioning, cognitive functioning, family functioning and sleep. From this review it appears that 
the SF-36 should be accompanied with a more specific measure to capture the full CU-related QoL 
experience and the preliminary evidence suggests that it may work well with the CU-Q2oL.   
 
SF-12 
The SF-12 (Ware, Kosinski and Keller, 1996) was developed because the SF-36 was deemed 
too lengthy for some larger scale research studies. It was required to not only be capable of explaining a 
minimum of 90% of the variance in the MCS and physical PCS of the SF-36, but also give comparable 
scoring patterns across its items and domains with a 2 minutes self-administration time. From previous 
results it was known that the MCS and PCS of the SF-36 provided evidence suggesting that it was 
psychometrically possible to reduce items without compromising comprehensiveness. They used SF-36 
data to perform validity tests to select and score items. 
 
Available in many languages, the SF-12 retains the same components and 8 domains of the SF-
36 but has 12 items (where 10 items replicate the MCS and PCS equivalents of the SF-36 without 
compromising completeness (6 of the domains) and 2 new added items to represent the remaining 2 
domains). Eight questions are answered on a continuous scale with the remaining providing dichotomous 
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response options. With a timeframe of 4 weeks higher scores mean better QoL.  The SF-12 did explain 
90% of the variance in the SF-36 and could draw upon similar statistical conclusions but a 10% decreased 
discrepancy in its validity coefficients was reported. This suggested that the SF-12 did not affect large 
group studies but would when used with small numbers or individuals. Large mean score differences of 
both measures were reported suggesting further caution when using the SF-12 as a shorter alternative.   
 
The review found no validation data undertaken in CU samples and in Study 1 it only featured 
as a secondary measure in a CU drug efficacy RCT study (Reeves et al. 2004). Its current lack of 
psychometric evaluation in CU suggests that the full version (i.e. the SF-36) appears to be a more 
recommendable option, however if successfully validated it would reduce respondent completion time.  
 
Nottingham Health Profile (NHP) 
The NHP (Hunt, McEwen and McKenna, 1985, 1986) was designed for health survey research. 
At the time of its development the authors believed that existing measures suffered from several issues. 
They were long, complicated, ambiguous, biased to the physician’s point of view, narrowly focused and 
resulted in composite scores limiting the analysis of specific areas (Hunt et al. 1985, 1986). The objective 
of the NHP was to produce a questionnaire good enough for use in both general populations and 
chronically ill groups. Around 2200 statements were collected from over 700 individuals describing the 
effects of bio-psycho-social aspects of their health. After testing in different patient groups, the NHP was 
created. The result was a 2-part health profile, part 1 containing 38 statements divided into 6 domains 
(i.e. sleep, mobility, energy, pain, emotional reactions, social isolation) and part 2 containing 7 statements 
relating to everyday life on a dichotomous scale (see Table 4.1, p103). With a completion time of 5-10 
minutes, scores range from 0-100 per domain where higher scores mean worse health status. 
 
The NHP has been psychometrically tested successfully in diverse patient populations and was 
used in the break-through study that highlighted the impact of CU on quality of life (O’Donnell et al. 1997) 
however it has not been psychometrically evaluated in CU samples. The social domain is also limited 
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and its cross-cultural adaptation is not well established outside the UK (Both et al. 2007). Further the 
author’s of the NHP state that using the seven extra statement items on top of the 6 NHP domains might 
become ‘cumbersome’ when multiple factors are being analysed. In terms of CU research this is 
particularly pertinent as CU researchers in clinical trials often use many other diagnostic and clinical 
measures in addition to quality of life in their studies and this may increase both participant burden in 
terms of completion time and the need to account for the extra variables in data analysis. The authors 
also note that the NHP represents rather severe problems so may not be sensitive to participants with 
milder health conditions. It seems clear that further psychometric testing of the NHP in CU is required.  
 
4.3.4: Instrument Review 2: Dermatology and Disease-Specific Instruments 
 
Freiburg Life Quality Assessment- Dermatoses (FLQA-d) 
The FLQA-d (Augustin et al. 2000) presented in 1 paper is a variant of several HRQoL 
questionnaires developed from the FLQA (Freiburg Life Quality Assessment). The aim was to create a 
HRQoL questionnaire that contained both generic and disease-specific components. The authors argued 
that current dermatology-specific measures were adequate for assessing QoL but that they lacked 
specificity for certain conditions. The FLQA-d was developed using CU, psoriasis and atopic dermatitis 
patients and experts in dermatology, psychology and statistics. Patients were asked to write down the 
most frequent problems experienced and presented with further questions (not stated). Responses were 
piloted in 26 patients before the new disease-specific items were added to the existing general FLQA. 
The 53-item FLQA-d consists of 40 generic and 10 specific items assigned to 6 a-priori scales plus 3 
visual analogue scales. Patients respond on a continuous 5-point Likert scale where higher scores equal 
lower HRQoL within a 1 week timeframe and responses are analysed by domain (Augustin et al. 2004). 
 
The FLQA-d validation involved 747 dermatology patients where 47 had CU. Psychometric 
testing established good distribution characteristics across domains except for moderate floor and ceiling 
effects for the social life and treatment domains. All domains showed good internal reliability with 
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Cronbach alpha’s at >0.7 (except treatment at 0.69). Test-retest reliability was good at >0.8 overall 
ranging from 0.68 for satisfaction to 0.9 for everyday life. The Questionnaire for chronic skin diseases 
(QCSD), Questionnaire on everyday life and the DLQI were used to assess convergent validity where 
significant correlations were found between the FLQA-d and comparable scales (e.g. FLQA-d emotional 
status with QCSD anxious-depressive mood). Discriminant validity was assumed as groups differed in 
five of the FLQA-d six scales and when compared to healthy controls. The FLQA-d demonstrated good 
responsiveness to change with all domains showing substantial significance (p< 0.0001). Even though 
the FLQA-d is one of the only instruments to include CU, it has not been used in CU samples outside of 
its development paper in 2000 and is rarely used in dermatology in general (Both et al. 2007).  
 
Dermatology Life Quality Index (DLQI)  
The DLQI (Finlay and Khan, 1994) is a controversial choice for inclusion in that its status as a 
multidimensional instrument is often challenged (Basara, et al, 2008; de Korte et al, 2002) but it is the 
most used instrument in skin QoL research (Both et al, 2007) and was involved in over 50% of the 
included papers in Study 1 and the convergent validity of virtually all instruments in this Study. 
 
The authors of the DLQI acknowledged that using disease-specific measures in dermatology did 
not allow for comparisons with other skin conditions and that many general measures at the time were 
too lengthy for routine clinical use. The aim was to develop a simple assessment tool applicable to all 
dermatology patients. They asked 120 patients attending their dermatology department to write down 
“…all the ways that your skin disease affects you”. This resulted in 49 items categorised and ordered by 
frequency of mentions. The chosen 10-items were piloted twice to confirm comprehensiveness and 
feasibility and subjected to preliminary tests in 200 patients and 100 controls with further validation testing 
in 53 patients. The result was the 10-item instrument with 6 ‘suggested’ domains. With a timeframe of 1 
week and completion time of 1-3 minutes, patients report on a 4-point Likert scale (note: 7 items have a 
not relevant option and item 7 is dichotomous). Scores range from 0-30 where higher scores mean poorer 
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QoL and are ideally scored compositely. Of the 32 skin diseases in its development, no CU samples were 
involved but data on its psychometric properties could be extracted from all but one of the included 
studies. 
 
Lennox and Leahy (2004) used data from 2 CU-related RCT studies to see if the DLQI would 
present with similar psychometric properties as the original 1994 paper.  In CU the DLQI showed good 
item distribution, free of floor and ceiling effects. Internal reliability for all items exceeded Cronbach’s 
alpha of 0.7 with exploratory and confirmatory analyses of >0.6 suggesting a 1 or 2 factor structure 
(except 0.37 for item 1 which still exceeding the original 0.3). Using the item response model to establish 
content validity, the DLQI showed a moderate magnitude and the ability to discriminate across different 
levels of QoL on all but 1 item. Construct validity was significantly different with discriminant validity 
correlations falling between 0.21-0.37 between DLQI and other study outcomes. As DLQI scores where 
in line with clinical changes in patients, this indicated sensitivity to clinical changes. Further one RCT 
study reported full psychometric performance data of the DLQI in CU (Spector et al, 2007), which mirrored 
Lennox and Leahy (2005) for internal consistency reliability (Cronbach alpha 0.87) and validity. This was 
also true for the DLQI’s ability to detect therapeutic changes over time providing further evidence of its 
ability to differentiate between different groups/ levels of outcome, responsiveness and sensitivity to 
clinical change. Despite this responsiveness Mylnek et al. (2008) in their clinical observation found that 
the DLQI correlated weakly with measures of disease activity including the UAS. Shikiar et al. (2005) in 
another study estimated the DLQI’s minimal important difference score to be between 2.24 to 3.10 to be 
used to establish a meaningful perceived change in patients. In the remaining validation studies the DLQI 
was used in the convergent validity of the FLQA-d and the Brazilian-Portuguese, Polish, Turkish, German 
and Spanish versions of the CU-2QoL which indicated strong convergence with conceptually equivalent 
items.  
 
The DLQI has a good record in CU research and unlike other measures it has been substantially 
validated in CU using large sample sizes, however evidence for its one-dimensionality (Basra et al. 2008; 
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Lennox and Leahy, 2005) means studies that report this instruments results by the suggested (not factor 
analysed) domains may be misleading in terms of evaluating what are meant to be multi-dimensional 
aspects of QoL. Liu et al. (2012) confirmed the possibility of a two-factor structure but this is still not in 
line with the suggested domains by its authors. However in routine care practitioners may prefer the ease 
of its composite score. Another limitation of the DLQI is that it also focuses more on disability and its 
popularity may lie in its quick administration time to patients, especially when many other factors are 
being assessed. Despite the popularity of the DLQI as the most used QoL instrument in dermatology 
(Basra et al. 2008) and its strong psychometric properties in CU it still remains a measure of disability not 
QoL (Both et al. 2007; DeKorte et al. 2002) hence it is not statistically tapping into the latent aspects it 
claims to explore.  
 
Skindex-29 
The Skindex-29 (Chren, Lasek, Quinn et al. 1997) is a revised version of the 61-item Skindex 
(Chren et al. 1996). It was recognized that the 15-minute completion time of the original increased patient 
burden and restricted its routine usage in research and practice (Chren et al. 1997). Further issues 
included its contentious evaluation and discrimination qualities and lack of responsiveness. On observing 
that many patients chose the same answers for many items 70% of the time, the objective was to address 
these issues.  
 
Using data from the Skindex-29 development study undertaken in a dermatology clinic and 
private practice, the authors analysed the most psychometrically sound Skindex items. After items were 
retained, reworded and generated the new measure was psychometrically tested. Factor analysis of the 
new items reflected domains more comprehensively, while reworded items allowed for better group 
discrimination. This resulted in a 30-item instrument with 3 domains. With a 4-week timeframe and 5-
minute completion time, patients respond on a 5-point scale where a score of between 0-4 is given. 
Higher scores indicate greater impact on QoL and are summed as domain scores. Even though the 
Skindex-29 has been extensively tested and has shown good psychometric performance in skin disease 
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populations, only 4 patients with urticaria were involved in its original development and the urticaria type 
was unreported and its CU validation was limited to use in the convergent validity of other instruments. It 
was used in the cultural validation of the Polish, German, Spanish and Turkish versions of the CU-Q2oL 
showing strong convergent validity however it has also shown evidence of some item redundancy with 
the CU-Q2oL.  
 
Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) 
The CU-Q2oL (Baiardini et al. 2005) was designed to measure QoL in individuals with CU. The 
authors observed the number of QoL studies available for other skin conditions and identified a number 
of concerns: (i) the lack of CU-QoL studies (ii) studies focusing mainly on clinical endpoints, (iii) common 
usage of general or dermatology-specific instruments because a disease-specific one did not exist. They 
believed that using generic measures because a specific one did not exist was unacceptable and that 
they might not be sensitive enough to detect concerns and changes over time. The aim of the paper was 
to develop a disease-specific measure and to evaluate its psychometric properties. The 23 items of the 
measure were generated in conjunction with 60 CU patients and experts in dermatology, immunology 
and allergy. A factor analysis identified a 6 dimensional structure explaining 60.0% of the variance in the 
sample. It takes 5 minutes to complete and patients answer questions on a 5-point Likert scale where 
higher domain scores (10-100) equals poorer QoL. 
 
Psychometric testing established good internal reliability for all domains exceeding a Cronbach 
alpha of 0.7 at group level (exception swelling at 0.65). Test-retest reliability (via ICC) was scored at 0.75 
for the majority of items. Completion of the SF-36 and CU-Q2oL in 125 patients showed good convergent 
validity where associations were in the expected directions with equivalent domains correlating with each 
other (examples are included in the SF-36 review above). Its responsiveness was found to be significant 
in 18 of 23 items and was significant for expected changes in disease severity on all scales. The CU-
Q2oL was concluded to be a reliable and valid measure for assessing QoL in CU and recommended for 
use in treatment assessment and decision-making by its authors.  
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As highlighted in the current study so far and Table 4.3 (p120), the CU-Q2oL has been 
comprehensively and successfully translated and validated into five further languages. All versions have 
reported high levels of internal consistency but not all have successfully replicated the factor structure of 
the original version by Baiardini et al. (2005) as can be observed in Table 4.3. (p120) Dispite the differing 
factor stuctures of the cross-culturally validated versions of the CU-Q2oL all have shown strong 
convergent validity with the Skindex-29. In a first example Valero et al. (2008) in their Spanish version 
found that the domains of pruritus and swelling significantly correlated with the Skindex-29’s symptoms 
scale (>0.60) and the CU-Q2oL impact on daily activities and limits domains significantly correlated with 
Skindex-29’s functioning. In a second example Mylnek et al. (2009) in their German version found a 
strong convergent validity between the CU-Q2oL functioning scale and the Skindex-29 functioning scale, 
the CU-Q2oL sleep scale with the Skindex-29 items 2 (sleep) and 30 (tired) and the CU-Q2oL mental 
status scale with Skindex-29 emotions scale. Further, as already examined earlier the original Italian CU-
Q2oL converged well with the SF-36, which is the only generic instrument to be tested in a QoL instrument 
validation study.    
 
The CU-Q2oL is a welcomed new addition in CU research that has had to rely on generic and 
dermatology-specific instruments that do not cover items such as swelling. As it covers areas that are 
specifically relevant to patients with CU it should be more sensitive in identifying the bio-psychosocial 
needs of these patients in clinical practice (i.e. helping in the treatment and decision making process) 
and when used longitudinally in medical and psychosocial interventions. 
 
When used alone the advantages and disadvantages of using a disease-specific measure should 
be balanced between the patient’s acceptance of them and the alternative use of a generic or 
dermatology-specific measure. Ideally it should be used with a generic-instrument to assess areas not 
covered in disease-specific instruments and to allow for cross-disease comparision to non-dermatological 
conditions to support that CU equally impacts QoL when evidence base grant applications are being 
proposed. The only cravat of this instrument is in the different variations being published in the literature. 
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Table 4.3: Versions of the Chronic Urticaria Quality of Life Questionnaire: Development and Psychometric Properties 
 
General  
 
Construction                           Description & Feasibility              Psychometric Properties                                                                                                     Cultural Validation 
Reference 
Language 
Development 
Validation Sample size 
Items/ Domains 
Response Score/Time Frame 
Reliability Validity Responsiveness Translation 
 
Baiardini et 
al. 2005  
 
Italian 
original 
 
 
Sample size: 76 
Development, 125 
validation (> 60% female) 
 
Measurement goal:To 
develop the first disease-
specific tool able to capture 
bio-psychosocial & practical 
aspects of HRQoL in CU  
 
Purpose: Evaluation/ 
Discrimination  
 
Item generation:  
Experts& Patients  
 
Item reduction:  
Experts& Patients  
 
 
Items:23 
 
Domains:6 
1. Pruritus, 
2. Swelling 
3. Impact on Life Activities 
4. Sleep Problems 
5. Looks 
6. Limits 
 
Response5 point Likert/  
 
Score: Domain*  
 
Timeframe: 15 days 
 
Understanding: NR* 
 
Completion time:5 minutes* 
 
Internal reliability: 
All Cronbach  between 
0.5-0.7 for all domains  
 
Test-retest 
ICC = >0.4 and <0.75 for 
items physical activity, 
social relationships, falling 
asleep’, bad mood. Other 
items 0.75 or greater.    
 
Content validity:Yes 
 
Convergent: Yes, Correlates well 
with equivalent SF-36, Skindex-29 
& DLQI domains.  
 
Discriminant:NR 
 
Responsiveness 
After 2/3 weeks 
highly significant 
responsiveness 
in18/ 23 items (p 
< 0.05 on all 
items). 
 
Not applicable 
 
 
 
 
Brzoza et 
al. 2011 
 
Polish 
 
 
 
 
 
 
Sample size: 126 (70.6% 
Female) 
 
Measurement goal: To 
adapt a Polish version & 
provide initial results.  
 
Purpose:Evaluation/ 
Discrimination 
 
Item reduction: Statistical 
(factor analysis) 
 
 
Items: 23 
 
Domains: 6 
 
1. Itching  
2. Swelling/ mental status 
3. Functioning 
4. Sleep 
5. Eating/limits 
6. Embarrassment  
 
 
 
Internal reliability: 
Cronbach alpha all > .7 
 
Test-retest: Interclass 
coefficient good for item 7 
& 8 & excellent for other 
items (> .75). 
 
Content validity:Yes 
 
Convergent: Yes, correlates well 
with items DLQI & Skindex-29 (all p 
<.0001 except embarrassment p 
<.0003). 
 
Discriminant:NR 
 
 
 
Responsiveness 
Statistically sig 
decreased 
severity & better 
QoL using UAS 
and CU-Q2oL 
scores from 
baseline to 4 
weeks (r = .49, p= 
.001. 
 
Forward: 
Yes 
Back: 
Yes 
Patient: 
Yes.  
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Table 4.3 continued 
 
General  
 
Construction                         Description & Feasibility               Psychometric Properties                                                                                                   Cultural Validation 
Reference 
Language 
Development 
Validation Sample size 
Items/ Domains 
Response Score/Time Frame 
Reliability Validity Responsiveness/
CSC 
Translation 
 
Diaz et al. 
2011 
 
Brazilian-
Portuguese 
 
Sample size:  112 (86% 
female) 
 
Measurement 
goal:Cross-cultural 
adaption 
 
Item reduction: 
Statistical (factor analysis) 
 
Items: 23 
 
Domains:3 
 
1: Sleep/mental status/ eating 
2: Pruritus/Impact on life activities 
3. Swelling/limits/looks 
 
Rest same as original 
 
Internal reliability: 
Cronbach alpha all > .8 
 
Test-retest: Interclass 
coefficient excellent for 
total score (.87) and 
individual scores (all .> 
78)  
 
 
Content validity:Yes 
 
Convergent: Good with DLQI items. 
Mean score with DLQI significant (r = 
.76. p < .000) 
 
Discriminant: Using ANOVA 
distinguished QoL between patients 
with low and high scores on the UAS.  
 
Responsiveness 
Correlation with 
UAS at baseline 
and four weeks 
moderate (r= .39, 
p < .0001) & null 
(r= .47, p = .056) 
respectively  
 
Forward: 
Yes 
Back: 
Yes 
Patient: 
Yes.  
 
 
Kocaturk et 
al. 2012 
 
Turkish 
 
 
 
 
 
Sample size: 140 (70% 
female) 
 
Measurement 
goal:Cross-cultural 
adaption 
 
Purpose: Evaluation/ 
Discrimination  
 
Item reduction: 
Statistical (factor analysis) 
 
Items: 23      
 
Domains: 6 
 
1. Itching  
2. Swelling/ mental status 
3. Functioning 
4. Sleep 
5. Eating 
6. Limits 
 
Rest same as original 
 
Internal reliability:All > 
.7 except Limits (.50) 
and Looks (.68)  
 
Test-retest: NR 
 
 
Content validity:Yes 
 
Convergent: Good with DLQI & 
Skindex-29 items. Total scores 
significant between CU-Q2oL & DLQI 
(r = .77, p = .001) and Skindex-29 (r= 
.74, p < .001)   
 
Discriminant: Using ANOVA 
distinguished QoL between patients 
with scores on the UAS in the 1 to 4 
quartile range. 
 
Responsiveness 
Two monthly 
intervals over 8 
weeks saw sig 
changes in UAS & 
CU-Q2oL score 
33.9 ± 19.6 to 
22.6 ± 16.2. (r = 
.44, p < .0001) 
 
 
Forward: 
Yes 
Back: 
Yes 
Patient testing: 
Yes 
 
 
Mylnek et 
al. 2009 
 
German 
 
 
Sample size: 157 
(Females 2:1 ratio) 
 
Measurement goal: 
Cultural adaption 
 
Purpose:Evaluation/ 
Discrimination 
 
Item Reduction: 
Statistical (factor analysis) 
 
Items: 23 
 
Domains: 5 
 
1. Functioning 
2. Sleep 
3. Itching/ embarrassment 
4. Mental status 
5. Limits looks 
Rest same as original 
 
Internal reliability: All 
>.7 except Limits/Looks 
(.52) 
 
Test-retest: NR 
 
 
Content validity:Yes 
 
Convergent: Good with DLQI and 
Skindex items. All two-tailed 
correlations significant (p>.001) 
 
Discriminant: NR 
 
 
NR 
 
Forward: 
Yes 
Back: 
Yes 
Patient testing 
Yes 
                                                                                                                                                                                                                                      
 
122 
 
Table 4.3 continued 
 
General  
 
 
Construction                         Description & Feasibility              Psychometric Properties                                                                                                    Cultural Validation 
Reference 
Language 
Development 
Validation Sample size 
Items/ Domains 
Response Score/Time Frame 
Validation Study/ Reliability Validity Responsiveness
CSC 
Translation 
 
Valero et 
al. 2011 
 
Spanish 
 
Sample size: 695 
475 (68% spontaneous 
CU) 
 
Measurement 
goal:Cross-cultural 
adaption 
 
Purpose: Evaluation/ 
Discrimination  
 
Item reduction: Patients 
& experts Factor analysis 
 
Items: 23 
 
Domains:6 
 
1. Pruritus, 
2. Swelling 
3. Impact on Life Activities 
4. Sleep Problems 
5. Looks 
6. Limits 
 
Rest same as original 
 
 
Validation Study size : 125 
 
Internal reliability:All alpha > 
.8 
 
Test-retest: NR 
 
 
Content validity:Yes (patients) 
 
Convergent: Good with 
Skindex-29 items. Correlation 
.81 with CU-Q2oL overall scores 
 
Discriminant:Using ANOVA 
Differentiated between different 
severities of wheals & pruritus  
 
 
Sig. correlations 
between baseline 
to 4 weeks of Cu-
Q2oL scores (all p 
< .0008) for 
subscales & 
overall score for 
patients reporting 
better health state 
transition. 
 
Forward: 
Yes 
Back: 
Yes 
Patient: 
Yes.  
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Being the only CU disease-specific QoL instrument for understanding the nature of QoL in CU 
samples, difficulties may occur in terms of being able to instantly compare results across studies, 
however in terms of the individual items this would not be a problem for conducting a meta-
analysis in the future. Further the labelling of some domains in some versions does not appear 
to reflect a particular concept (e.g. Swelling/mental status in Mylnek et al. 2009). When 
interpreting the findings of factor analysis (especially principal components analysis) researchers 
need to consider whether to keep items on individual’s subscales based on being statistically 
linked to a factor or whether items would be better conceptually placed elsewhere. 
 
4.4: Discussion  
The objective of this study was to systematically review QoL questionnaires used in CU 
research by assessing their psychometric properties to draw conclusions regarding their 
suitability for CU research. Overall the critical evaluation of the instruments in subsections 4.3.3 
and 4.3.4 implied that there is currently no one particular questionnaire that can be currently 
classified as the gold standard measure of quality of life in CU. Generic instruments lacked 
rigorous psychometric testing in CU, dermatology-specific instruments were controversial (e.g. 
no factorial validity, lack of clinical usage) and the plethora of versions of the CU-Q2oL made 
cross comparisons difficult to interpret. These findings will be discussed in turn with all 
questionnaires being discussed together with a main focus on the CU-Q2oL. 
 
Generic measures lack psychometric testing in CU 
This is not the first review to conclude the first point on generic measures. Both et al. 
(2007) in their systematic review of QoL instruments reported the lack of psychometric testing of 
generic instruments across dermatological conditions but this is not surprising considering that 
many were developed to measure health status or QoL in general populations. Regardless the 
SF-36 has the advantage over the WHOQoL brief and NHP in that its convergent validity with 
the disease-specific CU-Q2oL has been successfully established. However, if the convergent 
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validity of the WHOQoL and CU-Q2oL is tested in future this may change as the WHOQoL is a 
valid measure of QoL and not health status. Whatever the psychometric properties of these 
instruments are generic measures should be a compulsory part of overall patient-reported 
outcome in CU, at least at the policy and grant application level. For this reason and that on 
convergent validity reviewed earlier the SF-36 for now appears to be the most favourable generic 
instrument, however in the introduction it was stipulated that both a generic and specific 
instrument should be used to compensate for generic measures that do not cover disease-
specific aspects for a given population.  
 
Dermatology-specific instruments lack factorial validity or usage for CU research 
The second main finding was the lack of usage or factorial validity of the majority of 
dermatology-specific instruments in CU research. In respect to the FLQA-d, despite it being one 
of the only instruments to have been developed and validated with patients with CU in its 
research sample, it has not been used in CU samples outside of its development paper (Augustin 
et al. 2000) and has rarely been used in dermatology research in general (Both et al. 2007). In 
light of this the Skindex-29 and DLQI appear to be better options for CU research. The Skindex-
29 was found to be developed and validated in a dermatology patient sample which did not 
include those with CU however support for its validity for use in CU research has come indirectly 
through its use in the convergent validity of the psychometric and cultural validations of the 
Polish, German, Spanish and Turkish versions of the CU-Q2oL. In these studies the Skindex-29 
showed strong convergent validity but it also showed evidence of some significant item 
redundancy with the CU-Q2oL. This finding indicates that the Skindex-29 could be used alone 
without the complimentary use of the CU-Q2oL as they would be essentially measuring the same 
concepts. As it is dermatology-specific it is suggested that it would be a good choice when CU 
samples are being compared to other dermatological conditions only than the FLQA-d.   
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In contrast the dermatology-specific DLQI has an advantage over other FLQA-d and 
Skindex-29 in that it has been well validated and used in CU research. It assumedly exhibits 
what busy clinicians in practice really want which is something that is simple to use (one page, 
10 short items, < two minutes completion), quick and easy to score (simple addition with no 
standardising or weighting of domains), easy to interpret at a glance and integrates well into 
decision making. Further the DLQI has been used in 33 skin conditions, in 32 countries, in 55 
languages and has been subjected to 115 studies related to its psychometric properties (Basra, 
Fenech, Gatt, et al. 2008), hence there is a substantial amount of reference value data available 
to compare across CU samples and to other dermatological conditions. In light of this the DLQI 
does have psychometric problems. Referred to as a one-dimension instrument of disability and 
not QoL, a recent study subjected it to the rasch analysis questionnaire measurement model in 
psoriasis and atopic dermatitis and found major concerns in respect to its dimensionality, 
measurement properties, response format and ability to differentiate functioning by skin disease, 
age and gender (Twiss, Meads, Preston et al. 2012). Subsequently, it has been stated that the 
psychometric requirements for instruments have evolved since the DLQI’s development in 1994 
and researchers need to use better alternatives as its limitations now outweigh its simple 
applicable use (Nijsten, 2012).  
 
The CU-Q2oL as a step forward in CU-related quality of life research   
The CU-Q2oL addresses the limitations of the DLQI in that it is a CU-specific instrument 
and will therefore consist of items that this population will be more familiar with (i.e. it has good 
face validity). CU consensus management guidelines recommendation the disease-specific CU-
Q2oL as the official gold standard measure of CU-related QoL (Zuberbier et al. 2009b) but this 
may become a tenuous decision in future research and practice if issues regarding applicability 
and factor structure are not addressed. In respect to the former the CU-Q2oL is inferior in its 
applicability than the DLQI as it has over double the amount of items (23 verses 10) takes over 
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twice the time to complete (five verses two minutes) and most importantly it is considerably more 
difficult to score and interpret due to the need to standardise and transform the scores of the 
weighted domains to a 0-100 scale (meaning it is not easy to interpret at a glance). This indicates 
that it may work well in a research context where there is more time to interpret scores at the 
group level but may be more difficult to integrate it in busy tertiary CU clinics where applicability 
ultimately lies in the practicality of how quick they are to administer and their ability in helping to 
make decisions about patient care amongst an array of other consultation based procedures 
(Farnik and Pierzchala, 2012). One way to overcome this problem would be to send out the CU-
Q2oL with the patient’s appointment letter at the first consultation and follow-up phases of their 
consultations but this still does not resolve CU-Q2oL data analysis and interpretation in clinic to 
make quicker decisions about care.  
 
 One way to implement the CU-Q2oL better into clinical practice could be to implement 
what other researchers in QoL measurement have recently undertaken to overcome this problem 
which is to take advantage of new technological tools such as tablet computers and smart phones 
(Naik, Hess and Unruh, 2012; Zubaran and Tres, 2011). What this research has suggested is 
that through such devices patients can complete QoL measures before hospital visits at home 
and send them in advance or complete them pre-consultation in clinics. At the point of 
consultation the data is either already analysed by a simple computer program or ready for quick 
analysis during the consultation respectively.  
 
In terms of the factor structure of the CU-Q2oL, although it is good practice to cross-
culturally validate instruments, the differing published factor structures emerging from such 
analyses (see Table 4.3) brings the original item generation/ reduction process of the original 
Italian questionnaire items by Baiardini et al. (2005) into question. Where the Spanish version 
only underwent a language translation of the original Italian instrument the Brazilian-Portugese, 
                                                                                                                                                                                                                                      
 
127 
 
German, Polish and Turkish versions underwent an additional factor analysis of a translated 
version (see Table 4.3). Some of these versions have no resemblance to the original domains of 
Baiardini et al. (2005) and as mentioned earlier in this study have domain names which might 
make it difficult to establish what the essence of the domain is conveying (e.g. sleep/mental 
status/eating in the Dias et. al. (2011) Brazilian-Portugese version and swelling/ mental health in 
the Kocaturk et al. (2008) Turkish version). Such an occurrence makes it difficult to determine 
whether the original items cannot be replicated because they do not represent a valid subjective 
account of quality of life in CU or whether the non-identical versions are representing actual 
cross-cultural differences in CU-related outcome.   
 
Despite the identified shortcomings of the CU-Q2oL, it is unquestionably a measure of 
QoL not health status (e.g. SF-36; NHP) or disability (DLQI) created specifically for CU 
populations and for this reason it is worth pursuing ways to improve it. Such implementations are 
important in light of findings by Speight, Reaney and Barnard (2009) who found in their 
systematic review of QoL instruments in diabetes that researchers had chosen QoL measures 
in the past based on the following highly inadequate criteria: (1) the instrument had the term QoL 
in the title; (2) it was what others were using or (ii) it was the most easily accessible. The array 
of non-validated measures used to measure CU-related QoL from 1997 to 2005 is evident in CU 
research which lead to the development of the CU-Q2oL (Baiardini et al. 2005). A standardised 
expert consensus framework for cross-culturally adapting future language and psychometric 
translations of the instrument is recommended. This may include a standardised guide, which 
considers patient characteristics that were found to significantly relate to CU-related QoL in Study 
1 (e.g. concurrent physical urticaria, positive ASST tests, and concurrent angioedema), which 
could explain the differences in the versions and be controlled for.   
 
Two such confounding factors that have not considered in the development of the CU-
Q2oL is the strong and significant relationship between psychological variables and QoL. It was 
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reviewed in Section 1.5.5 that high CU-related anxiety and depression (as a clinical diagnosis or 
outcome as psychological distress) bared a strong negative correlation to CU-related QoL. More 
specifically studies found that those with higher formally diagnosed psychiatric morbidity (e.g. 
Staubach et al. 2006a; Ozkan et al. 2007; Uguz et al. 2008) or psychological distress outcome 
(e.g. Barbosa et al. 2011; Bzoza et al. 2011) scored significantly worse on QoL measures than 
those without. With up to two-thirds of individuals with CU estimated to have some level of co-
morbidity as a determinant or outcome (see section 1.5.4), such factors need to be accounted 
for in CU-related QoL questionnaire development as they may considerably alter the final 
instrument causing unaccounted for floor and/ or ceiling effects.  
 
Wider issues pertaining in quality of life research  
In addition to the main findings discussed, this systematic review study did confirm some 
wider issues that still prevail in QoL research and practice. The first related to the need to 
distinguish between whether one is measuring health status, disability or quality of life. As in 
other dermatology based QoL measurement systematic reviews the SF-36 and DLQI had to be 
included here as they had been previously used substantially to measure QoL, not disability or 
health status (see Table 3.1 QoL studies in CU summary table in Chapter 3 for many examples). 
As justified earlier, not including such measures would have biased the review, especially as the 
DLQI, that was (and probably still is) the unofficial gold standard QoL measure in dermatology 
research. Including the DLQI has allowed for its psychometric adequacy for research in CU to 
be critically evaluated in further detail and its psychometric ability to measure multi-dimensional 
CU-related QoL to be compared to other instruments. Of relevance to this, studies systematically 
reviewed in Study 1 using the DLQI predominantly reported a mild impact on QoL as to the CU-
Q2oL, which indicated a more moderate impact. With the CU-Q2oL being evaluated as a more 
adequate instrument than the DLQI, this indicates that CU has a more moderate impact on QoL. 
To support this, the generic SF-36 and dermatology-specific Skindex-29 (which showed good  
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convergent validities with the CU-Q2oL) also indicate a moderate impact of CU on quality of life.  
 
Another core question related to the applicability of QoL questionnaires in clinical 
practice (i.e. what the data will be used for). QoL measurement in CU clinics is not routine at 
present and whether they will continue to only be used as a clinical end-point in drug 
pharmaceutical trials or to help referrals to improve bio-psychosocial wellbeing is currently 
unknown. A study by Salek, Robert and Finlay (2007) found that of 64 dermatological 
consultations 37 (or 28.00%) of clinicians used QoL information if it was made available to them 
and 57.0% of these clinicians used the information they provided in decision-making processes 
about disease management. 
  
Methodological considerations of the existing review study 
This systematic review has highlighted important issues that researchers and clinicians 
need to consider, however its shortcomings do require some consideration. It should be 
remembered that the selection criteria was restricted to questionnaires and papers available in 
English language, excluding CU studies using culture-specific measures (Grob, et al. 1999). Also 
the suitability of other QoL questionnaires not featured in CU psychometric validation studies 
were not considered. However the instruments included in the review are the ones expected to 
be found in dermatology QoL research (Both et al. 2007) and instruments such as the 
Dermatology Quality of Life Scales (DQoLS; Morgan, McCreedy, Simpson, Hay, 1997), 
Dermatology-Specific Quality of Life (DSQoLS; Anderson and Rajagopalan, 1997) and the 
Sickness Impact Profile (SIP; Bergner, Bobbit et al. 1981) were also of American or European 
origin. The DQOLS has also been assessed to have problematic development and psychometric 
issues (Both et al. 2007) whereas the DSQL’s development and validation was limited to acne 
and contact dermatitis patients. Both instruments are rarely used in dermatology research and 
the SIP is a lengthy 136-item tool that mainly focuses on disability.  
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4.5: Recommendations and Conclusions 
Which instruments to select will depend upon the study design and the most important 
psychometric properties (e.g. responsiveness for longitudinal research and discrimination for 
cross-section studies). However if patients with CU are evaluated alone or compared with 
illnesses outside dermatology a combination of the SF-36 and CU-Q2oL (which have good 
convergent validity) is recommended. If CU is to be compared with other skin disorders, a 
combination of the SF-36 and Skindex-29 is recommended. In light of this the SF-36 and an 
English translated CU-Q2oL will be used in the theses commencing studies. 
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Chapter 5 
General Research & Analytical Methods 
 
5.1: Introduction 
Two systematic review studies were undertaken in the previous two chapters to provide 
consensus reference values on the impact of CU on quality of life (QoL) for comparative purposes 
in thesis’ proceeding studies and to establish which instrument/s were the most valid and reliable 
for CU research. This chapter describes the general methods used across the remaining studies 
of the thesis. Rationales for the study designs are justified and the illness population under 
investigation is described in terms of recruitment and selection. The instruments used to explore 
variables across studies are described including their validation and how they are scored and 
interpreted. The chapter ends with a rationale and account of the quantitative and qualitative 
techniques employed to test the thesis’ research hypotheses. 
 
5.2: Design Rationale 
A range of other research designs were employed in this thesis. A summary and 
explanation of why they were used are presented in the sections below.  
 
5.2.1: Psychometric Study 
The Revised Illness Perception Questionnaire (IPQ-R; Moss-Morris et al. 2002) and 
Beliefs about Medicines Questionnaire (BMQ; Horne et al. 1999) were respectively developed to 
tap into representations of illness and treatment and have produced replicable findings in a range 
of chronic illnesses (see section 2.2). Both have also been used to explore representations, QoL 
and psychological distress. Study 3 assessed their psychoimetrtic properties in CU. As both had 
not been used in CU it was important to determine if CU data collected from them represented 
an adequate fit of the questionnaires structures. 
 
                                                                                                                                                                                                                                                                                      
 
132 
 
5.2.2: Cross-Sectional Study 
Study 4 consisted of a cross-sectional study to determine if CU representations 
predicted QoL outcomes mediated by coping as predicted by the CSM (Leventhal et al. 1980; 
Leventhal, Nerenz and Steele, 1984). If confirmed it would help support that some of the variance 
in CU outcome could be explained by socio-cognitive factors. It would also place quality of life in 
CU in a new framework to explore CU representations as potential mechanisms of change in CU 
interventions. There is little evidence of coping as a mediator in the CSM (p36-37) but as this 
was the first exploration of the CSM in CU all avenues were explored.  
 
5.2.3: Qualitative Study  
Study 5 explored qualitative accounts of how individuals made sense of their CU via 
semi-structured interviews. This study was incorporated as much post-study ‘talk’ from 
participants in study 4 which expanded on their perceptions of CU went beyond the detail 
possible from the quantitative methods. This study used the methods of interpretive 
phenomenological analysis (IPA; Smith 1996; Smith, Flowers and Larkin, 2009) and the intention 
was not to confirm the CSM, however IPA follows a similar philosophy of assuming that there is 
an interaction between people’s cognitions and emotions where they are trying to make sense 
of their world that they often find difficult to express. It was for this reason IPA was chosen. 
 
Numerous qualitative approaches used previously to explore illness representations 
were considered including grounded theory and thematic analysis (e.g. Koenigsmann, Koehler, 
Regner et al. 2006; Wong, Kennedy, Marshall and Gaillot, 2011; Heyhoe and Lawton, 2009; 
MacInnes, 2006) and discourse or narrative analyses. Even though grounded theory (Birks and 
Mills, 2011) would have worked well in terms of drawing convergences within large samples for 
a more general conceptual explanation of socio-cognitive process with theoretical models, this 
study was not looking to analyse a large dataset to support a theory (as in studies 3 and 4). 
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Thematic analysis (TA) was considered as a good candidate as unlike grounded theory (GT) it 
is more flexible to use and not held to the methods of its philosophical position (to develop theory) 
but can use the methodologies of GT to summarise data and interpret what they mean (Braun 
and Clarke, 2006). The problem with TA is that an idiographic approach is not used and the 
whole dataset is usually analysed as to concentrating on an individual case and also looking for 
differences and divergences within the text (not that this cannot be done in TA). This study further 
explored CU specific information about the individual experiences in a small purposive sample 
and this is why IPA was chosen, particularly with its more structured methods. The discourse 
analysis approach is cynical about the accessibility of cognitions focusing on the functioning of 
language in a social context more than it’s meaning (Willig, 2007). Narrative approaches (Murray, 
2007) were considered but meaning-making goes beyond narratives (e.g. discourse). The study 
had implications for understanding more about the perceived CU lived experience.  
 
5.2.4: Longitudinal Study 
Study 6 used a longitudinal design to report an intervention aimed to establish if cognitive 
representations of CU were amenable to change and result in significantly better quality of life. 
It incorporated guidelines by the Medical Research Council (Campbell, 2000; Craig et al. 2012), 
those in behavioural medicine and health psychology (Davidson et al. 2003; Abraham and 
Mitchie, 2008), and CSM interventions (section 2.5, p45). Its’ measures derived from systematic 
review studies 1 and 2 which established reference values and valid measures of CU-related 
QoL and studies 3 and 4 which fulfilled the first two steps of MRC guidelines (see section 2.5) 
This study fulfilled the third step that interventions should ‘undergo a pilot study’. The study 
included psycho-education to change CU perceptions and action plans to change behaviours. 
Representations and QoL were assessed at baseline, one-month and 3-month post-intervention. 
It had research implications for developing an RCT to confirm the study effects and practical 
implications for incorporating such interventions adjunct to medical care. 
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5.3: Participants  
 
5:3.1: Recruitment  
All research data was obtained from patients diagnosed with chronic spontaneous 
urticaria (CU). Recruitment for all studies were possible through a collaboration initiated by the 
thesis author (DB) to Consultant Dermatologists at St. John’s Institute of Dermatology, St 
Thomas Hospital in London. An honorary research contract was agreed to allow access to 
patients. The hospital runs the only urticaria specialist clinic in the United Kingdom and referrals 
are taken from general practitioners and other health professionals nationwide and it not 
uncommon for patients to travel from all over the UK. Two recruitment strategies were employed 
across studies. Participants were identified through the clinics patient database or during their 
consultation with consultant dermatologists. Database patients were recruited by phone by the 
clinics administration staff that asked patients for permission for their contact details to be 
forwarded to the researcher. The researcher informed patients about the study. Clinic patients 
were informed by the consulting dermatologist and introduced to the researcher if an interest 
was shown. All patients received an invitation letter, research participant information sheet and 
a consent form to read to help them decide for at least a 24hr period.  
 
5.3.2: Sample Size 
Sample sizes across studies varied according to the design and methods used (see 
individual studies). Power analyses for quantitative studies were determined using the computer 
programme G Power 3 (Buchner, Erdfelder and Faul, 2007). Medium effect sizes (0.5), with a 
power of 0.8 and probability value of .05 were applied.  
 
5.3.3: Study Selection Criteria 
The selection criterion across studies (including systematic reviews) referred to 
European guidelines for urticaria (Zuberbier et al. 2009a). Participants were included if they: had 
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a medically confirmed primary diagnosis of chronic spontaneous urticaria (i.e. idiopathic or 
autoimmune); were at least 18 years old and spoke fluent English. Participants were excluded if 
they had: primary acute or physical urticaria or a formal psychiatric diagnosis.  
 
5.4: Measures 
 
5.4.1: Process Measures 
Revised Illness Perception Questionnaire (IPQ-R) 
The IPQ-R (Moss-Morris et al. 2002; Appendix 3a, pA11) measures common-sense 
beliefs about illness. Its subscales (with original Cronbach alphas) are described below.  
 
Illness Identity Subscale (.75):  
The identity subscale assesses symptoms attributed to illness. It consists of 14 
commonly experienced symptoms but itchiness, swelling and wheals common to CU were 
added. To avoid measuring somatisation participants are asked to report on a dichotomous scale 
whether they have experienced each symptom since their CU began before reporting if each is 
related to their CU. The more yes’ for the latter scale indicate a stronger identity.  
 
Cause Attributions Subscale 
The cause subscale measures 18 commonly reported causal attributions of illness. 
Participants indicate on a 5-point Likert scale (1= strongly disagree to 5= strongly agree) whether 
they believe each contributed to their illness. Items are further categorised into psychological 
(.86), risk factor (.77), immunity (.67) and accident/ chance (.23) causes.   
 
Seven Factor Solution Subscales 
The remaining subscales of the IPQ-R consist of 38 items across seven subscales 
(consequences (α .84), timeline acute/ chronic (α .89), timeline cyclical (α .79), personal control 
(α .81), treatment control (α .80), illness coherence (α .87) and emotional representations (α .88). 
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Participants indicate on a 5-point Likert scale whether they agree with each statement (where 1= 
strongly disagree to 5= strongly agree). Scores per subscale are summed and then divided by 
the number of items in that subscale. Higher scores represent perceptions of more serious 
consequences, chronic timeline, cyclical timeline and emotional representations but greater 
beliefs in personal and treatment control and illness coherence (understanding illness). In 711 
patients among 8 illness groups, all scales demonstrated good internal reliability, test-retest 
reliability, known group discriminant validity and predictive validity. The Internal reliability and 
structural validity of the IPQ-R is examined further in study 3. 
 
The Beliefs about Medicines Questionnaire (BMQ) 
The BMQ (Horne et al. 1999; Appendix 3a, pA12) assesses commonly held beliefs about 
taking prescribed medicines and treatments. Part 1 assesses general concerns about the 
harmful effects of medicines and their overuse by doctors. Only the second part BMQ-Specific 
was used and assesses beliefs about medications specifically prescribed for an illness. Its 
subscales are described below: 
 
Specific Necessity: This five-item subscale assesses beliefs about the necessity of taking 
medicines. Psychometric testing has shown good internal consistency across different illnesses 
(α > 0.7) and test-retest reliability. It’s good convergent validity was establishe and discriminant 
validity was confirmed which distinguished between different illness and treatment groups. 
 
Specific Concerns: This five-item subscale assesses concerns about taking CU medicines. 
Psychometric testing has shown that it has good levels of internal consistency across differing 
illnesses (Cronbach α> .63 to .8) and a test-retest reliability of .76 in asthma using Spearman’s 
rho. Good convergent validity was confirmed and discriminant validity tests distinguished 
between different illness and treatments groups. 
 
Participants indicate whether they agree with each statement on a 5-point Likert scale  
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(where 1= strongly disagree to 5= strongly agree). Scores are summed per subscale then divided 
by the number of items in that subscale leaving a score range of 1-5. Higher scores suggest 
stronger beliefs in the necessity of medicines and stronger concerns about usage. The Internal 
reliability and structural validity of the BMQ-Specific is examined further in study 3. 
 
The Brief COPE 
The Brief COPE (situational and retrospective format; Carver, 1997; Appendix 3a, pA13) 
assesses 14 conceptually different coping strategies. Its subscales (with original Cronbach α 
coefficients) are: Active Coping (.68); Planning (.73); Positive Reframing (.64); Acceptance (.57); 
Humour (.73); Religion (.82); Using Emotional Support (.71); Using Instrumental Support (.64); 
Self-Distraction (.71); Denial (.54); Venting (.50); Substance Use (.90): Behavioural 
Disengagement (.65); Self-Blame (.69). Respondents indicate on a 4-point Likert scale whether 
they agree with its statements (where 1= “I haven’t been doing this at all” to 4= “I’ve been doing 
this a lot”). Scores are summed per subscale (each has 2 items) and higher scores mean a 
greater use of a strategy. As recommended by the authors a PCA (using a non-orthogonal direct 
oblique rotation with Kaiser Normalisation) was undertaken using CU data from study 3 to reduce 
its number of variables (see Table 5.1, p139). The data met KMO criteria for sampling adequacy 
(MSA=.73) with individual KMO’s exceeding .6. Bartlett’s test of sphericity (x2 (66) = .346.27, p 
<.001) indicated the data was adequate for PCA which generated 4 components with 
eigenvalues greater than 1 and accounted for 69.63% variance.  
 
Component 1 consisted of the subscales active coping, planning, self-distraction and 
positive reframing and was named ‘pro-active coping’. Component 2 consisted of the behavioural 
disengagement, venting, denial and self-blame subscales and was titled ‘negative cognitive 
appraisal’. Component 3 consisted of the subscales humour, acceptance and a smaller loading 
for positive reframing. Even though positive reframing loaded statistically betteron component 1, 
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it was decided that it fitted conceptually better on component 3 and was moved there and named 
‘positive cognitive appraisal’. This final component contained loadings for ‘use of emotional 
support’ and ‘instrumental social support’ and named ‘use of support resources’. All scales 
showed good internal consistency, which ranged from .59 to .78. 
 
Table 5.1: Second order PCA pattern matrix of the COPE 14 a-priori subscales 
 
 
Subscale 
 
 
Component 
1 2 3 4 
 
Pro-Active Coping (.77) 
Self-distraction 
Active coping 
Planning 
 
Negative Cognitive Appraisal (.82) 
Behavioural disengagement 
Self-blame 
Denial 
Venting 
 
Use of Support Resources (.59) 
Use of instrumental social support 
Use of emotional social support 
 
Positive Cognitive Appraisal (.60) 
Positive reframing 
Humour  
Acceptance 
 
 
.78 
.73 
.52 
 
 
 
 
.41 
 
 
 
 
 
 
 
.53 
 
 
 
 
 
 
 
-.84 
-.80 
-.64 
-.59 
 
 
 
 
.41 
.51 
 
 
 
 
 
 
 
.82 
.76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
.45 
.79 
.74 
 
 
A reliability analyses of the Brief COPE 14 subscales found that 10 produced coefficients 
that were similar or better than the original validation paper. Denial and venting showed the best 
improvements (5.4 verses .81 and .5 verses .71 respectively). However self-distraction produced 
a coefficient of 4.6 as to .71, social support .57 as to .64, behavioural disengagement .55 as to 
.65 and religion .67 as to .82.  
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The Common-Sense Interview  
The Common-sense interview is a semi-structured interview schedule developed for the 
thesis (Appendix 4, pA37) and follows guidelines from Smith and Osborn (2003). Its purpose was 
to collect qualitative data on CU illness representations and lived experience for study 5. Its 
second purpose was for interviewing participants in study 6. The schedule asks questions 
regarding ones personal accounts of their illnesses (e.g. identity, cause, CU medicines, coping). 
Questions on QoL were not included as it was hoped that these would naturally emerge from 
responses to questions on representations and coping. Probing was used to obtain detailed 
accounts and allow novel insights to emerge. Prompts were kept to a minimum. 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
5.4.2: Outcome Measures 
Hospital Anxiety and Depression Scale (HADS) 
The HADS (Zigmond and Snaith, 1983; Appendix 3a, pA14) assesses state anxiety and 
depression. Its’ 14-items are equally divided between the two subscales of anxiety and 
depression. Respondents indicate on a 4-point Likert scale (0 to 3) how much they agree with 
the statements providing a score range of 0-21 per subscale. For both scores of 8-10 indicate 
possible disorder and 11-21 probable a disorder. Psychometric evaluation in outpatients and 
cancer patients demonstrated high levels of internal consistency (Anxiety Cronbach alphas .93; 
Depression, .90; Moorley, Greer, Watson et al. 1991) and face validity. Convergent validity was 
established with significant correlations between the HADS and similar scales (anxiety r = .54; 
depression, r = .79). In CU it has demonstrated good discriminant validity in those with and 
without a psychiatric diagnosis (Staubach et al. 2006). 
 
Reliability analysis and PCA of the HADS subscales 
A reliability analysis of the HADS subscales using CU data for chapter 4 showed 
Cronbach alphas for anxiety and depression of .84 and .87 respectively demonstrating good 
levels of internal consistency. A confirmatory PCA (using orthogonal Varimax method with Kaiser 
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Normalisation) showed factor loadings that demonstrated a near perfect rotational match where 
all depression items loaded on component 1 and all but 1 anxiety item (A4 ‘I can sit at ease and 
feel relaxed’) loaded on item 2.  
 
Table 5.2: Principle Components Analysis of the HADS in CU 
 
The data exceeded KMO criteria for sampling adequacy (MSA= .85) with individual values 
exceeding .7 and most > .8. Bartlett’s test of sphericity (x2 (91) = 572.43, p < .001) indicated that 
the data was adequate for PCA. This fixed 2-factor solution (eigenvalues greater than 1) 
accounted for 57.44% of the variance in the sample.  
 
MOS 36 Item Short-Form Health Survey (version 2)  
The SF-36v2 (Jenkinson, Stewart-Brown, Peterson, Paice, 1999; Appendix 3a, pA17) 
was reviewed extensively in Study 2 (p111) where it was recommended as the most valid and 
reliable measure of generic health status and QoL in CU (p130). In summary it has 36 items 
 
Item  
Component 
1 2 
 
D6 I look forward to the enjoyment of things  
D7 I can enjoy a good book or radio or TV programme 
D3 I feel cheerful 
D1 I still enjoy the things I used to enjoy 
A4 I can sit at ease and feel relaxed  
D2 I can still laugh and see the funny side of things 
D4 I fee as if I am slowed down 
D5 I have lost interest in my appearance 
 
A5 I get sort of frightened feelings like butterflies in the stomach 
 
A2 I get sort of frightened feeling as if something awful is about 
to happen 
 
A7 I get sudden feelings of panic 
A3 Worrying thoughts go through my mind 
A1 I feel tense and wound up 
A6 I feel restless as if I have to be on the move 
 
.801 
.783 
.779 
.779 
.739 
.688 
.637 
.497 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
.414 
 
.814 
 
.803 
 
 
.791 
.716 
.577 
.522 
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across 8 subscales (abbreviations and Cronbach alphas): physical functioning (PF; 0.92; role 
physical (RP; .95) bodily pain (BP; .85); general health perceptions (GH; .8); vitality (VT; .84); 
social functioning (SF; .85); role emotional (RE; .92) and mental health (MH; .84). Response 
options vary between subscales (3-5 point Likert scales) but items within each are summed 
before being transformed on a scale of 0 to 100 per domain (from worst health state to best 
respectively). Mean scores between 0- 49 indicate below average health and 51-100 as above 
average health. The SF-36 v2 has shown good internal consistency with all Cronbach alphas 
above .8 for all subscales. Construct validity (via t-tests) was established with poorer health 
scores for women and chronically ill populations (p <0.001). A PCA confirmed that its subscales 
could be reduced to 2-factors, the physical summary component (or PCS consisting of PF, RF, 
BP, GH) and mental component summary score (or MCS consisting of VT, SF, RE, MH). As it is 
a standardized measure with established reference values for the general population, further 
psychometric analysis was not required.   
 
The Chronic Urticaria Quality of Life Questionnaire (CU-Q2OL)  
The CU-Q2oL (Baiardini et al, 2005; Appendix 3a, pA15) was recommended as the most 
valid and reliable measure of disease-specific quality of life in patients with CU (p130) and 
extensively reviewed in chapter 4 (see p118-122) where it was show to have good psychometric 
properties. In summary it consists of 23 items across 6 subscales (pruritus; swelling; impact on 
life activities; sleep problems; limits and looks) where respondents indicate on a 5-point Likert 
scale whether they agree with its symptoms or statements (from ‘not a lot’ to ‘very much’). Higher 
scores indicate poorer HRQoL.  
 
Cultural Translation, Reliability and Principle Components Analysis of the CU-Q2oL  
As highlighted in the systematic review in Chapter 4 (p118-122) the CU-Q2OL at the time 
of the thesis’ duration was unavailable in English so a cultural adaptation was undertaken. The 
process included a collaboration made between the thesis author (DB) and academics in London 
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Metropolitan University’s language department. First the Italian version was forward translated 
to English independently by two academics that were fluent in both languages. Both translators 
then together worked on a combined version that was agreed to a consensus with the thesis 
author. Another academic who was blind to the Italian original then back translated this combined 
version into Italian. These were compared before adaptations and a consensus was made on 
the final English version. The CU-Q2oL original authors were contacted when necessary. All 
versions can be found in Appendix 3b, (pA27). 
  
A confirmatory PCA was conducted to establish how the current study sample data fitted 
the factor structure of the English translated CU-Q2oL. An orthogonal Varimax method with 
Kaiser Normalisation was used to rotate factors to a simple fixed 6-factor solution. The data 
exceeded the minimum Kaiser-Meyer-Olkin (KMO) criteria for measuring sampling adequacy 
(MSA= .89) with individual KMO values all between .8 and .9 represent good to superb adequacy.  
Bartlett’s test of sphericity (x2 (253) = 1458.11, p < .001) indicated that the data was adequate a 
PCA. The fixed 6-factor solution (eigenvalues greater than 1) accounted for 77.14% of the 
variance in the CU sample (Table 5.3, p143). 
 
 Component 1 consisted of 4 of 5 items representing the sleep problems subscale plus 
a loading for the conceptually similar impact on life activities item ‘interferes with sleep’ and a 
small loading for 1 looks item. Component 2 contained 5 of the 6 items that represented the 
impact on life activities subscale plus a small loading for the conceptually similar item ‘limits on 
sporting activities’ and a loading for ‘concentration’ from sleep problems. Component 3 failed to 
represent a component of the CU-Q2oL with 2 loadings for looks and 1 each for sleep problems 
(‘I feel nervous’) and impact on life activities (social activities). Component 4 loaded all 2 loadings 
for swelling but the 2 symptom items for pruritus also loaded on this component in addition to 
loadings 1 limit item (‘choosing clothing’). Component 5 contained both the pruritus items that 
loaded on component 4 plus 2 looks loadings.  
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Table 5.3: Principal Component Analysis of the CU-Q2oL 
 
Subscale 
 
Component 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
Q12 Wake up during the night  
Q13 Feel tired during the day because you      
        didn't sleep well at night  
Q11 Have difficulties falling asleep? 
Q07 Interfere with sleep  
Q14 Difficulty concentrating?  
Q05 Interfere with work 
Q06 Interfere with physical activities 
Q09 Interfere with social relationships 
Q23 Drug side-effects 
Q08 Interfere with spare time 
Q19 Embarrassed in public places 
Q18 Embarrassed by urticaria on body? 
Q15 Feel nervous 
Q16 Feel down 
Q03 Swollen eyes 
Q04 Swollen lips 
Q02 Wheals  
Q21 Clothing 
Q22 Interfere sport activities 
Q20 Cosmetics 
Q01 Pruritus (itching) 
Q17 Restrict what you eat? 
Q10 interfere with eating 
 
.84 
.77 
 
.75 
.69 
.51 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
.46 
 
 
 
 
        .45 
.42 
.79 
.71 
.65 
.64 
.62 
 
 
 
 
 
 
 
 
.44 
 
 
 
 
 
 
 
 
 
.52 
 
 
.77 
 
.74 
.71 
.59 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
.80 
.78 
.52 
 
 
 
.47 
 
 
 
 
 
 
 
 
 
 
 
 
 
.41 
 
 
 
 
.49 
.77 
.65 
.53 
.51 
 
 
 
 
 
 
.42 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
.46 
 
.76 
.56 
 
Component 6 like component 3 failed to represent a domain of the CU- Q2oL presenting for 1 
limits and 1 impact on life activities items both related to eating plus small loadings for 1 looks 
and 1 sleep item. In general the looks and limits domains presented as the most unstable items. 
However a reliability analysis of the newly English translated CU-Q2oL did show good levels of 
internal consistency with alpha coefficients all above .7 (of which 3 subscales were >.8). These 
finding matched or bettered the coefficients of the original development study (e.g. pruritus .9 as 
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to .79). The findings overall are in line with other CU-Q2oL revalidation studies that have failed 
to completely replicate the original and this has resulted in published culture-specific versions 
with different factor analysed domains (p118-122 for a full account). In order to not produce 
another version and in light of the good internal reliability produced here, it was decided to 
maintain the domains of the existing Italian version for the thesis and focus on the translation. 
 
5.4.3: Patient Characteristics Questionnaires 
You and Your urticaria Questionnaire (versions 1 and 2) 
The ‘You and Your Urticaria Questionnaire’ (Appendix 3a, pA10) was designed to obtain 
participant characteristics commonly found in the CU research literature and variables that may 
act as co-variants. Version 1 collects data on: gender; age; ethnicity; qualifications; occupational 
and marital status; CU subtype; angioedema; physical urticaria; diagnosing practitioner; age at 
disease onset; disease-duration; GP visits; CU medicines and dietary restrictions. Version 2 is 
used for study 6 adds ‘other chronic illness and previous counselling for CU’. Categorical data 
was dummy coded where necessary (e.g. white= 0; non-white= 1). 
 
Urticaria Activity Score-7* 
The urticaria activity score (UAS7; Mlynek et al. 2008; Appendix 3a, pA20) is a measure 
of CU disease-activity. Over a 7-day period respondents report their perceived itch severity on a 
scale of 0-3 (i.e. none, mild, moderate, and intense) and approximate number of wheals on the 
same scale (none, <20, 20-50 and >50 in 24hrs). Weekly total scores for each subscale range 
from 0-21 (combined total 0-42) where higher scores mean worse overall urticarial.  
 
5.4: Procedures 
A range of procedures was use across the thesis. The systematic reviews (studies 1 and 
2) entailed data extraction techniques from a standard protocol and CU data from the IPQ-R and 
BMQ (study 3) were subjected to reliability and factor analysis. Study 4 required participants to 
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complete questionnaire surveys by post or in clinic, while those in study 5 were interviewed and 
their data recorded and transcribed. Study 6 participants were subjected to interviews, 
questionnaire surveys, psycho-educational and behavior change techniques. More on these 
procedures can be found in the respective chapters.     
 
5.5: Research Ethics  
Studies 3-4 were approved by Guy’s REC, London and studies 5-6 by Hampstead NHS 
REC London. Guy’s Research and Development, London agreed both. The ethics application 
and supporting documents can be found in Appendix 5, pA52. The following documents can be 
found in Appendix 5: Consent form (pA71); and Research Participant Information Sheet (pA69). 
 
5.6: Data Analysis 
A range of statistical techniques was conducted analysed using SPSS and the AMOS 
structural equation modeling software package (both versions 19). 
 
5.6.1: Exploratory Data Analysis 
All quantitative data collected for studies 3, 4 and 6 were subjected to exploratory data 
analysis. Distribution tests were performed on continuous variable data to assess their suitability 
for undergoing parametric statistical analysis. If a variable had missing values these were 
specified by the value 200 (i.e. a figure not representative in any score values) with exception to 
the intervention in study 6 which used the Last Observation Carried Forward Method (LOCF) 
where the individual’s previous score on a variable is entered as recommended by the Panel on 
Handling Missing Data in Clinical Trials (2010). Skewness and kurtosis scores for each variable 
were observed and converted to a standardised Z-score by dividing each by their corresponding 
standard error to ascertain if both were significant enough to cause problems in the data. Where 
required outliers were removed or replaced with a score that was the variable mean plus two 
standard deviations as recommended by Field (2009). 
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5.6.2: Factor Analysis: Principle Components Analysis 
The internal consistency of all questionnaire subscales used in the thesis was examined 
by calculating their Cronbach alpha coefficients (Cronbach, 1951). First scores for each measure 
were checked for missing values and reversed-phrased items were adjusted to avoid biasing the 
alpha statistic and inappropriately lowering its value. Cronbach’s α scores range from 0 to 1 
where values of .7 and .8 suggest good reliability (Kline, 1999), however values were also 
compared to those of the questionnaires original development papers. 
 
The construct validity of questionnaires were analysed using principal components 
analysis (PCA) to determine whether the CU data collected were representative of the 
instruments respective structures. If the data did not support the questionnaires construct validity, 
subsequent exploratory PCAs were undertaken. To undertake subscale items were subjected to 
preliminary multicollinearity and item redundancy tests by generating Pearson correlation 
matrices and checking for correlations greater than 0.9 and determinants of the R matrix less 
than 0.00001 (value should be greater). To ascertain that the sample size and data were 
adequate for PCA Kaiser-Meyer-Olkin (or KMO) criteria for measuring sampling adequacy and 
Bartlett’s test of sphericity tests were undertaken. KMO values range between 0-1 and should as 
a bare minimum be 0.5 (Kaiser, 1974) where values of 0.5- 0.7 are said to be mediocre, 0.7- 0.8 
good, 0.8- 0.9 great and 0.9 superb (Hutcheson and Sofroniou, 1999). Bartlett's should be 
significant at p< 0.05. The type of extraction (orthogonal or direct oblique) and factors to retain 
was determined by those used by the instruments original authors, however only Eigen values 
greater than one were seen as significant factors and individual coefficients for an item loadings 
had to be above .4 (Kim and Mueller, 1978).  
 
5.6.3: Model Estimation and Goodness of Fit  
Model fit was examined by Chi-square analysis (x2). A non-significant chi-square (p>.05)  
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indicates that the model is a good comparative fit of the data. As the Chi-square statistic is 
affected by sample size (Fan, Thomspon and Wang, 1999) a number of goodness of fit indices 
were also analysed. The Comparative Fit Index (CFI) Normative Fit Index (NFI), Root Mean Sum 
of Error Approximation’ (RMSEA; and its 90% confidence intervals) and the RMSEA close fit 
(goodness of fit in the population) were examined (Bentler, 1990; Hu and Bentler, 1999), CFI 
and NFI values range between 0-1 where .9 or higher indicate a good fit. An RMSEA of .05 or 
less indicates a good fit and .8 an adequate fit. Close fit should be > .5 
 
5.6.4: Correlational Analysis       
To examine relationships between study variables (studies 3, 4 and 6) Pearson’s 
correlations were undertaken. Partial correlations were used to determine if significant 
relationships still held when patient characteristics were held constant. Correlations on non-
normally distributed variables were assessed using Spearman’s rho. Bonferoni corrections were 
applied to analyses to reduce the type-one error rate when doing multiple comparisons.   
  
5.6.5: Hierarchical Multiple Regression Analysis  
Hierarchical linear multiple regression was used to determine contributors and predictors 
of study outcomes. Only variables that correlated significantly to outcome variable under analysis 
was entered block-wise into each regression model with patients characteristics entered into the 
first block (where applicable) followed by illness and treatment perceptions, emotional 
representations and coping. The squared correlation coefficient (R2) was observed in the initial 
block to assess the proportion of variance explained in the model. Significant changes in R2 in 
subsequent blocks were determined by observing significant changes in the models F-ratio. The 
overall fit of each model was determined by observing the significance of the F-ratio assessed 
by analysis of variance (ANOVA) and the contribution of each predictor was assessed by 
observing its standardised beta coefficient (B), and its t statistic. For all statistics a p < .05 or less 
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indicated a significant finding. Multiple regression assumption checks were also undertaken. 
Scatter plots were generated to check for homoscedasticity and standard diagnostic tests were 
checked for extreme cases that might be influencing each model. Bonferoni corrections were 
applied to reduce type-one errors.   
 
5.6.6: Path Analysis 
To test for mediation between a predictor and outcome variable a path analysis based 
upon multiple regression analyses was undertaken. For mediation to occur Baron and Kenny 
(1986) state that (a) the predictor must significantly predict the mediator, (b) the predictor must 
significantly predict the outcome in the absence of the possible mediator, (c) the mediator must 
significantly predict the outcome. To test this criterion cognitive variables were regressed on the 
possible coping mediator to obtain path coefficients for predictors to coping. Second these 
predictors and the possible mediating coping variable were regressed on the outcome being 
tested. For the path diagram parameter estimates were calculated by the maximum likelihood 
(or ML) method to maximise the likelihood that the values obtained for the outcome variable in 
the path model were correctly predicted. The beta path coefficients obtained by the path model 
were checked to see if they replicated (or closely matched) those obtained by the multiple 
regressions analyse to see if they were a good fit. The estimated paths coefficients were used 
to estimate direct effects (no mediation involved), indirect effects (via a mediating variable) and 
total effects of the model (the sum of direct and indirect effects). Coping was a mediator if the 
direct effect of the predictor on the outcome was reduced upon the addition of the mediator. As 
recommended by Baron and Kenny (1986) the Aroian version of the Sobel mediations test was 
also used to test for significant indirect effects. The Sobel test (Sobel, 1982) is the sum of the 
square root of the raw unstandardised regression B coefficient weights and their corresponding 
standard error for both the predictor on the mediator variable and the mediator on the outcome 
variable. The Sobel statistic was calculated with a recognised interactive tool  
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(http://people.ku.edu/~preacher/sobel/sobel.htm). P <.05 indicates significant mediation.  
 
5.6.7: Multivariate Analysis of Variance (MANOVA) 
As multiple variables were being measured in study 6 over three time-frames, a repeated 
measures MANOVA was undertaken to allow the examination of differences between 
participants mean scores on combined outcome variables at 3 time points. Combining variables 
such as in MANOVA reduces type one error. To test MANOVA assumptions Pearson’s 
correlations were undertaken on outcome variables to confirm that they were significantly 
correlated without showing multicollinearity. As this was a within-group design with each 
participant acting as their own control (i.e. within groups error variance is reduced) no Levene’s 
or Box’s M test was undertaken. However, Mauchly’s test of sphericity was undertaken. A non-
significant result (p >.05) indicates that within group variance is approximately equal and suitable 
for MANOVA. Even though fewer participants are required for within group designs, error is 
reduced and statistical power is increased, Pillai’s Trace (V) was chosen as the preferred test 
statistic for the MANOVA analysis in light of the small sample size of this pilot study. A statistically 
significance result (p < .05) indicated a main effect for the intervention on the CU-specific 
outcome variables combined. The partial eta square or ŋ2 (i.e. the proportion of variance that one 
outcome variable explains when the other two are eliminated) was reported and the observed 
power of the analysis (.8 or above is suggested as a good level of power).  
 
A significant MANOVA was followed up by individual one-way univariate repeated 
measure ANOVA’s to establish which outcomes were significant. For each ANOVA the variance 
of the differences between scores from each participant was examined to see if they were equal 
as establishing multi-variate sphericity does not mean that the univariate ANOVA will also be 
spherical. Sphericity was again tested using Mauchly’s test. A non-significant result (p > .05) 
indicates that sphericity has been established and the standard F ratio test statistic for within-
group main effects can be trusted. If sphericity was violated for an ANOVA model the alternative 
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Greenhouse-Geisser corrected F ratio statistic was observed instead. A significant F (P < .05) 
indicates that a mean difference lies between timepoints. Again partial eta square (η2) and power 
was observed. In order to establish where differences laid pairwise contrasts were undertaken 
to compare mean scores from (1) baseline to post-intervention (T1 verses T2), (2) post-
intervention to follow-up (T2 verses T3) and baseline to follow-up (T1 verses T3) for each 
ANOVA. A Bonferoni correction was applied to pairwise analyses to reduce type one error.   
 
5.6.8: Interpretive Phenomenological Analysis (IPA) 
IPA was used to analyse the semi-structured interviews of women with CU. In IPA it is 
assumed that although ones cognitions cannot be directly accessed through their verbal 
accounts, they can be revealed through the IPA analytical process through the participants talk 
(i.e. transcripts). The IPA process is described in detail in Chapter 8. 
 
5.7: Conclusions 
The information in this chapter has described the general research methodologies 
employed throughout the remainder of the thesis to help answer its research questions and pre-
study analyses and to test the psychometric performance of CU data in the standardised 
questionnaires used to assess their suitability. The next chapter presents a factor analysis of the 
IPQ-R and BMQ in CU.  
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Chapter 6: 
Factor Analysis of the IPQ-R and BMQ-Specific in Chronic Spontaneous Urticaria (Study 3) 
  
6.0: Rationale for Study  
The Revised Illness Perception Questionnaire (Moss-Morris et al. 2002) and Beliefs about 
Medicines Questionnaire (Horne et al. 1999) were respectively developed to assess cognitive 
representations of illness and treatment however both had never been previously used in CU. The aim of 
this third study was to examine their internal reliability and factorial validity in CU to determine if they 
required psychometric adaptations before being used in proceeding studies.  
 
6.1: Introduction 
 
Illness perceptions are integral to the CSM because they act as exogenous latent factors that 
influence endogenous factors within the model (i.e. coping and outcome; Leventhal et al. 1980; 1984). 
Further a 45 study meta-analytic review (Hagger and Orbell, 2003) and proceeding studies support that 
they also inter-correlate in similar and predictable patterns across illnesses (See Chapter 2 for a full 
review). The IPQ-R (Moss-Morris et al. 2002) measures latent factors indicating illness perceptions and 
the (BMQ; Horne et al. 1999) further measures factors indicating beliefs about medications which has 
also been successfully replicated across chronic illnesses (see section 2.2.5, p31-33). In this third study 
it was hypothesised that in a CU sample: 
1. The IPQ-R identity subscale would distinguish between Identity and somatisation. 
2. The IPQ-R’s four-factor cause structure would show good levels of internal consistency.  
3. The IPQ-R’s remaining seven-factor structure solution would be:  
(a) Identified by CFA and (b) Show good levels of internal consistency  
4. The BMQ Specific 2-factor solution would be:  
(a) Identified by CFA and (b) Show good levels of internal consistency  
5.  CU representations overall would be held in patterns similar to other illnesses  
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6.2: Method 
 
6.2.1: Participants 
Recruitment  
IPQ-R and BMQ study data collected for use in the proceeding cross-section study (Chapter 7: 
Study 4) was obtained from patients diagnosed with active CU. Participants were identified and recruited 
predominantly from St Thomas’ Hospital’s St Johns Institute of Dermatology in London. The hospital runs 
the only urticaria specialist clinic service in the United Kingdom and referrals are taken from general 
practitioners and other health professionals nationwide for patients of all ages and it is not uncommon for 
patients to travel from all over the UK hence the representation of patients by geographical location is 
vast. In order to establish a collaborative relationship and allow for access to participants, the thesis author 
initially contacted Dermatologists specialising in urticaria. More detailed recruitment strategies and 
procedures can be found in Study 4.   
 
Sample Characteristics  
A total of ninety participants were approached to take part in this study (see Table 6.1, p153). Of 
these five did not return postal surveys, three approached in the clinic refused to participate and one’s 
data was removed due to being incomplete (> 30%). The final sample consisted of 81 participants, 
recruited from the outpatient urticaria clinic at St Thomas’ Hospital’s St Johns Institute of Dermatology. 
The majority were female and White British, in their mid-forties and were either married or co-habiting. 
Over half had either attended or completed a higher degree and slightly more were currently employed. 
The majority had experienced the condition for a median duration of 6.5 years but this ranged from 3 
months to over 40 years. Age of CU onset varied but on average most believed that their urticaria had 
started in their mid-thirties with just over half reporting experiencing both and angioedema. The majority 
(> 70%) confirmed a diagnosis by their dermatologist. The majority had visited their GP twice in the past 
6 months due to CU. Two-thirds were taking prescribed h1 anti-histamines and other prescribed 
medicines. Only nine used dietary restrictions.  
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Table 6.1: Patient Characteristics 
 
 
Variable 
 
 
N 
 
 
Percentage 
 
 
Gender (%) 
       Female/ Male 
Age (years) 
       Mean/  SD/ Range 
Ethnicity (%) 
       White British (%) 
       White European/ Other 
       Black/ Asian/ Mixed British 
Education (%)  
       None 
       GCSE/ O’ level 
       GCE/ A’ level 
       Higher Ed./ Degree 
       Not Specified 
Occupational status (%)   
       Employed 
       Unemployed 
       Retired 
       Studying 
       Not Specified 
Marital Status (%)   
       Single 
       Married/ Co-habiting 
       Divorced 
       Widowed/ Other 
Initial diagnosing specialist  
       General Practitioner 
       Dermatologist 
Experience Angioedema 
       Yes/ No/ Don’t know or not sure 
Age of onset (years) 
       Mean/ SD/ CI 
       Range (Inter-quartile range) 
Disease duration (yrs) 
       Median (range) 
GP visits in past 6 months   
       Mode (range) 
Prescribed CU Medicines  
       Anti-histamines 
       Anti-histamines with other 
       Other without anti-histamines 
       None 
Dietary restrictions 
       Yes/ No 
 
 
 
73.0/ 8.0 
n/a 
65.0 
 
53 
3.0/ 13.0 
6.0/ 5.0/ 1.0 
 
14.0 
91.0 
46.0 
2.50 
1.0 
 
50.0 
19.0 
10.0 
1.0 
1.0 
 
21.0 
48.0 
3.0 
6.0/ 3.0 
 
22.0 
59.0 
 
47/ 15/ 19 
 
------- 
------- 
 
------- 
 
------- 
 
19.0 
52.0 
9.0 
1.0 
 
9/ 72                               
 
 
 
90.1/ 9.9  
45.16 ± 14.04 (18 – 80) 
80.2  
 
65.43 
7/ 1.2  
7.4 / 6.2 / 1.2  
 
12.30 
7.30 
11.10 
56.80 
2.50 
 
61.7 
23.5 
12.3 
1.20 
1.20 
 
25.9 
59.3 
3.70 
7.4/  3.7 
 
27.2 
72.8 
 
58.0/ 18.5/ 23.5 
 
34.65 ± 16.27 (95% CI, 31.03- 38.27) 
1- 68.25 (25 years) 
 
6.5 (3 months – 40 yrs)  
 
2 (0 -50) 
 
23.50 
64.20 
11.10 
1.20 
 
11.1/ 88.9 
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6.2.2: Measures 
This study uses IPQ-R and BMQ that measure representations of illness and treatment 
respectively (see Chapter 5, Section 5.4, p135-7 for a detailed review of both instruments).  
 
6.2.3: Data Analysis 
Patient characteristics were analysed using descriptive statistics. The internal consistency of the 
IPQ-R and BMQ subscales were calculated using Cronbach alpha. The instruments construct validity 
were analysed using factor analysis. Model fit was examined by Chi-square analysis (x2) and goodness 
of fit indices. The identity subscale was subjected to reliability analysis and paired samples T-test to 
ascertain a difference between identity and somatisation. Inter-correlations between cognitions were 
analysed using Pearson’s correlation coefficients. Full details can be found in section 5.6 (p145) 
 
6.3: Results 
 
6.3.1: Distribution of Study Variables 
Exploratory data analyses of the IPQ-R and BMQ-specific study variables suggested the use of 
parametric statistical data analyses with the exception of the IPQ-R personal control subscale which 
showed significant kurtosis of 1.835  (z = 2.35, SE .53, p >.05) but non-significant skewness of -.46 (z = 
1.7, SE .27, p <.05). The shape of its distribution curve suggested that this variable could be subjected to 
parametric tests but with caution to the interpretation of its findings.  
 
6.3.2: Internal Reliability of the IPQ-R Identity Subscale 
Participants attributed a mean number of 7.65 ± 3.77 symptoms to their CU (95% CI, 6.82- 8.49) 
as to 9.49 ± 4.08 symptoms they reported to have experienced since their CU began (95% CI, 8.59-
10.40). To test that the identity subscale was measuring illness identity and not somatisation a paired 
samples t-test was conducted between both scores as recommended by the IPQ-R’s authors (Moss-
Morris et al. 2002). Both scores were significantly correlated (r=.75) but not enough to be measuring the 
same concept and this reflected in the significant difference between the two scores (t (5.53), p <.001). 
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Identity scores are illustrated in Table 6.2 below and show that the majority of participants reported 
wheals, pruritus and swelling as symptoms related to their CU. Other highly attributed symptoms included 
fatigue, sleep difficulties and pain however all symptoms were endorsed to some degree and with a 
Cronbach α of .84 the scale demonstrated a high internal consistency. 
 
Table 6.2: Symptoms Attributed to CU 
 
Symptom 
 
n 
  
 
 
             %  
 
Wheals* 
Pruritus* 
Swelling* 
Fatigue 
Sleep difficulties 
Pain 
Stiff joints 
Breathlessness 
Sore eyes 
Loss of strength 
Wheeziness 
Dizziness 
Headache 
Upset stomach 
Sore throat 
Nausea 
Weight loss 
 
78 
75 
72 
54 
49 
44 
35 
34 
34 
27 
27 
23 
21 
21 
17 
11 
  3 
 
96.30 
92.60 
88.90          
66.70    
60.50    
54.30   
43.20 
42.00                                             
42.00 
33.30 
33.30 
28.40 
25.90 
25.90  
21.00    
13.60    
  3.70 
 
6.3.3: Internal Reliability and Structural Validity of the IPQ-R Cause Subscales 
I) Internal Reliability 
A reliability analysis of the original four factor solution of the IPQ-R cause subscale based on 
Cronbach alpha demonstrated good levels of internal consistency. The internal reliability (exception 
immunity cause; 50 and 67), closely replicated the IPQ-R’s original alpha’s for psychological cause (.80 
in CU verses .86), risk factor cause (.70 verses .77) and accident/ chance (.22 verses .23). 
 
II) Confirmatory Factor Analysis (CFA) 
A CFA of the original IPQ-R cause subscales (represented in Figure 6.1, p157) suggested a 
significant difference between the present CU sample data solution and the hypothesised CSM four factor 
solution (X2= 245.31, df = 129, p =.0001) indicating that a comparative fit between the two was not 
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achieved. This lack of model fit was supported by an observation of the goodness-of-fit indices that also 
suggested a very poor model fit of the data. The NFI was .59, the CFI was .724, the RMSEA and itself 
confidence intervals were .11, (CI: .09 - .13) and RMSEA Close fit was .00. 
 
III) Exploratory and Confirmatory Principal Components Analysis 
As the CFA failed to achieve a comparable fit an exploratory PCA of the IPQ-R cause subscales 
18 items was undertaken to examine the fit in the current CU sample. Further the instruments authors 
recommend such a procedure in order to explore how these individual causal items are constructed in 
new illness populations. In order to do this a principle components analysis (PCA) was undertaken using 
the orthogonal Varimax method with Kaiser Normalisation to rotate factors to a simple solution. The data 
reached the minimum KMO criteria for measuring sampling adequacy (MSA= .78) with 13 of the 18 
individual KMO values falling above .7 (and others >.6.3). A Bartlett’s test of sphericity (x2 (153) = 539.413, 
p< .001) also indicated that the data was adequate for conducing PCA. Observing eigenvalues greater 
than 1 produced a six-factor solution accounting for 68.78% of the variance. 
 
Component 1 consisted of 3 of the 7 risk factor items (smoking, own behaviour and alcohol), 1 
item from the accident/ chance subscale (accident/ injury) and two high loadings of the psychological 
cause subscale. Component 2 loaded all 6 items that represented the psychological cause subscale 
however two of its items loaded better on component 1 (my mental attitude and personality). Component 
3 consisted of 3 risk factor causes but one of these included a second but higher loading for alcohol from 
component 1. This component also presented loadings for two immunity cause items. Component 4 
consisted of another risk factor item (medical care in past) and all 3 items that represented the immunity 
cause subscale but as just reported two of these also loaded on component 3. Component 5 consisted of 
a third loading for both personality and pollution together with the second accident/ chance item. The final 
component included a loading for another risk cause (hereditary) and a second small loading for the 
psychological cause overwork. Overall the psychological and immunity cause subscales were replicated 
by PCA but the risk and accident/ chance subscales were not.   
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Figure 6.1: Over-Identified Model of the IPQ-R Cause Subscales in CU 
 
A fixed-four factor solution conducted to replicate the hypothesised subscales explained 57.08% 
of the variance in the CU sample and is illustrated in Table 6.3 (p.158). A comparison of the exploratory 
and confirmatory PCA showed marginal improvements with Component 1 now consisting of 4 of the 7 
items that make up the risk factor scale, component 2 representing the psychological cause scale and 
component 4 items but immunity but evidently no identifiable component that represented the  
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Table 6.3: Principal Components Analysis of IPQ-R Cause Subscales  
 
Item 
 
                    
 
Mean 
 
 
 
S.D. 
 
 
 
KMO                                          
 
 
 
 
 
 
             Component/ Eigenvalue/ % Explained 
1                             2                                3                                4 
    5.66 
  16.84% 
1.71 
15.83% 
 1.59 
 13.69%  
 1.31   
 10.72%                        
 
Smoking (R) 
Accident or injury (A) 
My personality (P) 
My mental attitude (P) 
Alcohol (R) 
Family problems or worries (P) 
My emotional state (P) 
Stress or worry (P) 
Overwork (P) 
Diet or eating habits (R) 
Ageing (R) 
Altered immunity (I) 
A germ or virus (I) 
Poor medical care in my past (R) 
Pollution in the environment (I) 
My own behaviour  (R) 
Hereditary (R) 
Chance or bad luck (A) 
 
1.99 
2.03 
2.13 
2.36 
2.12 
2.76 
2.65 
3.62 
2.68 
2.64 
2.31 
3.44 
2.45 
2.09 
2.64 
2.42 
2.28 
2.80 
 
0.88 
0.84 
0.96 
1.02 
1.01 
1.16 
1.05 
1.03 
0.96 
0.99 
0.92 
1.18 
1.03 
0.90 
1.05 
0.95 
1.08 
1.17 
 
.800 
.882 
.789 
.841 
.766 
.707 
.755 
.773 
.766 
.702 
.792 
.639 
.676 
.694 
.737 
.827 
.671 
.635 
 
.818 
.711 
.687 
.644 
.475 
 
 
 
 
 
 
 
 
 
 
.451 
 
 
 
 
 
.496 
.526 
 
.751 
.681 
.653                  
.631 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
.422 
 
 
 
 
.777  
.665 
.655  
.487 
 
.544 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 .671  
 .613 
.548 
 .501 
-.433  
Key: R: Risk, P: Psychological, I: Immunity, A: Accident/ Chance, Highlighted section Identified CU-related personality induced self-destructive behaviour cause construct   
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accident/ chance subscale. Component 1 did not represent a particular IPQ-R cause construct but its 
indicators of psychological and risk factor items (smoking, my personality, my mental attitude, alcohol, my 
own behaviour) was label as induced self-destructive behaviour cause with a Cronbach of α X. Factor 
provided no conceptual (or meaningful) categorisation of causes.     
 
6.3.4: Internal Reliability and Structural Validity of the IPQ-R Seven Factor Subscale 
I) Internal Reliability: A reliability analysis of remaining IPQ-R subscales found good levels of internal 
consistency with Cronbach alpha coefficients of above .7 for all expect for emotional representations 
(.68). To establish how well the scores from the 38 items of the IPQ-R in the current CU sample fitted 
the 7-factor structure of the instrument a confirmatory CFA was undertaken. 
 
II) Confirmatory Factor Analysis (CFA): A CFA of the IPQ-R 7 factor scale solution is illustrated in Figure 
6.2 (p160). The CFA indicated a significant difference between the CU data solution and the hypothesised 
solution (X2= 1130.62, df = 644, p = .0001) indicating that a comparative fit between the two was not 
achieved. This lack of fit was further supported by an observation of the goodness-of-fit indices where the 
NFI= .48, the CFI=.66, the RMSEA (.98, (CI: .09-.11) and RMSEA Close fit= .000.   
 
III) Exploratory and Confirmatory Principal Components Analysis 
 As the CFA failed to achieve a comparable model fit an exploratory PCA of the IPQ-R seven 
factor solutions 38 items was undertaken to examine the fit in the current CU sample (see Table 6.4). As 
used by the IPQ-R authors an orthogonal Varimax method with Kaiser Normalisation was used to rotate 
factors to a simple solution. The data reached the minimum Kaiser-Meyer-Olkin (KMO) criteria for 
measuring sampling adequacy (MSA= .59) but shown in Table 6.3, 9 of the 38 items fell below the 
minimum .5 individual KMO value (questions 1, 6, 8, 15, 17, 28, 29, 30, 32). These items were kept to 
retain the original item structure of the questionnaire and however a Bartlett’s test of sphericity (x2 (703) 
= 1711.189, p<.0001) indicated that the data was adequate enough for conducting a PCA. The EFA using 
eigenvalues greater than 1, produced an 11-factor solution accounting for 74.6% of the variance. 
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Figure 6.2: Over-Identified Model of the IPQ-R 7-Factor Solution in CU 
 
Key 
               Latent Ill ness Perception  
               Factor 
               Observed questionnaire   
               Items (IP1-38)  
               Standardd error of item 
 
Factors 
TimeAC: Timeline acute/ chronic 
TimeCyc: Timeline Cyclical 
Cons: Consequences 
PControl: Personal Control 
TControl: Treatment Control 
ICoherence: Illness Coherence 
ERep: Emotional Representations 
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Component 1 contained 5 of the 6 items that represented the emotional representations subscale of the 
IPQ-R but also contained two loadings for three consequences items (Q9, 10 and 11). Component 2 
consisted of 4 of the 5 items that represented the illness coherence subscale and a single loading of the 
remaining emotional representation item (Q36 my CU doesn’t worry me). Component 3 contained 4 of 
the 6 items indicating the timeline acute/ chronic subscale and Component 4 retained all five items that 
represent the treatment control subscale. Component 5 consisted of 4 items of 6 of the consequences 
subscale, however two of these items also split loaded on component 1 (Q11 higher, Q10 lower) where a 
third consequence item singularly loaded (Q9). This component also featured a loading of the remaining 
timeline a/c item (Q18 my CU will improve in time). Component 6 consisted of 4 out of the 6 items 
indicating the personal control subscale and the remaining two items of this scale   (Q15: nothing I do will 
affect my CU, Q17: my actions will have no affect on the outcome of my CU) loaded onto component 7 
together will two second lower split loadings for two treatment control items (Q25, Q19). Component 8 
loaded three timeline cyclical items with the remaining loading on component 10. Component 9 did not 
represent any subscale and consisted of a personal control (Q12: there is a lot which I can do to control 
my symptoms), consequence (Q6: my CU is a serious condition) and timeline a/c item (Q5: I expect to 
have CU for the rest of my life) The remaining component 11 contained a single loading for the remaining 
illness coherence item (QI have a clear picture of understanding my condition). Even though the data 
closely represented the IPQ-R subscales the exploratory PCA generated eleven factors not seven. The 
fixed 7 factor confirmatory solution (presented in Table 6.7) explained 61.84% of the variance but retained 
the exploratory PCA factor loadings for four subscales (i.e. illness coherence, emotional representations, 
consequences and personal control) and resulted in improvements in one. As shown in Table 6.4 (p162) 
component 5 now represented all four timeline cyclical items (as to three), however this also resulted in 
the treatment control items shifting from loading together being split between components 2 and 6 scale 
with consequence and treatment control items respectively.    
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Table 6.4: Principal Component Analysis of the IPQ-R Seven Factor Solution in CU 
 
Item 
 
 
 
 
     Mean              S.D.           KMO                                         Component  /   Eigen value/  % variance      
1               2               3               4              5              6              7    
4.47          3.81           3.65         3.54         2.75         2.73         2.56 
11.75%     10.03%       9.60%      9.31%    7.23%       7.18%      6.74% 
 
35: 
38: 
34: 
33: 
11: 
09: 
37: 
22: 
20: 
07: 
10: 
18: 
21: 
26: 
27: 
25: 
24: 
36: 
03: 
 
My CU makes me feel angry (E) 
My CU makes me feel afraid (E) 
When I think about my CU I get upset (E) 
I get depressed when I think about my CU (E) 
My CU causes difficulties for those who are close to me (C) 
My CU strongly affects the way others see me (C) 
Having CU makes me feel anxious (E) 
My treatment can control my eczema (TC) 
My treatment will be effective in curing my CU (TC) 
My CU has major consequences on my life (C) 
My CU has serious financial consequences (C) 
My CU will improve with time (T a/c) 
The negative effects of my illness....* (TC) 
I don’t understand my CU (r) (IC) 
My CU doesn’t make sense to me (r) (IC) 
My CU is a mystery to me (r) (IC) 
The symptoms of my condition are puzzling to me (r) (IC) 
My CU does not worry me (E) 
My CU will last for a short time (Ta/c) 
 
3.31 
2.88 
3.57 
3.66 
3.46 
3.05 
3.57 
3.65 
3.14 
4.04 
3.08 
2.92 
3.30 
2.88 
2.78 
2.64 
2.59 
3.92 
3.86 
 
1.24 
1.23 
1.07 
1.05 
1.35 
1.25 
1.01 
0.80 
0.94 
1.13 
1.36 
1.06 
0.89 
1.15 
1.14 
1.14 
1.24 
0.99 
1.01 
 
.798 
.751 
.657 
.675 
.639 
.753 
.644 
.709 
.622 
.533 
.598 
.735 
.589 
.660 
.716 
.591 
.625 
.753 
.544 
 
.801  
.772    
.761 
.709 
.669 
.612 
.606 
 
 
 
.425 
 
 
 
 
 
 
 
 
 
 
 
 
 
 .456 
 .484 
 
-.699 
-.679 
 .652 
 .614 
 .485 
-.466 
 .426 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 .885 
 .874 
 .864 
 .789  
-.531 
 
 
 
 
 
 
 
 
 
 
 
 
 
.481 
 
 
 
 
 
 
.795 
Key: T a/c Timeline Acute Chronic,  C Consequences,  P Personal Control,  T Treatment Control     *.....can be prevented by my treatment
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Table 6.4: continued 
 
Item                                                                                                                                    Mean             S.D.           KMO                                         Component  /   Eigen value/  % variance      
                                                                                                                                                                                                     1               2               3               4              5             6             7    
                                                                                                                                                                                                   4.47          3.81           3.65         3.54         2.75        2.73       2.56 
                                                                                                                                                                                                  11.75        10.03          9.60         9.31         7.23        7.18       6.74                                                                                                                                                               
 
02: 
01: 
05: 
04: 
08: 
06: 
30: 
32: 
31: 
29: 
15: 
17: 
19: 
23: 
28: 
14: 
13: 
16: 
12: 
 
My CU is likely to be permanent rather than temporary (Ta/c) 
My CU will last a short time (Ta/c) 
I expect to have CU for the rest of my life (Ta/c) 
This CU episode will last for a long time (Ta/c) 
My CU does not have much effect on my life (C) 
My CU is a serious condition (C)  no load 
My symptoms come and go in cycles (TCY) 
I go through cycles in which my CU gets better or worse (TCY) 
My CU is unpredictable (TCY) 
The symptoms of my illness change a great deal from day to day (TCY) 
Nothing I do will affect my CU (P) 
My actions have no effect on the outcome of my CU (P) 
There is very little that can be done to improve my CU (r) (TC) 
There is nothing which can help my condition (TC) 
I have a clear picture of understanding my condition (IC) no loading 
The Course of my CU depends on me (P) 
What I do can determine whether my CU gets better or worse (P) 
I have the power to influence my CU (P) 
There is a lot which I can do to control my symptoms (P) 
 
3.39 
3.82 
3.34 
4.07 
3.93 
3.70 
3.68 
4.02 
4.00 
3.61 
3.43 
3.50 
3.22 
3.66 
3.27 
2.35 
3.04 
2.69 
2.76 
 
1.11 
1.22 
1.10 
0.80 
1.27 
1.03 
1.09 
0.95 
0.99 
1.13 
0.98 
0.97 
0.95 
0.94 
0.98 
0.97 
1.01 
1.02 
0.99 
 
.618 
.370 
.630 
.599 
.467 
.464 
.457 
.435 
.512 
.375 
.377 
.385 
.627 
.635 
.469 
.575 
.504 
.501 
.549 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
.450 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
.768 
.657 
.638 
.605 
.411 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
.845 
.810 
.638 
.539 
 
 
 
 
 
 
 
 
 
 
 
 
.768 
.647 
.554 
.524 
 
.
7
9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
.797 
. 87 
.684 
.484 
Key: T Treatment Control, IC Illness Coherence, TCY Timeline Cyclical, E Emotional Representations, r = reverse score  
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6.3.5: Internal Reliability and Structural Validity of the BMQ-Specific 
I) Internal Reliability  
A reliability analysis of the original two factor solution of the BMQ-Specific showed good levels of 
internal consistency with Cronbach alphas of .83 for necessity and .68 for concerns. 
 
ii) Confirmatory Factor Analysis 
A CFA of the BMQ-Specific subscales (shown in Figure 6.3, p165) suggested a significant 
difference between the CU solution and the hypothesised two-factor solution proposed by Horne et al. 
(1999) (X2= 88.03, df = 34, p =.0001) indicating that a comparative fit was not achieved. This lack of model 
fit was further supported by an observation of the goodness-of-fit indices where the NFI= .71, the  
CFI .78, RMSEA (and its confidence intervals) .14, (CI: .11 - .18) and RMSEA Close fit= .00.   
 
III) Exploratory and Confirmatory Principal Components Analysis 
As the CFA failed to achieve a comparable model fit, an exploratory factor analysis (EFA) of the 
BMQ-Specifics 10 items was undertaken to examine the fit in the current CU sample. As used by the 
instrument authors (and to allow for inter-correlations between items) a non-orthogonal direct oblique 
rotation with Kaiser Normalisation was used. The data met KMO criteria for sampling adequacy (MSA= 
.67) with individual item KMO values exceeding .5 (except ‘my CU medicines are a mystery to me’, .38). 
Bartlett’s test of sphericity (x2 (45) = 286.71, p< .001) also suggested that the data was adequate enough 
for conducting a PCA. Accounting for 75.95% of the variance, the EFA using eigenvalues greater than 1 
produced a 4-factor solution. 
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Figure 6.3: Over-Identified Model of the BMQ-Specific in CU 
 
                                                                
Component 1 consisted of four of the five items representing the BMQ specific necessity scale 
explaining 32.96% of the variance. Component 2 consisted of three loadings of items representing the 
BMQ specific concerns subscale and explained a further 21.16% of the variance, however one necessity 
item (i.e. ‘my CU medicines protect me from becoming worse’) and one concerns item (i.e. ‘my CU 
medicines disrupt my life’) loaded together on a third component explaining a considerable 11.5%. The 
remaining concerns item (i.e. ‘my medicines are a mystery to me’) loaded by itself on a fourth component 
and explained 10.31% variance. The exploratory BMQ presented partial evidence to suggest the presence 
of separate necessity and concerns factors, however as this was not perfect a confirmatory fixed 2-factor 
solution was further investigated. For this analysis the fixed solution accounted for a reduced 54.12% of 
the variance but demonstrated an exact rotational match with all specific necessity and specific concerns 
items loading on components 1 and 2 respectively. This exact match is show in Table 6.5 on page 166. 
 
Key:  
 
             Latent Factor 
 
             Observed questionnaire item          
             (SN1-5 and SC1-5) 
 
             Standard error 
 
 
SN = Specific Necessity item 
 
SC = Specific Concerns item 
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Table 6.5: Fixed Principal Components Analysis of the BMQ-Specific in CU 
 
 
 
Item 
 
 
Mean 
 
 
S.D. 
 
 
KMO                                          
 
 
Component / Eigen value/  % variance      
   1 
  3.30 
 32.96% 
    2 
  2.12 
21.16% 
 
Specific Necessity 
 
SN1: My life would be impossible without my CU medicines 
 
SN2: My health depends on my medicines 
 
SN3: My health in the future will depend on my CU medicine 
 
SN4: Without my CU medicines I would be very ill 
  
SN5: My CU medicines protect me from getting worse 
  
Specific Concerns 
 
SC1: Having to take CU medicines worries me 
  
SC2: I sometimes worry about the long-term effects of 
         my CU medicines 
 
SC3: My CU medicines disrupt my life 
 
SC4: I sometimes worry about becoming too dependent 
         on my CU medicines 
 
SC5: My medicines are a mystery to me 
 
 
 
 
3.65 
 
3.51 
 
3.20 
 
3.51 
 
4.03 
 
 
 
3.58 
 
4.16 
 
 
2.96 
 
3.35 
 
 
2.48 
 
 
 
 
1.09 
 
1.30 
 
0.99 
 
1.19 
 
0.85 
 
 
 
1.09 
 
0.95 
 
 
1.13 
 
1.12 
 
 
0.99 
 
 
 
 
.717 
 
.833 
 
.705 
 
.725 
 
.554 
 
 
 
.651 
 
.632 
 
 
.638 
 
.628 
 
 
.378 
 
 
 
 
.889 
 
.793 
 
.786 
 
.764 
 
.596 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
.844 
 
.773 
 
 
.559 
 
 
.571 
 
.501 
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6.3.6: Inter-Correlations between Illness Perceptions and Treatment Beliefs 
As shown in Table 6.6 (p168), inter-correlations between variables found logical patterns of 
relationships. The identity subscale strongly and significantly positively correlated with timeline 
acute/chronic (p<.01) consequences (p<.001) and specific necessity (p<.01) but no cause subscale. In 
contrast psychological causes strongly related to the other causes (all p< .01) and to a lesser extent 
emotional representations (p<.05). Immunity cause only positively correlated with the other causes (range 
p <.5 to .001) but accident/ chance significantly related to emotional representations (p<.01) and specific 
necessity (p<.05). Timeline acute/ chronic positively correlated with identity (p<.01), consequences 
(p<.001), emotional representations (p<.05) and specific necessity (p<.05), negatively with personal and 
treatment control (p<.05 and .01 respectively) but was not related to timeline cyclical (p> .05) which only 
strongly correlated to emotional representations (p .05). Consequences strongly and positively related to 
identity (p<.001), timeline cyclical (p<.001), emotional representations (p<.001), specific necessity (p<.01) 
and less for specific concerns (p<.05) but negatively for treatment control (p<.001). Personal control 
weakly correlated with treatment control (p<.05). Illness coherence bared strong negative relationships to 
emotional representations (p<.01) and specific concerns (p<.01). Emotional representations significantly 
correlated to all the other cognitions (ranging from p<.05 to .001) except for identity, risk factor and chance 
causes, and personal and treatment control (p> .05). Further specific necessity was strongly related to 
specific concerns. 
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Table 6.6: Inter-Correlations between Cognitive Representations  
 
 
 
ID     PSY C    RISK C     IMM C       ACC C      TIME (A/C)      TIME C         CON         P CON       T CON        IC               ER             SN                SC                                                                                                                                                                                                                        
 
Illness Identity  (ID) 
Psychological cause (PSY C) 
Risk factor cause (RISK C) 
Immunity cause (IMM C) 
Chance  cause (ACC C) 
Timeline-a/c (TIME A/C) 
Timeline cyclical (TIME C) 
Consequences (CON) 
Personal control (P CON) 
Treatment control (T CON) 
Illness coherence (IC) 
Emotional (ER) 
Specific necessity (SN) 
Specific concerns (SC) 
 
 
.141      .123          .040           .040          .373**             .050               .390***       -.082         -.133           .011           .133           .350**           .152  
 .569***      .302**        .397***     -.086              -.011               .005            .165           .062          -.207           .248*          .191             .193                   
  .606***      .466***       .006              -.083               .028            .213         -.068          -.090            .035           .148             .077  
 .281*          .000              -.007               .032            .029         -.148          -.018           .046           -.055           -.034       
 -.096               .158               .213            .097         -.025           .001           .302**         .287*           .094  
 .070                .453***      -.245*        -.299**       -.054          .278*           .282*          -.113    
  .170          -.164          .072          -.129           .362**         .079            -.029 
 -.090         -.431***     -.164           .555***       .390**           .227*          
 .285*         .149          -.063           .014              .105          
 .132            -.213           .049            -.107 
 -.341**       -.115             -.294**       
.332*           -.297**   
   .184        
 
 
*P < .05,  **P < .01,  ***P < .001 Significant 2-Tailed  (Bonferoni correction applied) 
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6.4: Discussion 
This study examined the internal reliability and construct validity of the IPQ-R and BMQ-
Specific in patients with CU using confirmatory factor analysis (CFA). It was hypothesised a priori 
that responses to items would be organised in such a way as to indicate the latent factors of 
illness and treatment perceptions. However despite the high levels of internal reliability presented 
by the instruments subscales, their hypothesised factor structures were not found by CFA. A 
possible explanation for this may be that the sample size was not adequate. However the 
goodness of fit indices not as affected by sample size also suggested a poor fit. An alternative 
explanation may lie in subtle structural schematic qualitative differences in how individuals with 
CU cognitively represent their illness. In light of this and an observation of residuals and 
modification indices (indicating the rejection of considerable numbers of items), it was decided 
to take an exploratory route via PCA. This made sense, as the studies sample size was adequate 
for conducting PCA on both instruments as originally undertaken by Moss-Morris et al. (2002) 
and Horne et al. (1999).  
 
Through confirmatory PCA this study did provide strong evidence to support the 
theoretically derived dimensions of cognitive representations in CU for the first time by 
substantially replicating much of the structure of the IPQ-R and completely replicating those of 
the BMQ-specific. This major finding not only provides support that the instruments are capable 
of ‘tapping’ into cognitive representations of individuals with CU, but the inter-correlations 
between the dimensions also suggest that these individuals hold these representations of CU in 
similar logical and schematic patterns demonstrated by Hagger and Orbell’s (2003) meta-analytic 
review.  
 
IPQ-R identity subscale 
One of the most supported dimensions was the identity subscale where the 
recommendation by its authors to add disease-specific symptoms further increased levels of 
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internal consistency. Further the addition of new symptoms to the IPQ-R by Moss-Morris et al. 
(2002) themselves was strongly supported in that all symptoms were endorsed to some degree 
by this patient population showing high internal consistency with or without the addition of CU 
specific items. However what made this finding more pertinent was that the subscale 
demonstrated an ability to dualistically establish that patients with CU were not reporting 
somatisation but that they were also cognitively labelling items that were both typical and atypical 
of CU symptomatology, a phenomenon previously overlooked by researchers. This finding has 
implications in that attributinh atypical somatic symptoms to CU may lead to reports of 
inappropriate coping behaviours and worse perceived outcomes as predicted by Leventhal’s 
CSM. To qualify this, the IPQ-R identity subscale was used in proceeding Study 4, providing 
strong and significant statistical evidence to support that this is the case.  
 
IPQ-R four factor cause subscale   
The most supported subscale here was psychological attributions, which loaded all six 
of its indicator items onto a single factor. This construct was further supported in that the original 
seventh psychological cause my own behaviour did not load as a psychological factor but 
similarly loaded with other risk factors as it did in Moss-Morris et al.’s (2002) IPQ-R development 
study.  Moss-Morris et al. (2002) do not explain this finding but a possible explanation is that the 
item my own behaviour is not a psychological item as labelled but actually a risk factor. When 
the risk factor subscale is observed further it contains behaviours that individuals do to 
themselves such as smoking, drinking alcohol and eating and although other items in this 
subscale such as hereditary and aging are not doing behaviours, they are processes that the 
body biologically does to itself. In contrast unlike Moss-Morris et al. (2002) the risk factor 
subscale demonstrated great instability in the current study in that its items loaded across three 
factors with my own behaviour itself split-loading across two of these factors. A closer 
observation of component one (consisting of risk factor and second loadings for two 
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psychological causes) resulted in a possibly meaningful categorisation of items for my 
personality, my own behaviour, my mental attitude, smoking and alcohol which was labelled as 
personality induced self-destructive behaviours. This labelling does appear to have some 
empirical support in the literature in that (as reviewed in Chapter 1, section 1.2.3) CU has long 
been associated with the pathological personality traits that are said to make them more 
susceptible to illness (Baiardini et al. 2011; Willemsen et al. 2008). Such personality induced 
self-destructive behaviours include alexthymia (i.e. difficulties in regulating emotions) indicated 
in up to 56.90% of CU inflicted individuals in one study by Barbosa et al. (2011) who also found 
this to be significantly related to exhibiting defence mechanisms that turn against the self and a 
need for external control independent of clinical variables (see section 1.2.3, p8 for studies 
supporting Barbosa et al. 2011). What is less supported in the literature is a role for smoking and 
alcohol abuse as an actual risk factor cause for the onset of CU. What is known is that alcohol 
use can worsen CU symptoms (Zuberbier et al. 2009b) and that both behaviours are both risk 
factors and coping strategies for dealing with stress in general (Moss-Morris e al. 2002; Carver, 
1997). A first possible explanation can be proposed here in terms of a self-reported personality, 
attitudinal state and behavioural causal component perceived to be guiding the use of alcohol 
and smoking as a coping strategy. Such an explanation would be in line with the common-sense 
models concept of the IF-Then rule (Anderson, 1983; Brownlee et al. 2000) and its over-lapping 
nature. Regardless of alcohol and smoking being labelled in the model as perceived causal risk 
factors of CU onset, they can also be labeled, as coping behaviours hence there might be 
potential conceptual overlap. As described in depth Chapter 2 (section 2.2.4) illness perceptions 
guide coping actions but it can sometimes be difficult to establish which factors are the perception 
and which are the coping actions, hence my personality, my own behaviour, my mental attitude 
maybe illness perceptions and smoking and alcohol self-report coping actions representing 
overlapping concepts.  
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In another explanation using the IF-Then concept all items representing this factor could 
represent an actual causal perception (e.g. “I believe my pathological personality, my negative 
mental attitude, my negative behaviour including drinking alcohol and smoking caused my CU”) 
but they could also all be coping procedures (I use my positive personality and mental attitude, 
alcohol and smoking as ways to cope with my CU). A third explanation would involve the bi-
directional nature of the IF-Then rule where the items are acting at times as both causal illness 
perceptions with corresponding coping actions in a bi-directional nature. It appears that further 
cross-validation of this subscale seems warranted in order to explore these possible 
explanations. For now it appears that individuals with CU think of their illness in terms of 
psychological attributions in line with the CU research literature that psychological aspects are 
the biggest cause of CU (e.g. O’Donnell et al. 1997; Berrino et al. 2006; Ozkan et al. 2007) but 
also in terms of particular psychological and risk factor indicators that represent a distinct CU 
specific causal attribution different to how the individuals in Moss-Morris’ et al. (2002) 
represented them.  
 
Another cause subscale with psychometric concerns was that of accident/ chance which 
was not replicated by PCA. A possible explanation for this may lie in its low internal consistency 
(α .22) suggesting that it could be eliminated as a subscale as it may not be adequate in tapping 
into this concept in CU. However the internal consistency of accident/ chance was equally low in 
Moss-Morris et al. (2002) at a = .23 and therefore in line with the scales original development. 
From the anecdotal evidence of illness perceptions reviewed in section 2.4.2 no indication of 
accident/ chance as a cause of CU was reported. In order to determine if this was a problem of 
low internal consistency or an irrelevant subscale, the responses of the open question part of the 
IPQ-R cause subscale was content analysed. Participants are asked an open question to rank 
what they believed caused their illness including those not listed. Responses could be themed 
into causes relating to stressful life events, medical/physiological or drug/chemical reaction  
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factors as shown in Table 6.7 below 
 
The free responses showed a pattern more in line with psychological and immunity 
causes (stressful life events and medical/ physiological/ drug/ chemical respectively) indicating 
that accident/ chance causes is not a salient and significant causal attribution in those with CU. 
A descriptive survey analysis of this subscale in the next study may lead to more conclusive 
explanations for whether accident/ chance causes are important in CU. As the psychological 
cause construct was fully replicated, the immunity cause construct was also completely 
 
Table 6.7: Participant Generated Causal Attributions of CU   
 
Theme 
 
Causal Atribution 
 
 
Stressful 
Life Events 
 
 
Childbirth, Pregnancy, Bereavement, Shock, Loss of job,  Divorce, 
Going on airplane for first time, Work environment, Work-life balance 
 
 
Medical / 
Physiological 
 
Thyroid, Allergy, Blood, Hormones, Body going through cycles, Natural body 
secretion 
 
Drug/ Chemical 
 
 
 
Botox, Antibiotics, Medication, Flu injection, IUD, Insect bite abroad,                             
chemical (e.g. hair dye), Weight gain 
 
 
supported by PCA. From the research literature reviewed in Chapter 1 it is known that up to 50% 
of CU cases may be implicated in immunity factors (Kaplan and Greaves, 2009; Sabroe and 
Greaves, 2006) so it is possible that the subject of auto-immunity had been communicated to a 
large proportion of the research sample. Despite this successful replication two risk factor items 
loaded on the factor representing immunity causes. These risk factors were eating behaviour 
and aging which in the context of CU research could be explained by CU’s history of being 
implicated in food allergy (Kulthanan et al. 2008) and the heuristic that the immune system 
becomes more compromised with older age (Miller and Maner, 2012).   
 
 In summary the PCA failed to replicate the four-factor causal attributions identified by 
Moss-Morris et al. (2002). From this study it can be concluded that the data only supported the  
 174 
 
existence of psychological and immunity causes in CU, however this partial replication in itself is 
important in this context as CU is empirically implicated in evidence for both psychological and 
immunity factors also indicating that it is these factors that are collectively more cognitively salient 
to those with CU. 
 
IPQ-R seven factor structure 
By PCA the CU data largely supported the theoretical constructs of illness perceptions. 
The most strongly supported dimensions were those of the two timeline constructs, 
consequences, illness coherence and emotional representations subscales. The timeline acute/ 
chronic and timeline cyclical indicator items unanimously loaded onto two separate factors with 
high levels of internal consistency and a non-significant correlation between them, supporting 
the argument by previous researchers using the original unrevised IPQ (Weinman et al. 1996) 
that chronicity and cyclical timeline are not one entity and should be measured separately. In 
relation to this it also supports Moss-Moss et al.’s (2002) decision to split and re-assess the IPQ 
timeline subscale as they stipulate it more useful in conditions that do not follow a simple acute-
chronic course such as autoimmune and skin conditions. In a CU context this makes sense as 
CU is medically known to be chronic both cyclical (Zuberbier et al. 2009a).  
 
Secondly the addition of a new illness coherence subscale was supported as its indicator 
items loaded together on a single factor distinct from the other theoretical constructs, however 
discrepancies did occur. One illness coherence item failed to load in the seven-factor solution 
(i.e. I have a clear picture of understanding my condition). On further examination it became 
apparent that this item was the only one in this subscale worded positively and not reverse 
phased (see Table 6.3) indicating that this might require rewording in future. However a re-
observation of the 11 factor exploratory PCA solution showed that this item loaded on its own as 
a single factor with an eigenvalue of 1.54 explaining 4.06% variance. As this item did not load 
this way in previous studies (Wittkoski et al. 2008; Moss-Morris et al. 2002; Hagger and Orbell, 
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2005) it appears more likely that this item represents a different and distinct latent factor to illness 
coherence or the other IPQ-R dimensions but this needs further.  
 
Thirdly the data supported the graphical presentation and construction of Leventhal’s 
CSM (see Figure 2.2, p26) in that all but one item/s indicating emotional representations (not 
included in the IPQ) loaded on its own factor separate to the other illness perceptions, therefore 
supporting that emotional representations are a separate entity. However the CSM proposes that 
emotional representations (ER) also inter-correlate with illness perceptions and an observation 
of Table 6.5 (p66) suggested that this was the case. Emotional representations correlated with 
all but a few illness perceptions and provided support for the extended CSM with significant 
relationships to specific necessity and concerns. Further findings from Study 4 in Chapter 7 
provided further support in that ER predicted some CU-related outcomes independently of illness 
perceptions. In light of these findings it could not be ignored that two consequence indicators 
cross-loaded higher on this ER scale and further the one remaining ER indicator cross loaded 
elsewhere on the consequences factor and factor indicating illness coherence. In respect to the 
former Wittkoski et al. (2008) did find that the ER and consequences items consistently loaded 
onto a single factor in atopic dermatitis but as this was not the case in CU a more viable possible 
explanation is that the items ‘My CU causes difficulties for those who are close to me’ and ‘My 
CU strongly affects the way others see me’ might have been construed as an emotional related 
difficulties and affect from significant others, however their lower cross-loading on their 
representative consequences factor suggest that these difficulties and affects are still 
consequences (just more emotional ones). A second explanation maybe that there is conceptual 
overlap in these constructs as found by Hagger and Orbell (2005) who also found this these IPQ-
R representations. Regarding consequences one of its indicators (i.e. my CU is a serious 
condition) did not load in the confirmatory PCA and loaded on a factor that appeared to have no 
conceptual meaning in the exploratory PCA (as removing this item in the analyses did not affect  
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the factor structure, it may be redundant in CU).   
 
The findings of the control subscales added to the argument of whether curability/ control 
is a single dimensional construct or whether it should be separated into personal control and 
treatment control. Four of six personal control indicator items did load on their own factor but two 
items loaded onto another factor with two treatment control indicators providing conflicting 
evidence of personal control as a separate construct but with some conceptual overlap with 
treatment control as found in previous studies (Wittkoski et al. 2008; Hagger and Orbell, 2003; 
Moss-Morris et al. 2002). Interestingly the same two treatment control items that loaded with 
personal control items in CU (i.e. there is very little that can be done to improve my illness and 
there is nothing which can help my condition) were identical to that found in atopic dermatitis 
(Wittkoski et al. 2008) suggesting that in pruritic skin disorders at least this conceptual overlap 
occurs. Even though the treatment control items became destabilised in the fixed 7-factor PCA 
solution it did remain relatively intact in the exploratory PCA suggesting that it is a separate 
construct to personal control. The other treatment control items (my treatment can control my 
CU and my treatment will be effective in curing my CU) loaded negatively on the factor 
representing consequences (discussed earlier in relation to the ER item also loading). In a CU 
context antihistamine medicines and avoiding eliciting stimuli are first line interventions linked to 
serious consequences if not adhered to (see sections 1.4) and a possible explanation for this 
may be that patients with CU in this study could not separate or distinguish this relationship from 
the consequences. Evidence for this can be found in the strong correlation between these two 
factors (r .431, p < .0001). 
 
BMQ-Specific/ inter-correlations  
The extended CSM constructs of specific necessity and specific concerns (Horne, 1999; 
2003) were strongly supported in that the fixed solution was a perfect rotational match (see  
Table 6.4). Even though it could be concluded that individuals with CU represent beliefs about  
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CU medicines as a two-dimensional construct, the exploratory PCA produced a four-factor 
solution loading one necessity and concerns item (my CU medicines protect me from become 
worse and my medicines disrupt my life) and a fourth containing a single item (my medicines are 
a mystery to me) with eigenvalues greater than one and considerable percentage variances of 
11.5% and 10.31% respectively. If this alternative solution is accepted a possible interpretation 
of this is a specific necessity and concerns construct plus a third cognitive schema representing 
the necessity of CU medicines despite the burden they place on daily CU self-management (i.e. 
cost-benefit dilemma) and a fourth acting as a treatment coherence concept similar to that of 
illness coherence. In support of both possibilities studies have replicated the two-factor structure 
(e.g. De las Cuevas et al. 2011; Mahler et al. 2010; Lihara et al. 2010) but Fancis et al. (2009) 
took this a step further by examining the structure of the BMQ, a surgery-specific adaption (BSQ) 
and a third combining the BMQ and BSQ and not only replicated the generic two-factors but the 
specific BSQ items loaded on their own factors. Further support for these constructs come from 
Study 4 where patients reported equal necessity and concern beliefs supporting Horne’s 
necessity-concerns differential (Horne, 2003) and logical inter-correlations with IPQ-R items 
respectively. 
 
The strength of this study is that patients with a medically confirmed diagnosis of CU 
were recruited that despite being from a tertiary service, represented the patient characteristics 
that would be expected in this patient population (see section 1.3, p10) and the systematic review 
Study 1 in Chapter 3). Further the CU data used to conduct the PCA was taken from study 4 
which had showed that both instruments have adequate psychometric properties in real research 
in respect to demonstrating an ability to predict CU-related outcomes (predictive validity) and 
follow the course of CU outcomes longitudinally (as demonstrated in Study 6) and this helps to 
counteract that the psychometric adequacy of the IPQ-R and BMQ are only based on the 
baseline cross-sectional data, however a limitation still pertains in that the structure of the IPQ-
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R and BMQ-Specific could not be replicated using the more robust hypothesis testing CFA 
method even though this was rectified using statistical techniques (i.e. PCA) used by the 
instruments developers and still a powerful and commonly used analysis of construct validity of 
which most cognitive representation studies are based (Hagger and Orbell, 2003). Research 
outside this thesis could combine future CU data from the IPQ-R and BMQ-Specific to increase 
the possible sample size required for CFA that may result in a replication of their respective factor 
structures. Combining the items of the both instruments for factor analysis may also be a line of 
enquiry to establish if illness and treatment perceptions load on their own representative factors 
as in Fancis et al. (2009).  
 
This is the first study to assess the factor structure of the IPQ-R and BMQ-Specific in 
CU and the findings provide preliminary evidence to suggest that both are adequate (if not 
perfect) tools for tapping into CU-related cognitive representations of illness and treatment. 
Researchers in future may want to explore the themes that emerged from structural 
discrepancies including the possibility of a CU-specific personality induced self-destructive 
behaviour causal attribution, treatment coherence and cost-benefit dilemma concept and the 
conceptual overlap between CU emotions and consequences in the quest for a perfect model fit 
of common-sense representations of CU. 
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Chapter 7 
Exploring Cognitive Representations and Coping in CU-Related Quality of Life and 
Psychological Distress (Study 4) 
 
7.0: Rationale for Study 
The work reported in this study used the common-sense model as a theoretical framework to 
explore (I) the nature of cognitive representations in CU and (II) relationships between cognitive 
representations, coping and CU-related QoL outcomes. The findings are discussed in terms of developing 
interventions on changing the patient’s illness model that might lead to better CU regulation.   
 
7.1: Introduction 
 
Illness perceptions are integral to the CSM (Leventhal et al. 1980; Leventhal, Nerenz and Steele, 
1984) that proposes that individuals simultaneously deal with their perception of illness and emotional 
responses to it. These processes are said to influences illness outcomes mediated by coping behaviour. 
Studies have either established partial mediation (e.g. Rutter and Rutter, 2002), failed to find mediation 
(e.g. Scharloo et al. 2005; Kaptein et al. 2006) or have omitted measuring coping altogether (e.g. Timmers 
et al. 2008). As this was the first exploration of the CSM in CU all avenues were explored. Treatment 
perceptions (Horne, 2003) were also studied in relation coping and outcome. The studies research 
hypotheses were to: 
1) Confirm that CU had a moderate negative impact on quality of life 
2) Confirm that poorer CU-related on quality of life would be significantly related to high levels of 
psychological distress.  
3) Individuals with CU would hold cognitive representations of their illness  
4) CU-related cognitive representations would be significantly related to coping behaviour 
5) CU-related representations would be significantly related to QoL and psychological distress 
6) The relationship between representations and outcome would be partially mediated by coping.  
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7.2: Method  
 
7.2.1: Design  
This cross-sectional survey required participants to complete questionnaires exploring: cognitive 
representations, coping behaviour, anxiety, depression, general health status, disease-specific quality of 
life and participant characteristics.  
 
7.2.2: Participants 
Participants had a confirmed diagnosis of chronic spontaneous urticaria and were recruited at St. 
John’s Institute of Dermatology, Guy’s and St. Thomas’ NHS Trust. The sample size required was 
estimated at 82 participants and was established using the programme G Power 3 (Faul, Erdfelder, Lang 
and Buchner, 2007) based upon correlation analyses, a medium effect size, a power of 0.8 and probability 
value of .05 two-tailed. The full recruitment process is reported in section 5.3.1 (p134). 
 
7.2.3: Measures 
The measures used in this study were the study-specific You and Your Urticaria Questionnaire,  
 IPQ-R, BMQ, Brief COPE, HADS, SF-36v2 and the CU-Q2oL. Detailed information on instruments can 
be found in Section 5.4, (p135). 
 
7.2.4: Procedure 
Participants completed questionnaires in one of two strategies, which are described below.   
Outpatient Clinic  
Patients were informed by their Dermatologist about the study being undertaken and if they would 
be interested in finding out more from the chief investigator (CI). Those confirming an interest were 
introduced to the CI in a private room. The Dermatologist presented the patient to the CI by name, current 
diagnosis and current disease status.  The CI introduced herself and provided a description of the study 
and asked if they wanted to know more. Patients were provided with a participant information sheet (PIS) 
to read and keep and given the opportunity to ask questions. Those declining were informed that they 
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could contact the CI using the contact details on the PIS if they changed their mind. Those agreeing tp 
participate completed and signed a consent form. Patients were then given the questionnaires to complete 
read and told to read the instructions carefully.  
 
Postal Procedure 
Patients were contacted by phone by the clinics administration team who asked for permission 
for the CI to contact them. The CI contacted those who agreed by phone and explained the purpose of 
the call. Agreeing patients were informed about the study, sent the PIS, consent form, questionnaires and 
a stamped reply envelope. Declining patients were thanked for their time  
 
7.2.6: Data Analysis 
Relationships between variables were explored using correlational analysis. Hierarchical linear 
multiple regression were used to determine the contribution of patient characteristics, cognitive 
representation and coping factors on 5 self-regulatory models of CU outcome. Path analysis based on 
multiple regression analyses were undertaken to test coping as a mediator of representations and 
outcome. Model fit was examined by Chi-square analysis (x2) and goodness of fit indices. Bonferoni 
corrections were applied to reduce type one error when doing multiple comparisons. Further details on all 
analyses can be found in section 5.6 (p145) 
 
7.3: Results 
 
7.3.1: Exploratory Data Analysis  
Exploratory data analyses suggested the use of parametric statistical data analyses with the 
exception of the variables disease duration and GP visits in the past 6 months, the Brief COPE negative 
cognitive appraisal, the SF-36v2 general health variable physical functioning and the CU-Q2oL’s swelling, 
impact on life activities and looks which were all significantly skewed. Removing outliers and extreme 
scores did not improve skew. The CU-Q2oL variables pruritus and limits appeared normally distributed 
but observations of their associated histogram and stem-and-leaf plots suggested that they might be of a 
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near bimodal distribution. Two further SF-36v2 subscales role physical and body pain were not 
significantly skewed but showed kurtosis with a build-up of scores on the right side of the distribution in 
line with physical function. It was decided that these variables would be explored using non-parametric 
statistics. The final two variables of concern, the IPQ-R personal control and SF-36v2 physical component 
summary (PCS) showed significant kurtosis. Their non-significant skew and the shape of their distributions 
curve suggested that they could be subjected to parametric tests but with caution in interpreting their 
findings.  
 
7.3.2: Patient Characteristics  
Participant data for Chapter 6 was used for this study. In summary, the study consisted of 81 
participants of whom the majority were female (90.1%), White British (80.2%), married or co-habiting 
(59.3%), employed (61.7%) with a mean age of 45.16 ± 14.06 years (95% CI, 42.04- 48.29, range 18- 80 
years) and age of onset 34.65 ± 16.27 years (95% CI, 31.03- 38.27). The majority were taking h1 anti-
histamine medicines alongside additional medications (64.2%).  
 
Relationships between Patient Characteristics and Study Variables 
Inter-correlations between patient characteristics and the study variables found numerous 
relationships: Younger patients were more likely to believe in accident/ chance causes (r = .22, p< .05), 
attributed a higher number of symptoms to their condition (r = -.26, p<.05), perceived CU to have more 
serious consequences (r = -.27, p<.05) but reported better levels of disease-specific QoL (r = -.42, p<.05). 
The remaining socio-graphic variables did not relate to the main study variables but exceptions were 
found. For ethnicity not being white was strongly and significantly related to a chronic timeline (r pb= -.28, 
p<.01) and poorer personal control (r = -.28, p<.01); poorer educational status to a necessity to take CU 
medicines (r pb= -.32, p<.01) and being employed to the use of support resources coping (r pb= .22, p 
<.05). Further being married was significantly related to less psychological cause perceptions (rpb= -.22, 
p =.03), better general mental health status (rpb= .27, p =.05) and better disease-specific QoL (rpb = -.29, 
p =.01). Gender was not explored due to the 9:1 ratio of female participants.  
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In terms of clinical characteristics those who developed their disorder earlier in life (i.e. age of 
onset) and hence had been experiencing CU longer also strongly and significantly reported a higher 
illness identity (r = -.3, p< 01) and more serious consequences (r = -.28, p =.01). Further experiencing 
angioedema was related to a chronic timeline (rpb =.22, p =.05) and taking CU medicines was significantly 
related to both a necessity to take CU medicines (rpb = -.27, p<.02) and better general physical health 
status (p<.05). Finally dietary restrictions were significantly related to concerns about CU medicines (rpb 
= -.26, p =.05) and positive cognitive appraisal coping (rpb = -22, p <.05). Risk factor and immunity causes, 
timeline cyclical, treatment control, illness coherence, emotional representations, proactive coping, use of 
support resources and depression were unrelated to patient characteristics.  
 
7.3.3: CU Outcome: Quality of Life and Psychological Distress 
The results of CU-related outcome are presented in Table 7.1 on page 184. On observation of 
Table 7.2 over a third reported poorer than average general physical and mental health status. However 
the overall distribution of scores suggested a moderate overall impact. A paired samples t-test confirmed 
that both aspects did not significantly differ from each other (t (1, 87), p >.05). Findings for disease-specific 
QoL mirrored health status with 35.6% reporting worse than average QoL and a moderate impact. CU 
appeared to impact appearance as much as physical aspects with poorer than average scores of 48.1% 
and 43.2% for pruritus and sleep problems respectively and 48.7% for looks. A post hoc Wilcoxon signed-
rank test confirmed that pruritus and sleep problems did not significantly differ from looks but they did 
when compared to other QoL aspects. Psychological distress was prevalent with possible/ probable 
anxiety totalling 65.2% and 35.0% for depression.  
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Table 7.1: Quality of Life and Psychological Distress in CU 
 
Subscale* (n- 81)                                        Mean/ SD  (CI 95%, lower- upper)                             Scale Scores Percentage                      α      Skew/ Error        Z              Kurtosis/ Error   Z 
 
 
 
 
 
 
 
 
 
Worse than average 
Unless otherwise stated 
 
 
Better than average 
Unless otherwise stated 
 
 
 
 
 
 
 
 
 
 
Psychological Distress 
Anxiety* 
Depression* 
 
General Health Status 
General physical health** 
General mental health** 
 
Disease-Specific Quality of Life 
Overall  
 
Aspects of Disease-Specific QoL           
Pruritus 
Swelling 
Impact on life activities 
Sleep problems 
Limits 
Looks 
 
 
9.45 ± 4.52   (CI 95%,  8.44 -10.45) 
6.55 ± 4.54   (CI 95%,  5.54 - 7.56) 
 
 
60.28 ± 23.83 (CI 95%, 55.01 - 65.55) 
57.04 ± 21.63  (CI 95%, 52.25 -61.82) 
 
 
42.52 ± 23.74 (CI 95%: 37.27- 47.77) 
 
 
 
 
 
 
 
 
 
 
28.90  possible disorder 
16.30  possible disorder 
 
 
35.80 
38.80 
 
 
35.60*** 
 
 
48.10 
16.00 
34.60 
43.20 
32.10 
48.70 
 
 
36.20 probable disorder 
18.70 probable disorder 
 
 
64.20 
60.50 
 
 
64.20 
 
 
40.70 
74.10 
60.50 
50.60 
61.70 
49.40 
 
 
.84 
.87 
 
 
.83 
.85 
 
 
.89 
 
 
.90 
.79 
.91 
.70 
.72 
.84 
 
 
 0.36/ 0.27 
 0.52/ 0.27 
 
 
-0.20/ 0.27 
  0.01/ 0.27 
 
 
 0.71/ 0.27 
 
 
-0.04/ 0.27 
 0.99/ 0.27 
 0.41/ 0.27 
 0.04/ 0.27 
 0.34/ 0.27 
 0.06/ 0.27 
 
 
 1.35 
 1.92 
 
 
 1.51 
 0.04 
 
 
 0.27 
 
 
-0.15 
 3.70*** 
 1.52 
 0.14 
 1.27 
 0.24 
 
 
-0.21/ 0.53 
-0.60/ 0.53 
 
 
-1.08/ 0.53 
-0.97/ 0.53 
 
 
-1.02/ 0.53 
 
 
-1.22/ 0.53 
-0.04/ .53 
-1.14/ 0.53 
-1.03/ 0.53 
-0.79/ 0.53 
-1.32/ 0.53 
 
 
-0.40       
-0.13 
 
 
-0.20 
-1.83      
 
 
 1.93 
 
 
-2.30    
-0.07 
 2.10* 
 1.94     
-1.50 
-2.50* 
Anxiety and depression* 8-10 = possible clinical disorder and 11-21= probable clinical disorder, General health status** 0= worse than average – 100= better than average    
Quality of life*** 0= better than average – 100= worse than average     
Skewness and/ or Kurtosis: *Z=1.96= Sig <.05       **Z=2.58= Sig <.01        ***Z=3.29 =Sig <.001
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When generic health status and disease-specific QoL domains were subjected to non-parametric 
correlation analysis a strong and significant negative relationship was found between the two concepts 
where those who reported lower than average generic health status also reported below average levels 
of disease-specific QoL. These findings confirmed the good convergent validity of the CU-Q2oL on SF-
36v2 found in study 2. 
 
7.3.4: Cognitive Representations  
 
Illness Identity 
The majority of participants identified wheals (96.3%), pruritus (92.6%) and swelling (88.9%) as 
symptoms related to their CU. Atypical symptoms included upset stomach (25.9%), headaches (25.9%) 
and sore throat (21.0%). The full list of CU symptoms can be found in Study 3 (Table 6.2, p155) 
 
Causal Attributions 
As presented in Table 7.2 (p186), almost two-thirds believed that their CU was caused by stress 
and nearly half reported the cause as altered immunity. Further a third reported that it was caused by 
chance (33.8%). When participants were asked if if they could think of any other factors that they believed 
may have caused their CU, their responses could be categorised into causes relating to stressful life 
events, medical/physiological or drug/chemical reaction factors. These item can be observed in the 
previous chapter (see Table 6.7, p173)    
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Table 7.2: Causal Attributions of Chronic Urticaria 
 
Cause (α) 
 
N 
                            Scale Scores (%) 
Strongly agree/ Agree Strongly disagree/Disagree 
 
Psychological (.80) 
 Stress or worry 
 My mental attitude 
 Family problems or worries 
 Overwork 
 My emotional state 
 My personality 
 
Risk factors (.70) 
 Hereditary 
 Diet/ eating habits 
 Poor medical care in my past 
 Own behaviour 
 Ageing 
 Smoking 
 Alcohol 
 
Immune (.50) 
 A germ or virus 
 Pollution in the environment 
 Altered immunity 
  
Accident or chance (.22) 
 Chance or bad luck 
 Accident or injury 
 
 
81 
80 
80 
80 
80 
79 
 
 
80 
79 
81 
79 
80 
80 
80 
 
 
79 
81 
79 
 
 
80 
80 
 
 
64.20 
12.60 
26.30 
21.30 
25.00 
08.90 
 
 
17.50 
20.20 
06.20 
13.90 
11.30 
06.30 
08.80 
 
 
16.50 
16.00 
49.30 
 
 
33.80 
05.00 
 
 
16.00 
62.50 
42.50 
42.50 
50.00 
69.60 
 
 
66.30 
51.90 
76.50 
58.20 
63.80 
76.30 
72.00 
 
 
53.20 
43.20 
22.80 
 
 
40.00 
75.00 
         *Scale: 1 strongly disagree – 5 strongly agree 
 
Other Cognitive Representations 
For the remaining perceptions (Table 7.3, p187) participants believed their CU to be a chronic 
and cyclical condition (>90%) with serious consequences (87.5%) and reported high emotional 
representations (87.7%). Forty-four percent reported having no personal control and similar proportions 
agreed (35.0%), disagreed (31.3%) or were undecided (33.8%) about whether what they did made 
symptoms better or worse. Beliefs in the necessity of taking CU medicines (88.6%) equalled concerns 
(87.3%) and 38.8% reported having a low illness coherence overall. 
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Table 7.3: Descriptive Summary of Cognitive Representations of CU 
 
 
Self-regulatory variable 
 
Items 
 
Mean 
(S.D.)* 
 
95% Confidence interval                   Scale Scores Percentage                                                Distribution  
 
 
 
 
Lower               Upper             Strongly agree/     Strongly disagree/      α            Skew/ Error       Z             Kurtosis/ Error      Z 
Bound               Bound            Agree                    Disagree 
 
Illness/ Treatment  n= 81/  
   Psychological Cause 
   Risk Factor Cause 
   Immunity Cause 
   Accident/ Chance Cause 
   Consequences 
   Timeline: acute/ chronic 
   Timeline cyclical 
   Personal control 
   Treatment control 
   Illness coherence 
   Emotional responses 
   Specific necessity 
   Specific concerns 
 
 
 
6 
7 
3 
2 
6 
6 
4 
6 
5 
5 
6 
5 
5 
 
 
 
2.70 ± 0.73       
2.79 ± 0.78 
2.22 ± 0.57 
2.50 ± 0.83 
3.61 ± 0.79 
3.61 ± 0.82 
3.91 ± 0.70 
2.95 ± 0.66 
3.41 ± 0.65 
2.83 ± 0.93 
3.49 ± 0.82 
3.63 ± 0.80 
3.29 ± 0.74 
 
 
 
52.50                    35.00                       .80           0.37/ .27          1.39         .020 / .53              0.04 
29.10                    70.00                       .70           0.17/ .27           0.62        -0.25/ .54            -0.46 
67.50                    32.00                       .50          -0.37/ .27         -1.39         -0.20/ .53             0. 38  
41.20                    42.50                       .22           0.29/ .27           0.69          0.49/ .53             0.39  
3.43                3.76                    87.50                    10.00                       .79          -0.39/ .27         -1.46         -0.29/ .54            -0.54 
3.43                3.79                    90.00                    07.50                       .78           0.02/ .27          0 .07          0.26/ .53             0.49 
3.75                4.07                    91.20                    05.00                       .75          -0.52/ .27         -1.90         -0.16/ .54             0.30   
2.80                3.09                    76.20                    15.00                       .75          -0.46/ .29           1.70          1.84/ .53            3.45** 
3.26                3.55                    95.00                    05.00                       .73           0.16/ .27           0.58         -0.28/ .53           -0.53 
2.62                3.04                    61.20                    38.80                       .84           0.03/ .27           1.19         -0.56/ .53           -1.05 
3.32                3.68                    87.70                    12.30                       .66          -0.16/ .27          -0.60         -0.05/ .53           -0.09 
3.44                3.81                    88.60                    11.40                       .83          -0.46/ .27            1.68        -0.46/ .54             0.86 
3.13                3.46                    87.30                    12.70                       .68          -0.21/ .27           -0.76        -0.23/ .54           -0.42 
 
Skewness and/ or  Kurtosis: *Z=1.96 = Sig < .05       **Z=2.58 = Sig <.01        ***Z=3.29 =Sig < .001 
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Interrelationships between cognitive representations are examined in Study 3 (Table 6.6, p168). In 
summary these showed patterns of relationships as would be predicted by the CSM.  
 
7.3.5: Coping 
 As shown in Table 7.4a the most reported was acceptance (80.1%). Other popular strategies 
included active coping, planning, using instrumental social support and self-distraction and humour. The 
least reported were substance use and denial but all strategies were reported by a quarter of participants.  
 
Table 7.4a: Self-Reported Coping Behaviours  
 
A-priori Cope Subscale 
 
N 
 
                      Percentage reporting behaviour 
 
 
  
Above scale mid-point 
Use a lot/ Medium amount 
Below scale mid-point 
Coping strategy not used 
  
Acceptance 
Active Coping 
Planning 
Instrumental. Social Support 
Self-Distraction 
Emotional Support 
Humour 
Positive Reframing 
Venting 
Religion 
Self-Blame 
Behavioural Disengagement 
Denial 
Substance Use 
 
80 
79 
80 
80 
79 
80 
80 
80 
80 
80 
80 
80 
80 
80 
 
80.10 
72.20 
68.70 
52.50 
49.40 
42.50 
36.20 
30.00 
27.50 
25.00 
23.70 
20.00 
13.70 
06.20 
 
02.50 
07.60 
17.50 
22.50 
24.10 
22.50 
33.80 
31.30 
36.30 
65.00 
48.80 
48.80 
72.50 
81.30 
 
.67 
.65 
.75 
.57 
.46 
.83  
.85 
.79 
.71 
.67 
.77 
.55 
.81 
.87 
 
The second-order PCA of the 14 subscales are presented in Table 7.4b. This PCA generated a 
four-component structure with eigenvalues greater than one and accounted for 69.63% of the variance. 
These were labelled Pro-active, Positive cognitive appraisal, Negative cognitive appraisal and Use of 
support resources. Over three quarters of participants reported using proactive coping and 41.5% positive 
cognitive appraisal strategies such as acceptance suggesting that large proportions were not. In contrast 
only 13.7% used negative cognitive appraisal strategies such as denial and self-blame and only a third 
reported using support resources.    
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Table 7.4b: Descriptive Summary of Second Order COPE Subscales in CU 
 
 
 Coping component 
 
Items 
 
Mean/ 
S.D.■ 
 
 
 
95% Confidence interval                Scale Scores Percentage 
 
 
Distribution  
 
 
 
 
Lower 
Bound 
 
 
Upper  
Bound 
 
 
Strongly agree/ 
Agree 
 
Strongly 
disagree/ 
Disagree 
 
Skew/ Error 
 
 
Z 
 
 
Kurtosis/ Error 
 
 
Z 
 
 
Proactive coping 
Negative cog appraisal 
Positive cog appraisal 
Support resources 
 
4 
4 
3 
2 
 
4.93 ± 1.52 
3.30 ± 1.39 
4.60 ± 1.51 
4.45 ± 1.64 
 
 
 
 
 
 
4.59 
2.99 
4.27 
4.09 
 
5.27 
3.60 
4.82 
4.94 
 
71.60* 
13.70* 
41.50* 
31.20 
 
28.4 
86.3 
58.5 
68.8 
 
-0.19/ 0.27 
 1.43/ 0.27 
 0.41/ 0.27 
 0.08/ 0.27 
 
-0.72 
5.32 
1.54 
0.30 
 
-0.71/ 0.53 
 1.87/ 0.53 
-0.46/ 0.53 
-0.88/ 0.53 
 
-1.34 
  3.51  
-0.89 
-1.65 
Second order PCA of Brief COPE subscales statistics: KMO criteria for measure of sampling adequacy= .73, Bartlett’s test of sphericity = (x2 (66) =.346.27, p< .001) 
■Skewness and/ or  Kurtosis: *Z=1.96 = Sig < .05       **Z=2.58 = Sig <.01        ***Z=3.29 =Sig < .001 
 
 
Key:  
Pro-active Coping: Active coping, Self-distraction, planning;  
Positive cognitive appraisal coping: Humour, acceptance, positive reframing,      
Negative Cognitive Appraisal Coping: Behavioural disengagement, self-blame, denial, venting;  
Use of Support Resources: Use of instrumental social support, use of emotional support 
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7.3.6: Cognitive Representations and Coping 
As highlighted in Table 7.5a (p191), cognitive representations were generally not related to coping 
but those who reported a strong illness identity and high emotional representations reported significantly 
greater use of proactive coping behaviours. However strong relationships were also found between a high 
illness identity, high emotional representations and the use of negative cognitive appraisal coping. All 
casual attributions (except chance) related to a greater use of proactive coping behaviours but 
psychological attributions were also significantly related to the use of negative cognitive appraisal coping. 
Serious consequences were also strongly related to negative cognitive appraisal coping (Table 7.5b, 
p191). A further three relationships found significantly positive relationships between illness coherence 
and use of positive cognitive appraisal coping, and high treatment control and emotional responses to a 
greater use of support resources. 
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Table 7.5a: Linear Relationships between Cognitive Representations and Coping Behaviours* 
 
                                  Identity    Psych      Risk        Immunity     Chance      Timeline    Timeline    Consequences    Personal     Treatment     Illness           Emotional       Specific     Specific          
                                                  Cause     Cause     Cause        Cause         (a/c)           Cyclical                                 Control       Control          Coherence   Responses     Necessity  Concern 
 
Pro-Active Coping     .319**      .227*       .277*       .287**          .129           .104           -.072          .066                    .211             .006             .055              .267*               .137          .207 
 
Pos. Cog. Appraisal  .174         .181        .177         .207             .170           .012            .052        -.005                     .091             .202            .241*             .073                 .011         -.025 
 
Use of Support          -.145       .012         .036         .054             .059          .107             .087          .030                   .165             .240*           .043              .224*               .102          -.173 
*p< .05, **p< .01,  ***p< .001 Significant 2-Tailed (Bonferoni correction applied) *Pearson’s r 
 
Table 75b: Non-linear Relationships Negative Cognitive Appraisal Coping* 
 
                                    Identity    Psych     Risk        Immunity    Chance      Timeline    Timeline    Consequences     Personal    Treatment     Illness             Emotional       Specific      Specific          
                                                   Cause     Cause     Cause        Cause        (a/c)          Cyclical                                   Control       Control         Coherence     Responses     Necessity   Concerns 
 
Neg. Cog. Appraisal    .226*       253*        .196        .058           .165           .215           .172          .348**                   -.067           -.115             -.133              .490***            .153            .215 
*p< .05, **p< .01,  ***p< .001 Significant 2-Tailed  (Bonferoni correction applied) *Spearman’s Rho 
 
Pro-active Coping: active coping, self-distraction, planning;  
Positive cognitive appraisal coping: humour, acceptance, positive reframing,      
Negative Cognitive Appraisal Coping: behavioural disengagement, self-blame, denial, venting;  
Use of support resources: use of instrumental social support, use of emotional support 
7.3.7: Cognitive Representations and Outcome 
As illustrated in Table 7.6a below perceptions of serious consequences presented as the 
strongest and most significant correlate of all outcomes bearing relationships to higher anxiety (p <.001), 
higher depression (p <.001), poorer general physical (p <.001) and mental health status (p <.001) and 
poorer disease-specific QoL (p <.001). Strong relationships were also found between a high illness 
identity, high emotional representations and outcome were correlations between psychological 
adjustment were always positive and QoL poorer than average. High chronicity and specific necessity 
beliefs presented a similar pattern but were unrelated to general physical health status and anxiety 
respectively. Specific concerns about CU medicines were related to higher levels of depression (p <.01), 
poorer general physical (p <.01) and mental health status (p <.01).  
 
Table 7.6a: Relationships between Cognitive Representations and Outcomes 
       
 
 
 
Anxiety 
 
 
Depression 
 
 
General PH* 
 
 
General   MH* 
 
 
Overall QoL             
 
 
Illness Identity. 
Psychological cause. 
Risk cause 
Immunity cause 
Chance cause 
Timeline-acute/chronic 
Timeline cyclical 
Consequences 
Personal control 
Treatment control 
Illness coherence 
Emotional Represent. 
Necessity 
Concerns 
 
 .373** 
 .272* 
 .191 
 .031 
 .224* 
 .259* 
 .114 
 .361*** 
 .188 
-.174 
-.163 
 .494*** 
 .214 
 .208 
 
 .426*** 
 .100 
 .080 
-.021 
 .114 
 .260* 
 .013 
 .448*** 
-.128 
-.360** 
-.208 
 .386*** 
 .330** 
 .305** 
 
-.582** 
-.039 
-.063 
 .019 
-.060 
-.289** 
-.004 
-.497*** 
-.080 
 .208 
.109 
-.297** 
-.436*** 
-.341** 
 
-.522*** 
-.230* 
-.158 
-.008 
-.147 
-.289** 
-.022 
-.434*** 
-.067 
 .241* 
 .191 
-.397*** 
-.358** 
-.308** 
 
 .577***     
 .123 
 .089 
-.022      
 .052   
 .589***   
 .101 
 .555***  
-.065                                                                                                                                                          
-.216          
-.168                         
 .385** 
 .419***                          
 .209 
*p<.05,  **p< .01,  ***p< .001 Significant 2-Tailed  (Bonferoni correction applied) PH: Physical health, MH: Mental Health 
 
 
 193 
 
Relationships between Cognitive Representations and aspects of Disease-Specific Outcome 
As presented in Table 7.6b below a high identity, beliefs of a chronic timeline and serious 
consequences were all strongly related to the self-reporting of more swelling, impact on life activities, 
sleep problems, limitations, concerns about looks (all p<.001) and pruritus (p<.01). Emotional 
representations were also significantly related to all outcomes and again more for concerns about looks 
over pruritus. Specific necessity beliefs also showed significant relationships to all outcomes but in 
contrast (and with exception of pruritus) specific concern beliefs also had a negative impact on all QoL 
outcomes. A greater understanding of CU was significantly related to less concern about looks and 
perceptions of better treatment control were significantly related to better aspects of QoL. 
 
Table 7.6b: Relationships between Representations and Disease-Specific Quality of life 
 
 
 
 
 
Pruritus 
 
 
Swelling 
 
 
Impact on 
Life activities 
 
Sleep 
Problems 
 
Limits 
 
 
 
Looks                   
 
 
Illness identity 
Psych cause 
Risk cause 
Immunity cause 
Ac/ chance cause 
Timeline a/c 
Timeline cyclical 
Consequences 
Personal control 
Treatment control 
Illness coherence 
Emotional 
Necessity 
Concerns 
 
 .295** 
 .105 
 .080 
-.005 
-.010 
.495*** 
 .012 
 .446*** 
 .020 
-.236* 
-.069 
 .231* 
 .301** 
 .060 
 
 .408*** 
 .043 
 .062 
 .093 
 .117 
 .339** 
 .053 
 .574*** 
 .111 
-.293** 
-.155 
 .356** 
 .395*** 
 .282* 
 
 .609*** 
 .174 
 .132 
-.006 
 .042 
 .506*** 
 .023 
 .537*** 
 .084 
-.286* 
-.085 
-.350** 
 .415*** 
 .244* 
 
 .479*** 
 .199 
 .141 
-.008 
 .002 
 .394** 
 .122 
 .344** 
-.063 
-.238* 
-.022 
 .275* 
 .264* 
 .364* 
 
 .457*** 
 .093 
 .148 
 .031 
. 066 
 .475*** 
 .069 
 .425*** 
-.027 
-.251* 
-.068 
 .364** 
 .307** 
 .267* 
 
 .388***     
 .136  
 .078 
-.057                                               
 .043  
 .556***  
 .234* 
 .457*** 
-.085                                                                                                                                              
-.219 
-.257*      
 .409*** 
 .277*               
 .277* 
*P < .05, **P < .01,  ***P < .001 Significant 2-Tailed (Bonferoni correction applied) 
 
Relationships between Representations and Outcome Controlling for Patients Characteristics 
Partial correlations were undertaken to determine if the relationship between significantly 
correlated cognitive representations and outcomes were still significant when controlling for socio- 
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demographic and clinical variables known to be related to these outcomes significant relationships 
between cognitive representation and CU outcomes still held when controlling for patient characteristics 
with the exception of that between psychological cause and general mental health status (r = -.23, p < 
.05). Controlling for marital status, this relationship was not significant (r = -.18, p >.05).  
 
7.3.8: Coping and CU Outcome 
When linear relationships between coping and outcome were examined both positive cognitive 
appraisal and use of support resources coping were unrelated to all outcomes (see Table 7.7a). In 
contrast the exploration of non-linear relationships between negative cognitive appraisal coping and 
outcome (Table 7.7b) found very strong and significant relationships to all outcomes. Linear relationships 
between proactive coping and outcome were only significant to anxiety, general mental health status and 
disease-specific QoL. Even though these relationships were not as strong as for negative cognitive 
appraisal coping, they were important as findings reported earlier found that 71.6% of participants used 
proactive coping with over just 13.7% who used negative cognitive appraisal.    
 
Table 7.7a: Linear Relationships between Coping Behaviour and Outcomes▲ 
 
 
 
 
Anxiety 
 
Depression 
 
PCS 
 
MCS 
 
Overall QoL         
 
Pro-Active Cope 
 
Pos Cog. Appraisal 
 
Use of Support 
 
 
.236* 
 
.181 
 
.010 
 
 
 .186 
 
-.107 
 
-.162 
 
 
-.192 
 
-.018 
 
 .153 
 
 
-.241* 
 
-.077 
 
 .069 
 
 
.268*               
 
.095 
 
.035 
 
      *P <.05 Significant 2-Tailed▲Pearson’s r 
 
Table 7.7b: Non-Linear Relationships between Negative Cognitive Appraisal and Outcomes▲ 
 
 
 
 
Anxiety 
 
Depression 
 
PCS 
 
MCS 
 
Overall QoL 
 
Neg.  Cog. Appraisal 
 
 
.564*** 
 
 
.450*** 
 
 
-.288** 
 
 
-.477*** 
 
 
-.447***      
 
     **P < .01, ***P < .001 Significant 2-Tailed   ▲Spearman’s rho 
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7.3.9: Self-Regulatory Predictors of Outcome 
These analyses examined relevant self-regulatory factors as predictors of five different models of 
CU outcome. The coping predictor featured in each model was pro-active and not negative cognitive 
appraisal coping. The justification for this was that the data that represented pro-active coping was 
normally distributed and therefore appropriate for multiple regression whereas the original data that 
represented negative cognitive appraisal coping behaviour was not (up to this point the latter has been 
examined using non-parametric statistics). Proactive coping was also the coping strategy used by over 
two-thirds of the study sample as reported earlier, however non-linear relationships found between 
negative cognitive appraisal and outcome appeared too important to ignore and therefore the data for this 
variable was re-coded into a discrete dichotomous score (i.e. 1= used strategy a lot/ medium amount and 
0= a small amount/ not at all) for exploratory purposes to examine its contribution. Only variables that 
correlated significantly to each outcome were entered block-wise into each regression model. As shown 
in Tables 7.8a-b (psychological distress) and 7.8c (QoL) on p196 and p197 respectively predictors 
explained 35.0 to 64.0% of the total variance in outcomes.   
 
Patient Characteristic Predictors of Outcome 
Only marital status contributed a significant 9% of the variance in generic mental health status (F 
(1, 74) = 7.09, p< 0.05) and together with age predicted a strong and significant 15% of disease-specific 
QoL (F (1, 74) = 3.77, p< 0.01).  
 
Cognitive Representational Predictors of Outcome 
Illness and treatment perceptions explained a strong and significant 35.4 to 60.6% of the variance 
in the outcome across the regression models. Emotional representations, which were entered in its own 
block across models explained a smaller but significant 4% and 9.6% of the variance in general mental 
health status and anxiety respectively.  
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Table 7.8a: Regression Models of Cognitions and Proactive Coping on Psychological Distress 
 
Regression Model 
 
Anxiety 
 
Depression 
 
Predictor Block  1 
 
β                     t- value 
 
β                     t- value 
 
Illness identity 
Psych cause 
Chance cause 
Timeline (chronic) 
Consequences 
Treatment control 
Necessity 
Concerns 
Block Model 
 
 
 0.26                2.24* 
 0.11                1.02 
 0.08                0.71 
 0.07               -0.61 
-0.03               -0.19 
 n/a                   n/a 
 n/a                   n/a 
 n/a                   n/a 
R2 25.8%,         Adj. R2  21% 
F (5,71) = 4.95*** 
 
 0.26                 -0.25* 
 n/a                    n/a 
 n/a                    n/a 
 0.01                  0.07 
 0.07                  0.52 
-0.23                -2.08* 
 0.16                 1.39 
 0.17                 1.52 
R236.3%,          Adj. R2  30.6% 
F (6,68) = 6.45*** 
 
Predictor Block  2 
 
 
 
 
 
Emotional representation 
Block Model 
 
 
0.41                   3.08** 
R2  35.4%,         Adj. R2  30.0% 
F (1,70) = 10.35** 
 
0.15                  1.14 
R2  37.5%,         Adj. R2  30.9% 
F (1,67) = 1.29 
 
Predictor block 3  
 
 
 
 
 
Proactive coping 
Block Model 
 
 
-0.00                 -0.01 
 R2  35.4%,         Adj. R2  28.8% 
 F (1,69) = 0.00 
 
n/a                     n/a 
n/a                     n/a                                     
n/a                     n/a 
 
Overall Final Model (F) 
 
F (1, 69) = 5.40*** 
 
n/a                     n/a 
*p< .05,  **p< .01, ***p< .001    
 
Table 7.8b: Regression Models of Cognitions and Negative Cognitive Appraisal 
Coping on Psychological Distress 
 
Predictor block 3▲ 
  
 
Negative cog. Appraisal 
Model 
 
 
0.22                 1.91 
R2  38.6%,       Adj. R2 29.9% 
F (1,66) = 2.38 
 
0.18                    1.54 
R2 37.5%,            Adj. R2  29.9% 
F (1, 66) = 0.00 
 
Overall Final model (F) 
 
F (1, 66) = 6.21***                                             
 
F (1/66) = 4.94*** 
*p< .05,  **p< .01, ***p< .001     ▲Blocks 1 and 2 was the same as proactive coping 
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Table 7.8c: Regression Models of Cognitions and Coping on Quality of Life  
                                        Generic physical health                Generic mental health                 CU-Specific QoL 
                                        Β                   t- value                      β                     t- value                   β                     t – value 
 
Age                                n/a                  n/a                             n/a                  n/a                         -0.01                0.17 
Marital status                 n/a                  n/a                             0.17               1.75                        -0.18                2.34* 
CU Medicines                0.08                0.94                           n/a                  n/a                          n/a                  n/a 
 
Block 1 Model               R2 4.8%,         Adj. R2  3.6%,           R2 8.70%,        Adj. R2  7.5%          R2 14.5%,       Adj. R2 12.1% 
                                       F (1,74) = 3.77                                 F (1,74) = 7.09**                            F (2,73) = 6.18** 
 
Illness identity              -0.38               -3.78**                       -0.34                2.94**                     0.26                 2.80** 
Psych cause                  n/a                  n/a                            -0.04              -0.43                         n/a                  n/a 
Chance cause               n/a                  n/a                              n/a                 n/a                          n/a                   n/a 
Timeline (chronic)        -0.02               -0.14                           -0.00              -0.04                        0.32                3.80*** 
Consequences             -0.20              -.2.06                            0.02               0.11                        0.21                2.0 
Treatment control          n/a                -1.46                             0.14               1.34                        n/a                  n/a 
Specific necessity        -0.15               n/a                              -0.14             -1.30                        0.12                1.47 
Specific concerns        -0.20               -2.03                           -0.15              -0.46                        n/a                  n/a 
 
Block 2 Model             R2 50.1%,        Adj. R2 45.8%             R2 43.4%,      Adj. R2 36.7%        R2 62.1%,        Adj. R2 58.8% 
                                     F (5,69) = 12.52***                             F (7.67) = 5.87***                         F (4,69) = 21.64***                         
 
Emotional represent    . -.02               -0.15*                           -0.24              -1.97*                      0.07                 0.74 
  
Block 3 Model              R2 50.1%,       Adj. R2 45.0%             R2 46.8%,     Adj. R2 39.5%         R2 62.8%,         Adj. R2 59.0% 
                                      F (1,68) = 0.2                                     F (1,66) = 4.15*                            F (1,68) = 1.43     
 
Proactive Coping as a final block entry▲ 
 
Proactive coping            n/a                n/a                               0.01                0.06                         0.11               1.30 
 
Block 4 Model              n/a                n/a                               R2 46.8%,        Adj. R2 38.6%        R2 63.8%,     Adj. R2 59.4% 
                                      n/a                n/a                               F (1,65) = 0.00                               F (1,67) = 1.68      
 
Overall Final model     n/a                n/a                              F (1,65) = 5.71***                            F (1,67) = 14.73***                   
 
Negative Cognitive Appraisal  as a final block entry▲ 
 
Neg Cog Appriasal       -0.05             -0.51                            -0.11               -1.05                          0.01                0.90 
 
Block 4 Model              R2 39.9%,        Adj. R2 33.8%           R2 46.9%,       Adj. R2 38.7%          R2 65.3%,     Adj. R2 61.1% 
                                      F (1,69) = 0.26                                  F (1,65) = 0.16                                F (1,67) = 4.66                     
 
Overall Final model     F(1,69) = 6.55***                               F (1,65) = 5.74***                            F (1,67) = 15.73***                 
*p< .05,  **p< .01, ***p< .001   ▲Coping variables were analysed separately in two different models  
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The best cognitive representational predictor of anxiety was illness identity (t (70)= 2.38, p< .05). 
Together with treatment control (t (68)= -2.04, p< .05) illness identity (t (68)= 2.15, p< .05) was also a 
significant predictor of depression. Again Illness identity (t (69)= -3.85, p< .001) with consequences (t 
(69)= -2.37, p< .05) and specific concerns (t (69)= 2.16, p< .05) significantly predicted general physical 
health status. Further illness identity (t (66)= -3.09, p< .01) together with emotional representations (t 
(66)= -2.04, p<.05) predicted general mental health status. Finally, illness identity (t (69)= 3.22, p< .01) 
and chronic timeline (t (69)= -3.8, p< .001) strongly predicted disease-specific QoL. 
 
Coping as Predictors of Outcome  
Weak relationships between proactive coping and outcome were reflected in their inability to 
significantly predict outcome in any regression model (all p >.05). Negative cognitive appraisal, which 
bared strong relationships to outcome, also failed to predict outcome across models (all p >.05).    
 
7.3.10: Coping as a Mediator between Representations and Outcome  
Finally path analyses were undertaken to examine whether the relationship between 
representation and outcome is mediated by coping behaviour. Earlier analysis had already established 
that negative cognitive appraisal was an insignificant predictor of all outcomes, as were proactive coping 
on depression, general physical health status and disease-specific QoL and therefore violated the third 
criteria for testing mediation (i.e. the mediator must significantly predict the outcome). No mediation tests 
were undertaken of these models. Only the cognitive representational components of identity, 
psychological attributions and emotional representations correlated to both proactive coping and anxiety, 
general mental health status and disease-specific QoL outcomes and therefore were subjected to further 
regression and mediation tests. The results of the mediation tests for each model including a summary of 
representational predictors of coping behaviour, path estimates of mediation effects and goodness-of-fit 
indices are presented in Table 7.9 (p199). 
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Table 7.9: Summary of Pro-Active Coping Multiple Regression Models, Mediation and Goodness of Fit Tests 
 
 
Model 
 
Overall 
Coping Model 
 
Possible predictor 
of pro-active coping 
 
β             t 
 
             
         Mediation Tests 
 
Goodness  of Fit Tests 
 
Direct     Indirect      Total        Sobel Test 
 
GFI                                     CFI    NFI     RMSEA 
 
Anxiety 
 
 
 
R2  17.4% 
Adj. R2  14.1% 
F (76) = 5.33** 
 
Illness identity 
Psychological cause 
Emotional representation 
 
.27      2.53*      .28           .00               1.28         -.0.01, p=.99 
.14      1.53       .12           .00                 .12         -.0.01, p=.99 
.21      1.92        .41          .00                 .41         -.0.01, p=.99 
 
x2 = 8.07, df = 9, p = .53      .1     .95       p < .001 (CI .00-.12) 
 
 
     
 
Generic 
Mental 
Health 
 
R2  17.4% 
Adj. R2 14.1% 
F(69) = 5.33** 
 
Illness identity 
Psychological cause 
Emotional representation 
 
.27      2.53*     -.39          .00               -.39          -.0.05, p=.96 
.14      1.53      -.06          .00               -.06           -.0.05, p=.96 
.21      1.92      -.22          .00               -.22           -.0.05, p=.96 
 
x2 = 32.64, df = 26, p= .17    .95    .85       p = .06 (CI .00- .11) 
 
 
     
 
Disease- 
specific 
QoL 
 
R2  15% 
Adj. R2 13% 
F (78) 7.04** 
 
Illness identity 
Emotional represent 
 
 
.292    .74**      .28          .03                .031            0.16, p= .26 
.232    .17*       .09          .002              .090            1.04, p= .30 
 
 
x2= 13.77, df= 15, p= .54       1     .93       p < .001 (CI .00- .1) 
 
 
*p<.05,   **p< .01,***p< .001   Key: GFI: Goodness of fit index, NFI: Normative Fit Index, RMSEA/ CI: Root Mean Square Error of Approximation (and its confidence interval) 
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Path Analysis Model of Anxiety 
The co-variances between cognitive representations in the anxiety model and paths from 
representations to coping and coping to outcome are illustrated in Figure 7.1 below. An initial 
observation of the path diagram confirmed that the co-variances between the predictor variables 
and the path coefficients between predictors and outcomes were a close match to their 
corresponding correlation matrix and multiple regression B coefficients with little error, however 
mediation tests shown in Table 7.9 (p199 above) and the coping to outcome path in Figure 7.1 
suggested that coping was not a significant mediator. Only illness identity presented as a 
significant predictor of proactive coping (p <.05). The path coefficients of both emotional 
 
Figure 7.1: Path Analysis Model Predicting Anxiety 
 
 
representations and psychological cause predictors on proactive coping were insignificant 
violating the second criterion for testing a mediation model. The indirect effect from emotional 
representation to anxiety via proactive coping was estimated as zero indicating that no mediation 
had occurred. These findings mirrored those of illness identity and psychological attributions that 
also failed to show mediation in the anxiety model, so even though proactive coping was related 
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to anxiety it did not appear to significantly predict it. The Sobel test confirmed a lack of mediation 
for identity and emotional representations on anxiety (p >.05). The remaining direct relationships 
in the path were not significant predictors of anxiety. A goodness of fit test (GFI) of the model 
produced a non-significant chi-square indicating the model as a good comparative fit. Other good 
fit indices applied the CFI indicated a perfect fit, the NFI was a good fit as was the RMSEA and 
its 90% confidence intervals and estimation of close-fit. Dropping the insignificant paths reduced 
the model fit and so they remained.  
 
Path Analysis Model of General Mental Health Status 
The co-variances between cognitive representations in the general health status model 
and paths from representations to coping and coping to outcome are illustrated in Figure 7.2 
 
Figure 7.2: Path Analysis Model Predicting General Mental Health Status  
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An observation of the path diagram confirmed that the co-variances between the 
predictor variables and the path coefficients between predictors and outcomes were again a 
close match to their corresponding correlation matrix and multiple regression B coefficients 
however, as for the anxiety model mediation tests shown in Table 7.9 (p199) and the coping to 
outcome path in Figure 7.2 suggested that no mediation had occurred between representations 
and outcome. Only Illness identity presented as a significant predictor of proactive coping (p < 
.05). In line with the anxiety model the maximum likelihood path coefficients from emotional 
representation to anxiety via proactive coping were estimated as zero and the total effect 
replicated the direct effect indicating that proactive coping was not a significant mediator between 
emotional represents and outcome. These findings mirrored illness identity and psychological 
attributions that also failed to show mediation here. The Sobel test confirmed the lack of 
mediation (all p >.05). The remaining direct relationships were not significant predictors.      
 
The goodness of fit test (or GFI) of the model indicated a good and comparative model 
fit. The CFI also indicated a good fit. The NFI fell slightly short of a good fit as was the RMSEA 
and its 90% confidence intervals and estimation of close-fit. Dropping the insignificant paths 
reduced the model fit and so remained in the model. Dropping the insignificant paths reduced 
the model fit further producing a significant chi-square so remained in the model.       
 
Path Analysis Model of Overall Disease-Specific Quality of Life 
The co-variances between cognitive representations in the overall disease-specific QoL 
model and paths from representations to coping and coping to outcome are illustrated in Figure 
7.3 (p203). The path estimates suggested that no mediation had occurred. Again Illness identity 
presented as the only significant predictor of proactive coping (p< .05) In line with other models 
the maximum likelihood path coefficients from emotional representation to anxiety via proactive 
coping were estimated as zero and the total effect replicated the direct effect 
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Figure 7.3: Path Analysis Model Predicting Disease-Specific Quality of Life 
 
 
indicating that proactive coping was not a significant mediator between emotional represents and 
outcome. Illness identity also failed to show mediation in this model and this was again confirmed 
by the Sobel test (all p >.05). The remaining direct relationships in the path were not significant 
predictors of outcome. The remaining direct relationships in the path were significant for marital 
status (p< .05) and timeline (acute/ chronic; p <.001) but consequences fell marginal of a 
significant direct relationship (p= .052). Age and specific necessity were not significant predictors 
of outcome. The CFI was 1 indicating a perfect fit and the NFI indicated a good model fit. The 
RMSEA and its 90% confidence intervals also indicated a good fit and an excellent close-fit well 
above the .50 recommendations. Dropping the insignificant paths reduced the model fit further 
producing a significant chi-square so remained in the model. 
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7.4: Discussion  
The aim of this study was to explore a role for cognitive representations of CU as 
determinants of CU-related quality of life outcomes within the CSM. This study first confirmed 
the hypothesis that CU has a moderate impact on quality of life (QoL) and is associated with 
significant psychological distress. The study’s main hypotheses were largely supported in that 
the data provided strong preliminary evidence to suggest that individuals with CU hold cognitive 
representations of their illness and they hold them in similar predictable relationships to other 
chronic illnesses. Further strong direct relationships were found between representations and 
outcome in directions predicted. Representations were the strongest predictors of CU-related 
outcomes explaining 35.4 - 60.6% variance across models but coping as a mediator was not 
supported. These findings and their implications are discussed below in the context of the studies 
methodological limitations.   
 
CU Outcome 
The first finding supported the hypothesis that CU had a moderate impact on QoL. This 
moderate impact is in line with the findings of the systematic reviews reported in studies 1 and 
2. The aim of study 1 was to systematically review the impact of CU on quality of life and the 
results were initially equivocal as they indicated that CU had a mild or moderate impact 
depending on which QoL instrument had been used within studies. More specifically a mild 
impact was reported if the DLQI (Dermatology Life Quality Index) had been used and a moderate 
impact for other QoL instruments (e.g. SF-36, Skindex-29; CUQ2-oL). The systematic review of 
QoL instruments (study 2) aimed to resolve this by determining which questionnaires were the 
most valid and reliable for CU research. Strong evidence from this review together with 
psychometric investigations from other studies (Twiss et al. 2012; Basra et al. 2008; Both et al. 
2007; Lenox and Leahy, 2004; De Korte el al. 2002; Nijsten, 2012) supported the supposition 
that the DLQI was not a valid measure of CU-related QoL. It was concluded in study 2 that the 
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SF-36 and CU-Q2-oL be used as measures of CU-related QoL. Their use in this study provided 
further evidence to support that the moderate impact found in this CU study sample is 
representative of the wider CU literature.  
 
A pertinent related finding in this study was that CU impacts all aspects of QoL and not 
just physical functioning. More specifically 35.8% of the sample reported poorer generic physical 
health (60.28 ± 23.83) as to 38.8% who reported worst generic mental health (57.04 ± 21.63) 
and further 48.1% as to 48.7% reported worse impact regarding disease-specific pruritus (itch) 
as to disease-specific Looks respectively. Such reports mirror the findings of the systematic 
review in study 1 that the impact on psychological aspects is often similarly (or more impaired) 
than the physical aspects (see section 3.3.4, p74), hence the CU sample in this study reflected 
the wider CU research literature. These findings supported that the psychosocial aspects of CU 
need to be addressed by health professionals working with these patients. The implications and 
practicalities of addressing psychosocial aspects of CU were discussed in great detail in Study 
1 (section 3.5) but in summary this concerned the absence of CU-based interventions in routine 
care (Maurer et al. 2011), whether dermatologists have the skill set and consultation time to help 
patients cope with the psychosocial aspects of CU and whether psychologists need to be 
integrated into existing dermatological services or part of a structured psychology referral 
system. In the wider context of psycho-dermatological research these findings support the case 
for equally addressing appearance issues in visible skin disorders (Thompson, 2005) including 
individuals with CU where the fluctuating nature of CU symptoms had previously lead health 
professionals to believe its appearance had little impact on those experiencing it. 
 
The secondary study outcome was psychological distress with mean scores of 9.45 ± 
4.52 for anxiety and 6.55 ± 4.54 for depression. With higher scores indicating worse outcome 
and scores of 8-11 for possible co-morbidity the sample was more anxious than depressed and 
this was reflected in the combined possible-probable prevalence rates of 65.2% and 35.0% for 
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anxiety and depression respectively. These findings are in line with the studies summarised in 
Chapter 1 in that individuals with CU appear to be relatively more anxious than depressed (12 - 
76.1% and 17- 43% respectively; see Table 2.1, p38), therefore they are consistent and 
representative of the research literature. 
 
Individuals with CU hold Cognitive Representations of CU  
In order to establish if representations of CU were significant correlates and predictors 
of CU-outcomes, it was first important to establish if individuals with CU held cognitive 
representations of their illness and if they held them in similar predictable relationships to other 
chronic illnesses. These hypotheses were initially supported in Study 3 in that the principal 
component analyses of the Revised Illness Perception Questionnaire (IPQ-R) and Beliefs about 
Medicines Questionnaire (BMQ) using CU data confirmed that these individuals cognitively 
configured perceptions of their illness in terms of identity, cause, timeline, cure/ control, 
emotions, necessity and concerns. In regards to the wider cognitive representational research 
literature this provided further support for the existence of these representations in another illness 
population (i.e. CU) but more specifically the data allowed for a closer examination of precisely 
how well individuals with CU actually understand their illness, how they assimilate and 
accommodate the symptom perceptions and social messages that are said to form them and 
how this can be changed.  
  
The data indicated that to experience CU was to associate the condition to a high 
numbers of symptoms (illness identity) perceived to be attributed to psychological stress and/ or 
altered immunity (cause). Further, to live with CU meant living with a chronic condition that would 
be around for a very long time, even maybe the rest of one’s life (chronic timeline) and it would 
come and go in unpredictable cycles (timeline cyclical). With such a timeline future prospects 
appear poor and it could be perceived in advance that CU would have serious consequences on 
one’s on-going bio-psychosocial functioning of which any hope to controlling it personally or with 
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treatment (control) is met with scepticism. Such representations are further compounded by a 
parallel high emotional response within the self (emotional responses). Even though this will vary 
to some degree across illnesses, it is known from Hagger and Orbell’s (2003) meta-analytical 
review of the CSM that it is typical for chronically ill individuals to represent their lived illness 
experience in such a way, particularly the negative relationship between control perceptions and 
other illness perceptions, but what is more pertinent is if these are actually true representations 
of CU.    
 
Identity, psychological attributions and emotional representations are predictors of CU outcome 
The majority of the sample did associate itching and swelling to their CU illness identity 
in line with a medical understanding of the condition (Zuberbier et al. 2009a) but they also 
reported atypical symptoms at least 20% of the time including upset stomach, headache and 
sore throat which are not recognised CU symptoms. According to the CSM it is not unusual for 
individuals to assimilate and accommodate both typical and atypical symptoms they have 
experienced since their illness symptoms began and it appears that as part of the CSM’s 
symmetry rule (i.e. linking symptoms to labels and labels to symptoms) this is what happens in 
many cases. Another explanation is that the sample was demonstrating somatisation but this 
was found to be insignificant. What is of great significance is that it was a high illness identity 
that was found to be the most influential component of CU representations strongly and 
significantly relating to poorer disease-specific aspects of QoL (itching, swelling, sleep problems, 
impact on life activities, limitations, looks) and directly predicting more anxiety, poorer general 
mental health status and overall disease-specific QoL. If illness identity is so core to CU-related 
outcomes these findings suggest that practitioners may have an opportunity during short 
consultations to considerably help improve the QoL of their patients by facilitating talk regarding 
cognitive representations of CU symptomatology and dispelling fact from fiction (i.e. checking 
knowledge and correcting misconceptions).   
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In line with other chronic illnesses two-thirds of the sample believed that psychological 
stress caused their illness (Hagger and Orbell, 2003). Psychological stress is not currently 
formally recognised as being a determinant (Maurer et al. 2011) but a growing evidence base is 
relating CU to stressful life events (e.g. Malhotra and Mehta, 2008; Dyke et al. 2008; Chung, et 
al. 2010a; Gupta and Gupta, 2012; Hunkin and Chung, 2012). The ability of stress to trigger or 
worsen pruritus in skin disorder has been well documented (e.g. Milard, 2005; Gupta and Gupta; 
2004; Picardi and Abeni, 2001) and CU itself has been recognised as a psychogenic condition 
since the 1950’s (Rees, 1957; Shipman, et al. 1959) but exactly how stress relates to CU process 
is not completely understood and more research is needed (Gupta and Gupta, 2012; Hunkin and 
Chung, 2012; see section 1.2.3 for a review). It seems that this belief in individuals with CU has 
some credence but with psychological attributions relating to higher emotional representations, 
broadening the patient’s causal model to other factors may be critical for reducing high emotional 
responses. High emotional representations itself significantly predicted higher anxiety and poorer 
mental health suggesting that regardless of the nature and directions of the relationships 
between psychological factors and CU they have implications for incorporating interventions that 
help these individuals to self-regulate stress.  
 
Although many of the remaining perceptions were not significant predictors of outcome 
it could be hypothesised by the dynamic nature of the CSM that cognitive representations co-
vary in such a complex way that insignificant predictors of outcome may indirectly influence 
significant ones. It is this co-varying nature that allows for other misconceptions of CU in regard 
to timeline, control, coherence and medicine beliefs to be challenged by health professionals. 
CU is chronic in timeline but up to 50% of cases go into remission within 2-3 years and no cases 
of CU over a lifetime have ever been reported (Maurer et al. 2010) so holding these perceptions 
(50% of sample) may have detrimental effects on patients’ future planning. The duration of CU 
cannot be predicted but there are factors such as disease-severity and experiencing concurrent 
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physical urticaria that can prolong duration (Maurer et al. 2010). Timeline was also related to 
reporting more serious consequences, poorer disease control and high emotional 
representations, so changing timeline perceptions may allow individuals to have a more positive 
outlook about controlling CU and planning the future.  
 
It is known that getting the right combinations of CU medicines can be complicated 
(Zuberbier et al. 2009b) as it is highly individualised for each patient. First-line anti-histamine 
medicines may be increased up to fourfold and other treatments may be added including steroids 
and immunity-depressants, which may have harmful side effects (Zuberbier et al. 2009b). It is 
not surprising then that 88.0% of the sample believed in the necessity of CU medicines but were 
equally concerned about side effects (87.3%). In fact specific concern beliefs also had a negative 
impact on all CU-related QoL outcomes. Little is known about how much individuals with CU 
perceive and understand the process of testing different medicine combinations, the raising of 
doses above licensed recommendations and how much this process is explained to them but 
one explanation is that the urgency by doctors to find the right combinations may increase the 
patients’ specific necessity beliefs but in the knowledge that the solution may have side effects 
that they should equally be concerned about. However it is indicated that up to two-thirds of those 
with CU wait for symptoms to appear before taking prescribed medicines (Maurer et al. 2009b) 
and this raises questions regarding whether they do not take CU medicines as prescribed 
because they are worried about side effects and then only take them when symptoms begin to 
reduce a toxic load. Also it raises the question concerning whether these patients believe that an 
absence of symptoms means an absence of active CU at particular periods of time. Discussing 
patient’s perceptions of the treatment experience during consultations may help to balance 
beliefs in regard to whether the costs out-weigh the benefits, so they are taken in the absence of 
symptoms. However maybe these patients don’t understand the CU patho-physiological process 
and how CU medicines work. In support of this explanation those who reported stronger illness 
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coherence significantly reported less emotional representations and less concerns about taking 
CU medicines.  
 
With nearly 50% of the study sample reporting that they did not understand CU 
(consistent with a recent survey of over 300 CU patients; Maurer et al. 2009a) and a third 
wondering if their actions would make their CU better or worse, it appears that urticaria services 
need to adopt some form of psycho-educational strategy beyond the standard short consultation. 
In support of this, perceptions of better treatment control significantly related to better aspects of 
QoL. Previous studies have found that cognitive representations are amenable to change and 
improve outcome (e.g. Fortune et al. 2004; Petrie et al. 2002; Karamanidou et al. 2008; see 
section 2.5.3, p50).  
 
Other factors: Age and Marital Status 
Even though patient characteristics were not significant predictors of outcome, marital 
status and age did feature significantly in the regression models of CU outcome. Marital status 
(i.e. being married/ co-habiting) predicted a significant 9% of the variance in generic mental 
health status suggesting that the presence of a partner may further enhance interventions and 
be a source of support. This finding helped to strengthen the validity of earlier correlations that 
married/ cohabiting patients reported significantly less psychological attributions, better generic 
mental health status and better QoL. The wider research literature has recognised the important 
role of significant others in CSM interventions in terms of support and how the partners’ 
representations of their partners’ illness may impact outcomes (Sterba, DeVellis, Lewis, DeVellis, 
Jordan, Baucom, 2008; Broadbent, et. al. 2009; 2009b; Keogh, White, Smith, McGilloway, 
O’Dows, Gibney, 2007). Further being married/ co-habiting with older age strongly predicted 
better overall disease-specific QoL. A possible explanation for this is that the support of a partner 
together with the experience of living with CU together may play a role. This is merely speculative 
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but it is known that skin disorders in general do impact on relationships including coping and 
adjustment, appearance and shame, body image and sexual intimacy (Anthis, 2005). Younger 
age and earlier age of onset was also related to a strong illness identity (i.e. reporting more 
symptoms of ones symptoms to ones CU) and perceiving CU to have serious consequences on 
outcome. Whether this is just correlational is unknown but there is a growing literature on the 
impact of skin disorder throughout the life span (Warren, Kleyn and Gulliver, 2011; Thompson, 
2005) and how this plays a role in CU may be important in identifying factors that result in better 
adjustment.  
 
Coping 
In the current study there was an opportunity to study coping. The research literature on 
coping in CU is scarce, but comparisons could be made one of the more comprehensive studies 
undertaken by Chung et al. (2010b). Using the Brief COPE, acceptance was reported as the 
most used coping strategy, a variable that has no equivalent item in the Ways of Coping Checklist 
used by Chung et al. (2010b). However this study relatively confirmed Chung’s et al. (2010b) 
reports for conceptually equivalent strategies widely used in the current study which were active 
coping, planning, seeking instrumental social support and self-distraction (see Table 7.10; p212). 
The only discrepancy was that reports of substance use were considerably lower in this study 
compared to Chung et al. (2010b). These findings provide evidence that despite the negative 
impact of CU on quality of life, individuals with CU engage in more positive and strategic coping 
behaviours in an attempt to improve outcome. This was further confirmed by the descriptive 
analysis of the fourfactor second-order principal components analysis undertaken of the Brief 
COPE were positive coping (proactive coping, 
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Table 7.10: Coping in CU: Study 4 and Chung et al. (2010b) 
 
This study 
 
% 
 
Chung et al. (2010b)                                                                         
% 
 
Active 
Planning 
Seeking instrumental social 
support 
Self-distraction 
Humour 
Venting 
 
72.2 
68.7 
52.5 
49.4 
42.5 
27.5 
06.0                  
 
Concentrating on procedures for self-management                  68.0 
Coming up with solution                                                            66.0 
Seeking social support                                                              75.0 
Tried not think about it                                                               73.0 
Not to take it too seriously                                                         71.0 
Keeping feelings to/ Not letting others know oneself      64.00/ 62.0                                         
Turned to eating, drinking and/ or smoking                               53.0  
 
71.6% and positive cognitive appraisal, 41.5%) prevailed over negative coping (negative 
cognitive appraisal, 13.7%). It does also suggest that if provided with more fruitful coping 
strategies through action plans (an integral part of CSM interventions) these individuals may 
already possess a motivational drive towards self-regulating their illness. What needs to be 
considered in respect to these findings is that the CSM postulates that coping procedures do not 
function in isolation but are influenced by cognitive representations (i.e. the IF-THEN rule). The 
IF-THEN rule was supported in respect to illness identity and emotional representations that 
together indicated that individuals with CU use parallel cognitive representations of danger and 
fear which act as driving motivators for adopting coping procedures. 
 
Discrepancies  
Despite there being much evidence to support a common-sense model of CU-related 
QoL outcomes, discrepancies did occur in this study. First the model predicts that the path from 
representation to outcome is mediated by coping but this did not occur. For example 
representations did predict coping behaviours but these representations also directly predicted 
outcome independent of a coping mediator. In terms of the CSM research literature this is not an 
unusual occurrence. It was highlighted in chapter 2 that some studies have failed to find 
mediation. The most obvious explanation is a disease-specific one in that this does not occur in 
CU but another is a psychometric one. It has been suggested that studies often use generic 
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questionnaires (Hagger and Orbell, 2003), but studies using such measures have found 
mediation (e.g. Rutter and Rutter, 2002). Rutter and Rutter (2002) used the COPE inventory but 
did not factor analyse the individual coping strategies to reduce the number of factors. It could 
be that the reduced Brief COPE factors in this study reduced its sensitivity to find mediating 
relationships. This explanation could be tested in future studies.  
 
Second, those who reported a strong illness identity and high emotional representations 
not only reported significantly greater use of negative cognitive appraisal coping procedures (as 
would be predicted) but also proactive coping. An explanation might be found in the nature of 
the coping procedures in that the former is a thinking process and the later a doing process. It 
could be that despite the negative thinking about the impact of CU on one’s lived experience, 
one has to continue to strive for positive and proactive ways of getting out of one’s predicament. 
Positive and negative coping procedures also related to poorer outcomes, a finding mirrored in 
the dermatological condition alopecia (Cartwright et al. 2009). It was suggested here that the 
Brief COPE may lack discriminatory power but CU is complex with an unclear course and a more 
likely explanation may lie in research suggesting that enforcing problem solving strategies in the 
face of what seems to be an uncontrollable situation may result in poor adjustment similar to 
negative forms of coping (Carver and Conner-Smith, 2010).  
 
Finally perceptions of serious consequences were the strongest correlate of all 
outcomes but did not predict them. One explanation may lie in CU itself. It was theorised in 
Section 3.4.1 that CU’s daily fluctuating and cyclical nature in symptom presentation, often with 
concurrent multiple physical urticarias might impact study findings. It might be that such factors 
allow CU to be perceived to have serious consequences (hence the high correlations) but the 
contents of this perception fluctuates so much depending on CU’s presentation at any moment 
in time that its effect on outcome are difficult to predict. CU is very complex and a more qualitative 
approach may help answer these questions.  
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Methodological Limitations 
In light of the findings of this study, the limitations of the study do require consideration. 
Firstly the cross-sectional design of the study meant that causality could not be established. 
Future longitudinal studies may provide further insight into how representations of CU and coping 
behaviours change over time and in effect impact QoL and psychological distress. Such studies 
may explain the lack of predictive contribution of the serious consequences illness perception 
that strongly correlated to outcome. It would also eliminate the retrospective reporting nature of 
cross-section studies in which participants are required to recall a lot of information particularly 
a daily fluctuating condition such as CU. Despite this limitation however the study did find logical 
patterns amongst the research sample, many of which were CSM confirming and other possibly 
more CU specific. Second it would not be unreasonable to hypothesize that poorer quality of life 
and psychological distress may influence coping behaviours that in turn change the cognitive 
representation. For example feeling good and asymptomatic one day may result in not 
participating in the coping action (e.g. planning) that helped that good feeling and engage in 
another (e.g. denial) leading to a change in thought process (I am no longer in danger and don’t 
need to get emotional). In defence of this study the CSM does propose that outcomes can impact 
representations and further one can find oneself moving between cognitions and coping and 
coping and outcome as the CSM acts as a dynamic model of attempts to self-regulate illness. 
This makes sense as the model has its foundations grounded in cybernetic control theory (a bio-
feedback system of self-regulatory control; see section 2.1.1, p19). In a real world context 
practitioners would assess patients to determine where in the cycle to intervene (from the top-
down or bottom-up).      
 
In regard to the study participants, females’ substantially outnumbered male’s 9:1. Even 
though this discrepancy is not dissimilar to previous dermatology based illness perception 
studies (see section 2.4.1, p42), it is difficult to establish why this is the case. One explanation is 
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that CU is a visible condition and may impact on issues regarding physical appearance that 
mainly effect women (Hassan, Grogan, Clark-Carter and Richards, 2009). Another explanation 
may lie in research supporting that men seek health services less than women (Hunt, Adamson 
and Galdas, 2012) so are less likely to be recruited. In defence of this study women do greatly 
outnumber men in CU research in ratios found in this study sample and the age distribution was 
also in line with other CU research (see section 3.3.1, p60).  
 
In respect to measures, although the HADS is a valid measure of anxiety and 
depression, it is still a screening measure. A diagnostic assessment would have allowed for a 
more reliable measure especially in regard to being able to separate clinical disorder as a 
personality variable or as a result of distress. To minimise this possible occurrence the psychiatric 
status of patients were established at the recruitment stage of the study. Second, disease-
severity was not measured and this missed an opportunity to establish if cognitive 
representations and coping behaviour are the better significant predictors of outcome. It is 
recommended that this be addressed in future studies. Further medication adherence was not 
measured. In hindsight it could have been included as another secondary measure as a way of 
exploring cognitions as predictors of what is known about oral medication usage in CU, which 
can be evidently non-adherent (Maurer et al. 2009b). 
 
7.5: Conclusion and Recommendations 
To conclude, with cognitive representations predicting a considerable 35.4 to 60.6% of 
the variance in primary QoL and secondary psychological distress, developing and integrating 
evidence-based psycho-educational initiatives and routine care approaches that focus on 
changing the patients implicit model of CU may prove cost effective by encouraging patient 
behaviour change that leads to better CU self-regulation and self-management and therefore 
less visits to dermatological services. 
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Chapter 8  
Making Sense of Common Sense: An interpretive Phenomenological Analysis of Cognitive 
Representations, Coping and Outcome in Chronic Urticaria (Study 5) 
 
8.1: Introduction and Rationale 
Much post-study ‘talk’ from participants, which expanded on their CU representations beyond the 
detail possible from quantitative methods used in Study 4, went undocumented as it lacked the richer 
accounts that qualitative methodology allows.  The lack of qualitative data on lived experiences in CU 
(see Broom, 2010 and Soloman and Gould, 2011 for examples) further instigated this study that 
interviewed the CU perceptions of 4 women using interpretive phenomenological analysis. The premises 
of studying cognitive representations are to explore how individuals make sense off and respond to illness 
(see chapter 2). This study used CSM components as the basis for developing the semi-structured 
interview schedule that would allow for this richer understanding. Questions on outcome were not created 
as it was hoped that these would naturally emerge from verbalisations on perceptions 
 
8.2: Method 
 
8.2:1: Design 
This qualitative study used the methods of IPA (Smith 1996; Smith, Flowers and Larkin, 2009). 
In IPA it is assumed that although ones cognitions cannot be directly accessed through verbal accounts, 
they can be revealed through the IPA analytical process through the participants talk (i.e. transcripts). IPA 
assumes that there is an interaction between people’s cognitions and emotions where they are trying to 
make sense of their personal and social world that they often find difficult to express and it is the 
researchers and participants place to make sense of it all. Although this study was not to validate the 
CSM, IPA shares the communality of recognising this interaction of cognitive-emotional processes and 
sense-making that is involved. IPA concerns itself with symbolic interactionism (how individuals 
cognitively construct meaning and make sense of objects or events within their personal and social world, 
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and a double hermeneutic (or two stage interpretive process) of the researcher making sense of the 
participant making sense of their world but also using questioning hermeneutics (e.g. what is the individual 
trying to achieve or is unaware of).  
 
8.2.2: Participants and Context:   
Four participants were recruited from the weekly urticaria clinic at St John’s Institute of 
Dermatology, London (an account of the clinic can be found on page 134. IPA’s originator Jonathan Smith 
recommends a sample size of 4-10 for doctorates and emphasised that larger numbers do not equal 
better IPAs.  Participants were informed about this study by the researcher and provided with pre-study 
recruitment documents before embarking on an interview date (see p134). In line with a purposeful 
homogenous sample recommended for IPA individuals could participate if they were female with a primary 
diagnosis of CU and between 27-57 years old. This demographic was in line with the CU research 
literature reported in the systematic review in Chapter 3 (see p60). Those without a good command of 
English were excluded. The sample consisted of four females whose characteristics are described in 
Table 8.1 below. 
 
Table 8.1: Participant Characteristics 
 
Name* 
 
Diagnosis        Age            Ethnicity             Occupation      Marital Status      Disease duration (years) 
 
Karen 
Hanna 
Paula 
Jess 
 
Autoimmune      50             White British        Housewife         Married                   21  
Idiopathic           45             White British        Dog Walker       Co-habiting            32  
Idiopathic           47             White British        Teacher            Married                   32 
Autoimmune      52             White British         Writer               Married                   48  
    *Assigned name to protect real identity 
 
8.2.3: Data Collection and Procedure 
A semi-structured interview schedule including questions on CU perceptions and (see p139; 
Appendix 4, pA37) was created using guidelines from Smith and Osborn (2003). Participants decided 
whether to undertake the interview at their home or at the clinic in a private room. Interviews were recorded 
and lasted approximately 20 minutes. At the end of the interviews participants were debriefed and  
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interviews were transcribed verbatim with personal identifiers removed.   
 
8.2.4: Data Analysis 
The first interview was played back and read a couple of times to allow familiarity with the text. 
The text was then explored to identify novel disease-specific themes. This was done through a free textual 
analysis of the data to observe and note down any associations, comments and use of language and 
these were noted in the left hand margin of the transcribed interview text. 
 
Emergent Themes 
The text was read (and re-read) to identify novel emerging themes and these were annotated in 
the second margin with theme titles and quotations from the text extracted to qualify each emerging 
theme. Themes were first listed in the chronological order of the text but were then clustered if they 
appeared to form a part of the same concept. These clusters were then further grouped into sub-ordinate 
themes with a name that represented the clusters. Super-ordinate themes were identified by putting like 
themes with like (abstraction), noticing emergent themes that drew a group of similar themes together 
(subsumption), finding oppositional relationships (polarization), identifying narrative elements 
(contextualisation) and the frequency of themes in the text and their functioning. Themes identified in the 
first case were searched for in the four proceeding transcripts and new themes were searched for and 
adjustments made to accommodate these and any similarities and/ or differences. Themes and super-
ordinate themes were merged together for the group into higher order themes.    
 
8.2.5: Validity and Quality 
Approaches to assessing the validity and reliability of quantitative research include those by Elliot, 
Fischer and Rennie (1999) and Yardley (2000). The originators of IPA Jonathan Smith (Smith et al, 2009) 
used guidelines by Yardley (2000) and for this reasons these criteria were used. How each was met is 
described below:  
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Sensitivity to Context 
This criterion first demonstrates an awareness of the existing literature and theory either for the 
topic under investigation (e.g. CU, QoL, cognitive representations) or the underpinning of research itself 
(i.e. IPA) and the data collected from participants. These was supported by the introductory reviews in 
Chapters 1-2, by Sections 8.1 and 8.2 in this chapter and in the way study data was collected (all section 
8.2) by evidencing the researchers interpretations from material drawn from participants with verbatim 
extracts from the data respectively. This criterion can also be shown by being sensitive to the studies 
socio-cultural setting (see section 5.3.1, p134) and issues of power between the researcher and 
participant. For the latter (as reported earlier) participants had the opportunity to be interviewed at the 
clinic or in their home. Further the researcher kept interviews informal, wore causal but smart clothing, 
avoided sitting behind a desk and sat on a seat of a similar level to facilitate an equal relationship.   
 
Commitment, Rigour, Transparency and Coherence 
Commitment is the level of engagement the researcher has through the experience of the 
qualitative method used and knowledge of the field under study. The researcher has undergone 
postgraduate training in IPA. The thesis so far has demonstrated the researcher’s knowledge of the topic 
area. The rigour of the study pertains to its thoroughness by choosing an appropriate study sample (see 
section 8.2.2) and the attention to detail in the analysis. The latter was established by treating whole 
transcripts as data and an audit trail consisting of a chronological extraction and analysis of themes for 
interview 1 is presented as evidence of this in Appendix 4, (pA38). Transparency and coherence relate to 
how clearly stages of research has been outlined in the write up and how participants were selected 
(section 8.2.2), how interview schedules were constructed and conducted and the steps used in analysis 
to establish if arguments fit between the research undertaken and philosophical assumptions of the 
approach. Interview questions were constructed based on previous questionnaires for exploring cognitive 
representations (p139) but were open-ended with a minimum of prompts/ probes. The extraction of 
themes and the reflexive account provide further support for coherence. 
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Impact and Importance 
Even when qualitative studies are conducted sensitively it has to present something useful about 
the topic or contribute to practice and policy. This is supported in the results/ discussion section.  
 
Self-Reflexivity 
Quantitative research attempts to minimise researcher bias in the methodological process 
however qualitative research accepts inevitably that the researcher’s assumptions and views will have an 
impact on how data is collected and analysed regardless of attempts to eliminate bias. It is recommended 
that the researcher declare their assumptions and views that may have impacted on this study (Yardley, 
2000; Elliot et al. 1999). These views are provided in the statement below:    
I am a British female in my thirties. I have a personal interest in people, well-being and doing sport activities outside work and 
academia, hence my personal interests have somewhat informed my interest in health psychology. I do not like to place myself 
into a theoretical box but neither do I like to ‘sit on the wall’. Although I have a bias towards being a social cognitivist (especially 
when they precede behavioural processes) I prefer to take an integrative approach deciding for myself which theoretical models 
or methods (qualitative or quantitative) are best for studying particular phenomena. For example although I perfectly 
understand that people socially construct their environments in their own personal way, I believe that they are also cognitively 
processing these social interactions within the constraints in thinking set upon them by the socio-cultural institutions (e.g. 
educational, political, religious) for which they came to be who they are. It is in these institutions that individuals will share 
group communalities in how they think and how they will interpret events. From my experience of interacting with people with 
dermatological conditions such as CU, I have drawn my own conclusion that it is a condition that can happen to anyone as 
bio-psychosocial determinants appear to come into play both objectively in the predominant quantitative research literature 
and subjectively in over 100 patient qualitative narratives at the urticaria clinic. I am also diagnosed with idiopathic CU (i.e. of 
unknown cause) and this was discovered at this same urticaria clinic several years ago. It is this situation that ultimately 
positions me as both a researcher and patient trying not to make prior assumptions about the study data being analysed and 
being mindful not to ask probing questions that only ‘find’ themes within the data that is saliently reflective of my own personal 
subjective cognitive representations of CU. 
 
8.3: Results and Discussion 
 
8.3.1: Overview of Master and Sub-ordinate Themes 
The verbatim accounts of participants clustered around four master themes and twelve 
subordinate themes (1) which are presented in Table 8.2 (p221) with an indication of where they can be 
found in the interview transcripts (See Appendix 4, pA38).  
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Table 8.2: Summary of Master and Sub-Ordinate Themes 
 
Master Theme: Sub-Ordinate Theme 
 
Karen 
 
Hanna 
 
Paula 
 
Mary            
 
A Self that is difficult to understand or be understood 
1: An Anomaly that needs to be understood by the self 
2: An Anomaly of the Self that others don’t understand 
3: Perceptions of a Body that is at War with itself 
  
It Will Go but It Will Come Back 
1: Predictability verses Certainty 
2: Fear of Reoccurrence 
3: Loss of Control over the Self 
4: Strategies that keep it at bay are often limited or ineffective 
              Oral 
              Topical 
              Dietary 
5: Barriers to accessing help when it comes back 
 
Psychosocial and Appearance issues ascribed to Itching and 
Swelling  
1: Feelings of Shame & Self-Consciousness due to Fear of Exposure 
2: Impact of CU Appearance & Symptoms on Personal Relationships 
 
CU Medicines as a Health Threat Verses Health Saviour 
1: CU Medicines as a Necessary Evil 
2: CU Medicines as a Friend verses a Foe 
 
 
 
6: 229-234* 
1: 2-4 
2: 31-32 
 
 
7: 237-246 
6: 212-18; 5: 171-3 
3: 94-95 
 
5: 151-154 
5: 189-90; 6:191-92; 6:202 
3: 103-105 
7: 246-249; 254- 6 
 
 
 
3: 74-76 
3: 78-80 
 
 
4: 129-131 
4: 120-121; 4: 137 
 
 
 
2: 37-41 
4: 148-50 
1: 30-31 
 
 
2: 53-4; 2:63-4; 139-141 
5: 160-163 
3: 88 
 
5: 169-171; 3: 92-6 
 
 
4: 122-127 
 
 
 
3: 79-83 
 
 
 
4: 112-117 
4: 119-120 
 
 
 
5: 182-185 
1: 3-5 
1: 32-33; 
 
 
3:88; 3: 90-91; 2:53-55 
5: 162-165 
3:85 
 
3: 109-110       
 
 
 
 
 
 
4: 153; 5: 158 
3: 80-1; 4: 149-151 
 
 
4: 124-26; 4: 141-145 
3: 109-10; 3: 113; 4: 114-16 
 
 
 
4: 125-6 
1: 13-15  
2: 35-363: 77-80 
 
 
2: 35-7; 3: 113-5 
3: 105-7 
5: 85-6 
 
 
 
 
6:200-4 
 
 
 
4: 149-156 
5: 158-160 
 
 
6: 208-11 
6: 204-06 
 
Note: *Denotes page number in transcript followed by line number in transcript in Appendix 4 (further examples are presented in text)  
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8.3.2: Master Theme 1: A Self that is difficult to understand or be understood 
Three themes identified appeared to cluster around one master theme that was labelled 
a self that is difficult to understand or be understood.  
 
Theme 1: An Anomaly that needs to be understood by the Self 
The first theme revealed a need for the women to learn more about their CU beyond the 
formal diagnosis they were given but some perceived this to be more difficult than others: 
Hanna: ...there’s not a lot, there isn’t a massive amount out there but when I was told what it was I sort of did a bit 
of research online but that’s about it but there isn’t a huge amount to find out really. I think all erm certainly not for 
sort of like me there might be for medical professionals but I don’t really understand that so there’s not a lot for just 
me (2: 37-41)     
 
Paula: erm, after I was diagnosed at my GP and then referred to a couple of places before I was referred here [St 
Thomas’] I was researching around it and my mum’s a doctor as well so researching with her and the internet 
research and library researching you know the causes and the treatments, there’s quite a bit of information on it (5: 
182- 185) 
 
Mary: I’ve researched I’ve looked on the Internet I just know what all the possibilities are (4:125-6) 
  
Karen used the interview as an opportunity to access lots of information that she was struggling 
to find elsewhere (this occurred after the interview had ended)1. 
Karen: I'd be interested to know whether there are studies on it and whether there is likely to be a cure. Do you 
know anymore than I giving you have access at the clinic? (6: 229-234) 
 
In these accounts the women seem to be thinking about their own understanding and 
predicament. After an initial diagnosis of CU by their practitioner they appear to indirectly reveal 
a lack of enough disease information in order to comprehend what they are going through. Such 
an interpretation comes from a need to seek more information about the condition, which comes 
from a range of sources. How one comes to learn more about CU appears to be dependent on 
one’s ability to systematically research the available information out there (i.e. the internet, 
libraries) and having access to those with the skills and knowledge to understand more (e.g. 
                                                          
1As the participants in this IPA study were recruited as part of the intervention study reported in Chapter 9, they had the same 
opportunity as these participants to ask questions which would facilitate in changing their perceptions of their illness.     
 223 
 
mother being a doctor, access to ask experts). These factors seem to impact whether a little or 
a lot of specific information will be found and at the right level to understand what has been found. 
Such accounts are not uncommon as in the face of an illness crisis one of the most common 
illness (or health seeking) behaviours is to find out more about one’s condition (Chung et al. 
2010). In the preceding study one of the most prevalent coping strategies in CU was to seek 
instrumental social support (52.5%) and this had been supported in the published research 
literature by Chung et al. (2010) who reported this to be as high as 75.0% of their CU sample. In 
a larger context the women’s quotes further show a need for illness coherence, a concept first 
introduced by Moss-Morris et al. (2002) that is indicative of a meta-cognition where one is 
thinking about their own understanding of their chronic illness (e.g. Moss-Morris et al. 2002; 
Cameron et al. 2009), hence seeking information about CU in this context can be viewed as a 
perception or a coping strategy.  
 
When asked if they understood CU to be an illness Karen and Paula seemed to imply 
that CU only felt like an illness when symptoms were being experienced at its worst.  
Karen: When I’m ill with it when it’s not but like; now I’m in remission; so I don’t think about it but when I actually got 
it, I find it debilitating and so yes I do (1: 6-7) 
 
Paula: Yeah, it has an effect, when it’s at its worst everyday so yeah 
 
Hanna first appeared to disagree but presented this ideology in a less obvious way. In this 
interpretation Hanna does not view CU as an illness as it appears not to fit well into her schema 
of what an illness should be:  
Hanna: Erm, no not really, no not an illness, no because it doesn’t make me feel ill but you know it’s, it’s a condition 
I would call it rather than an illness…it’s not like your ill, it’s just erm, it’s a bit like eczema I suppose you know you 
got a condition it’s a skin condition erm I, I wish I could explain it better I guess (5: 176-178) 
 
Mary was sure that it was and qualified why: 
Mary: Yes I do…well I’ve had it forty-eight years so I’ve had a long time to get used to it. I’ve been pushed, prodded, 
poked, stuck with needles you know it’s been called different things throughout my lifetime, at times it was idiopathic, 
sometimes it was autoimmune (1: 13-15) 
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These accounts provide a more general insight into what these women believe it means 
and feels like to be ill. For example a distinction is made between what is an illness (more serious) 
and what is a condition (less serious) and whether CU is seen as an illness appears dependent 
on the presence (or absence) of symptoms and/ or how unwell symptoms makes one feel inside. 
Such views are not uncommon as how one interprets illness is said to be influenced by ones 
symptom perceptions (e.g. Hanna: no not an illness, no because it doesn’t make me feel ill but 
you know it’s, it’s a condition; Pennebaker and Skelton, 1981; Pennebaker, 1982; Pennebaker, 
1983) and social messages of what to expect from ones exposure to their socio-cultural 
environment (Yes I do [believe it’s an illness]…I’ve been pushed, prodded, poked, stuck with 
needles you know, it’s been called different things [by doctors] throughout my lifetime; Scambler, 
1981; Freidson, 1970). 
 
Theme 2: An Anomaly of the Self that others don’t understand 
In an attempt to understand CU itself the accounts in this subtheme suggested that 
others also did not know or understand what CU was:   
Karen: Erm I call it urticaria erm but I know that its autoimmune spontaneous urticaria I know that’s what it is but if 
I refer to, when I speak to people who don’t know I just tell them it’s allergies because I can’t be bothered to explain 
it but for myself its urticaria (1:2-4) 
 
Paula: I do call it urticaria, it feels like it’s, at times it’s been like a big, it’s like I call it when I describe it to people 
allergies and that I have a rash because obviously, it’s so unheard of [laughs] (1: 3-5)     
 
Hanna: I’ve had it since I was thirteen when I first had it and again everyone said it was allergies (1:26-27) It’s a 
funny condition because you try and explain it to people and then they don’t get it until they see it (5: 175-176)...I 
guess it’s a bit like they do ask me what is it, what’s causing it, why can’t it be cured but I don’t know, I don’t know, 
I don’t know. They don’t seem to think that you just have it and you have to live with it (4:148-50) 
 
Mary expressed ease in explaining CU but as an allergy none the less: 
Mary: Usually in laymen’s terms I say to them erm if you can’t  eat strawberries it’s that kind of thing or if you’ve had 
an anti-biotic that’s disagreed with you that’s the kind of thing it is on steroids [laughs]  usually that’s what I do I’m 
very open I will talk about it with people who ask me about it…I’m not ashamed of it, not proud of it either but live 
with it so I’m happy to explain (2: 70-74) 
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These quotes indirectly imply that the women come to an understanding that their illness 
is little known to significant others and the general public and this view is qualified by the women’s 
need to frequently explain it to others. CU also appears to be difficult to explain for those who 
experience it and the best way to explain it is to liken it to a predicament that most people would 
have experienced at least once in their lives: an allergic reaction. This comparison seems to 
clarify the nature of CU to others in most cases but Hanna’s experiences indicate that some may 
perceive CU as an actual allergic reaction that does not need to be self-endured. It is not 
surprising that these women would use allergy as a synonym for CU symptoms as the end result 
and appearance of this skin disorder is identical to that of an allergic reaction (Brown et al. 2007; 
Kulthanan et al. 2008). Most people will also have had an experience of an acute allergic reaction 
resulting in the wheal and flare of urticaria commonly known as nettle rash or hives at some point 
in their lives (Schofield et al. 2009), hence such an explanation immediately allows one to 
empathise and begin to place themselves in the women’s experience. What is most pertinent 
here is that the women themselves appeared to have an understanding of other peoples 
understanding of what an allergy is. This understanding is in terms of its abstract label and 
concrete symptoms and sensations perhaps reflecting a common understanding learned from 
illness information assimilated from within a common socio-cultural environment. 
 
A closer analysis of the dialogues appeared to reveal a relationship between the women 
themselves initially believing the condition to be actually caused by an allergy and a perpetuation 
of such beliefs by continuous misdiagnoses by doctors also trying to understand  
Karen: Not until I got my diagnosis erm I mean I’ve had it erm, I’m 50 now and I’ve had it since I was 29 but for 
many many years I thought it was allergies so I was probably diagnosed, I’m not sure 5 or 6 years ago was when I 
actually finally was diagnosed with the condition, that’s when I first heard of it (1: 20-23) 
 
Hanna: Only after going to see many erm doctors because originally it was classed as an allergy so I went to all the 
allergy clinics and had all the tests and stuff so for ages it was just allergy and then it was diagnosed as urticaria 
eventually but it took a while erm so once I knew what it was why I call it that (1: 7-10) 
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Paula: As a baby myself I had what the doctors thought was an allergic reaction, when my feet swelled I couldn’t 
put my shoes on and it did spread and it had the wheals and the classic symptoms of urticaria and so I’m 31 now, I 
guess that’s been a break (2: 57-60)....[As a child] they suggested a lot of things and I had lots of allergy tests but 
within six months it had gone again completely and so they didn’t find any pattern with it [2:66-67]. 
 
Mary: I think it was just I got the impression it was much a learning process for the person who was doing the tests 
as it was me trying to find out so (1: 9, 13-17). My earliest was four I erm remember being told that I can’t eat 
grapefruit, they probably didn’t know what it was and just like an allergic rash so just picked something and said you 
can’t eat that so erm I just avoided grapefruit for erm for a lot of years (1: 19-21) 
 
A commonality across transcripts was the women’s apparent perception that 
understanding CU was as much a journey for diagnosing health professionals as it was for the 
self. CU is portrayed as a little known illness often misunderstood by clinicians trying to diagnose 
it and so difficult to understand that even doctors themselves come to instinctively labelled CU 
symptoms to an unknown allergy. Similarly across transcripts the women noticeably had to 
experience undergoing many tests, interventions and labels for their illness experience over 
many years before a final diagnosis of idiopathic or autoimmune CU was diagnosed. Such 
experiences suggest that from the process of first experiencing symptoms to diagnosis it was 
initially accurate for these women to explain the illness as an allergy.  
 
Such accounts of these women’s lived experiences are indicative of what others living 
with CU maybe experiencing. In respect to these women’s specific experiences it is known that 
CU is not comprehensively understood and expert researchers and practitioners are always 
trying to find answers as to its aetiology, process and treatments which varies considerably 
between patients (Zuberbier et al. 2009a, b). It is not uncommon for patients with CU to undergo 
numerous tests to identify what they have (Zuberbier et al. 2009a, b; Kozel et al. 2003). In fact a 
recent survey of 776 health professionals (including dermatologists and GP’s) it was reported 
that 82% had attempted to find an underlying cause for CU symptoms with very limited success 
(Weller, Viehmann, Brautigam, Krause, Siebenhaar, Zuberbier and Maurer, 2013). Further, less 
than one-third was familiar with CU management guidelines that reflected in important early 
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diagnostic tests such as the ASST (only undertaken by 10% of practitioners) and 23% had 
prescribed sedating anti-histamines, which are no longer recommended. Ferrer, Jaurequi, 
Bartra, Davila, del Cuvillo, Montoro. et al. (2009) had earlier found similar results when they 
reported that practitioners found it difficult to implement CU guidelines and so prescribed large 
amounts of sedating anti-histamines. They concluded that non-experts appear to experience 
difficulties in differentiating between CU and physical urticaria that may inevitably affect disease-
control and patient satisfaction.  
 
The above studies demonstrate that CU is complex. Urticaria itself can be both an illness 
and a symptom of another disease and is often co-morbid with forms of urticaria (Brodell and 
Beck, 2008; Zuberbier et al. 2009a). Such complexities may be perpetuated by beliefs that CU 
is caused by allergy even though this is rare (Kaplan, 2004; Zuberbier et al. 2006). Such 
complexities have lead dermatologists and patients to label CU as an enigma (Zuberbier, Grattan 
and Maurer, 2009) and health professionals often view patients with CU as ‘difficult to satisfy and 
hard to guide’ (Weller, Viehmann, Brautigam, Krause, Siebenhaar, Zuberbier and Maurer, 2012). 
The women’s individual reports indeed reflect that CU is difficult to understand by the self and 
others. 
 
Theme 3: Perceptions of a Body that is at War with Itself 
In a variation on this master theme, the sample verbalised their own understanding of 
what they believed to be happening inside them and why during an episode of CU:  
Karen: It's my own immune system that’s erm attacking me, that's how I see it, it's my own body attacking me and 
I’m not sure really what triggers that but what's happening (2: 31-32)  
 
Paula: I, maybe physically doing too much for myself, feels like I’m fighting myself from the inside out....like my body 
is fighting myself when I feel too tired, too tired my body, when I’m exhausted I watch out (1: 32-33; 2: 35-36) 
 
Hanna: I assume that like an allergy your bodies reacting to something but I don’t quite know what (1:30-31) 
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Mary: My immune system is attacking itself & when it attacks itself it crashes a bit like a computer does & you like 
the blue screens of death & then all hell breaks loose until it kicks up symptoms of diseases & there are a lot of 
autoimmune diseases so that’s my own understanding of it (3 :77-80) 
 
Despite a lack of specific formal content in their vivid descriptions the women 
demonstrated an understanding of their bodies overall reaction during the CU pathophysiological 
process. All used terminology such as body attacking, fighting myself from inside out and bodies 
reacting to something implying that the body is somewhat at war with itself. Only Karen and Mary 
use the formal term immune system and attacking reflecting some knowledge of their skin 
disorders implicated origins in altered immunity (both have autoimmune CU subtype). In contrast 
the absence of these terms in Hanna and Paula’s accounts appear to reflect their idiopathic CU 
diagnosis as they used the words reacting and fighting instead. The idiopathic nature of her CU 
seems to imply a need for Paula to combine her explanation of CU process with a guess as to a 
cause (becoming too tired or exhausted). Hanna in a different way uses the word allergy to 
describe the CU process but the “...like an allergy” in her reply suggests that it is not allergy or 
caused by allergy but using the term makes for a good analogy for articulating the CU process. 
Mary also makes use of an analogy and likens her failing immunity to a computer system 
breaking down which also implies a causal factor. These personal accounts are what one may 
expect in respect. Though not an allergy (Kulthanan et al. 2008) CU follows a similar patho-
physiological process (see section 1.2, p4) so the use of such battling words to articulate it to 
others is a logical one. The research literature also supports that up to 50% of CU cases is 
implicated somewhat in auto-immunity (Kaplan and Greaves, 2009; Sabroe and Grattan, 2006) 
where the body is literally attacking itself but idiopathic CU is not immune or allergy related and 
any implicating factors usually serve as exacerbating factors as to causes.  
 
Before symptoms appeared the women’s accounts support that they were all aware 
when they would to be in the face of an illness threat as they felt sensations building up, knew  
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that they meant CU and could predict what the outcome would be:  
Karen: I know its autoimmune spontaneous urticaria...hives which can be on any part of my body & erm angioedema 
whereby my lips and my eyes all swell up as well….I feel it coming on, it feels tingly, knows it’s coming can feel it 
you know coming up a part of my skin    
 
Hanna: Urticaria that’s what I call it...I get big hives on my skin’...my hands my feet will swell up so that I can’t bend 
my fingers you know their so swollen. I get it in my joints particularly on my elbows & that’s really painful. I can get 
it in my mouth, in my eyes, in my throat or just... hives on my skin     
 
Paula: I do call it urticaria...when it comes up the ordinary urticaria, the tingling & erm at home or when at  home 
again I can feel it be it comes up and makes all of my skin quite sensitive...the pressure urticaria would make me 
have wheals and swelling at least on my feet (1: 03, 18-19)  
 
Mary: I come out in a rash…spectacularly…when I was a child it was a rash erm & it would start either on my arms, 
knees…pressure points…in cold water my skin would just go blotchy then it would itch for days…progressed as I 
got older, menopausal…angioedema & anaphylactic shock & urticaria vasculitis (1: 26-28) If I take a lid of a jar & it 
won’t come of it’s got resistance cause it’s too tight I know that my hands going to swell up latter & erm it tingles & 
I know it’s going to…I get a tingle in my lip so I know my lips gonna swell up & when my eyes are gonna to swell 
up… it’s just a feeling (2: 40-43) 
 
Mary also refers to CU as ‘IT’ in a likely attempt to separate CU, an external entity from herself:  
Researcher: what is your own name for it? 
Mary: IT [laughs] 
Researcher: It? 
Both: IT [both laugh] (1: 2-5) 
 
In an attempt to understand CU Hanna and Paula express feeling singled out, as the one who 
has to deal with CU symptoms. 
Hanna: I don’t really know why it happens I don’t know what causes it I don’t know what I can do to avoid it I you 
know I don’t know why I had it in the first place (2: 43-44) 
 
Paula:  I don’t know but it doesn’t make sense to me with the ordinary urticaria of why and don’t know exactly why 
and why me other than anyone else (2: 39-40) 
 
...and again both women provide possible respective explanations of maintaining and causal 
factors.    
Hanna: I don’t know but I do know that it’s made worse by stress... erm & I think the more stressed I got about it the 
worse it got & that you know I think the stress didn’t help (2: 49-53) 
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Paula: I don’t know why it doesn’t make sense to me with the ordinary urticaria...(2: 38-40)I had my daughter and 
then immediately got it, you know before she was almost 6 months old it felt like it was a result of that but just from 
my head that is you know (2: 48-50) 
 
Karen and Mary’s diagnosis of autoimmune CU seemed to help their understanding: 
Karen…Linked to having an underactive thyroid that’s what I believe, that’s what I’ve been told erm but erm my 
underactive thyroid is under-controlled (2: 45-7) 
 
Mary: Something that happened when I was born. I think I was just born with slightly weird immune system that’s 
what I prefer to think about... I think it’s just part of me, it’s something my body decides to do to me every now and 
again (3: 93-96)…I’ve been clutching at straws trying to relate it to you know when it flared up was I stressed was I 
when it came back? The stress thing I always erm I absolutely understood if I’m stressed it doesn’t help. I absolutely 
do not believe that stress caused it erm chiefly (4:139-41) 
 
There is considerable support that stipulates that in the face of an illness threat 
individuals apply the symmetry rule first proposed by Meyer et al. (1985). It describes how 
individuals experience symptoms, search for abstract information and find a cognitive schema 
(or label) for that experience that in itself is based on concrete evidence undertaken by searching 
for body sensations (Meyer, Leventhal and Gutman, 1985).  
 
The symptoms cognitively represented by the women as CU (i.e. itchy wheals, swelling 
causing pain) are in line with a medical understanding of CU (Zuberbier et al. 2009a) and 
expressed together with the sensations experienced (e.g. tingling) create a vivid picture of these 
women’s experiences which mirrors study reports by Yosipovitch et al. (2002). According to 
Leventhal’s common-sense model these perceptions (known as ones illness identity) initially 
develop through personal experiences of illness and/ or symptom perceptions. Much of the initial 
research on symptom perceptions was undertaken by Pennebaker and colleagues (Pennebaker 
and Skelton, 1981; Pennebaker, 1982; Pennebaker, 1983) who demonstrated in a series of 
studies how one perceives symptoms is influenced to some degree by how much they focus on 
internal states and how this is interpreted from their cognitive schema. However illness identity 
has been shown to share inter-correlations with other empirically known illness perceptions 
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including attaching causal attributions to one’s illness. As stated earlier the women give their CU 
process an illness label but causal links are made. Except for immunity, psychological stress and 
stressful life events are evident in their accounts as casual or maintaining factors. The former is 
made explicit in the transcript examples and the later involve examples including childbirth. 
These women’s accounts mirror Berrino et al.’s (2006) study which reported that 30% believed 
their CU was caused by psychological factors and Ozkan et al. (2007) in their study found this to 
be as high as 81%. As highlighted earlier there is no definitive cause found in up to 70% of CU 
cases (Saini, 2011) but as suspected by these women there is evidence supporting a role for 
pychological stress in CU cause, maintenance and process (e.g. Broza et al. 2008; Chung et al. 
2010a; Dyke et al. 2008; Section 1.2.3, p8). 
 
8.3.3: Master Theme 2: It Will Go but It Will Come Back 
The second overarching theme clustered around perceptions that CU was an 
unpredictable illness with an uncertain prognosis. Accounts provided across transcripts 
suggested that the only thing that was predictable and certain was that it would go away, but it 
would always come back but the timing of such certainties could not be precisely predicted. A 
lack of predictability of the certainty of remissive and active states presented with related themes 
concerning the limited strategies available to control it personally and the accessibility of gaining 
treatment control strategies when symptoms spontaneously reappeared again.   
 
Theme 1: Predictability Verses Certainty 
A major theme across all transcripts was the belief that CU is very unpredictable and 
there is no way of determining when it would come and go but what was certain was that 
sometime in the future it would definitely come back:   
Karen: [what] I find very frustrating about it is that because it’s one of these illnesses if you like which goes into 
remission so you have months of not getting it then one of the last times it happened to me it came back very, very 
suddenly. It was worse than ever and I had no medication at that point (7: 237-246) 
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The lack of medication implied that it could not be predicted when the reoccurrence of symptoms 
would come back in order to retrieve medications for a pre-empted outcome. Further examples 
of this certainty-predictability phenomenon are revealed in accounts provided from different parts 
of the transcripts.   
Hanna:…the stress didn’t help I, but anything else I don’t know it just seems to be completely random (2:53-
54)....since I was 22 I’ve had it more regularly but I’ve just had two years without any symptoms erm but it’s started 
to come back again so I’ll go through another round with it I suppose (2: 63-65)...you know you think here we go 
again & you know the and you can’t see at as you don’t know when it’s going to stop you just you know there’s no, 
there’s no end in sight to it (4: 139-141) 
 
Paula: No, not on any level, at any time, I don’t feel I have control over it (3: 88)....Because of it being so 
spontaneous, I still, maybe I do have some degree of control but it’s certainly not predictable for me for at least three 
years (3: 90-91)...Erm, I think it feels like it has come to me maybe three years ago and it barely, it feels as if it’s 
burning out now and less frequent and know I maybe have it on and off through my life (2: 53-55) 
 
Mary: The duration of the flare-ups as well used to be 6 months to a year then it went to 4 years, 5 years, 6 years 
so yeah a bit of a rollercoaster  (2: 35-37); Everything that goes in me or on me will react so I prefer to just think that 
it will come back. I find it psychologically easier to deal with it will come back (3:113-115 
 
Three of the women perceived CU as life-long and probing further into such perceptions resulted 
in the following responses:  
Paula: because of what doctors here have told me about the burnout cycle and erm because as a baby myself I 
had what the doctors thought was an allergic reaction, when my feet swelled I couldn’t put my shoes on and it did 
spread and it had the wheals and the classic symptoms of urticaria and so I’m 31 now, I guess that’s been a break 
(2: 57-60) 
 
Karen: Erm well I've had it now for twenty something years and you now that the hospital, their wonderful but I’ve 
never been lead to believe that, never been given an indication that there is a likely cure (4: 141-146) 
 
Hanna: I’ve never been given anything or any idea that there might be something that stops it (3:95-96) 
 
The sample appeared to come to terms with the belief that they would be living with an episodic 
illness with uncertainties about a cure ever becoming available to stop it returning. 
Paula: No, I don’t believe that [a cure] because there is just so much trial and error, things with the medications no, 
maybe there will be I’d like to think that there would be but it just even with the medication it just still feels out of 
control so I’m struggling to have faith in that (4: 28-30) 
 
 233 
 
When participants were probed further there seemed to be a common understanding that a cure 
is uncertain because CU is not deemed as important, large scale or serious enough to gain 
adequate funding for finding a cure. 
Karen: My belief is that it probably erm I don't know that's but I’m guessing that it does not get as much money on 
research and stuff because it not life threatening necessarily and so my guess is not so much money spent on it 
erm so I don't think that there will be a cure, not in my lifetime. [Lower tone] I don't think so sadly.....I wish there was 
(4: 141-146) 
Paula: I think because research is on a small population in country suffer from it I guess urticaria and all the research 
being done all of the time I think maybe it’s there’s not a lot of funding in it I guess because of the small population 
I’m not sure that’s just really my naive opinion, yeah [laughs] (3:95-96) 
 
Hanna took the alternative view that CU is too multi-factorial for a cure to end it all: 
Hanna: I suppose it’s difficult if you don’t know what causes it. If its stress and a cure for stress well I suppose I 
don’t think so as everybody has different triggers as to what causes it so I don’t think they will be a cure [at] all for it 
I doubt it (3: 103-5) 
 
Mary’s response implied that in the time she’s had CU [48 years] they would have found one by 
now  
Mary: ...Probably because I’ve had it for such a long time 
 
Words and terms such as ‘random’, ‘go through another round with It’, ‘bit of a roller-
coaster’ and ‘back suddenly’ seem to depict the women’s feelings of the unpredictable course of 
CU and lack of identifiable markers that one could use to predict itse return. What they do reflect 
is a timeline perception (Moss-Morris et al. 2002) where chronically ill individuals create distinctly 
separate cognitions as to the chronicity and cyclical timeline of their condition. The apparent 
cognitive schema of CU course and prognosis made by these women is in line with a current 
understanding of CU (Maurer et al. 2011). The unpredictability of CU itself is summed up in its 
umbrella term chronic spontaneous urticaria, the spontaneous meaning that it mysteriously 
disappears as it first appeared and its reoccurrence is difficult to predict (Maurer et al. 2011). The 
examples in the women’s transcripts imply that this interpretation of CU as cyclical and lifelong 
may have been strengthened by the long duration of their illness (symptom perception) and 
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having no clear information provided by doctors regarding prognosis (social messages). In 
contrast the women’s accounts may provide an indirect insight into the medical professions 
inability to do so as they are also trying to understand CU course that varies considerably 
between cases (Zuberbier et al. 2009). Overall CU is viewed as incurable due to being too rare 
and heterogeneous which here seems to equate to CU being a poor candidate for research 
funding.       
 
Theme 2: Fear of Reoccurrence 
The second theme was centred on fears of the condition coming back after a period of 
remission. Participants gave accounts implying that one should not dwell on this coming back 
but put strategies in place to deal with a possible reoccurrence:    
 
Hanna: think you just deal with it, I just hope I’m not gonna have an attack. I do worry that if I’ve got something 
planned that it erm its not gonna crop up and I might take a, make sure I’m taking my medications a week in advance, 
cause sometimes you take it and it’s been a while (5: 160-163). 
 
Mary: Mine comes and go in cycles. The way I actually psychologically deal with it is to never think it’s gone, never 
think it’s gone that’s how I deal with it. It’s kind of better the devil you know theory. I can’t cope it breaks my heart 
every time it comes back (3: 105-07).      
 
Karen: For my fiftieth birthday I didn't drink I was frightened of triggering it erm so my thought process is to think 
positively and just give myself the best shot of it not coming back. One of the things they say triggers it is stress. It's 
very difficult to avoid stress in your life but when I am stressed its erm very, very aware that I might be causing it to 
come back. The other thing I don't ever do which is a change in my life style never sunbathe, I used to sunbathe a 
lot, I used to go abroad on holiday to sunny beaches and lay on the beach, never, ever sit in the sun now (6: 212-
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A closer observation of Karen’s transcript revealed what appeared to be a contradiction in her 
above account and an earlier dialog regarding a fear of reoccurrence (i.e. thinking about CU and 
also not thinking about CU during remission):  
Karen: yep but when it’s not with me for months like now then I'm I don't think about it. I not thinking everyday its 
coming I generally just don't think about it but it’s just, in fact I kind of always make a point of not thinking about it 
‘cause I don't want to tempt fate (5: 171-173)   
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Holding such a view seemed to reveal a difficult situation for Karen that she might not have been 
aware of that by trying not to think about it and tempt fate she actually thinks about it (i.e. what 
to do) in order to avoid the reoccurrence. This is demonstrated again in the following response 
were Karen indicates another change in her health habits plus a developing self-awareness of 
self-regulating internal bodily states:   
Karen: Erm it’s made me become more health conscious, I don’t drink alcohol at all for fear of triggering it, I erm, I 
still exercise but I am much more conscious of not exercising enough or too hard (2: 59-61) 
 
Paula also affected by co-morbid delayed pressure urticaria (or DPU)2 also verbalised 
preventative measures but found this easier to do for the DPU as she knew what the causes 
were as to the CU which she stated earlier “I don’t know but it doesn’t make sense to me with 
the ordinary urticaria” (2: 39). 
Paula: erm, I guess watching time again with my lifestyle making sure I’m moving, buy big baggy clothes and not 
wear socks all day, plan my day and time with my kids and things and outside socially so that I’m not on my feet a 
long time or wearing the same type of clothes all day so it’s the physical things that I can do to avoid the pressure 
urticaria (5: 162-165) 
 
Researcher: Okay, you said the pressure urticaria affects you more than the ordinary urticaria [CU synonym] 
 
Paula: Yes I think so and if I can avoid it slightly [the CU] it’s easier as well (5:166-167) 
 
These transcript examples imply that the women are always thinking about CU whether 
they are actively experiencing CU symptoms or in a period of remission as in these states a 
variety of cognitive and behavioural coping strategies are in place to minimise the impact of 
reoccurrence even when reoccurrence cannot be predicted. Whether it’s taking medications a 
week before social events, avoiding alcohol before birthdays, avoiding the sun and stress or 
changing exercise behaviour one must maximise the chance that CU will not come back 
especially at times were it could possibly coincide and interfere with important events. The 
incorporation of coping strategies to minimise serious consequences highlights how CU seems 
                                                          
2Delayed pressure urticaria is a physical urticaria caused by applying pressure to the skin (e.g. by wearing a belt, bra, watch or 
simply sitting for too long. Over the course of the day, such areas with result in a weal and flare reaction ) 
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to be placed at the core of ones existence for which all future planning and decisions are based 
upon. Such experiences of CU are not dissimilar to other reports in this thesis and in the 
published research literature. O’Donnell et al. (1997) in the first study of CU on quality of life 
found that 46.0% of their 100 participants reported concerns about the unpredictability of CU and 
Chung et al. (2010) found that individuals with CU tried not think about CU (73.0%) but 
concentrated on self-management procedures (68.0%) and finding solutions (66.0%).  
 
Theme 3: Loss of Control over the Self 
The most transparent and succinct response was that CU is not a condition that one 
personally controls but one that as a separate entity totally takes control: 
Karen: When it is with you and it’s got its grip on you it’s debilitating (2: 63-64)...no I think it controls me when it's 
with me (3: 94-95)  
 
Hanna: No, no not at all. No I don’t know how to control it don’t know what to do (3: 88) 
 
Paula: No, not on any level, at any time, I don’t feel I have control over it (3: 85) 
 
Mary: None, no control over it whatsoever, absolutely no control. No it can be very, very overwhelming and erm my 
faith really helps me with that. (5: 85-6) 
 
Mary’s way of dealing with it was to see the CU as a separate entity to the self and by doing this 
she could cope better with it:  
Mary: it’s all encompassing if you let it get a grip on you which is why I call it IT and which is way I say I got IT, IT 
hasn’t got me I deal with it better that way because if, if I let IT get control of me, my god it’s a horrible place to be   
(6: 224-6) 
 
The multiple use of the word no at the beginning of three of the four extracts together 
with terms such as grips on you (Karen, Mary), don’t know, overwhelming, debilitating, all-
encompassing in response to the ability to personally control CU appears to show the women’s 
overall feeling of complete helplessness to exert any control over the emerging symptoms and 
sensations they are experiencing. Together the words imply that one will be paralysed to 
undertake any other life activities and will just have to let the process happen as inevitably they 
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have no choice. In Mary’s extract she separates CU from the self and turns to religion implying 
that an outside force bigger than herself maybe the only source of comfort for her.  
 
At first such words and the interpretation of them seem to contradict the interpretation of 
the previous theme in that a range of active and positive coping strategies are reported in order 
to cope with CU and minimise reoccurrence. One interpretation is that maybe despite ones active 
efforts to prevent reoccurrence in remission or reprieve days, when the symptoms do arrive 
nothing in place is strong enough to stop it. In study 4 the data indicated that a strong illness 
identity and high emotional representations significantly related to a greater use of negative 
cognitive appraisal coping (as would be predicted) but also proactive coping. Positive and 
negative coping procedures also related to poorer outcomes. Conclusions were made 
suggesting that enforcing positive problem solving strategies in the face of what seems to be an 
uncontrollable situation may result in poor adjustment similar to negative forms of coping (Carver 
and Conner-Smith, 2010). Such an explanation seems applicable here. The feelings of lacking 
personal control over CU may further indirectly indicate a highly bio-medical approach to self-
regulating CU, relying heavily on treatment control outcome expectancies, which is 
understandable as this is how CU is currently managed (Zuberbier et al. 2009b). Throughout the 
transcripts the women suspected that stressful life events could be a maintaining factor but these 
were never considered in terms of how to personally recognise, control and manage such 
circumstances.  
 
Theme 4: Strategies that keep it at Bay are often Limited or Ineffective 
A frequent topic across transcripts was the role CU medicines and the reliance on them 
to control symptoms. However despite a dependency on them, accounts implied that they were 
perceived as often unreliable and ineffective again reflecting the notion of uncertainty in fending 
of symptoms. Such dependency is reflected particularly in Hanna’s account:  
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Hanna: ...I don’t know whether because it just makes me feel better if I’m taking something to be honest, don’t know 
how effective they are but yeah I would like not to have anything you know available (3:108-110) 
 
Mary's response implied that until she finally convinced doctors about the possibility of using 
cyclosporine (a second-line oral CU medicine) nothing had worked: 
Mary: yes I’d like to thank the person who invented cyclosporine from the bottom of my heart. I tried to get on it for 
years (6: 198-199)  
 
This theme could be further broken down by medication type but regardless of administration 
similar perceptions prevailed 
 
Oral Medicines: 
Karen: They haven't helped me the cyclosporine I say is a very strong drug and it didn't help me but that's my own 
experience the doctors tell me [there] are people it has helped and the urticaria has gone away forever and I wasn't 
that person sadly so therefore I would have to say no [they didn’t work] (5: 151-154) 
 
Hanna: Not really, there’s not a lot you can do it, it just nothing you can do to, to prevent it all anything you just can’t 
get through it so there’s really no point in dwelling about it I guess (5: 169-171)...I don’t think they do particularly 
[CU medicines] and I don’t know, I mean I’ve tried various things and at the moment... but I still get the symptoms I 
don’t think it, I don’t know whether it lessons it but I don’t think it controls it, it certainly does not stop it (3:92-96) 
 
Paula: ...I haven’t seen really direct results except for the steroid treatments at all, so sceptical (3: 109-110) 
 
Topical Medicines: 
Karen: I think there's a limit to what I can do. I must say I have cold creams, I don't find the creams effective I might 
get a bit of short reprieve with but I've never found a cream that will take it away or even take the itch away over a 
period length of time (5: 189-90; 6: 191-192)...I put the cream on and then I will get a bit of reprieve but not forever 
just a wee while (6: 202)   
 
Other non-medication strategies were also experienced as ineffective and further reflected 
uncertainties in an ability to stop symptoms coming back:    
Dietary: 
Karen: when it was bad last time I tried to stick to the diet...and I think it may have helped but I couldn't be sure be 
course it was coming to the end of its cycle so I don't know but now (3: 103-105) 
 
Paula: yeah, I’ve followed the food, the food, action sheet with the list of you know cutting out different food groups 
at different times and I didn’t notice an effect (2: 42-43) 
 
Mary decided to take a positive attitude to what she could eat as to what she could not eat: 
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Mary: I say what I can eat rather than what I can’t cause it’s just ridiculously long (3: 10) 
 
As the women explicitly implied having no personal control over CU, they also felt they had no 
external control either with the medication and avoidance strategies available to them. This is in 
line with CU treatment being dominated by CU medicines, which are often ineffective or are only 
partially effective in up to 50% of patients (Maurer et al. 2010). Eliciting mechanisms are also 
rarely identified (Zuberbier et al. 2009b; 2012). CU medicines are a complicated issue and as 
reviewed in chapter 1 it is not unusual for patients to be prescribed up to four times the licensed 
dosage and then proceed to second-line and highly individualised third-line treatments with drug 
combinations which can have harmful side effects long-term (Zuberbier et al. 2009b; 2012). As 
bio-medical theories of CU cannot predict with interventions will improve which outcomes (Saini, 
2011) there is no guarantee that the drugs will work but that the right combination will be identified 
(see section 1.4, p11 for a review).   
 
Theme 5: Barriers to accessing help when it comes back    
The dependence on CU medicines was further reflected in this fourth theme that 
highlighted a need to have access to emergency CU medicines that do work (i.e. steroids) in the 
eventuality that it would (at a time that couldn’t be predicted) come back.   
Karen: I just needed help and I did say to the doctors about that that given the nature of this illness they have to 
have a system whereby if suddenly you have a flare-up and you feel you need help you need to be able to just get 
into that clinic without a whole series of very, very stressful phone-calls and that that, that really upset me (7:246-
249)...But I think that I cannot believe that I have been the only person to have experienced that, that really stressed 
me out cause I thought oh my God what more can they do, because it was really bad (7: 254-256) 
 
Hanna: It’s just because my GP won’t give me [steroids] well I’ve asked him could I have steroids so that if I do get 
an attack that I’ve got them here and he refused this and he won’t let me have them and he’s like no you can’t you 
can only take them so long not long-term, so I have to go over to my GP physically to get steroids after I’ve had an 
attack. I’d rather just have some here to use as and when and I assume there is a reason as to why he won’t give 
them to me (4: 122-127) 
 
Mary: [Cyclosporin] I tried to get on it for years and every time I suggested it to the doctor cause I said I looked on 
the internet and I knew that there had been success with it and I wanted to try it and everyone kept saying no. and 
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it wasn’t necessary then I started coming up with these photographs and taking them and erm and suddenly I was 
here and on it before I could blink and I say first tablet everything was fine (6: 200-204) 
 
The selected texts here demonstrate the apparent barriers caused by a health system 
that does not really understand CU and its cyclical nature. The women’s accounts portray the 
difficulties and perseverance required in order to access steroid medications when they begin to 
feel CU symptoms emerging after a period of remission. This experience itself seems to be a 
stressful one that may amplify the attention paid to emerging CU symptoms and sensations and 
the fear of experiencing an episode with no strategy in place for reprieve. Steroid medications 
are prescribed in cases of active CU when symptoms are severe due to the possible harmful 
side effects, hence the difficulties experienced by the women attempting to access them after a 
state of remission may indirectly imply and confirm research suggesting that non-expert doctors 
find CU patients difficult to treat (Weller, et al. 2012). 
 
8.3.4: Master Theme 3: Psychosocial/ Appearance issues ascribed to Itching and Swelling  
Questions regarding the physical appearance of CU were never asked during the 
interviews but emerged as an overarching theme across transcripts. In contrast questions 
regarding mood and personal/ social relationships were asked and were originally categorised 
as separate themes, however both were always discussed within the context of appearance 
suggesting the serious consequences of CU was tied up in emotions about appearance. The two 
sub-themes of this master theme represented a three-way relationship between emotions, 
interpersonal interactions and the appearance of CU symptoms on the body.   
 
Theme 1: Feelings of Shame and Self-Consciousness due to Fear of Exposure 
Accounts indicated that the appearance of CU symptoms had a detrimental impact on 
the women’s self-concept and how others viewed them in public, so much that the anticipated 
judgement and responses from others of the symptoms appearance could be said to have 
become more important than the debilitating effects of experiencing the symptoms. In some 
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cases fear of such judgements due to shame often resulted in feelings of self-consciousness and 
social isolation:  
Karen: when I'm out and about I think, I feel self-conscious, I think people must be looking and thinking what's wrong 
with her and I couldn't walk the street I should explain it but you know I don't (3: 74-76)      
 
Hanna: if I get it on my face, I’m not going to leave the house and you know it’s like I don’t want to see anybody 
because it looks ugly you know big lumps on your skin you know and your hands are so swollen and you can’t put 
your shoes on and you can’t go out and you don’t want to see anybody. I’ve had it when my lips have really swollen 
up you know I don’t want to see anybody (3: 79-83). 
 
Paula: Erm just quite self-conscious I guess when it’s showing and especially when I’ve slept a few times and woken 
up and where it swells on my face and so yeah disgusting, really self-conscious just so self-aware of how I’ll be 
physically looking and going to the hospital to get the medications for the swollen face it’s just, it’s just awful. I think 
it could makes me, if I was a less confident person it could make me feel really on edge and need to have time of 
work for emotional stress and physical (4: 153; 5: 158) 
 
Further accounts by Karen positioned her as a social outcast however the discourse also 
indicated that she believed she was worthy of others distain almost presenting an empathy for 
anyone unfortunate enough to be associated with or in close proximity to her.  
Karen: I can see it must drive people mad, there's nothing worse than sitting beside someone scratching away it 
gives you the heebie-jeebies doesn't it [heckles and laughs out loud] 
 
Paula also seemed to adopt this position but believed that her personality enables her to deal 
with it positively, however eventually she would succumb.    
Paula: Erm, I think at first when I was in school and the children would see it on me and go awh what is that on you, 
it could have [been bad] but because it came and went and that I guess with the older children at school it was okay. 
It could have I think if I was not feeling okay with myself you know (3: 83-86)...if it was to continue to be bad as it 
was at its worse point I’d genuinely think my job would be effected I think emotionally I could be really affected and 
self-conscious and really aware of the physical side of it and how much that effects my life and I have no idea until 
I suffer with this how people, how physically you feel and how you look matter I guess to me and other people, to 
children particularly in school (5: 174-178) 
 
…however  
Karen: erm I'm different, not totally different yeah I mean I get on with my life I would do everything I would normally 
do but your waking up and you just feel miserable.  
 
When asked Mary’s response implied that she had transcended such experiences over time: 
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Mary: affected socially] I used to be I’m not anymore. I think as you get older you, you care less really, I prefer now 
to actually explain what’s wrong & people want to know…children particularly full of questions but again you know 
taking the erm cyclosporine there isn’t anything to see, erm I was pumped up on steroids at one point erm which 
psychologically [was] very upsetting because I’ve always had a weight problem, I’m always fighting to stay slim and 
you put me on steroids & [laughs] five stone before you can blink & an awful lot of comfort eating as well as taking 
steroids it means I could eat so I did [laughs] anything dipped in chocolate, my best friend, [laughs] (4: 149-156)            
 
As stated earlier questions regarding looks and appearance was not a part of the 
interview schedule but frequently emerged in respect to discussing symptoms and emotions. The 
women indicated an amplified sense of not only their self-awareness of CU but also others 
amplified awareness (or perceived amplified awareness) of the visibility of their CU symptoms. 
They verbalise both its impact on their physical attractiveness and the impact on others who 
have to see its appearance and watch the associated scratching behaviours. The need to 
conceal oneself or engage in social isolation appears to be an act that will not only protect the 
self but also protect others. Together with the need to explain it, get used to it and even 
sympathise with others seeing it suggests that the women perceive CU symptoms to be both 
socially stigmatising and an unacceptable condition for which one should enforce a sense of self-
blame and disgusts towards the self. This portrayal of CU is in line with Ozkan et al. (2007) who 
found that 78.0% of their participants reported CU to have consequences regarding a disturbed 
body image, attitudes towards others, attractiveness and feeling different, self-conscious and 
embarrassed. 
 
The perception that the self and others should see CU in this way suggests the 
assimilation and accommodation of negative symptom perceptions and social messages about 
skin disorder. This interpretation of the women’s experience is supported with a strong research 
literature which suggests that skin disorders are heavily stigmatised in most societies bringing 
feelings of shame on the individual experiencing it as well as blaming and stigmatising those 
individuals (Thompson, 2005). In many societies perfect skin is associated with beauty, 
cleanliness and an indication of good health, bad skin portrayed as ugly, a sign of poor health 
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and a sign of punishment on the inflicted person (Kent, 2005). Further visible skin imperfections 
can be seen as contagious (Kent, 2005). Kent & Keohane (2001) found that skin disorder patients 
experience two types of stigma: enacted stigma: (direct experience of being rejected) and 
vicarious stigma (observing someone else with condition being rejected by others) and the 
women state feelings about the former in their accounts but it is difficult to interpret whether these 
are actual or perceived. Further evidence comes from the social media that strongly projects 
ideals of beauty and this often includes having perfect blemish free skin (Magin, Adams, Heading 
and Pond, 2009). Magin, et al. (2009) used thematic analysis and identified a theme interlinking 
relationships between skin disease, ideals of beauty and the role of media. They found that 
participants identified ideas of perfect skin mediated by media portrayals and this precipitated 
psychological morbidity in women but not men. They concluded that there is more pressure on 
women to look physically perfect, which like in this study would be in conflict with the visibility of 
CU symptoms.   
 
In study 4, it was the disease-specific QoL outcome of looks (48.7% sample) that was 
reported to be as marginally worse than pruritus outcome (48.1%) indicating that the 
psychosocial and emotional aspects of CU can be similarly or worse impaired than the physical 
aspects that medical practitioners primarily focus on (Magin, Adams, Heading and Pond, 2009). 
However there is evidence in the accounts that one can overcome these feelings either through 
personality factors or over time.  
  
Theme 2: Impact of CU Appearance and Symptoms on Personal Relationships 
This theme related to the impact of CU symptoms and its appearance on how one 
interpreted the responses of their partner in private. In the first account Paula states that her 
husband could not come near her physically due to the effects of her dual diagnosis:    
Paula: Yeah, and when it was at its worse my husband couldn’t even come near me physically at all ‘cause everyday 
I would have either the pressure or ordinary urticaria (3:80-81) 
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Indeed such a reply could be interpreted as her husband keeping his distance as not to touch 
her and exacerbate symptoms but a later quote from Paula implies this talk to be associated to 
her embarrassment that she becomes unattractive and undesirable when symptoms are visual 
and could only see her husband responding in line with her developed negative self-perception 
of the self: 
Paula: I think about how it looks on my body or when it’s on part of my body show all to my husband when it’s on 
my body just disgusting, it just looks so painful and it is so painful & angry I guess, it’s just disgusts me and pain 
from it (4: 149-151) 
 
Mary describes a similar past symptoms-appearance experience that she has transcended over 
time.  
Mary: I don’t like looking at myself when it’s bad but again that’s something that erm has got easier as I’ve got older. 
I think once I got into my forties & I allowed my husband to take photographs of me when I’m bad I was able to take 
to the hospital (5: 158-160) 
 
Karen’s relationship with her partner was less about the appearance of CU but the emergence 
of a different self ascribed to urticaria symptoms. Paula describes herself as ‘more grumpy’ when 
she is experiencing symptoms and seems to attribute such behaviour to exerting stress onto her 
husband. The operative word here is the use of the word ‘probably’:   
Karen: Oh yeah it stresses my husband... [3 second pause] probably, probably my husband, cause probably I'm 
more tired because you know you don't often sleep well with it, I'm probably a bit more grumpy (3: 78-80) 
 
However there is evidence in the transcripts that appearance and attractiveness is important to 
Karen. 
Karen: ...might scratch my skin with my nail, it will mean red if you know what I mean that mark will not go away (1: 
16-17) 
 
Despite the impact of symptoms and appearance on relationships, significant others were 
sympathetic to the experience which is highlighted best by Mary:     
Mary: We had a conversation not very long ago about erm I am not my illness I have to remind him [husband] 
occasionally that I’m a can do person not a can’t do person...as I said, IT’s is not me, I’ve got IT, IT has not got me 
& I can find that actually very frustrating to be a victim, to be treated like a victim and I’m not & he’s wanted to help 
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& he does help me, cuddles me when I’m having a bad day ...he’s been my absolute rock right the way through & 
we’ve been married thirty years... he’ll never let me come here on my own & that kind of thing so yes [laughs] (5:16-
178)                
 
The impact of the appearance of CU symptoms and the emotional response appears to 
continue in private as it does in public but is much more focused on issues concerning the ability 
to look attractive and desirable to one’s partner or husband and the conflict it can cause. The 
transcript examples from the women also appear to indicate the difficulties also experienced for 
partners trying to be understand which can cause stress for both parties but also a source of 
support. Again there are indications that such conflicts and becoming at ease with one’s body 
can get better over time. Not much is known about the impact of CU on interpersonal 
relationships but these accounts are not dissimilar to the impact of chronic skin disorders on 
relationships found in the wider research literature. Skin disorders are known to impact 
relationships in respect to appearance and shame, body image, sexual intimacy, coping and 
adjustment (Anthis, 2005). In a recent study Magin, Adams, Heading and Pond (2010) identified 
a theme regarding the effects of skin disorder on self-perceived sexual attractiveness, self-
confidence, capacity for intimacy and sexual well-being using thematic analysis. They found that 
issues related to self-image and self-esteem resulted in the avoidance of intimacy even in long-
established relationships that related to appearance of the skin and not the genital area.               
 
8.3.5: Master Theme 4: CU Medicines as a Health Threat Verses Health Saviour 
 
In this master theme CU medicines are both a health saviour and a health threat.  
 
Theme 1: CU Medicines as a Necessary Evil 
In this subtheme steroid medications appeared to take on the role of a necessary evil 
one must accept to alleviate symptoms.  
Hanna:...with the steroids I suppose cause I don’t know you know that they can be quite dodgy to take long-term 
but they do seem to be the most effective thing to take...I don’t really know about it to be honest. If its anti-histamines 
then there are probably no side effects but anything else I’m a bit weary of long-term (4: 112-117) 
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Paula: I’d like to think that when it does flare up really badly that on a regular basis there’s medication that hasn’t 
got the side-effects of the steroid treatments has I guess to just help manage the illness, rather than feeling out of 
control with it (4: 124-26)...If there was, no steroid treatment, nothing, I think it would just get so bad that...I think my 
body would be one whole, erm wheal it will be awful. I think honestly I wouldn’t be able to leave the house, I don’t 
think I’d live, honestly, that is a bit dramatic maybe (4: 141-145) 
 
Mary: I was concerned when I saw that the side effects came in a book rather than a sheet of paper erm but 
compared to what was happening to me erm I was willing to put up with just about anything and something suddenly 
erm growing an admirable moustache was a small price to pay compared to what I was going through (6: 208-11) 
 
 
In Karen’s situation this can be interpreted as an exchange of losing one set of CU-specific 
symptoms for steroid specific negative side effects which is very much resented: 
Karen: ...the only thing I can do to get a reprieve from it is to take steroids and I hate taking steroids. I hate the 
steroids makes me feel agitated and puffy and sore and swollen and unwell (3: 92-95)...Erm but then it gets flares 
up and is really bad then there isn't anything that I like and only thing that can give reprieve as I said is the steroids. 
And I hate, try to resist taking them as much as I can (4: 129-131) 
  
In these accounts it is evident that steroids are the only CU medicines that the women 
can trust to relieve CU symptoms. The commentaries on steroid side effects in parallel to the 
need to take steroids implies the intensity of symptoms are so unbearable that they result in a 
desperation and urgency to seek reprieve from something that they perceive could put their 
health in further danger. There is strong support that chronically illness individuals weigh up the 
necessity of taking medicines with concerns about side effects (Horne, 1999; 2003).  
 
Theme 2: CU Medicines as a Friend verses a Foe 
Although steroids and other CU medicines were seen as a necessary evil the following 
accounts reflected opinions regarding generally embracing and welcoming the existence of CU 
medicines (especially steroids) and attitudes towards medicines in general.   
Hanna: Oh I’m all for them, you should, I would take whatever is necessary [laughs] whatever’s necessary, yep 
[laughs] (4: 119-120) 
 
Paula: I’m open minded to actual medication but I haven’t seen really direct results except for the steroid treatments 
at all, so sceptical but open minded to it (3: 109-110)...thinking about having a second child and the methotrexate 
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that was recommended erm after researching and after the opinions from the doctors here, that wasn’t suitable but 
other than that I’ve taken any medication that has been recommended by the consultants here (3: 113; 4 114-116)  
Mary: Hell yeah [both laugh] yes I’d like to thank the person who invented cyclosporine from the bottom of my heart 
(6: 199-200) I was a very good candidate for cyclosporine and that I am entirely grateful so yes I do to think  
It’s imperative because I don’t know what would happen without. I probably do know what would happen (6: 204-
206) 
 
...however Karen held an opposing view indicating that all CU medicines are bad for your health 
and indicates that she may feel that they are overused by doctors 
Karen: ...don't like any of the medications I have taken always have not felt well when I'm on them. (4: 120-121)... I 
absolutely stand by that I don't want to pump my body full of chemicals (4: 137)  
 
When probed further Karen presented a dialogue that indicated that her perceptions may have 
stemmed from watching her mother’s experiences of taking medicines of which the costs 
appeared greater than any benefits (known as the necessity-concerns differential concept Horne, 
2003).   
Karen:  I hate with a passion all the medication and I would do anything in my power to resist having to take them. 
I feel strongly about that... my mother was a very ill women and I watched her for fifteen years of her life on 
medications and all the side effects and the symptoms none of them seemed to benefit her greatly and just don't 
want to be that person, it must sound really dramatic [laughs] (2: 64-69) 
 
In this theme CU medicines again can be seen as both a health saviour and a threat but 
how one comes to such an opinion appears to be assimilated through both symptom perceptions 
and social messages as it develops for perceptions of illness. The opinions of doctors and 
watching the experiences of significant others on medicines appear integral to forming the 
treatment perception as well as one’s own experiences of taking them. The final perception my 
result in a view that CU medicines (and medicines in general) are here to help or are harmful 
and overprescribed by doctors.     
 
The individual accounts are in line with the research literature supporting that ill 
individuals do not only have beliefs about the necessity and concerns of prescribed medicines 
but also about medicines in general and their overuse by doctors (e.g. Horne, Weinman and 
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Hankins, 1999; Mahler et al. 2012, De las Cuevas et al. 2011; Iihara, et al. 2010; Francis, et al. 
2009). Further as perceived by Karen who has an opposing view to the other women, research 
has shown that concern beliefs may also be influenced by ones perceptions of their personal 
sensitivity to the side-effects of what they see as harmful treatments and their overuse by doctors 
(Horne, et al. 2013).   
 
8.4: Conclusion 
This study explored cognitive representations and lived experiences in CU. Using the 
methods of IPA twelve themes and four master themes were established. The researchers 
overall interpretation of the women’s experiences is summarised below and in Figure 8.1 (p249)   
CU is depicted as a chronic skin disorder that is difficult to understand by the self and 
others (including doctors) also trying to understand its unexplained symptom presentation; an 
illness that is certain to go through periods of active states and remissive episodes but the 
presence of such states cannot be predicted. Such certainties and unpredictability induce fears 
of CU reoccurrence and the loss of self-control over the experience which is further exacerbated 
by the perceived limited and ineffective strategies available to gain self-control and barriers to 
access those that work. CU itself induces feelings of shame, self-consciousness and self-blame 
due to perceived social stigmatisation about visible skin disorders and associated scratching 
behaviours it encourages which extends to feeling undesirable and unattractive in personal 
intimate relationships. In order to gain some form of effective treatment control at the worst times 
one must separate oneself from any negative beliefs about CU medicines (and medicines in 
general) and embrace the benefits.    
 
The women’s experiences in all master themes confirmed study 4 findings that there is 
a need to change misconceived representations of CU. However, this study differed from study 
4 in that it was indirectly revealed throughout the transcripts that health professionals (especially 
in primary care) also appear to require access to more CU educational resources.  
 
Patient resources that increase a basic knowledge of CU could have a dual purpose. 
The first could provide information on CU illness and treatment including how the skin disorder 
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is assessed and diagnosed, its symptoms and process, which factors are known or are 
associated with its cause, duration and maintenance and the individualised nature of the 
treatment.  The second could be a resource that keeps patients up-to-date on the latest  
 
Figure 8.1: A Qualitatively Derived Common Sense Representation of CU based on IPA 
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between primary care practitioners and consultant dermatologists. For the patients this may 
result in better disease control and the reduction of barriers when emergency medicines are 
required, leading to better doctor-patient relationship and patient satisfaction. However, as the 
transcripts indicate, problems with CU are not limited to concerns about understanding and 
treatment but also the emotional, social and interpersonal impact on ones lived experience.  
 
As stated earlier there are currently no psychological interventions available in CU. The 
findings of this qualitative study and the CU literature suggest that the input of professional 
psychological services either through referral or by integration into existing dermatological 
departments is required. Such input could include psycho-education to challenge misperceptions 
of CU and incorporate action plans of how to identify and cope with potential psychological 
factors involved in triggering CU (after remission and during active disease) and the helplessness 
experienced when medical interventions are failing. They could also help with strategies for 
coping with the emotional aspects and in developing strategies for dealing with the 
embarrassment caused by CU’s appearance and symptoms in social situations and in intimate 
personal relationships. 
 
The current study highlighted the substantial similarities as to differences in personal 
accounts of cognitive representations and coping with CU which were consistent with the current 
medical understanding of CU and the structure of CU services. In addition to highlighting lived 
experiences in CU for the first time, the women’s accounts in this respect may reflect other 
individual patient accounts and concerns that may arise during consultations and therefore not 
only compliment quantitative accounts but help in the development of CU specific self-regulation 
and management strategies.  
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Chapter 9 
Development, Pilot and Evaluation of an Intervention designed to Change Cognitive 
Representations & Quality of Life in Chronic Urticaria (Study 6) 
 
9.1: Study Rationale 
This chapter reports the development, piloting and evaluation of a CSM intervention aimed to 
establish if cognitive representations of CU are amenable to change and result in significantly better 
quality of life. It was designed using guidelines by the Medical Research Council (Campbell, 2000; Craig 
et al. 2012) and CONSORT (Altman et al. 2012), designing interventions in behavioural medicine and 
health psychology (Davidson et al. 2003; Abraham and Mitchie, 2008) and information from CSM 
interventions (reviewed in section 2.5, p45). The pilot had research implications for developing an RCT to 
confirm the study effects and practical implications for incorporating psycho-education interventions into 
routine care to facilitate better disease management. 
 
9.2: Introduction 
With no known cure, the primary aim of CU treatment is to reduce disease-severity and improve 
quality of life (Zuberbier et al. 2009b; 2012). In order to do so patients are recommended to take CU 
medicines and avoid exacerbating factors. However as reviewed in Chapter 1 existing bio-medical 
theories of CU aetiology cannot predict which treatments will impact which outcomes (Saini, 2011) and 
triggering factors of CU are rarely identified (Zuberbier et al. 2009a, b; 2012). One psychological factor 
that has been found to be a contributor of illness outcome has been cognitive representations of illness 
(Hagger and Orbell, 2003) that in study 4 was found to be significant predictors of CU-related quality of 
life outcomes. Cognitive representations have been found to be amenable to change via intervention 
leading to improvements in a range of illness outcomes (see section 2.5, p45) indicating that changing 
perceptions of CU may also improve CU-related outcomes.  
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9.2.1: Structure and Contents of a CU Intervention based on the CSM 
The pilot was structured using behavioural interventions guidelines by Davidson et al (2003) that 
consider seven structural features in that are explained in-turn below. 
 
(1) Contents and Elements 
This current study used Behaviour Change Techniques (BCTs) as defined by Michie and 
colleagues (Abraham and Mitchie, 2008; Michie, van Stralen and West, 2011). Cognitive determinants of 
the CSM were not directly mapped to particular BCTs by Abraham and Mitchie (2008) but they did map 
them to Carver and Schiere’s self-regulation theory (Carver and Scihere, 1998) which is a generic version 
of the CSM (Leventhal, Meyer, Nerenz, 2003), hence BCTs for the former would be relevant to the later. 
The BCTs are as stated below (see Table 2.2; p48 for details).  
(1) Prompting specific goal setting 
(2) Reviewing behavioural goals  
(3) Providing self-monitoring of behaviours  
(4) Providing feedback on behaviour  
BCTs recommended by Abraham and Mitchie (2008) fit well into self-regulation theory in that the individual 
is seen as part of an active problem solving system attempting to self-regulate by applying meaningful 
goals and achieving them through directed behaviours that remove barriers to those goals (Scheier and 
Carver, 2003), however undertaking BCT’s only addresses behavioural aspects of the CSM. In the CSM 
the content specific determinants cognitive representations also act as mechanisms of change and are 
fundamental to the prompting of undertaking behavioural goals. Unlike conventional educational 
approaches this top-down approach using abstract/ cognitive strategies uses the patient’s own model of 
illness as a basis for filling in gaps in knowledge, challenging misconceptions, providing the patient with 
a conceptual framework for the illness so that they can recognise that it is still chronic when asymptomatic, 
hence the new conceptual framework provides the patient with an implicit model to appropriately interpret 
bottom-up information generated by behaviours (McAndrew et al. 2008).  
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In line with the model incorrect perceptions are tackled at the abstract and experimental level of 
the representation (i.e. combining abstract information of the illness along the dimensions of the 
representation with concrete imagery of the disease). Such strategies are central to CSM interventions 
however it has been observed that although published studies describe the nature of the disease-specific 
informational content of their programs, they do not describe the mechanisms of change from the 
assimilation of the new information or how it is actually accommodated. In light if this incorporated the 
Representational Approach to Patient Education (or RA) by Donovan and colleagues (2001; 2007). 
 
The RA (Donovan et al. 2001; 2007) combines the CSM with the model of conceptual change by 
Posner, Strike, Hewson and Gertzog (1982). The model of conceptual change complements the CSM as 
it explains how individuals go through a process of learning new information, often having to reconfigure 
or adapt existing cognitive structures in order to accommodate them. The model proposes that we all 
have a network of concepts in our minds known as a conceptual ecology. These concepts are interrelated 
and the development of this ecology (i.e. learning) happens in two distinct processes: assimilation and 
accommodation. Assimilation occurs when individuals fit new incoming information into an already 
developed cognitive schema or conceptual framework.  
 
In the context of cognitive representations of illness, the RA postulates that patients already hold 
knowledge and ideas about their condition and interactions occur between new information being 
assimilated and the existing cognitive representation. Unfortunately accommodation does not always 
occur and instead patients may force incoming information into existing ones. The aim of the approach is 
to facilitate the accommodation process to allow for conceptual change. After a process of conceptual 
change the complimentary bottom-up approach of action planning follows an initial top-down cognitive 
process. This is important as evidence suggests that when practitioners focus on the patient’s model of 
illness (top-down) this elicits more patient questions about the illness but it is action plans (bottom-up) 
that results in more discussion on the psychosocial aspects of treatment and lifestyle factors as to the 
representation (De Ridder et al. 2007). With the findings of CU patient behaviours reviewed earlier  
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(Maurer et al. 2008) eliciting behavioural plans after a process of conceptual change may prove critical.  
 
The representational approach acknowledges that as individuals have a well-developed 
conceptual ecology (those interacting together as a representation of the illness) the process of 
conceptual change can be difficult as patients may present with resistance if the new information is seen 
as a threat to their existing representational model. Donovan et al (2001, 2007) suggest that if conceptual 
change is not spontaneous (as is often the case when the patient has had time to reflect on their views) 
that links between current representations, coping behaviour and consequences generated by the patient 
should be facilitated. The RE consists of the following 7 elements: (1) representational assessment; (2) 
identifying and exploring gaps, errors & confusions; (3) creating conditions for conceptual change; (4) 
Introducing replacement material; (5) Summary; (6) Goal setting and planning and (7) Follow-up contact: 
goal and strategy review. Each element is described in Table 9.2, p258).  
 
Remaining elements 
The remaining elements of Davidson et al. (2003) were first reviewed in Chapter 2 in relation to 
how these were represented in previous published CSM interventions. In general CSM interventions have 
been delivered by psychologists, nurses or a combination of these professionals to a range of patient 
groups and have been undertaken in either secondary out-patient hospital clinics or university 
departments where the interest has been in behavioural medicine. Further most have been brief 
consisting of up to three sessions of 30-60 minutes over 3 weeks on a one-to-one basis with a follow-up 
phone-call were a generic protocol has been followed but tailored to the patient’s individual needs. These 
remaining elements of CSM based interventions were also considered in the current intervention and are 
specified further in section 9.2.3 (p257). The study aims are stated below:  
 
9.2.2: Research Questions 
1. To test the feasibility of undertaking a CSM intervention in individuals with CU  
2. To determine whether changing cognitive representations of CU has an immediate effect on  
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self-reported disease-specific QoL, generic mental health status (GMHS) and anxiety levels. 
3. To establish if the effect on disease-specific QoL, GMHS and anxiety levels persisted at 3 months 
post intervention from baseline and 3 months post intervention. 
4. To evaluate the patient experience over the intervention process 
It was predicted that the intervention would be feasible and have an effect on changing the study variables 
that would persist at 3 months compared to baseline and post-intervention.  
 
9.2: Method 
 
9.2.1: Design 
This study was a pilot intervention consisting of a within group repeated measures design where 
participants undertook the intervention and completed assessments at baseline (T1), 1 month post-
intervention (T2) and 3 month follow-up (T3). The dependent variables were changes in disease-specific 
quality of life (QoL), GMHS and QoL and anxiety over time. 
 
9.2.2: Participants 
Participants were recruited from the Urticaria Clinic at St. John’s Institute of Dermatology, St 
Thomas’ Hospital London as described in chapter 5 (p134). The estimated sample size was 16 
participants. This was undertaken using the programme G Power 3 (Faul, Erdfelder, Lang and Buchner, 
2007) for an MANOVA (repeated measures, within-factors), looking for a medium effect size (0.5), a power 
of 0.8 and probability value of .05 on a criteria of 1 group and 9 measurements per respondent based on 
the primary outcomes of overall disease-specific QoL, GMHS and anxiety at 3 time-points (his figure was 
timed by 5 (80) for attrition rates). As the study was originally an RCT, all consenting participants were 
allocated to the intervention or control group using a block randomisation procedure created by computer 
programming experts within the researcher’s institution. A flowchart of participant’s through the study (and 
the elimination of the control group) is illustrated in Figure 9.1 (p256)  
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Figure 9.1: Flowchart of Participants through the Intervention Process 
Enrolment                                                                                                                                   
                                                                                                                                                                  
 
                                                                                                                                                                                                                    
Allocation 
 
  
 
 
Baseline 
Assessment 
 
 
  
 
Time 2 
Assessment 
 
Follow-up    
 
 
A total of 83 participants were approached mostly in the clinic but also by phone to take part in 
this study. Of these 19 were found to be ineligible and 7 changed their mind after an initial interest to 
participate. Ineligible participants were confirmed as having a primary physical urticaria or had changes 
to their medications prior to starting. The greatest reason for not participating included living too far away 
to attend the study as well as the routine dermatology appointments. A total of 57 participants were 
enrolled to take part and randomised to the intervention (29) or control group (28). At this point 33 
participants were lost to attrition that consisted of 11 interventions and 22 controls. As the attrition rate 
was twice the ratio of the interventions and numbers were low, it was decided to eliminate the control 
group, as there was a possibility of losing more of this group that would complicate data analysis. Eighteen 
intervention participants completed baseline assessments and 15 undertook the intervention and 
completed post-intervention and follow-up assessments.  
Patients Approached/ Eligibility Assessment 
N = 83
 
 
Block Randomisation  
N= 57 
(15 x 4 blocks)  
 
 
Randomised to Control N= 28 
 
 
Randomised to Intervention N= 29 
 
 
Challenging Illness Perceptions  
Original Intervention Group N= 15 
 
 
Follow-up phone-call N= 15 
 
 
Complete Baseline Questionnaire Pack Assessments N= 24 
18 Interventions & 6 Controls 
 
Complete Questionnaire Pack N= 15 
 
 
 Completed 3-month follow-up 
assessments & evaluation  
N= 15 (9 evaluations completed) 
 
 
 
 
 
 
Not eligible  
N = 19 
No interested 
N = 7 
 
 
Control 
Group 
removed due 
to high 
attrition  
N= 6  
Intervention 
attrition  
N= 3 
 
 
Attrition 
Intervention 
N= 11 
Control  
N= 22 
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9.2.3: The Intervention   
This intervention was adapted and formulised with CU specific psycho-educational information 
and action planning content by the PhD author and is shown in Table 9.1 below.  
 
Table 9.1: Structure of CU-Specific CSM Intervention 
 
No 
 
Structural Element Name 
 
CU-Specific Structural Element 
 
1 
 
Contents & elements 
 
Part 1: Changing Perceptions (See Table 9.3) 
(1) Representational assessment;  
(2) Identifying and exploring gaps, errors & confusions 
(3) Creating conditions for conceptual change  
(4) Introducing replacement material 
(5) Summary  
(6) Goal setting and planning  
(7) Follow-up contact: goal and strategy review   
 
Part 2: Developing an action plan (See Table 9.4) 
(1) Prompting specific goal setting  
(2) Reviewing behavioural goals 
(3) Providing self-monitoring of behaviours  
(4) Providing feedback on behaviour which were first defined 
 
2 
 
Characteristics of those delivering 
interventions & its recipients 
 
Delivered by Thesis author a PhD researcher under the supervision of a 
Registered Health Psychologist.  
The recipients were patients with a formal diagnosis of chronic 
spontaneous urticaria (CU)  by a consultant dermatologist 
 
3  
 
The setting 
 
Specialist urticaria clinic (tertiary NHS hospital service) or patients home 
 
4  
 
Mode of delivery  
 
One-to-one 
 
5  
 
Intensity  
 
Two weekly sessions plus follow-up phone-call  
 
6  
 
Duration  
 
30–60 minutes 
 
7  
 
Adherence to delivery protocols 
 
Protocol is specified in Section 9.2.6 
 
Contents and Elements  
Session 1 Part 1: Changing Perceptions: Representational Approach to Patient Education (RA) 
The RA framework consists of 7 elements (Table 9.2; p258). Each are followed in sequence but 
the researcher can move from one stage to another depending on where the participant takes the process. 
To fulfil element 1 (Representational assessment) the interview schedule developed in Study 5 was used 
to elicit participant’s baseline CU representations (see page 139 and Appendix 4, pA37). 
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Table 9.2: The Representational Approach to Patient Education 
 
 
Element 
 
Goals 
 
1 
 
Representational 
assessment 
 
The patient is encouraged to describe representation of illness along the five 
components of illness perceptions to identity gaps and errors of perceptions. 
 
2 
 
Identifying & exploring 
gaps, errors & confusions 
 
The patient is encouraged to talk about experiences that developed illness perceptions  
and determine their commitment to these beliefs 
 
3 
 
Creating conditions for 
conceptual change 
 
 
Goal is to help patient recognize the limitations of their existing conception of illness. 
How erroneous cognitions can have negative effects. In patients where this does not 
happen naturally during the process direct links between presentations, coping 
behaviour and the consequences the patient has self-generated is facilitated.    
 
 
4 
 
Introducing replacement 
material 
 
Credible information is provided to fill gaps in knowledge, sort confusions to replace 
existing misconceptions  
 
 
5 
 
Summary 
 
The benefits of acting on the new information is discussed 
 
 
6 
 
Goal setting & planning 
 
Patient & clinician develop goals and actual strategies to improve illness outcome 
 
7 
 
Follow-up contact: goal & 
strategy review 
 
To establish if the patient was able to do strategies. Problems are identified including 
concerns. Did goal work and was it reached?  
 
 
Questions from the schedule are presented one at a time to elicit answers concerning the participants 
existing knowledge of the CSM component in question and how they developed. As the questions of this 
schedule are open ended and include pre-empted probes and prompts this allowed the researcher to elicit 
how perceptions are originally developed and therefore fulfilled element 2 (Identifying and exploring gaps, 
errors and confusions). Misconceptions, negative beliefs and gaps in the patient’s knowledge about the 
component in question is then identified and acknowledged during the participant’s response. In Section 
9.1 it was explained that individuals have a network of concepts in their minds known as a conceptual 
ecology which interrelate and develop learning in two distinct processes: assimilation and 
accommodation. Element 2 partially assists the former process (i.e. individual’s assimilate new incoming 
information from the researcher into an already developed cognitive schema) as gaps in knowledge are 
being filled but the accommodation of some of this new knowledge may be restricted as it is not fitting 
well into their existing concept causing resistance. The conceptual change process occurs in Element 3 
(creating conditions for conceptual change) and resistance is intercepted by linking gaps, misconceptions 
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and coping procedures to consequences. It is said to occur when:  
(I) The individual becomes dissatisfied with their existing conception. 
(II) The new conception presented seems intelligible so it makes better sense.  
(III) The new conception seems plausible so it could actually be true.  
(IV) The new conception seems that it may lead to a positive cognitive change.  
Change may happen when the individual has had the chance to comment on his or her own ideas.  
 
The contents of element 4 (introducing replacement material) is the most detailed aspect of 
development as it includes the CU-specific standardised psycho-educational material that needs to 
integrate well within the components of the CSM but also be adaptable enough not to bombard 
participants with the same generic educational material. Information is presented in a neutral manner and 
the type and depth of information given was dependent upon the participants existing understanding and 
the amount of detail necessary. All educational information was derived from Chapter 1 but presented in 
lay terms and checked by Dermatologists at the urticaria clinic. During this process the researcher is 
mindful of identifying areas that require action planning. How the interview questions relate to CSM and 
education material is shown in Table 9.3 (p260). 
 
Although the RA improves the application of CSM interventions, it does not cover emotional 
representations, which is often absent from CSM interventions (Cameron and Jago, 2008). Emotional 
representations are linked to held representations to determine if they are warranted and if behavioural 
strategies could reduce fear. This was especially true for consequences, as this had been intricately 
related to emotions in studies 5. For element 5 the information provided is verbally summarised and 
reiterated especially information that was initially challenged by participants before it was accepted to 
change their conceptual model of CU. The participant has the opportunity to ask for further clarification. 
 260 
 
Table 9.3: Intervention Psycho-Educational Material 
 
Component Common-Sense Interview question Psycho-educational material Knowledge summary 
 
Identity 
 
Can you tell me about your chronic urticaria 
symptoms? 
 
▪Illness label 
▪Definition & recognised symptoms   
▪Other reported symptoms/ reactions                  
 
▪Chronic urticaria (Idiopathic, auto-immune) 
▪Six weeks + to years of Itching wheals and/ or painful swelling  
▪Sleep disturbance, fatigue 
 
Illness 
coherence 
 
 
Can you tell me about what you know about chronic 
urticaria? 
 
▪CU terminology/ co-morbid urticaria 
▪Basic patho-physiological process 
▪Diagnostic tests  
 
▪Acute/ chronic/ physical  
▪Adapted from chapter 1, in lay terms suited to patient   
▪ASST, thyroid stimulating hormone, Allergy etc. 
 
Cause 
 
I am interested in what you believe is causing your 
urticaria. What do you believe is causing your 
urticaria?  
 
▪There is no known cause  
▪Allergic immunological 
▪Non-allergic immunological  
▪Non-immunological 
 
▪Theories  
▪Allergens, pseudo-allergens 
▪Body fluids, positive ASST; malfunctioning cells  
▪Infections, psychological stress, personality                                                                                                                                                                                                                      
   
 
Timeline 
 
Some patients believe that their CU is short term, 
others long term, some believe that their CU will 
come & go over time. What is your view on this? 
 
▪CU duration statistics 
▪Factors affecting duration                            
 
Taken from Chapter 1, section 1.5.1  
Disease-severity, > Swelling, positive ASST+; physical urticaria 
 
Consequences 
 
Patients often report the consequences of CU on 
their lives. In what ways would you say CU has 
affected your life? 
 
▪Addressed in Element 3 & action plan    
 Dependent on type of and degree of   
 perceived consequence/s  
 
▪Eliciting ideas for action plan.  
▪Identifying support resources/ services collaboratively with patient  
▪Signposting to other professionals  
 
Emotional 
Representation 
 
Patients often report that CU can have an emotional 
impact on their lives. How does CU affect you? 
 
▪Linked to negative cognitions (esp.   
  consequences) on specific outcome 
 
--------------------------------------------------------------------------------------------- 
 
 
Control   
 
How do you currently control your CU symptoms?  
 
 
▪Avoiding potential triggers 
▪Correct use of CU medicines 
 
▪Pseudo-allergens, stress (e.g. prioritising, planning, relaxation) 
▪Taking prescribed medicines when symptomatic & asymptomatic 
 
 
Necessity 
 
How much do you believe in your medicines to 
control CU where 0 mean no belief & 10 total 
belief?” 
 
▪How CU medicines prevent symptoms 
▪How prescriptions are determined  
 
▪Basic physiological process/ how symptoms inhibit process 
▪First line anti-histamines, Second line (> dosage), Third-line 
 
 
Concerns 
 
What are your views on your CU medicines?  
Do you have concerns about CU medicines? Why? 
 
▪Safety record of first-line treatments 
 
▪History of anti-histamines, side effects of steroids 
▪CU treatments and effects 
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Session 1 Part 2: Developing the Action Plan:  
By removing misconceived cognitions participants are proposed to be in a better position to 
decide how to partake in fruitful self-management behaviours and this forms a CU-specific version of RA 
elements 6 (goal setting and planning) and 7 (follow-up contact: goal strategy and review) that is in line 
with BCT’s for self-regulation theory (i.e. prompt specific goal setting, prompt review of behavioural goals, 
provide self-monitoring of behaviour, provide feedback on performance; Abraham and Mitche, 2008) 
defined in Table 9.4 below. 
 
Action plans are developed to focus on issues in CU disease self-management (i.e. avoiding 
triggers and taking CU medicines) and findings reported from studies 1 to 5 regarding feared 
consequences and detrimental QoL outcomes that may require attention. The development of an action 
plan of behaviour change (proceeding a period of cognitive change) is non-prescriptive and a shared 
decision making process should occur between the researcher and patient. How elements 6 and 7 are 
mapped onto specific BCTs is shown in Table 9.4 below. 
 
Table 9.4: Mapping RA Elements to Behaviour Change Techniques 
 
RA Element 
 
Behaviour Change Technique (BCT) 
 
6: Goal setting & planning 
 
 
(1) Prompting specific goal setting 
(3) Providing self-monitoring of behaviours  
 
 
7: Follow-up contact:  
    goal strategy & review 
 
 
(2) Reviewing behavioural goals 
(3) Providing self-monitoring of behaviours  
(4) Providing feedback 
 
 
Goal Setting and Planning (Element 6 of RA) 
Firstly a clear goal is defined so that both the researcher and patient know where to target. Areas 
for change should have emerged from the interview. It is hoped that the patient’s goal is to change their 
behaviour instigated by a conceptual change in their cognitive representation of CU. The participant 
choses a goal as this is more likely to increase their feelings of self-efficacy. It is important that behavioural 
goals (e.g. I will use my anti-itch cream as advised) and outcome goals (e.g. to reduce itch) are 
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differentiated from each other. Behavioural goals may include: Taking shower at the right temperature; 
reduce intake of pseudo-allergens; remember to take medicines as prescribed; confidence to visit GP 
when medicines stop working; do relaxation exercises to reduce stress. Outcome goals may include: To 
reduce itching and/ or swelling; start taking part in activities; get better nights sleep. Brainstorming was 
used to generate ideas between the researcher and participant and a focus here is to draw on the patient’s 
own internal resources and social support networks.  
 
The next step was to arrive at an actual plan. To examine the feasibility of reaching the goal the 
concept of SMART goals (Doran, 1981) was used to assist the patients self-monitoring of the newly 
proposed behaviours. SMART goals should be Specific (clearly defined) Measurable, Attainable (can be 
reached within the confines of the patient’s abilities), Realistic (e.g. knowledge, support networks, 
resources available) and Time bound (enough time to achieve goal). An example of a SMART goal on 
the action plan worksheet created for the study is shown in Box 1 below. Participants were sign-posted 
to other professionals (e.g. dermatologist, GP) and NHS expert approved websites and material if 
concerns were outside of the researcher’s professional remit.  
BOX 1 
 
Follow-up Contact: Goal Strategy & Review: (Element 7 of RA) 
The final part of the intervention entailed a follow-up phone-call where participants are asked to 
provide feedback on how they are managing their new behaviours. If problems occur the patient is 
prompted to think about how things could be changed and what barriers caused the goal not to be 
maintained and revisions are made. The patient continues to monitor the behaviour for the next month 
using the action plan. At one month the patient was contacted to provide feedback on goals achieved. 
 
SMART goal: 
 
I want to sleep better (outcome goal) 
Specific 
 
Measureable 
 
Attainable 
Realistic: 
Time bound: 
I will take my last daily dosage of CU medicines at 8pm in the evening with my evening meal to allow  
them to continue to work before I go to bed (behavioural goal) 
I will keep a diary next to my bed and write a note of my ability to concentrate during the day and 
wakefulness I feel in the morning 
Yes I will keep my medicines on the dinner table as a visual reminder 
Yes I eat my dinner at home most days at this time  
I  will try this for a month to see if this works 
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9.2.4: Measures and Materials 
Participants completed the IPQ-R, BMQ, HADS, SF-36v2 and CU-Q2oL (described in detail on 
from page p135) and a Participant Evaluation Questionnaire. This study-specific measure was designed 
as a patient self-report evaluation of the intervention. Participants agree or disagree to statements on a 
5-point scale regarding: recruitment, assessments, and interviews, education, challenging perceptions, 
action plans, sessions and overall intervention. Higher scores indicate more positive evaluations. 
Participants also completed pre-study ethics documents, Copies of these, the common sense interview 
and action plan worksheet can be found in Appendices 4 and 5.  
 
9.2.5: Procedure 
Approximately one week before appointments participants were contacted by phone and 
prompted to start completing the baseline questionnaires. Approximately a week after completing the 
assessments participants met with the researcher for the first session. The researcher structured the 
session by stating the time available; the interviews informal nature and the opportunity to ask questions. 
At this point participants were asked to hand over their baseline assessments and the one-to one session 
began as detailed in Section 9.2.3 either at the clinic or in the patient’s home. A week later participants 
were contacted by phone for the second session to feedback and review the action plan as detailed in 
Section 9.2.3. At the end of this session a second and third questionnaire pack was provided. One month 
post-intervention participants were again contacted by phone and prompted to complete and send the 
second questionnaire pack and at three months post-intervention participants were prompted to post the 
third questionnaire pack which containing the study evaluation questionnaire.  
 
9.2.6: Data Analysis 
Missing data were subjected to the Last Observation Carried Forward method (see page 263). 
Correlational analysis explored relationships between patient characteristics and dependent variables to 
determine co-variation. A one-way within groups repeated measures MANOVA (multivariate analysis of 
variance) determined if the outcomes combined were significant. A significant MANOVA (p < .05) was 
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followed up by a series of one-way repeated measure ANOVA’s and pairwise contrasts to compare mean 
scores from (1) baseline to post-intervention (T1 verses T2), (2) post-intervention to follow-up (T2 verses 
T3) and baseline to follow-up (T1 verses T3) for each ANOVA. Bonferoni corrections were applied to 
reduce type one error. Participant’s evaluations were reported using descriptive statistics 
 
9.3: Results 
 
9.3.1: Exploratory Data Analysis  
Exploratory data analyses suggested the use of parametric statistical data analyses with the 
exception of the variables disease duration which was significantly skewed, post-intervention anxiety and 
baseline CU disease-activity which both showed significant kurtosis and post-intervention generic mental 
health status which showed both significant skew and kurtosis. Attempts to normalise the data of these 
variables by removing outliers and extreme scores did not improve the distribution. After a closer 
observation of box and whisker plots and the distribution graph for post-intervention anxiety together with 
its non-significant skew it was decided that this variable would be subjected to parametric statistical 
analysis. After an observation of the histogram for post-intervention generic mental health status it was 
concluded that these variable would be subjected to parametric statistical analysis. All cognitive 
representation variables were normally distributed. 
 
9.3.2: Participant Characteristics 
As presented in Table 9.5 the study sample consisted of 15 participants of whom the majority 
were White British females with a mean age of 45 years old. The majority were either married or co-
habiting, had attended higher education, were in fulltime employed and had been diagnosed with 
idiopathic CU. All but 1 had experienced angioedema and all but two had at least one physical urticaria. 
Twenty-percent reported a family history of urticaria and 46.7% had other co-morbid diagnoses. The 
median disease duration was four years (range, 1-36 years). The majority were taking h1 anti-histamines 
with other medications and had seen their GP for CU on approximately 4 occasions. 
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Table 9.5: Descriptive Summary of Patient Characteristics 
Variable N (15)          Percentage (%) Statistic 
 
Gender (%) 
       Female/ Male 
Age (years)  Mean ± SD/ Range 
Ethnicity (%) 
       White British/ European (%) 
       Black British/Other 
Education (%) 
       GCSE/ O’ level 
       GCE/ A’ level 
       Higher Ed./ Degree 
Occupational status (%) 
       Employed 
       Not employed 
       Not Specified 
Marital Status (%) 
       Single                                                   
       Married/ Co-habiting 
       Divorced 
       Widowed/ Other 
Chronic urticaria 
       Idiopathic 
       Autoimmune 
Diagnosing specialist 
       Dermatologist 
       General Practitioner  
Experience Angioedema (swelling)  
       Yes/ No 
Concurrent physical urticaria 
       Yes/ No 
Other chronic illnesses 
       None  
       Underactive thyroid 
       Diabetes 
       Coeliac disease 
       COPD 
       ? 
Age of onset (years)   
       Mean/ SD/ CI / Range 
Disease duration (yrs) 
       Median (range) 
GP visits in past 6 months  
        Mean/ SD/ CI / Range 
Prescribed CU Medicines 
       Anti-histamines                                     
       Anti-histamines with other     
Family History of CU 
       Yes 
       No                
 
 
12/ 3 
    ----- 
 
13 
2 
 
3 
3 
9 
 
12 
3 
 
 
3 
10 
1 
1 
 
9 
6 
 
13 
2 
 
14/ 1 
 
13/ 2 
 
8 
2 
2 
1 
1 
1 
          
15 
 
15 
 
15 
 
5 
10 
 
3 
12 
 
 
80/ 20 
----- 
 
73.33 
6.67 
   
20.00 
20.00 
60.00 
 
80.00 
20.00 
 
 
20.00 
66.70 
6.70 
6.70 
 
60.00 
40.00 
 
86.67 
13.33 
 
93.3/ 6.70 
 
86.70/13.00 
 
53.3 
13.33 
13.33 
6.67 
6.67 
6.67 
 
-------- 
 
 --------  
 
--------  
 
33.3 
66.7 
 
20.0 
80.0 
 
 
 
45.93 ± 09.85 (32 - 66) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
37.93 ± 14.71 (CI 95% 29.79- 46.08) 
 
4, CI, 95%, 3.09 – 14.95 (1 - 36) 
 
2.47± 2.03 (CI 95%, 1.34- 3.59 (0 - 6) 
 
 
 266 
 
9.3.3: Descriptive Summary of Study Variables  
 
Quality of Life Outcomes 
 
Participant’s baseline mean scores on QoL outcome variables are summarised in Table 9.6a 
below. Three-fifths percent reported experiencing a worse than average disease-specific QoL. With a 
mean score of 54.99 ± 25.65 this represented a moderate impact of CU on QoL. In line with these findings 
baseline generic mental health status scores (52.38 ± 10.99) also represented a moderate impact in just 
over half of the research sample. Sixty-percent scored over the scale mid-point for experiencing probable 
clinical anxiety with measures of central tendency indicating that the sample were more mildly rather than 
moderately/ severely anxious. The UAS indicated that the CU sample experienced moderate disease at 
baseline.  
 
Table 9.6a: Descriptive Summary of Baseline Quality of Life Related Outcome Variables 
 
▲            Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL): 0 – 50: Better than average, 50-100 Worse than average   
▲▲        Short Form 36 item Health Survey UK Version 2 (SF-36v2)  
           Mental Component Summary: 0 – 50: Worse than average, 50-100 Better than average 
▲▲▲    Hospital Anxiety and Depression Scale (HADS)  
           Anxiety subscale: Outcome 8-10 possible clinical disorder, 11-21 probable clinical disorder 
▲▲▲▲Urticaria Activity Score (UAS): 0 – 42 higher scores mean worse activity 
 
 
 
 
 
Variable                                              N         Mean/ SD (CI 95%, lower- upper)                 Scale Scores Percentage (%) 
 
 
 
 
 
 
 
 
 
Worse than  
average 
 
 
Better than  
Average 
 
Disease-Specific Quality of Life▲ 
General Mental Health Status▲▲ 
Anxiety▲▲▲ 
Urticaria Activity Score▲▲▲▲ 
 
15 
15 
15 
14 
 
54.99 ± 25.65  (CI 95%, 40.79 -69.20) 
52.38 ± 10.99  (CI 95%, 46.29 – 58.46) 
11.13 ± 03.56 (CI 95%: 09.16- 13.17) 
22.21 ± 12.19 (CI 95%: 15.17 – 29.26) 
 
60.00 
53.30 
60.00 
64.30 
 
40.00 
46.70 
40.00 
35.70 
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Cognitive Representations 
Participant’s baseline mean scores on the cognitive representation variables are summarised in 
Table 9.6b below. Participants reported an average of 7 symptoms related to their CU. Just over half 
agreed in psychological causes and two-thirds immunity causes. For the remaining perceptions 
participants agreed or strongly agreed that their CU had a chronic and cyclical timeline and had serious 
consequences but to some degree agreed that they had some treatment control but less personal control. 
Almost all believed they had some knowledge of CU (scores around the scale mid-point) and all agreed 
that CU conjures up high emotional representations. Further, the majority believed in the necessity of 
taking CU medicines and a nearly the same percentage we concerned about side effects. 
 
Table 9.6b: Descriptive Summary of Baseline Cognitive Representation Variables 
 
    ▲IPQ-R: 0 – 50: Better than average, 50-100 Worse than average   
    ▲▲Identity 0 – 17 Symptom range 
    ▲▲▲BMQ-Specific: 0 – 50: Worse than average, 50-100 Better than average
 
Variable                                              N         Mean/ SD (CI 95%, lower- upper)             Scale Scores Percentage (%) 
 
 
 
 
 
 
 
 
 
Strongly 
Agree/ Agree 
 
Strongly Disagree/ 
Disagree 
 
Illness perceptions▲ 
    Identity▲▲ 
    Psychological cause 
    Immunity cause 
    Timeline: acute/ chronic 
    Consequences 
    Personal control 
    Treatment control 
    Illness coherence 
    Timeline cyclical 
    Emotional representations 
Treatment Perceptions▲▲▲ 
    Specific necessity 
    Specific concerns 
 
 
15 
15 
15 
15 
15 
15 
15 
15 
15 
15 
 
15 
15 
 
 
7.70 ± 1.98 (CI 95%: 6.64- 8.83) 
2.60 ± 0.89 (CI 95%: 2.16- 3.16) 
2.97 ± 1.12 (CI 95%: 2.35- 3.59) 
3.50 ± 0.68 (CI 95%: 3.13- 3.88) 
3.49 ± 0.78 (CI 95%: 3.06- 3.93) 
2.60 ± 0.71 (CI 95%:  2.21-2.99) 
2.90 ± 0.55 (CI 95%: 2.59--3.21) 
3.02 ± 1.18 (CI 95%: 2.37- 3.67)  
3.58 ± 0.49 (CI 95%: 3.31- 3.85) 
4.12 ± 0.81 (CI 95%: 3.67- 4.58) 
 
3.66 ± 0.82 (CI 95%: 3.21- 4.12) 
3.47 ± 0.86 (CI 95%: 3.00- 3.95) 
 
 
n/a 
60.00  
66.70 
93.30 
93.30 
60.00 
80.00 
96.67 
100.00 
100.00 
 
93.30 
86.70 
 
 
n/a 
40.00 
33.30 
6.70 
6.70 
40.00 
20.00 
3.33 
0.0 
0.0 
 
6.70 
13.30 
 268 
 
9.3.4: Relationships between Participant Characteristics and Study Variables 
 
Quality of Life Related Outcomes 
 
It can be observed from Table 9.7 on page 269 that participant socio-demographic and clinical 
characteristics were overall unrelated to the study outcome variables. Exceptions included older age being 
significantly correlated to worse CU disease severity (p <.05) and marital status (i.e. being married/ co-
habiting) significantly relating to post intervention and follow-up QoL (both p <.05) but not baseline reports. 
Most pertinent were the strong and significant negative relationships between being married or co-habiting 
with levels of baseline, post-intervention and post-intervention levels of anxiety (p < .01). In light of these 
findings, marital status was considered as a co-variant of baseline anxiety. Age was also considered as 
a co-variant of CU disease-severity.  
 
Cognitive Representations  
Cognitive representations were also unrelated to participant characteristics (table not shown) with 
exception to perceptions of serious consequences positively correlating with age at onset (r = .74, p <.05), 
having co-morbidity (r = .60, p <.01), less disease duration (r = -.56, p <.05) and being employed (r = .53, 
p <.05), personal control which negatively correlated with age (r = -.67, p <.01) and specific concern 
beliefs with age of onset (r = .54, p <.05). These participant characteristics were treated as possible co-
variates of the cognitive representation ANOVA’s undertaken later in the chapter.  
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Table 9.7: Relationships between Patient Characteristics and QoL Related Outcome  
  
Baseline  
QoL♦  
 
 
Post-Intervention  
QoL 
 
Follow-up  
QoL 
 
Baseline 
GMHS▲  
 
 
Post-Intervention 
GMHS   
 
Follow-up  
GMHS 
 
 
Baseline  
Anxiety  
 
 
Post-Intervention   
Anxiety 
 
Follow-up 
Anxiety 
 
Baseline  
UAS► 
 
 
 
 
 
Gender* 
Age*  
Ethnicity○  
Education○  
Occupation○ 
Marital status○ 
CU diagnosis○ 
CU subtype○  
Angioedema○ 
Physical urticaria○  
Age at onset○ 
CU Medicines○ 
Co-morbidity○ 
 
 
.466 
.105 
.138 
-.236 
-.088 
-.416 
.170 
.375 
.074 
.064 
.282 
.370 
-.235 
 
.313 
.222 
.149 
-.268 
-.199 
*-.561 
.023 
.502 
.297 
.117 
.374 
.259 
-.225 
 
.267 
.082 
.092 
-.384 
-.086 
*-.596 
.263 
*.559 
.089 
.106 
.227 
.245 
-.203 
 
-.064 
.127 
-.234 
.171 
.308 
.501 
-.074 
-.158 
.205 
.343 
.037 
.068 
-.024 
 
.091 
.272 
.067 
.208 
.045 
.325 
-.210 
-.141 
.058 
.150 
.123 
.045 
-.026 
 
.110 
.324 
.182 
.279 
-.023 
.390 
-.308 
-.289 
.087 
-.005 
.153 
.180 
-.061 
 
.151 
.067 
.471 
.041 
-.371 
**-.663 
.186 
.032 
.234 
-.300 
.008 
.286 
.103 
 
.166 
.034 
.437 
.204 
-.389 
**-.673 
.161 
.000 
.191 
-.313 
.041 
.300 
.204 
 
.205 
-.069 
.390 
.122 
-.310 
**-.704 
.324 
.036 
.071 
-.316 
-.085 
.246 
.241 
 
.394 
*.610 
.288 
-.188 
-.298 
-.225 
-.218 
.007 
.098 
.005 
.374 
.483 
-.272 
  
 
Disease duration▪ 
 
 
.027 
 
-.061 
 
.086 
 
-.110 
 
.054 
 
-.169 
 
.238 
 
.127 
 
.233 
 
.019 
 
○Pearson’s r, ▪Spearman’s rho         Significance: *p < .05,  **p < .01, ***p < .001   ♦QoL: Quality of Life ▲GMHS: Generic mental health status   ► 
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9.3.5: Effect of Intervention on Combined Quality of Life Related Outcomes 
 
The first analyses examined the effect of the intervention on the combined study outcome 
variables of disease-specific quality of life (DSQoL), generic mental health status (GMHS) and levels of 
anxiety from baseline, post-intervention and 3 months follow-up via a one way repeated measure 
MANOVA.  Using Pillia’s Trace as the test statistic the MANOVA indicated a strong significant within-
subjects main effect for the intervention on the combined CU-specific outcome scores (V= .88, F (6, 9) = 
11.23, p < .001). This strong significant effect was also supported by alternative test statistics (Wilks’ 
Lambada, Hotelling’s Trace and Roy’s Largest Root), which produced the same multivariate results (all p 
< .001) with a partial eta square of .88 and observed power statistic of 1.00. As the MANOVA was strongly 
significant a series of one-way univariate repeated measure ANOVA’s were undertaken to establish which 
outcomes were significant. These are reported in the sections below.    
 
9.3.6: Intervention on Disease-Specific Quality of Life 
With higher scores indicating worse disease-specific QoL outcome participant’s scores 
decreased from baseline to post-intervention and again from post-intervention to follow-up indicating 
incremental improvements in CU-related QoL over time (see Table 9.8 below and Figure 9.2, p271). 
 
Table 9:8: Effect of Intervention on Disease-Specific Quality of Life  
 
Variable 
 
 
Baseline (T1) 
(Mean SD) 
 
 
Post Intervention (T2) 
Mean (SD) 
 
3 Months Follow-up (T3) 
Mean (SD) 
(n= 15 ) (n= 15) (n= 15) 
 
Disease-Specific▲  
Quality of Life  
 
54.99 ± 25.65* 
 
 
 
46.33 ± 25.24 
 
39.36 ± 25.94 
▲Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL): 0 – 50: Better than average, 50-100 Worse than average   
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Figure 9.2: Graph to show changes in Disease-Specific QoL scores over the Study▲
 
▲Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL): 0 – 50: Better than average, 50-100 Worse than average   
 
To establish the effect of the intervention on disease-specific QoL a repeated measures ANOVA 
of mean scores (with sphericity assumed: X2 (2)= 3.44, p >.05) was undertaken. The ANOVA established 
a strong significant within-groups main effect found for timeline (F 2, 28)= 16.22, p <. 001). With a partial 
eta square of η2 = .54 and an observed power of 1.00, this indicated that DSQoL explained some of the 
variance not explained by generic mental health status (GMHS) or anxiety. Pairwise contrasts confirmed 
a significant mean difference between T1 verses T2 (p= .04) and even stronger significant mean 
differences between T2 verses T3 (p = .01) and T1 verses T3 (p = .01).   
 
9.3.7: Intervention on Generic Mental Health Status 
With higher scores indicating better reports of Generic Mental Health Status and QoL Participants’ 
mean scores suggested that CU outcome had improved over the course of the study (see Table 9.9 p272). 
This pattern is graphically presented in Figure 9.3 (p272) and confirms this pattern from baseline to post-
intervention and follow-up.  
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Table 9:9: Effect of Intervention on Generic Mental Health Status 
 
Variable 
 
 
Baseline 
(Mean SD) 
 
 
Post Intervention 
Mean (SD) 
 
3 Months Follow-up 
Mean (SD) 
(n= 15 ) (n= 15) (n= 15) 
 
Generic mental 
health status  
 
 
52.38 ± 10.99 
 
 
60. 25 ± 9.67 
 
63.45 ± 10.70 
 ▲Short Form 36 item Health Survey UK Version 2 (SF-36v2) Mental Component Summary score: 0 – 50: Worse than average, 50-100 Better than average 
     
 
Figure 9.3: Graph to show changes in Generic Mental Health Status Scores over the Study▲ 
 
▲Short Form 36 item Health Survey UK Version 2 (SF-36v2) MCS score: 0 – 50: Worse than average, 50-100 Better than average 
 
With sphericity not assumed (X2 (2) = 14.13, p = .001; ε .60) a repeated measure ANOVA of 
GMHS was undertaken using the Greenhouse Geisser statistic. The ANOVA established a strong 
significant within-groups main effect found for timeline (F 2, 16.84) = 18.47, p < .001). With a partial eta 
square of η2 = .57 and an observed power of 0.99 this indicated that GMHS explained some of the 
variance not explained by the other outcome factors. Pairwise contrasts taken for GMHS confirmed strong 
significant mean differences overall between T1 verses T2 (p =. 01), T2 verses T3 (p = .01) and T1 verses 
T3 (p =.01).   
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9.3.8: Intervention on Anxiety 
The mean scores for anxiety at baseline, post-intervention and follow-up are presented in Table 
9.10 below. With higher scores indicating worse levels of anxiety, the scores suggested that reports of 
this CU outcome had improved at post-intervention from baseline with marginal improvements at 3 months 
follow-up. These results are also presented graphically in Figure 9.4 (p274).   
 
Table 9:10: Effect of Intervention on Anxiety 
 
Variable 
 
 
Baseline 
(Mean SD) 
 
Post Intervention 
Mean (SD) 
 
3 Months Follow-up 
Mean (SD) 
(n= 15 ) (n= 15) (n= 15) 
 
Anxiety  
 
11.13 ± 3.56 
 
 
9.67 ± 2.94 
 
9.47 ± 3.09 
▲Hospital Anxiety and Depression Scale (HADS) Anxiety subscale: Outcome 8-10 possible clinical disorder, 11-21 probable clinical disorder 
 
With sphericity not assumed (X2 (2) = 6.08, p <.05; ε .73) a repeated measure ANOVA of anxiety 
undertaken using the Greenhouse Geisserr statistic established a strong significant within-group main 
effect found for timeline (F (2, 20.39) = 31.18, p < .001). With a partial eta square of η2 =.69 and an 
observed power of 1.00 this indicated that anxiety explained some of the variance not explained by the 
other outcome factors. Pairwise contrasts of mean scores for levels of anxiety (with Bonferoni corrections 
applied) confirmed strong significant mean differences overall between T1 verses T2 (p = .001) and T1 
verses T3 (p = .01) but mean differences between T2 verses T3 was insignificant (p >.05).   
 
Effect of intervention on anxiety controlling for marital status:  
In section 9.3.4 correlations undertaken between participant characteristics and the outcome 
variables found a strong significant relationship between marital status (i.e. being married or co-habiting) 
and lesser levels of anxiety at baseline, post-intervention and follow-up. In order to examine marital status 
as a possible confounding factor of the study manipulation (i.e. changing cognitive representations) the 
anxiety ANOVA was undertaken again as a repeated measures analysis of co-variance (ANCOVA) with 
marital status as the moderating co-variate. Using Pillai’s Trace as the 
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Figure 9.4: Graph to show changes in Anxiety over the Study▲ 
 
▲▲Hospital Anxiety and Depression Scale (HADS) Anxiety subscale: Outcome 8-10 possible clinical disorder, 11-21 probable clinical disorder 
 
multivariate test statistic a strong significant within-groups effect for changes in anxiety scores over the 
course of the study was found as it did in the original analysis (V= .67, F (2, 12.38)= 12.39, p < .001; η = 
.67; observed power .98) however there was no significant interaction between marital status and anxiety 
over time (V= .23, F (2, 12)= 1.74, p > .05; η =23; observed power .29). More specifically changing 
cognitions and actions to reduce anxiety scores was independent of the impact of any moderating affects 
of marital status over time. With sphericity not assumed (X2 (2) = 6.41, p = .04) univariate findings using 
the Greenhouse-Geisser statistic confirmed this main effect on anxiety (F (1.41, 18.39)= 20.61, p = .001; 
η = .61; 1.00) and the non-significant interaction effect with marital status (F (1.41)= 1.28, p > .05; η = .09; 
.21). However, when both ANOVA and ANCOVA analyses are compared the impact of marital status 
resulted in a reduced F ratio and a much reduced significance level for effects on anxiety over time (F  (2, 
20.39) = 31.18, p < .001 for ANOVA verses (F (1.41, 18.39)= 20.61, p = .001 for ANCOVA). In line with 
the original analyses within subject contrasts indicated a strongly significant difference between mean 
scores for anxiety from baseline to post-intervention (F (1, 13)= 26.75, p < .001) but not from post-
intervention to follow-up.  
 
9.3.9: Effect of Intervention on Cognitive Representation Components    
The first analyses examined the effect of the intervention on the combined cognitive  
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9
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representation variables from baseline, post-intervention and 3 months follow-up. Multivariate test 
statistics could not be produced due to insufficient residual degrees of freedom but as no groups were 
involved here the within-groups effect results were observed. Using Greenhouse-Geissar corrected 
estimates of sphericity not assumed the MANOVA indicated a strong significant within-subjects main 
effect for the intervention on the combined CU-specific outcomes (F (6.49, 90.84) = 16.76, p < .001). This 
strong significant effect was also supported by the alternative Huynh-Feld statistic (p < .001, partial eta 
square .55, observed power 1.00). As the MANOVA was strongly significant a series of one-way univariate 
repeated measure ANOVA’s (with Bonferoni corrections applied) were undertaken to establish which 
relationships were significant. The findings of changes in cognitive representations over time are 
presented in Table 9.11a (p276) 
 
An initial observation of Table 9.11a (p276) indicated improvements on each component from 
baseline to post-intervention (T1-T2), and from baseline to follow-up (T1- T3) with exception to immunity 
cause, but little improvement (but maintained scores) from post-intervention to 3-month follow-up (T2-T3). 
Univariate analyses of the representation models indicated strong and significant improvements for all 
components (p <.001) with the exception of psychological cause and treatment control which both showed 
a tendency towards significance.  
 
Pairwise comparisons (see Table 9.11b, p277) confirmed that the strongest improvements from 
T1 maintained to T3 were for lesser serious consequence and emotional representations perceptions (p 
< .001) followed by perceptions of more personal control, lesser timeline cyclical beliefs and greater 
specific necessity beliefs. Further participants reported lower symptoms attributions (illness identity), a 
reduction in chronicity beliefs and increased illness coherence (understanding CU; p < .05).  
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Table 9:11a: Effect of Intervention on Cognitive Representation Components 
 
Variable 
 
 
Baseline (T1) 
(Mean SD) 
 
 
Post Intervention (T2) 
(Mean SD) 
 
3 Months (T3) 
(Mean SD) 
 
Sphericity  
 
 
ANOVA  
(F) 
 
Sig. 
P Value 
 
Partial η2 
 
Power 
 
(n= 15 ) (n= 15) (n= 15)      
 
   Identity 
   Psychological cause 
   Immunity cause 
   Timeline: acute/ chronic 
   Consequences 
   Personal control 
   Treatment control 
   Illness coherence 
   Timeline cyclical 
   Emotional representation 
   Specific necessity 
   Specific concerns 
 
7.73 ± 1.98 
2.67 ± 0.90 
2.97 ± 1.12 
3.50 ± 0.68 
3.50 ± 0.78 
2.60 ± 0.71 
2.90 ± 0.55 
3.02 ± 1.77 
3.80 ± 0.49 
4.12 ± 0.81 
3.66 ± 0.82 
3.47 ± 0.86 
 
3.93 ± 1.53 
3.11 ± 0.78 
3.01 ± 0.98 
3.07 ± 0.73 
2.87 ± 0.71 
3.36 ± 0.82 
3.43 ± 0.64 
3.94 ± 0.72 
3.17 ± 0.65 
3.24 ± 0.49 
4.17 ± 0.63 
2.92 ± 0.44 
 
3.67 ± 1.35 
3.13 ± 0.77 
3.20 ± 0.98 
2.89 ± 0.73 
2.57 ± 0.71 
3.56 ± 0.82 
3.44 ± 0.64 
4.14 ± 0.72 
3.17 ± 0.65 
3.04 ± 0.49 
4.20 ± 0.63 
2.54 ± 0.42 
 
X2 (2)= 30.44, p < .05 
X2 (2)= 07.07, p < .05 
X2 (2)= 13.37, p < .05 
X2 (2)= 3.10, p > .05 
X2 (2)= 1.38, p > .05 
X2 (2)= 0.90, p >.05 
X2 (2)= 0.39, p >.05 
X2 (2)= 6.59, p < .05 
X2 (2)= 0.96, p >.05 
X2 (2)= 07.9, p < .05  
X2 (2)= 1.06, p >.05   
X2 (2)= 6.15, p < .05  
 
 
(F 1.05, 14.71)= 36.99 
(F 1.41, 19.73)= 30.55 
(F 1.23, 17.05)= 00.44 
(F 2, 28)= 08.64 
(F 2, 28)= 34.42 
(F 2, 28)= 19.64 
(F 2, 28)= 02.98 
(F 1.43, 20.03)= 11.07 
(F 2, 28)= 11.35 
(F 1.38, 19.25)= 31.60 
(F 2, 28)= 10.24 
(F 1.5, 20.3)= 13.32 
 
<. 000 
= .060 
>.05 
<. 000 
<. 000 
<. 000 
= .070 
<. 000 
<. 000 
<. 000 
<. 000 
<. 000 
 
.73 
.20 
.03 
.38 
.71 
.58 
.18 
.44 
.45 
.69 
.42 
.49 
 
1.00 
0.51 
0.10 
0.95 
1.00 
1.00 
0.53 
0.98 
0.99 
1.00 
0.98 
0.99 
*Scale: 1 strongly disagree – 5 strongly agree (scores spiit at scale mid-point 0-2.4= strongly disagree/ disagree, 2.5-5 strongly agree/ agree 
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Table 9:11b: Pairwise Comparisons of Intervention over Time 
 
 
 
Representation 
Baseline -  
Post-intervention 
(T1 to T2) 
Mean difference 
Post-intervention - 
3 Months 
(T2 to T3) 
Mean difference 
Baseline -  
3 Months 
(T1 to T3) 
Mean difference 
   
Identity 
Psychological cause 
Immunity cause 
Timeline: acute/ chronic 
Consequences 
Personal control 
Treatment control 
Illness coherence 
Timeline cyclical 
Emotional representation 
Specific necessity 
Specific concerns 
 
*3.80 
n/a 
n/a 
*.43 
***.62 
**-.77 
n/a 
*-.92 
**.41 
***.88 
**-.51 
*.55 
 
0.27 
n/a 
n/a 
1.73 
*.30 
-.19 
n/a 
-.21 
-.01 
.19 
-.03 
*.38 
 
*4.07 
n/a 
n/a 
**.60 
***.93 
***-.96 
n/a 
-.1.12 
**.41 
***1.08 
**-.55 
**.93 
     *p < .05     ** p < .01     *** p < .000 
 
9.3.10: Correlations between Change Scores in Cognitions and QoL Outcomes over Time 
As the control group had been eliminated from the study due to attrition, it was still difficult to infer 
that the significant changes in QoL outcomes overtime were due to addressing cognitive representations 
in the intervention. In order to infer this to some degree changes in cognitive representation components 
at three time-points (T1-T2, T1-T3 and T2-T3) were correlated with changes in QoL outcomes at the same 
respective time-points. Guidelines for using simple change scores in correlational analyses by Gardner 
and Neufeld (1987) for correlating one variable change score with another was used. Scores for all 
variables where first transformed to a change score by subtracting T2 from T1, T3 from T1 and T3 from 
T2 before correlations were undertaken using Pearson’s r. The results can be found in Table 9.12 (p 278).   
 
Anxiety  
Correlations between anxiety and cognitive change scores found a significant relationship 
between anxiety and identity change from baseline to post-intervention (T1-T2; p <.05) and this 
relationship was stronger between baseline to 3-month follow-up (T1-T3; p <.01). Another significant  
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Table 9.12: Correlations between Cognitive and QoL Outcome Change over Time 
  
Residual Change Correlation Coefficient to QoL Outcome (r) 
 
 Baseline – Post 
intervention  
(T1–T2) 
Post-Intervention – 
Follow-up 
 (T2 – T3) 
Baseline –  
Follow-up 
 (T1 – T3) 
Mean 
Change 
 
r 
Mean 
Change 
 
r 
Mean 
Change 
 
r 
Anxiety Change       
Identity -3.80 *-.437 -.27   -4.07  **-.548 
Psychological Cause .45  .02  .47 ▲.402 
Immunity Cause .04  .18 *-.510 .23  
Consequences -.62  -.30  -.92 ▲-.351 
Timeline Cyclical -.41 ▲-.352 -.16  -.41  
Coherence .92  .21 ▲.380 1.12 ▲.399 
Emotional Representation -.88  -.20 *.458 -1.08  
Specific Necessity .51 *.454 .03 **.627 .55   
Specific Concerns -.55  -.38 *.515 -.93  
Mental Health Status        
Immunity Cause .04  .18 *.488 .23 ▲.389 
Consequences -.62 ▲-.382 -.30  -.92  
Timeline Cyclical -.41  -.21  -.41 ▲-.613 
Emotional Representation -.88 **-.608 -.20  -1.08  
Specific Necessity .51  .03  .55 ▲.361 
Quality of Life       
Immunity cause .04 **.662 .18 *-.483 .23  
Consequences -.62 . -.30  -.92 *.503 
Personal Control .76  .20  .96 *451 
Emotional Representations -.88  -.20 *.429 -1.08  
Specific Necessity .51  .03 **.559 .55  
Specific Concerns 
 
-.55  -.38 **.640 -.93  
   *p < .05     ** p < .01   ▲Trend (p = .06) Note: Only significant and trend correlations included in table      
 
correlation was found at T1-T2 for anxiety and specific necessity change scores (P < .05) and this 
relationship strengthened further between T2-T3 (p < .01). The most significant correlations with anxiety 
and cognitive change scores were found between post-intervention to 3-month follow-up (T2-T3) for 
immunity causes, emotional representations and specific concerns (all p <.05). Finally a number of 
relationships that were not significant but deemed worthy of reporting consisted of change score 
relationships trends between anxiety and timeline cyclical at T1-T2, psychological cause and 
consequences at T1-T3 and illness coherence at both T2-T3 and T1-T3 (all p= .06).         
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Generic Mental Health Status  
  Correlations between generic mental health status (GMHS) and cognitive change scores found 
a significant relationship with emotional representations at T1-T2 (p <.01). This was also found for GMHS 
and immunity cause between T2-T3 (p < .05) but this relationship was just short of significance at T1-T3 
(p = .06). Further notable trends were found between GMHS change scores and change scores for 
timeline cyclical and specific necessity at T1-T3 (p = .06). 
 
Disease-Specific Quality of Life   
Significant relationships were found for disease-specific quality of life (DSQoL) and cognitive 
change scores. A strong and significant relationship was found between DSQoL change and immunity 
cause change at T1-T2 (p < .01) and to a lesser extent at T2-T3 (p <.05). Another significant relationship 
was found between DSQoL and emotional representations at T2-T3 (p <.05), but this was stronger for 
both specific necessity and concerns at the same time-point (both p <.01). Further significant changes 
scores were found for DSQoL change with consequences and personal control between T1-T3 (p < .05).   
 
9.3.11: Participant Study Process Evaluation  
The final set of analyses evaluated the participant’s experience of the study process in terms of: 
(1) recruitment; (2) assessments; (3) education and challenging perceptions; (4) action plans and (5) 
overall Intervention. Data was available from nine of the fifteen respondents (60%). 
 
Recruitment process  
The majority of participant’s agreed that the recruitment process (illustrated in Figure 9.5a; p280) 
was positive in all aspects, strongly agreeing with how they were approached, contacting the researcher, 
the comprehensibility of the study purpose, complaints procedure and informed consent (questions 1-5). 
However a fifth were ambivalent about the researchers’ explanation of the study and/or how personal 
data would be handled and about a quarter were ambivalent about how information could be sort outside 
the PIS (participant information sheet).   
 280 
 
Figure 9.5a: Participant Recruitment Process Evaluation 
 
Assessments: Questionnaires  
The second set of questions (6-9) concerned the participant’s experience completing the studies 
assessments. The findings are presented in Figure 9.5b  
 
Figure 9.5b: Participant Evaluation of Questionnaires and Urticaria Activity Score 
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It can be observed from Figure 9.5b that the majority agreed that the questionnaires were easy to use in 
terms of the instructions, understanding the items and the times taken to complete them. However, just 
over 60.0% could not decide on these aspects in regard to the UAS.    
 
Psycho-Education and Challenging Perceptions  
The third set of questions (10-14) concerned the participant’s experience of the actual 
intervention. As shown in Figure 9.5c on page p282 all participants agreed that they understood the 
research questions and were excellently delivered by the researcher. In respect to the psycho-educational 
material the majority of the sample agreed that the delivery, contents, relevance to their own CU was 
excellent but as can be observed in Figure 9.5c (p282) there were areas of concern. Although only 10% 
could not decide if the interview questions were relevant to their CU or the quality of the interview content, 
a fifth were undecided about the content of the emotional representations material and this extended to 
its relevance for 20.0% and delivery or just over 10.0%. Further just over 60.0% were undecided about 
the control content of the material and 36.4% its delivery but despite this the entire sample believed the 
control material was relevant to CU management. Regardless, the majority of reported (90.1%) agreeing 
that the researcher always respected their viewpoint on their CU experiences and the remaining strongly 
agreed.   
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Figure 9.5c: Participant Evaluation of Psycho-Education and Challenging Perceptions 
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Action Plans  
The next questions (15-17) concerned the participant’s experience of undertaking the 
action plan with the researcher. Even though the majority of participants believed that they had 
an equal role in developing their action plan and that it was easy to follow (both 81.8%), it can 
be seen from Figure 9.5d below that nearly two-thirds of the sample were undecided as to 
whether it would be useful for their future CU self-management.   
 
Figure 9.5d: Participant Evaluation of Action Plans 
 
 
Sessions  
Questions 18-19 asked participants how they found the length of time allocated for the 
intervention (this ranged from approximately 45 minutes to 90 minutes depending on the 
participants level of understanding and needs) and the rating of the intervention session overall. 
The findings are presented in Figure 9.5e (p284). 
 
A considerable 72.7% agreed that their session was of a good duration and nearly 10% 
strongly agreed but almost a fifth were undecided as to whether the timing of their session  was 
long enough.  In respect to its overall efficacy of the sample were divided as to agreeing 
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Figure 9.5e: Participant Evaluation of Sessions  
 
(or strongly agreeing) that the intervention was efficious and being unsure about this. Despite 
this finding no participant disagreed or strongly disagreed as the ineffective of the intervention.     
 
 Most useful aspects of Intervention 
The final question (20) asked the study participants what they believed to be the most 
important aspect of the intervention. The results are presented in figure 9.5f below.  
 
Figure 9.5f: Most useful Aspects of Intervention
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An observation of Figure 9.5f (p284) indicates that the research sample as a whole 
agreed that all aspects of the intervention where beneficial to some degree particularly the 
session interviews and in self-monitoring ones itching and swelling. More so 90.1% strongly 
agreed that the core aspect of the intervention (providing knowledge about CU not previously 
known or understood) was the most beneficial. No area was seen as irrelevant but a substantial 
proportion of the sample was overall undecided as to how beneficial the developing of the action 
plan was collaboratively with the researcher or the follow-up phone-call.   
 
 9.4: Discussion 
The aim of this study was to test the feasibility of a brief intervention designed to change 
CU-related QoL outcomes by changing representations of CU. The second aim was to determine 
whether CU representations itself was amenable to change and if both changes would persist 
over time. This study provided evidence to support both and was overall acceptable and 
beneficial to participants experiencing moderate CU. The findings are discussed further below.  
  
Cognitive representations of CU are amenable to change via intervention 
The first major finding was that cognitive representations of CU were amenable to 
change via intervention. Strong and significant changes in most representational components 
were found from baseline to 4-weeks post-intervention (T1- T2). However there were minimal 
changes from post-intervention to 3-months follow-up (T2-T3) but the similar scores between 
these time-points indicated that initial improvements in represents about CU in the predicted 
directions didn’t improve further or decline, but were maintained overtime (hence the strong 
significant differences from baseline to 3 months). Such findings are in line with the changing 
illness perceptions research literature reviewed in chapter 2 that such brief interventions can 
have a strong impact on how individuals see their condition (e.g. Petrie et al, 2002; Broadbent et 
al, 2002). It also supports the need for CSM based interventions in CU discussed in Study 4 
(section 7.4). The implications of these findings are further discussed later in the chapter. 
 286 
 
One concern was that although cognitive representations of CU were improved and 
maintained over time, both causal attributions and treatment control perceptions did not 
significantly change over time. Why this is the case is difficult to determine. Psychological and 
immunity causes were included in this study as they dominated in Study 4 over risk and accident/ 
chance causes. For immunity causes a possible explanation is that participants already 
understood the immunity origins of CU before the intervention. This information usually comes 
from the patients’ dermatologist during the diagnostic process when deciphering between 
whether patients have idiopathic or autoimmune urticaria (Zuberbier et al, 2009, 2012). Further 
in qualitative study 5 all participants reported CU in an immunological context. However scores 
for psychological causes and treatment control from T1 to T2 were reaching significance with 
increasing beliefs in psychological causes and better treatment control at time T1 to T2 (p= .06 
and .07) hence maybe the sample size was too small to reach a potential significant effect or the 
psycho-educational material was not detailed or clear enough. 
 
An intervention Designed to Change Representations of CU results in better CU Outcome   
Even though it was easier to assume that changes in cognitive representations were as 
a result of directly targeting cognitive representations in the intervention, the elimination of the 
control group made drawing this conclusion to QoL-related outcomes more difficult to conclude 
despite the positive findings of the multivariate analyses undertaken. To infer to a degree that 
changes in QoL outcomes were a result of challenging cognitions in the intervention, correlations 
between cognitive change scores and QoL outcome change scores over time were correlated. 
These analyses confirmed the second major finding that a brief intervention designed to change 
perceptions of CU can result in better self-reported disease-specific QoL, better generic mental 
health status and reduced anxiety levels that persist over time. Not all cognitive changes over 
time significantly related to changes in all QoL outcomes, however this was expected as not all 
CU cognitive representations are related to all outcomes (hence some cognitions are more 
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important to particular outcomes than others). The importance here was that all components 
played a part in some aspect of QoL outcomes and it can be deciphered as to which cognitive 
components where the most important for targeting particular outcomes that persist over time. 
Examples in this study included challenging illness identity to reduce the number of symptoms 
attributed to ones CU to reduce anxiety and increasing necessity beliefs about taking CU 
medicines while reducing concerns about taking them to improve CU disease-specific QoL.  
 
Not all significant change score relationships occurred from baseline to post-intervention 
to 3-month follow-up but only between 4-week post-intervention and 3-month follow-up (T2 to 
T3). An example included emotional representations, specific necessity and specific concern 
change on DSQoL change. It is suggested that maybe not all psycho-educational material gets 
assimilated straight away but may take up to a month to be accommodated before persisting at 
3-months. In respect to challenging necessity and concern beliefs about taking CU medicines to 
improve DSQoL this would make sense as positive changes in CU medicine uptake behaviour 
resulting from a change in CU treatment beliefs may take more time to learn before mastering.  
 
In contrast emotional representations and GMHS change scores only persisted from 
baseline to 4-weeks post-intervention before becoming insignificant at 3-month follow-up. The 
emotional impact of CU is a topic that those experiencing CU often report as neglected by health 
professionals (Maurer et al. 2011) and maybe the intervention fell short by only merely raising 
awareness of the emotional impact of CU. This may have resulted in participants feeling better 
mentally about the emotional impact of CU being acknowledged, but it might have needed more 
than educational awareness alone to maintain this effect over time by incorporating action plans 
for emotions as standard (not an option). For example Cameron and Jago (2008) who focus their 
research predominantly on the emotional aspects of the CSM have used writing exercises that 
propose to help by getting ones feelings onto paper before then externalising them. However, in 
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patients with years of unaddressed emotional distress it may require more than a belief psycho-
educational intervention (as the one in this study) to implement such strategies to be beneficial. 
This would further explain the insignificance at 3-month follow-up.  
 
One aspect that could not be dismissed was the numerous trends found between 
change scores over time that just fell short of a significant result (p =.06). It would have been 
easy to eliminate these correlations statistically as if they were significant they would have been 
weakly so. However it was felt that these trends had to be interpreted within the context of the 
small sample size of this study and that they mostly occurred between baseline and 3-month 
follow-up scores (T1-T3). From these observations it is more likely that the study just required a 
considerably larger sample size to reach significance for these relationships. This interpretation 
is also more credible as these trends made conceptual sense (e.g. change correlations between 
perceiving less serious consequences of CU and reporting lower levels of anxiety).  
 
Overall the findings indicate that a greater knowledge and understanding of one’s CU as 
an illness may play a role in how the condition is maintained and experienced over time. Such 
findings are in line with previous studies that have not necessarily aimed to change QoL 
outcomes but have challenged patient’s perceptions of their illness to change variables other 
than just merely the representations itself. For example Petrie et al, (2002) found that changing 
illness perceptions improved functional outcomes such as returning to work and attending 
rehabilitation after myocardial infarction. In the context of QoL outcomes itself, it was highlighted 
in chapter 2 (see Table 2.1, p38) that much of the research specifically on representations of 
illness and QoL has been cross-sectional and of the longitudinal studies undertaken (Chaboyer 
et al, 2010; Stafford et al, 2009; LIwellyn et al. 2007a) only the natural course of representations 
over time on QoL has been examined. This study not only supports cognitive representations as 
psychological process factors on CU but also as mechanisms of change of CU-related QoL  
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outcome. These implications are discussed below.  
 
CU is implicated in Socio-Cognitive Processes and Mechanisms of Change 
The ability of this study to change cognitive representations of CU resulting in better QoL 
outcomes has far more reaching implications then supporting the implementation of CSM 
interventions. It implies that CU aetiology may in part be implicated in psychological (or socio-
cognitive) mechanisms that are able to improve CU QoL-related outcomes outside of the medical 
model. Such findings suggest a role for psychological process in CU outcome that is in opposition 
to existing CU research attempting to identify the physiological mechanisms that are considered 
as the driving force of CU process and outcome (see Section 1.2, p 5). The findings further help 
to contribute to how CU psychological processes actually function specifically in CU which is still 
largely misunderstood compared to other skin disorders (Gupta and Gupta, 2012). 
 
Indeed CU researchers may need to see CU more bio-psychosocially not just in terms 
of QoL outcomes and how CU medicines may impact on bio-psychosocial functioning over time, 
but in how psycho-educational processes and action plans may be complementary in CU medical 
RCT’s. Together both may potentially allow participants to not only make more knowledgeable 
decisions about self-managing symptoms through CU medicines, but the knowledge itself may 
lead to better self-regulation and internal control of the self. Such strategies may result in a 
reduction in CU medication usage over time (or better adherence to prescribed medicines). 
Further, such strategies may help reduce the financial burden of healthcare costs incurred by 
patients including that of CU medicines which are usually taken in highly individualised and 
different combinations; Zuberbier et al. 2009b).  
 
The Intervention fills a Gap in the Absence of a Psychological Intervention in CU  
The main findings of this study do not only have implications for CU research but also 
for CU-related clinical practice. CU management guidelines stipulate that there are no CU  
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psychological interventions (Zuberbier et al. 2009b, 2012; Maurer et al. 2011) Dermatologists 
and other medical practitioners have often stated that they recognise a role for psychological 
variables in CU but argue that studies have lacked causality (Zuberbier et al. 2009b). When 
psychological interventions are applied to dermatological conditions they have been perceived 
as poorly designed and implemented and it has been hard to decipher what mechanisms are 
significant and result in changes in outcome (Papadopulos et al. 2005). However, the introduction 
of MRC guidelines, guidelines for complex behavioural interventions and the work of Michie and 
colleagues (Mitchie et al, 2004, 2011) on deciphering what behavioural change techniques work 
with what health models in intervention development has contributed to minimalizing such 
methodological problems (see section 2.5, p45). 
 
The current intervention has considered many of these concerns as it was designed 
using MRC guidelines for designing good quality evidence based interventions. More specifically 
this intervention that was largely acceptable to patients was underpinned within a theoretical 
framework (Craig et al. 2012; Campbell et al. 2000) where the underlying mechanisms within the 
framework and important outcomes had been determined through modelling. Further although 
complex in its design the intervention undertaken in this study was transparent and easy to 
implement as its structural elements were clearly defined as proposed by Davidson et al. (2003) 
and individual behaviour change techniques were mapped onto the models behavioural 
determinants as recommended to facilitate behaviour change (Abraham and Mitchie, 2008; 
Mitchie et al, 2004, 2011). Most important the path from CU process to outcome could be 
measured, analysed and evaluated throughout the intervention. Such well-developed strategies 
as those implemented in this study may act as a framework for health professionals working with 
individual’s with CU to help them understand their condition more which may lead to better plans 
of actions, especially for those who find CU patients difficult to work with, however this may work 
better for urticaria specialist dermatologists, nurses and psychologists who themselves have a  
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better knowledge of CU identity, cause, timeline, consequences, control and treatments.  
 
A Partner or Significant Other maybe an Instrumental (but not compulsory) Source of Support  
An important finding of the intervention was the overall insignificant role of patient 
characteristics across the course of the study (especially for cognitive representations) however 
there was evidence to suggest that being married or co-habiting with a partner may act as a 
moderating factor on particular outcomes. Inter-correlations between the study variables found 
a weak but significant relationship between marital status (i.e. being married/ co-habiting) at post 
intervention and follow-up QoL (both p < .05) but not baseline reports and a strong and significant 
negative relationship between being married/ co-habiting with levels of baseline, post-
intervention and follow-up levels of anxiety (p < .01). This is not the first time that marital status 
has emerged as one of the few socio-demographic variables to significantly impact CU outcome 
as it explained a significant 9.0% of the variance in the CSM model of GMHS in study 4 (F (1, 
74)= 3.09. p< .01) and with age predicted 15.0% of the variance in disease-specific QoL (F (1, 
74)= 3.77. p< .01). In Study 4 the presence of a partner was discussed in relation to it possibly 
enhancing interventions further as a source of support for the CU patient and research has 
supported the positive impact of partners in CSM interventions (Sterba et. al. 2009; 2009b; 
Keogh, et al. 2007) however contradictions did occur between this study and study 4. Although 
marital status is somehow implicated in CU it did not correlate with anxiety at all in study 4 as it 
did very strongly here. In contrast its ability to predict GMHS in study 4 was contradicted here 
also as this was insignificant. Why this has occurred is difficult to decipher but candidates might 
include cross-sectional verses longitudinal reports, feeling different when one is embarking on a 
new intervention for CU that is psychological in nature or even knowing that one is going to 
receive some form of new professional support and input. Although marital status was found to 
not be a co-variant of outcome in the main analysis it did appear to reduce the effect and this 
indicates that it plays a role somewhat that requires future research investigation.       
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A CSM Intervention to Change CU Cognitions & QoL Outcomes is Acceptable to Patients 
One of the main aims of the intervention was not only to see significant improvements 
in cognitions and QoL outcomes but to also examine the participant’s experiences during the 
course of the study. It was evident from the findin’gs that the majority of the research sample 
was happy about the way they were approached and recruited and they were happy with 
completing the questionnaires and undertaking the interviews. The most rewarding aspect was 
the core aspect of the intervention, which was to challenge cognitive representations and impart 
new knowledge and understanding and all participants reported that the researcher always 
respected opposing viewpoints, however areas for improvement were also highlighted.  
 
Approximately a fifth of participants experienced difficulties in understanding the 
explanation of the study at recruitment and in the intervention itself around a fifth had concerns 
about the knowledge contents of emotional representations and a quarter did not like its delivery. 
Over half of participants were also unsure about the control aspects of the intervention. The 
biggest concern involved the action plans. Despite their ease of use participants were undecided 
on their usefulness. The second concern were the equal numbers of participants who either 
agreed or strongly agreed as to the efficacy of the intervention and those who were undecided 
(however no one disagreed with it).  
 
In respect to understanding the recruitment material participants could have been 
involved in the development of the instruments in terms of assessing the language and the layout 
but the concens raised about the control and emotional aspects of the intervention in the context 
of CU makes sense. They are two of the aspects of CU that patients often report to be the most 
problematic and not adequately addressed by health professionals in general (e.g. Zuberbier et 
al. 2009b; Maurer et al. 2009a, b, 2011). If this study were to be replicated, the researcher may 
need to take the lead in raising and addressing both control and emotional aspects in the action 
plan phase as standard to all participants in addition to other areas they would like to address as 
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a priority as the study evaluation indicates that psycho-education alone for both components was 
not enough. Undertaking this strategy may allow for the actual action plan to be evaluated as a 
more fruitful part of the intervention that contributes to improving QoL outcomes even if this only 
consists of discussing what procedures will be undertaken to improve control and emotional 
representations for the participant beyond the researchers skills remit (e.g. psychological therapy 
referral or appointments to discuss sub-optimal medicines with a consultant dermatologist). This 
might also address why treatment control perceptions not only failed to change over time but 
also did not correlated to changes in QoL outcomes over time (both discussed earlier). The 
concerns regarding addressing emotional representations in the intervention were already 
discussed on pages 287 and 288 and does mirror the participants’ evaluation in that it required 
a more practical approach in action planning then just raising CU emotional awareness. 
 
Methodological Issues and Considerations  
Despite the novel findings and insights of this study, numerous methodological 
considerations required discussion. The current study was originally planned as an RCT but the 
high attrition rates, particularly from the control group instigated a study redesign to incorporate 
a within group repeated measures design to maintain the longitudinal nature of the study. 
Although not an RCT (and creating difficulties in analysing cognitive change on QoL outcomes) 
such designs are advantageous as each participant acts as their own control and within-group 
variance is significantly reduced (Howitt & Cramer, 2011). Further it also allows for fewer 
participants to be analysed in respect to the smaller sample (Howitt & Cramer, 2011). A major 
reason for attrition was that this study was competing with studies recruiting patients to CU 
pharmaceutical trials for which the drugs on trial became routine care for the patient and an 
exclusion criterion for this study. In addition to sample size concerns the intervention could have 
benefited from a more standard six-month (and even one year) follow-up period which would 
determine better whether cognitive and QoL-outcome change relationships either maintained or 
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declined over a longer time period of time and therefore further validating the intervention. Dispite 
this the study still presented with a good degree of power and effect size.   
 
This study would have benefited with a grant, which would have allowed for more home 
visits to patients and for a larger study that could have recruited patients with CU in GP surgeries 
in primary care or other hospital dermatology departments. Such larger scale studies would 
require the training of staff to learn more about CU and its treatment through training days and 
workshops so that they could implement the intervention as required. Further more funding would 
have allowed for the development and creation of promotional material such as booklets, leaflets 
and/ or a website for both health professionals and patients which tell them more about CU under 
the components of the CSM and how to access relevant services. This would have 
complemented the intervention. Other considerations include undertaking it as a group 
intervention similar to Fortune et al. (2004) psoriasis CSM intervention. Some of the sessions in 
the intervention lasted up to ninety minutes and in reality this is not feasible or cost effective. 
Another strategy raised in study 4 was to develop a training strategy to help health professionals 
who work with CU to raise the issue of patient’s perceptions during consultations. The 
development and piloting of the CU intervention reported in this chapter would support a funding 
proposal as it is more clearly defined in terms of MRC and other guidelines then other CSM 
interventions reported in the literature. Unfortunately this study was in principal supported by a 
provisional grant through St John’s Institute of Dermatology, London but it would have meant 
implementing it considerably beyond the timeline for completing the thesis as a whole.             
 
9.5: Conclusions 
This is the first study to attempt the development and piloting of a CU psychological 
intervention. It is a complex intervention designed to be transparent and easy to replicate. The 
study supported that a brief intervention designed to change cognitive representations of CU can 
also result in significantly better self-reported QoL outcomes. 
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Chapter 10 
General Discussion 
 
10.1: Chapter Summary and Overview of Theses Findings  
Chronic Spontaneous Urticaria (CU) has unknown aetiology and negatively impacts 
quality of life (QoL). One modifiable factor is ones illness representations that the Common-
sense Model (Leventhal, Meyer and Nerenz, 1980) predicts guide coping procedures that impact 
outcomes. The aim of the thesis was to test the model in CU and determine if representations 
and QoL in CU were amenable to change via intervention. The thesis produced evidence to 
support the following: 
1. Individuals with CU hold illness representations in relationships predicted by the CSM.  
2. These representations relate to aspects of quality of life outcome independent of coping. 
3. Disease-specific representations entail managing psychosocial/ appearance issues. 
4. CU representations are amenable to change and result in better self-reported QoL. 
In addressing preliminary methodological issues the following was also supported 
1. CU has a moderate impact on QoL and with a similar impact on bio-psychosocial aspects.  
2. Quality of life in individuals with CU is more impaired than healthy adults and similar or 
worse in certain aspects compared to other chronic conditions.    
3. Quality of life in CU is best measured with the SF-36 and CU-Q2oL. 
The aim of this chapter is not to discuss these results in great detail (as this was done extensively 
in the respective chapters each finding was reported in, but moving forwards to looking at findings 
as a whole and sum-up the possible impact they might have on how quality of life in CU is 
researched, how practitioners view CU management and how patients with CU perceive its self-
regulation. It is only through the findings relevance to the care of these patients in relation to CU 
research and management practices that they are more likely to be utilized by research-
practitioners and contribute to actual patient care in real life. 
 296 
 
10.2: Contribution of Thesis to CU Quality of Life Research, Practice and Policy 
 
10.2.1: CU Quality of Life Research 
The original main aim of the thesis was to integrate quality of life research and practice 
in CU within the socio-cognitive framework of the CSM. As introduced in the preface and chapter 
1, CU has a significant negative impact on QoL in which existing biomedical causal theories do 
not predict which mechanisms or mechanisms of change (i.e. avoiding triggers and taking CU 
medicines/ treatments) predict outcomes (Saini, 2011; Zuberbier et. al. 2014). Although there is 
already a growing empirical research literature on psychological process and outcome in CU, 
much of this is data-driven (see sections 1.2.3, 1.3, 2.4.2) and the classification of CU is not 
always clear (a problem that still endures; Toubi, Grattan and Zuberbier, 2015; Gimenez-Arnau, 
Grattan, Zuberbier and Toubi, 2015).  The major contribution of the thesis is that it has placed 
CU within an alternative well-established psychosocial framework that has a strong empirical 
evidence base. More specifically the CU research data has provided strong evidence to support 
that CU cognitive representations act as not only mechanisms of CU-related QoL but (acted 
upon) they can serve as mechanisms of change using standardized behavior change techniques 
(Michie, Atkins and West, 2015).  
 
For CU research the above discovery is a momentous theoretical and empirical leap as 
it challenges the view that CU should only be studied as a pathophysiological phenomenon. Even 
though a social-cognitive etiology has not been proven outright here the socio-cognitive 
processes of CU perceptions and emotional representations are somehow implicated 
significantly to CU processes when the disease is already acquired and implicated to its 
maintenance and QoL-related outcomes. Second unlike existing CU bio-medical models, the 
path from process to outcome can be followed and evaluated suggesting that by using 
mechanisms of cognitive representation change (i.e. self-regulation BCT’s and challenging 
perceptions) aspects of QoL outcome can be changed in a more positive direction. In essence 
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from a psychosocial viewpoint, CU appears (at least from these research data) not to be ‘an 
enigma’ as viewed from a medical and lay perspective (Zuberbier, Grattan and Maurer, 2009; 
Weller et al. 2012), as it seems to have some defined predictable path. However it must be 
acknowledged that pathophysiological theories have contributed to understanding it more (see 
section 1.2.2, p5), hence it is suggested that CU research needs to not move away from bio-
medical models but to incorporate socio-cognitive components (e.g. cognitive representations) 
as part of a more bio-psychosocial approach to broaden the CU causal model and therefore 
increase lines of investigation to improve outcome.  
 
As measuring QoL is a primary outcome in CU research, one way of incorporating 
cognitive representation measures is within drug trials. They may help to determine how 
perceptions of CU illness and treatment change over the course of treatments designed to 
improve QoL.  Such instruments could also be used as a screening tool to establish baseline 
perceptions of CU prior to a trial. This would allow any misconceptions at the start to be 
challenged leading to participants to hypothetically adhere to study protocols more.  
 
From a psychological research perspective future research needs to further explore the 
CSM precursors of social messages and symptom perceptions more, not only from the patient’s 
perspective (as discussed in section 7.4) but from the research-practitioners perspective also. In 
the IPA (Chapter 8) themes emerged that reflected the research literature that health 
professionals working with CU lack adequate knowledge of the disease, find it difficult to treat 
and its patients difficult to manage or satisfy, reflecting the research literature (Weller et al. 2012).  
Interpretations of the IPA suggested that these helped to form the patients own perception of 
their CU as a condition that is ‘difficult to understand or be understood’ (see Table 8.2, p221). 
Exploring the researchers and health professionals own CU symptom perceptions, social 
messages and representations in relation to CU and CU-related QoL might provide some insight 
into how practitioners and patients draw different perceptions and views.  
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10.2.2: CU Quality of Life Clinical Practice and Patients  
Indeed the successful integration of CU into a psychosocial framework such as the CSM 
has direct benefits to health professionals in clinical practice and presents as the second major 
contribution of the thesis. From a sole bio-medical perspective CU might seem like a difficult to 
treat condition to practitioners due to its unknown etiology and treatment options, which cannot 
guarantee better outcome. Together with a lack of knowledge and understanding of CU and 
limited options available to help the patient, practitioners may either feel like they are failing their 
patient or externalising the inability to help by transferring the blame towards the patient. The 
CSM framework applied provides the practitioner with a script to follow to help communicate with 
the patient in a more effective way (see section 9.2.3, p257). Practitioners can raise the issues 
of CU perceptions during consultations in terms of its components and challenge any 
misconceptions using these strategies or they can use empirically supported BCT’s as 
mechanisms of change for those components. A script is important as research suggests that it 
is the communication of the CSM that results in the uptake of newly learnt behaviors and less so 
the interpersonal skills of the practitioner (Philips, Leventhal and Leventhal, 2011). Such 
communication may not only highlight misconceptions that were affecting outcomes, but also 
interpersonal, social and appearance issues which may require a psychology referral.  
 
Despite these new initiatives for supporting individuals with CU, pathophysiological 
breakthroughs that have contributed to understanding CU more (Maurer, Church, Goncalo, 
Sussman and Sanchez-Borges, 2015) again cannot be ignored and increasing the patients 
necessity to take CU medicines and reducing their concerns about side effects through 
discussing treatment beliefs might increase QoL outcome and adherence to treatment (of course 
a measure of adherence would also be required). As discussed in Chapter 7 it was difficult to 
decipher whether CU medicines are sub-optimal because the patient has misconceptions about 
regular intake or whether the medicines were actually not satisfactory, however the intervention 
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and qualitative study did provide insights suggesting both scenarios, reflecting the research 
literature (Maurer et al. 2011; Maurer et al. 2009b). 
 
For the CSM to work in clinical practice (as discussed in detail in chapters 7 and 9) it 
needs to be considered that skin health professionals require the skills training to raise 
perceptions with patients, undertake those BCT’s and know when issues surpass their skills set 
and refer on to psychology services. In essence such training and its application takes part of 
the control of the condition from the practitioner to the patient. By having misconceptions of CU 
challenged and by assimilating and adopting new perceptions and BCTs, the patient is able to 
self-regulate and manage symptoms and consequences better, still under supervision but 
independently from professional care in everyday life.  
 
10.2.3: CU Quality of Life Policy 
In order for new interventions to be adopted and applied to practice by practitioners they 
are best integrated into consensus guidelines for CU management. Although the original 
guidelines for CU management state that psychological interventions are necessary, they only 
focus on avoiding triggering factors and the level of evidence for CU drug interventions (Zuberbier 
et al. 2009b). This hasn’t changed in a recent updates (Zuberbier, Aberer, Asero, Bindslev-
Jenson, Brozoza, Canonica et al, 2014) and a way to change this is to promote psychological 
interventions where the path from process to outcome can be evaluated. Another major 
contribution of the thesis is that it has provided the stepping-stones for this within the remit of 
MRC guidelines and guidelines for behavior change interventions (Mitchie et. al, 2015; 2011; 
2008; 2004) and therefore presents the CSM as a model for improving CU-related quality of life 
at conferences to improving quality of life related outcomes.  
 
Health psychologists will be integral to this new development as they have the trained 
expertise in research, teaching, training and developing/ delivering evidence based interventions 
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that can only contribute to the growing multi-disciplinary area of psycho-dermatology that in 
practice is recognizing the need to incorporate psychology services in the UK (Turner, Smith, 
Thomas and Jackson, 2015). The work in this thesis through systematic reviews, psychometric 
analyses, empirical research and intervention development, application and evaluation is a 
testament to this. Since the undertaking of the thesis there have been further major 
developments in respect to guidelines on undertaking CSM interventions (Jones, Smith and 
Llewellyn, 2015), using BCT’s in behavior change interventions as mechanisms of change 
(Michie, et. al 2015) and new MRC guidelines on process evaluating complex interventions with 
cognitive components (Moore, Audrey, Barker, Bond, Bonell, Hardman et al, 2015) that was 
lacking. These developments utilised appropriately can only help to improve the methodological 
rigor of the next potential stage of this thesis which would be to undertake a large scaled RCT 
aimed as changing perceptions and CU-related QoL outcomes in CU. 
 
10.2.4: Reference Values and Measurement 
Before the methodological limitations of the thesis as a whole is discussed, it is worth 
mentioning again the contribution it has made to studying chronic spontaneous urticaria (CU) 
itself. During the introductory chapters a case was presented for the need to integrate CU 
outcome into socio-cognitive models to explore new potential predictors of outcome, however in 
doing so it became clear that studying CU itself was problematic. Prior to the thesis issues 
regarding classifying CU, the homogeneity of CU samples within studies and the use of different 
QoL instrument types across CU studies emerged (discussed in detail in previous chapters) and 
it was decided that these would have to be resolved before investigating the thesis’ main aims 
and objectives. A major contribution of the thesis is that it has attempted to provide both 
researchers and practitioners with standardised CU epidemiological and QoL-related 
measurement reference values analysed by systematic reviews which can be referred to for 
comparison in future studies. Indeed these values and measurement recommendations as 
 301 
 
intended were used in the proceeding studies where patient characteristics and findings reflected 
the wider research literature. Importantly these novel studies present new insights into CU-
related QoL in formally diagnosed homogenous samples of patients with chronic spontaneous 
urticaria. Since the undertaking of this thesis a separate questionnaire to measure angioedema-
related QoL separately to urticaria (the AEQoL) had been produced (Welden, 2014) and an area 
for future research would be to use this instrument to explore cognitive representations of 
angioedema and decipher whether patient characteristics produce similar results and similar 
impact on QoL. As discussed in detail in chapter 7 whether QoL outcome data will be used for 
testing the efficacy of CU medicines as to targeting predictors of aspects of QoL including looks 
and appearance remains to be seen.  
 
10.3: Thesis Studies Contribution to Understanding the CSM 
As the study of the CSM has contributed to a better understanding of CU process and 
outcome, the data collected from CU research participants has also contributed to understanding 
the the CSM and its measurement. Firstly, in the IPA reported in Study 5, interviewees described 
the regular pruritic wheals and swellings that emerged in CU but also the tingling and pain 
sensations experienced that led them to label this occurrence as urticaria. Such reports are 
evident of the CSM’s symmetry rule of linking symptoms to labels and labels to symptoms (e.g. 
Meyer, Leventhal and Gutman, 1985; see section 2.2.1) however the quantitative IPQ-R illness 
identity subscale by Moss-Morris et al. (2002) does not cover sensations. Further although it 
accounts for deciphering identity from somatisation it may also encourage symptom over-
reporting. Participants of study 5 responding to open-ended questioning only reported itching 
and swelling but in study 3 approximately 7 symptoms were chosen from the IPQ-R. In light of 
this there is maybe a need to consider changing to an open scale that includes questions on 
sensations. Second, coping is an integral component of the CSM governed by cognitive 
representations of illness (the IF-THEN rule) and acting as a mediator between representations 
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and outcome. The IF-THEN rule was to a degree supported in Study 4 (see Section 7.3.6, p190) 
but mediation failed to occur, contributing to on-going debates as to the importance of coping in 
the CSM (see section p27).  
 
10.4: Methodological Considerations and Limitations  
This thesis has produced novel insights into quality of life, self-regulation and CU 
however they need to be considered in light of the limitations of the methods used. The studies 
consisted of a high number of female participants. Such a bias may suggest that the findings are 
only applicable to CU in women. However as stipulated in Chapter 1, females greatly outnumber 
males in CU and such ratios were confirmed in the systematic review study so indeed the 
participants were representative of the condition and the research literature. It was this that 
guided the decision to include women only in qualitative study 5. In doing so maybe there was a 
missed opportunity to explore CU in a small male sample to examine possible gender 
differences. Researches may consider exploring this in future including deciphering whether 
being female is characteristic of CU or if less males seek professional help.  
 
Another issue related to participants was that they were recruited from an NHS tertiary 
service. Patients from tertiary services may present with more severe disease and not be 
representative of those in primary care. However the patient characteristics within the thesis 
studies largely matched those of the CU literature, hence it is argued that the participants in the 
thesis were representative of the CU literature. 
 
Issues did pertain to the preliminary studies that were undertaken to strengthen the 
methodology of the thesis. The data of the QoL systematic review study were qualitatively 
reviewed however the diverse range of QoL instruments using different domains, scoring 
systems and levels of specificity made quantitative analysis impossible. Further the items of the 
different CU-Q2oL’s could have been entered into a single meta-analysis to determine a new  
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instrument. Such an analysis could be undertaken in future. 
 
The Hospital Anxiety and Depression Scale was used to measure psychological distress 
and was a good model fit of the CU data via PCA however it needs to be considered that it is not 
a diagnostic measure of clinical state anxiety and depression but merely a clinical indicator of it. 
A diagnostic approach would have been ideal but was outside the practicalities and financial 
resources of the thesis. Further, the failure to find coping as a significant mediator may have 
been reflected in using a generic measure but the COPE questionnaire is a popular instrument 
for studying coping in the CSM, (see Table 2.1, p38), however it might not make it the most 
appropriate and researchers may consider developing a CU disease-specific instrument.          
 
One of the shortcomings of Study 4 was that it was based on a cross-sectional design 
and despite the path analysis undertaken no real causal inferences could be made. The CSM 
proposes a path from cognitions, coping to outcome but it is possible for QoL to guide coping 
behaviour that in turn change the cognitive representation, indeed the dynamic nature of the 
model does allow for this bottom-up processing. The longitudinal design of the intervention 
somewhat attempted to resolve this however the interventions high attrition rates and the 
elimination of the control group did not really allow findings to be as generalizable as they could 
have been. In light of this the intervention was found to have adequate statistical power and 
effect size and its well-structured development and implementation to relevant guidelines 
suggested a strong potential to undertake it as an RCT. 
 
10.5: Conclusions and Future Directions 
The six studies undertaken in this thesis have provided strong evidence to support that 
chronic spontaneous urticaria is implicated in not only bio-psychosocial outcomes but also bio-
psychosocial processes. It has highlighted the need to understand CU first as an illness and how 
quality of life is realistically experienced. This needs to be measured appropriately in order for 
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the exploration of new (and old) possible contributors of its process, maintenance and outcome 
to be adequately explored. Only by doing this and in a multifaceted way can dermatologists and 
psychologists help the patient with CU to self-regulate this condition better.  In undertaking this 
empirical challenge the thesis has supported that quality of life outcomes in CU can be 
determined by cognitive representations of illness and further challenging patients existing 
negative and maladaptive representations can result in better self-reported quality of life and 
reduced psychological distress.   
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